 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1603
Global, regional, and national disability-adjusted life-years 
(DALYs) for 315 diseases and injuries and healthy life 
expectancy (HALE), 1990–2015: a systematic analysis for the 
Global Burden of Disease Study 2015
GBD 2015 DALYs and HALE Collaborators*
Summary
Background Healthy life expectancy (HALE) and disability-adjusted life-years (DALYs) provide summary measures of 
health across geographies and time that can inform assessments of epidemiological patterns and health system 
performance, help to prioritise investments in research and development, and monitor progress toward the 
Sustainable Development Goals (SDGs). We aimed to provide updated HALE and DALYs for geographies worldwide 
and evaluate how disease burden changes with development. 
Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) 
for all-cause mortality, cause-specifi
 c mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 
195 countries and territories from 1990 to 2015. We calculated DALYs by summing years of life lost (YLLs) and 
years of life lived with disability (YLDs) for each geography, age group, sex, and year. We estimated HALE using 
the Sullivan method, which draws from age-specifi
 c death rates and YLDs per capita. We then assessed how 
observed levels of DALYs and HALE diff
 ered from expected trends calculated with the Socio-demographic Index 
(SDI), a composite indicator constructed from measures of income per capita, average years of schooling, and total 
fertility rate.
Findings Total global DALYs remained largely unchanged from 1990 to 2015, with decreases in communicable, 
neonatal, maternal, and nutritional (Group 1) disease DALYs off
 set by increased DALYs due to non-communicable 
diseases (NCDs). Much of this epidemiological transition was caused by changes in population growth and ageing, 
but it was accelerated by widespread improvements in SDI that also correlated strongly with the increasing 
importance of NCDs. Both total DALYs and age-standardised DALY rates due to most Group 1 causes signifi
 cantly 
decreased by 2015, and although total burden climbed for the majority of NCDs, age-standardised DALY rates due 
to NCDs declined. Nonetheless, age-standardised DALY rates due to several high-burden NCDs (including 
osteoarthritis, drug use disorders, depression, diabetes, congenital birth defects, and skin, oral, and sense organ 
diseases) either increased or remained unchanged, leading to increases in their relative ranking in many 
geographies. From 2005 to 2015, HALE at birth increased by an average of 2·9 years (95% uncertainty interval 
2·9–3·0) for men and 3·5 years (3·4–3·7) for women, while HALE at age 65 years improved by 0·85 years 
(0·78–0·92) and 1·2 years (1·1–1·3), respectively. Rising SDI was associated with consistently higher HALE and a 
somewhat smaller proportion of life spent with functional health loss; however, rising SDI was related to increases 
in total disability. Many countries and territories in central America and eastern sub-Saharan Africa had 
increasingly lower rates of disease burden than expected given their SDI. At the same time, a subset of geographies 
recorded a growing gap between observed and expected levels of DALYs, a trend driven mainly by rising burden 
due to war, interpersonal violence, and various NCDs.
Interpretation Health is improving globally, but this means more populations are spending more time with functional 
health loss, an absolute expansion of morbidity. The proportion of life spent in ill health decreases somewhat with 
increasing SDI, a relative compression of morbidity, which supports continued eff
 orts to elevate personal income, 
improve education, and limit fertility. Our analysis of DALYs and HALE and their relationship to SDI represents a 
robust framework on which to benchmark geography-specifi
 c health performance and SDG progress. Country-
specifi
 c drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform fi
 nancial 
and research investments, prevention eff
 orts, health policies, and health system improvement initiatives for all 
countries along the development continuum.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Lancet 2016; 388: 1603–58
This online publication has been 
corrected. The corrected version 
first appeared at thelancet.com 
on January 5, 2017
See Editorial page 1447
See Comment pages 1448 
and 1450
*Collaborators listed at the end 
of the Article
Correspondence to:
Prof Christopher J L Murray, 
2301 5th Avenue, Suite 600, 
Seattle, WA 98121, USA
cjlm@uw.edu
 Articles
1604 
www.thelancet.com   Vol 388   October 8, 2016
Introduction
Summary measures of population health are crucial inputs 
to guide health system investments and set priorities at 
global, regional, national, and subnational levels. The 
Millennium Development Goals (MDGs), which sought to 
reduce extreme poverty and improve health, expired in 
2015, and were replaced by the 2030 Agenda for Sustainable 
Development, or Sustainable Development Goals (SDGs).1 
The shift from the MDGs to the SDGs refl
 ects a broadening 
of the global development agenda,2,3 expanding to include 
targets for non-communicable diseases (NCDs) and 
indicators that consider the interplay of environmental, 
societal, and economic factors on health.4 Within this 
context, summary population health measures are 
advantageous because they can easily be used to show 
progress toward SDG 3—to “ensure healthy lives and 
promote well-being for all at all ages”—and provide a 
metric by which comparative progress on other SDGs can 
be monitored.5 Summary measures also provide insights 
into whether, as societies live longer, they spend more or 
less of their time with functional health loss, known as the 
expansion or compression of morbidity, respectively, 
which has profound implications for societies and the 
fi
 nancing of health systems.
Two types of population health summary measures 
exist: health expectancies and health gaps.6 Healthy life 
expectancy (HALE), which originates from Sullivan,7 
provides a single summary measure of population health 
by weighting years lived with a measure of functional 
health loss experienced before death. Many health 
expectancy measures have been proposed, but HALE is 
the only one that captures a full range of functional 
health loss.8–10 Health gap measures capture diff
 erences 
between a population and some normative standard such 
as a maximum lifespan in full health. Disability-adjusted 
life-years (DALY) are a widely used gap measure,6,9–11 
representing the sum of years of life lost (YLLs) due to 
premature mortality and years lived with disability 
(YLDs). YLLs quantify the gap between observed 
mortality and a normative life expectancy,12 and YLDs 
capture the prevalence of conditions that lead to non-fatal 
health loss while accounting for the severity of those 
conditions. Health gap measures can be easily 
disaggregated to examine contributions of relative 
morbidity and mortality, individual diseases, injuries, 
and attributable risk factors.
The Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) study is the most comprehensive source of 
comparable summary population health measures 
because of its inclusion of country-level results, 
uncertainty quantifi
 cation, and its eff
 ort to maximise 
comparability across geography, time, and across diff
 erent 
health conditions. Alternative summary health assess-
ments are not as standardised or comprehensive, with 
studies reporting only incomplete time-series, no 
uncertainty measures, or only a subset of countries and 
causes.13–15 WHO published DALY estimates for 2 years 
(2000 and 2012), with 132 causes and 174 countries and 
Research in context
Evidence before this study 
Disability-adjusted life-years (DALYs), a summary measure of 
population health based on estimates of premature mortality 
and non-fatal health loss, originated from the initial Global 
Burden of Disease (GBD) study in 1993. DALYs, in combination 
with other summary measures such as healthy life expectancy 
(HALE), off
 er relatively simple yet powerful metrics against 
which progress and challenges in improving disease burden and 
extending healthy lifespans can be eff
 ectively monitored over 
time. Published in 2012, GBD 2010 provided updated estimates 
of DALYs due to 291 causes and HALE in 187 countries from 
1990 to 2010. GBD 2013 extended this time series to 2013, 
with 188 countries, and 306 causes. Novel analyses for 
quantifying epidemiological transitions were introduced as part 
of GBD 2013, enabling a comparison of shifts in years of life lost 
(YLLs) and years lived with disability (YLDs) with increasing 
levels of development. WHO has produced estimates of DALYs 
and HALE largely based on GBD 2010 and GBD 2013; however, 
modifi
 cations were implemented for a subset of causes, 
disability weights, and countries, and a normative life table of 
91·9 years at birth was used for calculating YLLs. 
Added value of this study 
For GBD 2015, we generated estimates of HALE and DALYs for 
315 causes by geography, sex, and age group from 1990 to 
2015 for 195 countries and territories. We constructed a 
summary metric referred to as the Socio-demographic Index 
(SDI) based on measures of income per capita, average years of 
schooling, and total fertility rate. We estimated SDI for each 
geography-year, and characterised the average relationship for 
each age, sex, and cause for DALYs and HALE with SDI. Using 
these relationships, we calculated expected levels of DALYs, life 
expectancy, and HALE for each geography over time. We 
compared observed patterns of both DALYs and HALE with 
those expected on the basis of SDI, allowing us to explore where 
health gains exceeded—or lagged behind—corresponding 
changes in development.
Implications 
Since 1990, overall health has improved in most countries, with 
particularly large gains occurring in the past 10 years. Although 
improved health means longer lifespans, it also translates to 
more years of functional health lost. The fraction of overall life 
expectancy spent in poor health is generally constant or has 
slightly declined in some countries, a result driven by declines in 
DALYs due to communicable, maternal, nutritional, and neonatal 
causes and increases in others, mainly non-communicable 
diseases. Country-specifi
 c drivers of disease burden, particularly 
when observed DALYs are higher than expected on the basis of 
SDI, should inform country-specifi
 c inquiry and action.
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1605
without uncertainty intervals. These estimates were 
derived primarily from GBD 2010 results, but were 
modifi
 ed in 60 countries and for 12 cause groups 
separately estimated by WHO and UN agencies.13,16,17 
WHO applied the same approach for GBD 2013 results 
and used their own life tables to produce HALE estimates 
for 2015.14 The European Commission (EC) and 
the Organisation for Economic Co-operation and 
Development (OECD) also reported healthy life expectancy 
estimates for European countries from 2004 through 2014, 
but these were based on self-reported health status.18,19
Here we present GBD 2015 fi
 ndings for DALYs and 
HALE, building upon updated estimates of mortality, 
causes of death, and non-fatal health loss.12,20 Overall 
analytic approaches are similar to previous GBD 
studies,9,10 but include new mortality and morbidity data, 
refi
 ned methods, and expanded geographies.12,20 This 
report supersedes all previous GBD studies on DALYs 
and HALE through the estimation of a complete time-
series for 1990 to 2015. To facilitate a more in-depth 
examination of the drivers of DALY and HALE trends, we 
assess how HALE, along with overall and cause-specifi
 c 
DALYs, change as geographies move through the 
development continuum. We use this analysis to 
benchmark overall progress and decompose observed 
disease burden compared with levels expected for specifi
 c 
causes on the basis of development alone, to highlight 
potential areas for policy investment or further research.
Methods
Overview
Detailed methods for estimating DALYs and HALE, 
including analytic approaches for mortality and non-fatal 
health loss estimation, are provided in related pub-
lications.12,20 Additional detail on GBD metrics and 
defi
 nitions are found elsewhere.21 Interactive tools are also 
available to explore GBD 2015 results and data sources. 
This analysis follows the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER), which 
includes recommendations on documentation of data 
sources, estimation methods, and statistical analysis.22,23
In brief, the GBD geographic hierarchy involves 519 total 
geographies within 195 countries and territories, 21 regions, 
and seven super-regions. This study reports results for all 
countries and territories. The GBD cause hierarchy has 
four levels of classifi
 cation and causes reported within each 
level that are mutually exclusive and collectively exhaustive. 
The full GBD cause list with corresponding International 
Classifi
 cation of Diseases (ICD)-9 and ICD-10 codes are 
available in our publications on cause-specifi
 c mortality12 
and non-fatal health outcomes.20
Estimation of mortality and non-fatal health loss
We estimated all-cause and cause-specifi
 c mortality with 
a multistep computation process, which included 
systematically addressing known data challenges, such as 
diff
 erent coding schemes, diff
 erent age-group reporting, 
variation in certifi
 cation, misclassifi
 cation of HIV
/AIDS 
deaths in some countries, misclassifi
 cation of maternal 
HIV
/AIDS deaths, and incorporation of population-based 
cancer registry data, before computation of cause-specifi
 c 
mortality with analytic tools such as Cause of Death 
Ensemble Modelling (CODEm). Each death could have 
only one underlying cause. Additional detail, including 
model specifi
 cations and data availability for each cause-
specifi
 c model, can be found in the supplementary 
material of the GBD 2015 mortality and causes of death 
publication.12 We calculated normative life tables based on 
the lowest death rates for each age group among 
geographies with total populations greater than 5 million. 
We computed cause-specifi
 c YLLs by multiplying cause-
specifi
 c deaths by the life expectancy at the age of death 
(ie, 86·59 years at age 0 years; 23·79 years at age 65 years) 
from this normative life table, and then used the GBD 
world population age standard to calculate age-
standardised mortality rates and YLL rates.12
Our most commonly used analytic approach to 
estimate non-fatal health loss was DisMod-MR 2.1, a 
Bayesian meta-regression tool that synthesises diverse 
data sources to produce internally consistent estimates of 
incidence, prevalence, remission, and excess mortality. 
The use of other methods to estimate non-fatal health 
loss was determined by cause-specifi
 c data availability 
and epidemiological characteristics.24 Additional detail, 
including model specifi
 cations and data availability for 
each cause-specifi
 c model, can be found in the 
supplementary material of the GBD 2015 non-fatal 
publication.20 Each non-fatal sequela was estimated 
separately. We then applied a microsimulation framework 
to assess the occurrence of comorbidity in each age 
group, sex, geography, and year separately. Disability 
from comorbid conditions was apportioned to each of 
the contributing causes. GBD disability weights were 
based 
on 
population 
surveys 
with 
more 
than 
60 000 respondents, and previous studies show that 
disability weights do not signifi
 cantly vary across 
geographies, income, or educational attainment.25,26 In 
this study, disability weights are invariant over geography 
and time, although the distribution of sequelae, and 
therefore the severity and cumulative disability per case 
of a condition, can diff
 er by age, sex, geography, and year.
Estimation of DALYs, HALE, and corresponding 
uncertainty
DALYs are the sum of YLLs and YLDs as estimated in 
GBD 2015 for each cause, geography, age group, sex, and 
year.12,20 Using methods developed by Sullivan,7 we 
calculated HALE by age group within abridged multiple-
decrement life tables and estimates of YLDs per capita 
for each geography–age–sex–year from 1990 to 2015.8,10,27
For all results, we report 95% uncertainty intervals (UIs), 
which were derived from 1000 draws from the posterior 
distribution of each step in the estimation process. UIs are 
distinct from confi
 dence intervals, because confi
 dence 
For the interactive visualisation 
of GBD 2015 results see 
http://vizhub.healthdata.org/
gbd-compare/
For the data citation tool see 
http://ghdx.healthdata.org/gbd-
data-input-sources
 Articles
1606 
www.thelancet.com   Vol 388   October 8, 2016
intervals only capture the uncertainty associated with 
sampling error, whereas uncertainty intervals provide a 
method for propagation of uncertainty from multiple 
sources including sampling, model estimation, and model 
specifi
 cation. 95% UIs represent the ordinal 25th and 
975th draw of the quantity of interest. For mortality and 
YLLs, UIs refl
 ect uncertainty that arises from sample sizes 
of studies used as data sources, adjustments to sources of 
all-cause mortality, parameter uncertainty in model 
estimation, and specifi
 cation uncertainty for all-cause and 
cause-specifi
 c models. For prevalence, incidence, and 
YLDs, UIs refl
 ect the uncertainty that arises from sample 
sizes of studies used as data sources, data adjustments 
from non-reference defi
 nitions, parameter uncertainty in 
model estimation, and uncertainty in the disability 
weights. In the absence of any direction information about 
the correlation between uncertainty in YLLs and YLDs, we 
assumed uncertainty in age-specifi
 c YLDs is independent 
of age-specifi
 c YLLs in DALYs and death rates in HALE. 
Epidemiological transition and relationship between 
DALYs, HALE, and SDI
We examined the relationship between DALYs, HALE, and 
the Socio-demographic Index (SDI).28 SDI was constructed 
based on the geometric mean of three indicators: income 
per capita, average years of schooling among people aged 
15 years or older, and the total fertility rate. SDI values were 
scaled to a range of 0 to 1, with 0 equalling the lowest 
income, lowest schooling, and highest fertility rate 
observed from 1980 to 2015, and 1 equalling the highest 
income, highest schooling, and lowest fertility rate 
assessed during that time. The average relationships 
between each summary health measure and SDI were 
estimated using spline regressions. These regressions 
were used to estimate expected values at each level of SDI. 
Additional detail on SDI computation and geography-
specifi
 c SDI values are available in the appendix (pp 4–5 
and pp 74–80).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had fi
 nal responsibility for 
the decision to submit for publication.
Results
Global trends for DALYs and HALE
Worldwide total DALYs due to Group 1 causes fell from 
1·2 billion (95% CI UI 1·2–1·2) in 1990, to 741·6 million 
(703·9–787·7) in 2015, whereas total DALYs due to NCDs 
increased from 1·1 billion (1·0–1·2), to 1·5 billion (1·3–1·7; 
fi
 gure 1; table 1). Total injury DALYs were relatively 
unchanged between 1990 and 2015. All-age DALY rates for 
NCDs changed little between 1990 and 2015, whereas they 
declined substantially for Group 1 causes. Taking into 
account population ageing, DALY rates for Group 1 causes 
and NCDs both decreased (fi
 gure 1). For injuries, 
reductions in all-age DALY rates and age-standardised 
DALY rates were similar between 1990 and 2015.
HALE at birth increased to 60·9 years for men and 
64·9 years for women in 2015, rising 2·9 years and 
3·5 years since 2005, respectively (table 2). The gap 
between life expectancy and HALE, which represents 
years of functional health lost, widened between 2005 
and 2015 from 7·7 years to 8·1 years for men, and from 
9·4 years to 10·0 years for women. Life expectancy at age 
65 years was 15·5 years for men and 18·5 years for 
women, while HALE was 11·9 years and 14·2 years for 
each sex, respectively (table 2).
Global causes of DALYs
In 2015, Group 1 causes accounted for 30·1% (95% UI 
28·6–31·7%) of global DALYs, with NCDs leading to 
59·7% (57·8–61·5) and injuries to 10·1% (9·5–10·7; 
table 1). Since 2005, DALYs due to many of the world’s 
leading communicable causes substantially declined, yet 
burden increased for a subset of infectious diseases. Age-
standardised DALY rates from HIV
/AIDS and malaria 
each fell by more than 40% and lower respiratory 
infections and diarrhoeal diseases had decreases in total 
and age-standardised rates of DALYs of more than 20% 
(table 1). From 2005 to 2015, reductions in both total and 
age-standardised DALY rates due to tetanus and measles 
surpassed 50% and 70%, respectively. African trypano-
somiasis, a disease targeted for elimination, saw both 
total DALYs and age-standardised rates fall by more than 
70% since 2005. DALY rates substantially fell for all types 
of hepatitis, with age-standardised DALY rates from acute 
hepatitis A declining by more than 35% by 2015. However, 
both total DALYs and age-standardised DALY rates from 
dengue increased by more than 50%. Although the west 
African Ebola virus outbreak peaked in 2014,29 Ebola virus 
disease still caused substantial DALYs in 2015 (table 1). 
Maternal disorders signifi
 cantly declined from 2005 to 
2015, with total DALYs and age-standardised rates each 
falling by more than 20%. Reductions in the global 
burden of neonatal disorders were somewhat less 
pronounced; for instance, the number of DALYs due to 
neonatal sepsis was largely unchanged (table 1).
In 2015, cardiovascular diseases, cancers, and mental 
and substance use disorders were among the leading 
causes of NCD burden (table 1). For many NCDs, including 
most cardiovascular causes and most cancers, total DALYs 
increased but age-standardised DALY rates declined. 
Nearly all neurological disorders increased in total DALYs, 
including Alzheimer’s disease and other dementias, which 
rose by more than 30%, whereas age-standardised rates 
either moderately decreased (eg, Alzheimer’s disease and 
other dementias) or were relatively unchanged (eg, 
Parkinson’s disease). Total DALYs from low back and neck 
pain also increased, rising by more than 17%. Cirrhosis 
caused more DALYs in 2015 than in 2005, although age-
standardised DALY rates signifi
 cantly fell. A similar overall 
See Online for appendix
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1607
trend was found for diabetes and chronic kidney disease, 
with all aetiologies apart from chronic kidney disease due 
to diabetes, showing signifi
 cant declines in age-
standardised DALY rates amid rising total DALYs. For 
other NCDs, namely those associated with skin diseases, 
sensory conditions, and oral disorders, total DALYs 
signifi
 cantly increased from 2005 to 2015, and age-
standardised DALY rates either somewhat increased or did 
not signifi
 cantly change since 2005. Age-standardised 
DALY rates due to chronic obstructive pulmonary disease 
fell by more than 20% from 2005 to 2015, while those due 
to asthma decreased by almost 17%. Peptic ulcer disease, a 
leading cause of digestive disease burden, saw marked 
reductions in total DALYs and age-standardised DALY 
rates, with the latter decreasing by nearly 30% (table 1).
A number of NCDs signifi
 cantly increased in terms 
of total burden and age-standardised DALY rates. 
Osteoarthritis was the most notable example, with total 
DALYs rising by 35% and age-standardised DALY rates 
by 4% between 1990 and 2015. Major depressive disorders 
and drug use disorders, particularly of opioids and 
cocaine, both increased in total DALYs and age-
standardised rates; however, age-standardised DALY 
rates from alcohol use disorders dropped by 19%. Total 
DALYs and age-standardised DALY rates from chronic 
kidney disease due to diabetes also signifi
 cantly increased 
by 2015. Male and female infertility accounted for a 
relatively small fraction of NCDs, but burden due to both 
causes increased signifi
 cantly since 2005. Oral disorders 
and sense organ diseases also had increased total DALYs, 
whereas age-standardised DALY rates were relatively 
unchanged since 2005.
Unintentional injuries and transport injuries each saw 
age-standardised DALY rates signifi
 cantly decrease (20% 
and 17%, respectively). Road injury burden signifi
 cantly 
declined from 2005, with age-standardised DALY rates 
falling by 18% by 2015. Among unintentional injuries, 
drowning had the largest reduction in both total burden 
(26%) and age-standardised DALY rates (32%). Age-
standardised DALY rates from self-harm and interpersonal 
violence both fell by more than 16% since 2005. DALYs 
due to forces of nature, war, and legal intervention 
increased from 2005 to 2015, although not signifi
 cantly; 
this rise was primarily driven by escalated violence and 
war in the Middle East. Despite still causing major health 
loss in 2015, forces of nature caused far fewer DALYs than 
in 2005, mainly because there were no large-scale losses of 
life like that seen in the 2005 earthquake that killed more 
than 70 000 people in India and Pakistan.
Changes in leading causes of disease burden over time
In 1990, lower respiratory infections, preterm birth 
complications, and diarrhoeal diseases were the three 
leading causes of global DALYs; by 2015, only lower 
respiratory infections remained in the leading three 
(fi
 gure 2). Many Group 1 causes had signifi
 cant declines 
for total burden, as well as all-age DALY rates and age-
standardised DALY rates, for both time periods; these 
causes included tuberculosis, meningitis, diarrhoeal 
diseases, protein-energy malnutrition, preterm birth 
complications, tetanus, and measles. Such reductions 
across measures of DALYs contributed to downward shifts 
in relative ranks for most Group 1 causes over time. 
Malaria and HIV
/AIDS both diverged from this trend, 
Figure 1: Trends from 1990 to 2015, by GBD Level 1 cause, in global DALYs (A), crude DALY rates (B), and age-standardised DALY rates (C)
The diff
 erence in trends between (A) and (B) is caused by population growth and the diff
 erence between (B) and (C) is caused by changes in the percentage 
distribution of the population by age. Shaded areas show 95% uncertainty intervals. DALYs=disability-adjusted life-years. 
1990
1995
2000
2005
2010
2015
400
800
1200
1600
Global DALYs (millions)
Year
1990
1995
2000
2005
2010
2015
5000
10 000
15 000
20 000
DALY rates per 100 000
Year
1990
1995
2000
2005
2010
2015
10 000
20 000
A
B
C
DALY rates per 100 000
Year
Communicable, maternal, neonatal, 
and nutritional diseases
Non-communicable diseases
Injuries
 Articles
1608 
www.thelancet.com   Vol 388   October 8, 2016
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
All causes
2 553 306·8
(2 373 137·6 to 
2 756 328·0)
2 464 895·4
(2 259 889·0 to 2 696 510·8)
–3·5
(–5·3 to –1·8)*
41 561·7
(38 640·8 to 
44 850·4)
34 445·7
(31 603·0 to 37 654·3)
–17·1
(–18·7 to –15·7)*
Communicable, maternal, 
neonatal, and nutritional diseases
968 014·5
(931 809·4 to 1 012 327·9)
741 595·9
(703 928·7 to 787 659·9)
–23·4
(–25·2 to –21·7)*
14 297·6
(13 766·0 to 14 955·1)
10 007·2
(9 498·5 to 10 629·3)
–30·0
(–31·6 to –28·5)*
HIV/AIDS and tuberculosis
148 685·6
(141 013·7 to 160 635·2)
106 991·8
(99 680·8 to 116 789·9)
–28·0
(–30·6 to 
–25·1)*
2296·0
(2172·7 to 2490·5)
1 435·5
(1 336·0 to 1 569·2)
–37·5
(–39·6 to –35·0)*
Tuberculosis
49 769·6
(43 196·4 to 60 348·2)
40 302·2
(34 065·8 to 49 653·9)
–19·0
(–24·2 to –13·6)*
817·0
(708·5 to 990·9)
552·4
(467·2 to 681·3)
–32·4
(–36·7 to –27·9)*
HIV/AIDS
98 916·1
(94 515·6 to 103 953·2)
66 689·5
(63 342·9 to 70 788·3)
–32·6
(–35·2 to –29·5)*
1478·9
(1414·0 to 1553·2)
883·1
(839·2 to 937·1)
–40·3
(–42·6 to –37·5)*
HIV/AIDS—tuberculosis
19 327·0
(15 512·5 to 22 015·1)
11 621·9
(8 955·5 to 13 412·3)
–39·9
(–44·2 to –34·5)*
289·6
(232·8 to 329·8)
154·0
(118·7 to 177·7)
–46·8
(–50·7 to –42·1)*
HIV/AIDS resulting in other 
diseases
79 589·0
(74 869·9 to 85 308·1)
55 067·6
(51 480·9 to 59 294·3)
–30·8
(–34·2 to –26·9)*
1189·3
(1119·8 to 1277·1)
729·1
(681·9 to 784·8)
–38·7
(–41·7 to –35·3)*
Diarrhoea, lower respiratory,  and 
other common infectious diseases
333 534·0
(317 202·5 to 351 569·5)
242 875·8
(230 350·0 to 255 919·1)
–27·2
(–30·2 to 
–24·2)*
5005·5
(4769·5 to 5269·7)
3326·2
(3158·6 to 3503·4)
–33·5
(–36·2 to –30·9)*
Diarrhoeal diseases
98 394·2
(90 909·6 to 106 634·4)
71 589·5
(66 442·9 to 77 205·8)
–27·2
(–33·2 to –20·8)*
1479·8
(1371·9 to 1598·4)
976·9
(908·1 to 1 052·7)
–34·0
(–39·3 to –28·4)*
Intestinal infectious diseases
15 062·4
(8 707·5 to 24 651·4)
12 632·0
(7 250·5 to 20 762·5)
–16·1
(–22·9 to –9·9)*
216·0
(124·9 to 353·2)
170·8
(98·2 to 280·7)
–20·9
(–27·3 to –14·9)*
Typhoid fever
12 543·9
(6 953·1 to 21 143·4)
10 575·6
(5 896·1 to 17 598·0)
–15·7
(–22·7 to –9·3)*
179·8
(99·7 to 302·9)
143·0
(79·8 to 237·7)
–20·5
(–26·9 to –14·2)*
Paratyphoid fever
2393·2
(1119·8 to 4569·5)
2014·8
(960·5 to 3848·4)
–15·8
(–24·2 to –7·4)*
34·4
(16·1 to 65·6)
27·2
(13·0 to 52·0)
–20·8
(–28·7 to –12·6)*
Other intestinal infectious 
diseases
125·4
(39·3 to 243·9)
41·5
(16·3 to 81·3)
–66·9
(–78·0 to –47·0)*
1·8
(0·6 to 3·5)
0·6
(0·2 to 1·1)
–69·3
(–79·5 to –51·6)*
Lower respiratory infections
135 293·2
(127 083·7 to 143 499·4)
103 048·6
(96 128·2 to 109 078·8)
–23·8
(–28·2 to –19·4)*
2 070·3
(1 939·4 to 2 189·6)
1428·5
(1330·5 to 1511·1)
–31·0
(–34·8 to –27·1)*
Upper respiratory infections
2 661·2
(1 550·4 to 4 406·1)
2868·4
(1650·2 to 4785·2)
7·8
(5·2 to 9·7)*
40·1
(23·5 to 66·4)
38·7
(22·3 to 64·5)
–3·5
(–5·6 to –2·1)*
Otitis media
3444·4
(2276·8 to 5004·0)
3497·6
(2284·9 to 5088·5)
1·5
(–1·3 to 4·1)
50·9
(33·7 to 74·1)
47·3
(30·9 to 68·7)
–7·2
(–9·9 to –4·9)*
Meningitis
28 394·6
(24 170·2 to 32 237·2)
25 394·6
(21 653·2 to 30 649·0)
–10·6
(–20·1 to 3·8)
416·8
(355·2 to 471·9)
342·4
(292·3 to 412·8)
–17·8
(–26·4 to –4·6)*
Pneumococcal meningitis
7826·5
(6404·7 to 9672·3)
7773·4
(6353·4 to 9900·2)
–0·7
(–11·2 to 14·9)
115·3
(94·8 to 141·6)
104·9
(85·9 to 133·4)
–9·0
(–18·5 to 5·3)
Haemophilus infl
 uenzae type B 
meningitis
8507·6
(6656·5 to 10590·4)
5345·7
(4146·7 to 7103·2)
–37·2
(–45·8 to –25·0)*
123·3
(96·7 to 153·4)
71·9
(55·9 to 95·4)
–41·7
(–49·7 to –30·5)*
Meningococcal meningitis
5239·8
(4012·0 to 6704·3)
5065·6
(3879·5 to 6721·8)
–3·3
(–16·9 to 16·3)
76·6
(59·0 to 97·6)
68·2
(52·3 to 90·3)
–11·0
(–23·4 to 6·9)
Other meningitis
6820·7
(5665·6 to 8234·7)
7210·0
(5953·9 to 8958·4)
5·7
(–4·6 to 20·3)
101·7
(84·9 to 122·0)
97·4
(80·5 to 120·9)
–4·2
(–13·1 to 9·0)
Encephalitis
8850·1
(8064·3 to 9665·8)
8452·5
(7668·6 to 9411·6)
–4·5
(–11·6 to 2·9)
132·1
(120·8 to 144·2)
114·6
(104·0 to 127·6)
–13·2
(–19·7 to –6·8)*
Diphtheria
443·2
(229·3 to 905·0)
170·8
(83·4 to 388·7)
–61·5
(–86·1 to 3·5)
6·4
(3·3 to 13·1)
2·3
(1·1 to 5·2)
–64·2
(–87·1 to –3·7)*
Whooping cough
8559·1
(3269·5 to 19234·7)
5070·5
(1815·7 to 10791·8)
–40·8
(–77·3 to 62·2)
123·2
(47·0 to 276·7)
68·0
(24·3 to 144·7)
–44·8
(–78·8 to 51·2)
Tetanus
7213·2
(6251·3 to 9082·1)
3510·0
(3002·2 to 4502·9)
–51·3
(–58·0 to –43·8)*
105·1
(90·6 to 134·4)
47·1
(40·3 to 60·6)
–55·1
(–61·2 to –48·1)*
Measles
24 602·4
(9 272·8 to 51 178·0)
6150·1
(2193·1 to 13467·4)
–75·0
(–84·4 to –59·0)*
355·1
(133·9 to 738·2)
82·7
(29·5 to 181·1)
–76·7
(–85·5 to –61·8)*
Varicella and herpes zoster
616·0
(521·8 to 727·1)
491·2
(386·1 to 625·3)
–20·3
(–33·2 to –4·3)*
9·7
(8·2 to 11·5)
6·8
(5·3 to 8·6)
–29·9
(–40·6 to –16·7)*
(Table 1 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1609
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Neglected tropical diseases 
and malaria
116 583·6
(96 865·6 to 137 551·5)
79 212·2
(63 820·2 to 97 299·0)
–32·1
(–40·2 to 
–23·7)*
1710·8
(1422·4 to 2019·1)
1066·4
(859·1 to 1310·2)
–37·7
(–45·1 to –30·1)*
Malaria
90 438·1
(73 336·5 to 107 546·9)
55 769·6
(42 478·4 to 69 078·5)
–38·3
(–48·1 to –27·8)*
1315·8
(1067·0 to 1562·5)
749·3
(571·0 to 927·9)
–43·1
(–52·0 to –33·4)*
Chagas disease
243·6
(220·0 to 273·5)
236·1
(211·8 to 265·3)
–3·0
(–8·5 to 3·0)
4·4
(4·0 to 5·0)
3·4
(3·1 to 3·9)
–22·7
(–27·0 to –18·0)*
Leishmaniasis
1367·1
(878·4 to 1979·8)
1418·9
(1005·8 to 1913·8)
3·8
(–8·6 to 19·3)
20·1
(13·0 to 28·9)
18·9
(13·4 to 25·5)
–5·9
(–16·9 to 8·0)
Visceral leishmaniasis
1334·4
(844·9 to 1949·5)
1377·4
(965·4 to 1863·8)
3·2
(–9·2 to 19·1)
19·6
(12·4 to 28·5)
18·3
(12·9 to 24·8)
–6·3
(–17·4 to 7·9)
Cutaneous and 
mucocutaneous leishmaniasis
32·6
(15·2 to 63·3)
41·5
(19·4 to 81·0)
27·3
(23·6 to 30·6)*
0·5
(0·2 to 1·0)
0·6
(0·3 to 1·1)
11·4
(8·2 to 14·5)*
African trypanosomiasis
803·1
(425·6 to 1311·4)
202·4
(104·6 to 322·3)
–74·8
(–80·4 to –68·2)*
11·8
(6·3 to 19·3)
2·7
(1·4 to 4·3)
–77·2
(–82·3 to –71·3)*
Schistosomiasis
3417·7
(1883·7 to 6044·0)
2613·3
(1409·9 to 4695·8)
–23·5
(–30·6 to –6·7)*
51·1
(28·4 to 90·0)
35·1
(19·0 to 62·9)
–31·3
(–37·7 to –16·2)*
Cysticercosis
369·6
(260·6 to 489·8)
303·6
(211·4 to 410·9)
–17·9
(–22·7 to –13·5)*
5·9
(4·2 to 7·8)
4·1
(2·9 to 5·5)
–30·4
(–34·3 to –26·5)*
Cystic echinococcosis
174·1
(141·3 to 212·4)
172·6
(132·1 to 220·6)
–0·8
(–7·4 to 4·5)
2·8
(2·2 to 3·4)
2·4
(1·8 to 3·0)
–14·7
(–20·2 to –10·2)*
Lymphatic fi
 lariasis
2476·6
(1272·2 to 4008·8)
2075·0
(1120·5 to 3311·5)
–16·2
(–32·1 to –3·8)*
38·9
(20·0 to 63·1)
28·1
(15·2 to 44·9)
–27·7
(–41·5 to –17·0)*
Onchocerciasis
1441·6
(835·2 to 2288·7)
1135·7
(545·8 to 2005·7)
–21·2
(–38·6 to –4·8)*
22·5
(13·2 to 35·5)
15·5
(7·5 to 27·3)
–31·2
(–46·8 to –16·0)*
Trachoma
282·6
(194·3 to 396·1)
279·2
(192·5 to 396·2)
–1·2
(–5·6 to 3·0)
5·5
(3·8 to 7·7)
4·2
(2·9 to 5·9)
–23·9
(–27·6 to –20·3)*
Dengue
1132·8
(795·9 to 1616·2)
1892·2
(1266·7 to 2925·2)
67·0
(16·8 to 166·1)*
16·6
(11·7 to 23·8)
25·5
(17·1 to 39·5)
53·5
(7·3 to 144·1)*
Yellow fever
400·8
(83·3 to 1083·2)
329·8
(66·9 to 898·1)
–17·7
(–34·1 to 1·7)
5·8
(1·2 to 15·6)
4·4
(0·9 to 12·1)
–23·0
(–38·2 to –4·9)*
Rabies
1760·6
(1525·6 to 2019·8)
931·6
(779·2 to 1120·9)
–47·1
(–54·2 to –39·3)*
26·4
(23·0 to 30·2)
12·6
(10·6 to 15·2)
–52·1
(–58·6 to –45·2)*
Intestinal nematode infections
4404·5
(2719·6 to 6783·4)
3378·3
(2046·2 to 5294·5)
–23·3
(–27·4 to –18·2)*
65·8
(40·6 to 101·4)
45·6
(27·6 to 71·4)
–30·7
(–34·5 to –26·1)*
Ascariasis
1693·0
(1061·5 to 2610·7)
1075·4
(685·1 to 1660·9)
–36·5
(–43·1 to –29·5)*
25·2
(15·8 to 39·0)
14·5
(9·2 to 22·4)
–42·5
(–48·6 to –36·2)*
Trichuriasis
653·1
(357·9 to 1076·3)
544·1
(289·3 to 946·1)
–16·7
(–30·6 to 3·7)
9·8
(5·4 to 16·1)
7·3
(3·9 to 12·8)
–24·9
(–37·5 to –6·7)*
Hookworm disease
2058·4
(1275·6 to 3171·3)
1758·8
(1085·8 to 2755·1)
–14·6
(–19·9 to –9·4)*
30·8
(19·0 to 47·4)
23·7
(14·7 to 37·1)
–22·9
(–27·7 to –18·1)*
Food-borne trematodiases
1625·6
(793·1 to 3058·3)
1686·5
(855·0 to 3072·8)
3·7
(–0·5 to 10·1)
25·1
(12·3 to 47·0)
22·6
(11·5 to 41·0)
–10·0
(–13·5 to –5·2)*
Leprosy
30·8
(20·6 to 43·0)
31·0
(20·8 to 43·6)
0·6
(–1·5 to 2·9)
0·5
(0·4 to 0·8)
0·4
(0·3 to 0·6)
–19·2
(–20·8 to –17·4)*
Ebola virus disease
0·8
(0·7 to 1·0)
295·4
(238·3 to 353·8)
36 024·8
(36 010·3 to 
36 054·6)*
0·0
(0·0 to 0·0)
3·9
(3·2 to 4·7)
31 654·0
(31 640·5 to 
31 681·3)*
Other neglected tropical diseases
6213·6
(3655·0 to 11309·8)
6461·0
(3516·3 to 13769·5)
4·0
(–18·2 to 40·2)
91·8
(53·8 to 167·4)
87·6
(47·7 to 187·2)
–4·6
(–24·9 to 28·6)
Maternal disorders
20 797·1
(19 462·4 to 22 290·3)
16 282·0
(14 542·5 to 18 451·2)
–21·7
(–30·1 to –11·7)*
299·0
(279·8 to 320·7)
212·6
(189·9 to 240·9)
–28·9
(–36·5 to –19·8)*
Maternal haemorrhage
5614·4
(4 902·4 to 6 402·8)
4645·8
(3 769·9 to 5 636·8)
–17·3
(–28·9 to –4·6)*
81·1
(70·8 to 92·3)
60·7
(49·3 to 73·6)
–25·1
(–35·6 to –13·5)*
Maternal sepsis and other 
maternal infections
1443·1
(1195·4 to 1742·2)
1050·0
(792·7 to 1382·8)
–27·2
(–41·1 to –10·8)*
20·8
(17·3 to 25·1)
13·7
(10·4 to 18·0)
–34·1
(–46·8 to –19·0)*
(Table 1 continues on next page)
 Articles
1610 
www.thelancet.com   Vol 388   October 8, 2016
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Maternal hypertensive disorders
3939·7
(3391·5 to 4579·2)
2938·0
(2318·0 to 3698·5)
–25·4
(–35·9 to –13·2)*
56·1
(48·3 to 65·2)
38·3
(30·2 to 48·2)
–31·7
(–41·2 to –20·7)*
Maternal obstructed labour and 
uterine rupture
1905·3
(1592·5 to 2242·8)
1627·1
(1257·6 to 2025·1)
–14·6
(–25·4 to –2·4)*
27·7
(23·2 to 32·5)
21·2
(16·4 to 26·4)
–23·2
(–32·9 to –12·2)*
Maternal abortion  miscarriage  
and ectopic pregnancy
2366·6
(1992·0 to 2830·9)
1809·7
(1416·9 to 2283·6)
–23·5
(–34·2 to –12·1)*
34·0
(28·7 to 40·8)
23·6
(18·5 to 29·8)
–30·5
(–40·1 to –20·1)*
Indirect maternal deaths
2192·6
(1803·5 to 2621·7)
1744·2
(1299·7 to 2286·8)
–20·4
(–33·2 to –3·4)*
31·4
(25·9 to 37·5)
22·7
(17·0 to 29·8)
–27·6
(–39·0 to –11·9)*
Late maternal deaths
449·8
(295·7 to 652·2)
377·7
(244·8 to 562·2)
–16·0
(–26·8 to –2·6)*
6·5
(4·2 to 9·4)
4·9
(3·2 to 7·3)
–23·6
(–33·7 to –11·4)*
Maternal deaths aggravated by 
HIV/AIDS
149·9
(96·3 to 204·8)
122·1
(73·3 to 176·5)
–18·6
(–35·2 to 4·2)
2·2
(1·4 to 3·0)
1·6
(1·0 to 2·3)
–27·1
(–42·1 to –6·8)*
Other maternal disorders
2735·8
(2324·0 to 3245·0)
1967·5
(1578·3 to 2434·9)
–28·1
(–36·5 to –18·1)*
39·3
(33·4 to 46·6)
25·7
(20·6 to 31·7)
–34·7
(–42·4 to –26·1)*
Neonatal disorders
239 098·4
(232 872·7 to 246 048·9)
197 924·8
(191 388·9 to 204 751·8)
–17·2
(–19·2 to –15·4)*
3370·5
(3282·2 to 3468·1)
2638·3
(2551·0 to 2 729·5)
–21·7
(–23·6 to –20·0)*
Neonatal preterm birth 
complications
99 050·0
(92 118·6 to 110 250·8)
74 833·6
(68 500·3 to 83 015·4)
–24·4
(–29·6 to –19·2)*
1396·6
(1298·8 to 1554·2)
997·5
(913·1 to 1106·5)
–28·6
(–33·4 to –23·6)*
Neonatal encephalopathy due to 
birth asphyxia and trauma
79 423·6
(72 215·4 to 87 185·6)
67 856·5
(61 497·7 to 75 824·7)
–14·6
(–21·7 to –6·7)*
1118·8
(1017·3 to 1228·6)
904·4
(819·6 to 1010·5)
–19·2
(–26·0 to –11·7)*
Neonatal sepsis and other 
neonatal infections
30 510·1
(21 830·7 to 40 329·6)
30 454·5
(21 591·8 to 39 747·9)
–0·2
(–16·2 to 20·3)
429·6
(307·4 to 567·7)
406·0
(287·8 to 529·8)
–5·5
(–20·6 to 13·9)
Haemolytic disease and other 
neonatal jaundice
6427·0
(4234·6 to 9708·3)
4504·0
(3202·7 to 6420·6)
–29·9
(–44·1 to –13·6)*
90·9
(60·0 to 137·0)
60·1
(42·7 to 85·6)
–33·9
(–47·2 to –18·6)*
Other neonatal disorders
23 687·6
(17 420·2 to 30 795·3)
20 276·2
(15 531·0 to 25 385·9)
–14·4
(–32·8 to 7·1)
334·6
(246·3 to 434·7)
270·4
(207·1 to 338·5)
–19·2
(–36·6 to 1·1)
Nutritional defi
 ciencies
84 133·3
(65 215·4 to 108 480·6)
76 517·1
(58 781·9 to 100 939·6)
–9·1
(–15·2 to –3·5)*
1242·7
(964·9 to 1598·6)
1034·4
(795·9 to 1 363·6)
–16·8
(–22·4 to –11·7)*
Protein-energy malnutrition
26 655·2
(21 449·8 to 32 723·9)
21 094·0
(16 844·2 to 26 299·5)
–20·9
(–34·5 to –4·8)*
395·1
(319·4 to 484·0)
286·5
(228·9 to 356·6)
–27·5
(–39·8 to –13·0)*
Iodine defi
 ciency
2320·5
(1500·7 to 3422·1)
2476·4
(1592·8 to 3662·1)
6·7
(3·4 to 9·9)*
35·3
(22·8 to 52·1)
33·4
(21·5 to 49·4)
–5·2
(–8·4 to –2·4)*
Vitamin A defi
 ciency
209·5
(130·8 to 309·2)
232·4
(143·4 to 346·3)
10·9
(7·5 to 14·6)*
3·1
(2·0 to 4·6)
3·1
(1·9 to 4·7)
0·2
(–2·7 to 3·3)
Iron-defi
 ciency anaemia
52 951·3
(36 342·0 to 74 873·5)
51 217·1
(35 014·4 to 72 661·0)
–3·3
(–4·8 to –1·8)*
778·6
(534·8 to 1 099·4)
690·8
(472·4 to 979·6)
–11·3
(–12·7 to –10·0)*
Other nutritional defi
 ciencies
1996·8
(1378·4 to 2848·4)
1497·2
(1135·7 to 1983·7)
–25·0
(–43·3 to –9·4)*
30·5
(21·2 to 43·5)
20·5
(15·7 to 27·1)
–32·7
(–48·9 to –19·0)*
Other communicable, maternal, 
neonatal, and nutritional 
diseases
25 182·6
(20 002·2 to 31 397·3)
21 792·2
(17 474·0 to 26 922·3)
–13·5
(–18·6 to –7·8)*
373·1
(298·4 to 462·5)
293·8
(235·7 to 362·6)
–21·2
(–25·9 to –16·1)*
Sexually transmitted diseases 
excluding HIV
12 378·7
(7 831·6 to 18 396·6)
10 330·9
(6 583·0 to 15 315·1)
–16·5
(–24·2 to –8·6)*
178·7
(113·6 to 264·7)
138·1
(87·9 to 205·0)
–22·7
(–29·6 to –15·5)*
Syphilis
11 190·5
(6 607·1 to 17 280·8)
8957·1
(5273·2 to 13969·7)
–20·0
(–28·4 to –11·8)*
160·9
(95·4 to 247·9)
120·1
(70·8 to 187·2)
–25·4
(–33·3 to –17·7)*
Chlamydial infection
337·0
(194·2 to 537·7)
369·8
(214·0 to 595·4)
9·7
(6·5 to 13·0)*
4·9
(2·8 to 7·8)
4·8
(2·8 to 7·7)
–2·3
(–5·0 to 0·5)
Gonococcal infection
382·8
(238·6 to 573·0)
469·8
(283·4 to 716·8)
22·7
(15·9 to 28·1)*
5·6
(3·5 to 8·4)
6·1
(3·7 to 9·3)
8·8
(2·8 to 13·8)*
Trichomoniasis
167·4
(67·1 to 354·8)
194·3
(77·8 to 412·1)
16·1
(15·0 to 17·2)*
2·5
(1·0 to 5·4)
2·6
(1·0 to 5·4)
1·0
(0·3 to 1·8)*
Genital herpes
197·8
(61·5 to 468·3)
236·4
(74·3 to 555·8)
19·5
(17·4 to 23·0)*
3·2
(1·0 to 7·6)
3·2
(1·0 to 7·5)
0·7
(–1·5 to 5·2)
Other sexually transmitted 
diseases
103·2
(74·9 to 139·2)
103·5
(74·3 to 141·2)
0·3
(–3·1 to 3·2)
1·6
(1·1 to 2·1)
1·4
(1·0 to 1·9)
–13·2
(–16·1 to –10·6)*
(Table 1 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1611
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Hepatitis
6042·4
(5738·7 to 6344·8)
4925·3
(4634·8 to 5229·3)
–18·5
(–22·7 to –14·1)*
93·0
(88·6 to 97·5)
66·7
(62·8 to 70·8)
–28·3
(–31·9 to –24·6)*
Acute hepatitis A
1486·6
(1058·5 to 1896·9)
1030·3
(714·9 to 1335·9)
–30·7
(–39·7 to –20·8)*
21·5
(15·2 to 27·5)
13·8
(9·6 to 17·9)
–35·6
(–43·9 to –26·4)*
Hepatitis B
2693·5
(2298·5 to 3080·0)
2449·1
(2083·5 to 2799·2)
–9·1
(–15·4 to –2·0)*
44·0
(37·8 to 50·0)
33·4
(28·5 to 38·1)
–24·1
(–29·2 to –18·6)*
Hepatitis C
98·4
(26·2 to 220·4)
89·1
(25·5 to 201·9)
–9·5
(–23·3 to 7·6)
1·6
(0·4 to 3·7)
1·2
(0·3 to 2·8)
–25·9
(–37·5 to –11·0)*
Acute hepatitis E
1763·9
(1304·1 to 2265·3)
1356·8
(972·0 to 1794·4)
–23·1
(–31·6 to –14·0)*
25·9
(19·0 to 33·7)
18·3
(13·1 to 24·2)
–29·6
(–37·1 to –21·6)*
Other infectious diseases
6761·5
(4784·8 to 8106·7)
6536·0
(4527·7 to 7935·6)
–3·3
(–13·9 to 9·2)
101·3
(72·0 to 120·9)
89·0
(61·6 to 107·8)
–12·2
(–21·6 to –1·0)*
Non-communicable diseases
1 322 207·9
(1 181 179·7 to 
1 471 448·8)
1 473 508·2
(1 309 803·2 to 1 650 147·4)
11·4
(9·7 to 13·0)*
23 220·2
(20 898·5 to 
25 689·0)
21 062·4
(18 790·6 to 23 518·0)
–9·3
(–10·9 to –7·9)*
Neoplasms
187 562·1
(183 699·7 to 191 539·2)
209 359·2
(204 155·5 to 214 470·1)
11·6
(9·3 to 14·2)*
3424·3
(3356·2 to 3494·4)
3024·4
(2949·8 to 3098·9)
–11·7
(–13·4 to –9·7)*
Lip and oral cavity cancer
2954·1
(2866·9 to 3050·0)
3780·1
(3645·7 to 3928·9)
28·0
(23·9 to 32·6)*
53·7
(52·1 to 55·4)
53·7
(51·8 to 55·8)
0·1
(–3·1 to 3·7)
Nasopharynx cancer
1805·8
(1477·1 to 1912·4)
1911·7
(1562·1 to 2040·2)
5·9
(–2·2 to 12·4)
30·9
(25·4 to 32·7)
26·5
(21·6 to 28·2)
–14·3
(–20·6 to –9·0)*
Other pharynx cancer
1419·9
(1374·7 to 1468·8)
1715·7
(1635·4 to 1795·0)
20·8
(15·2 to 26·3)*
25·9
(25·1 to 26·8)
24·3
(23·2 to 25·4)
–6·3
(–10·7 to –2·1)*
Oesophageal cancer
10 665·4
(10 313·5 to 11 043·9)
9 854·4
(9 465·3 to 10 270·8)
–7·6
(–12·4 to –2·1)*
201·0
(194·5 to 207·8)
143·6
(137·9 to 149·5)
–28·6
(–32·2 to –24·4)*
Stomach cancer
18 665·9
(18 186·3 to 19 175·5)
17 439·6
(16 876·7 to 18 034·6)
–6·6
(–9·7 to –3·3)*
350·6
(341·9 to 360·0)
255·9
(247·9 to 264·5)
–27·0
(–29·4 to –24·5)*
Colon and rectum cancer
14 409·5
(14 108·0 to 14 779·0)
17 026·6
(16 586·7 to 17 504·7)
18·2
(15·7 to 20·9)*
274·0
(268·2 to 280·8)
251·3
(244·9 to 258·4)
–8·3
(–10·2 to –6·2)*
Liver cancer
19 643·6
(16 871·4 to 20 641·2)
20 578·0
(18 937·8 to 21 915·3)
4·8
(–1·4 to 15·5)
350·9
(302·8 to 368·5)
292·1
(269·1 to 311·0)
–16·8
(–21·4 to –8·7)*
Liver cancer due to hepatitis B
8420·5
(7092·2 to 9020·2)
8029·5
(7279·6 to 8795·5)
–4·6
(–11·2 to 8·2)
143·4
(121·3 to 153·7)
110·6
(100·4 to 121·2)
–22·9
(–27·9 to –12·9)*
Liver cancer due to hepatitis C
2897·4
(2607·7 to 3109·1)
3324·0
(3012·2 to 3573·6)
14·7
(10·3 to 20·2)*
55·5
(50·1 to 59·5)
49·3
(44·9 to 52·9)
–11·2
(–14·4 to –7·1)*
Liver cancer due to alcohol use
4786·9
(4075·0 to 5168·7)
5888·5
(5368·4 to 6441·0)
23·0
(14·8 to 36·1)*
89·2
(76·2 to 96·3)
84·8
(77·5 to 92·7)
–4·9
(–11·1 to 4·8)
Liver cancer due to other 
causes
3538·8
(3022·8 to 3829·6)
3336·0
(3019·1 to 3637·7)
–5·7
(–11·2 to 3·8)
62·9
(54·1 to 68·1)
47·4
(42·9 to 51·6)
–24·6
(–28·9 to –17·5)*
Gallbladder and biliary tract 
cancer
2448·7
(2359·2 to 2524·3)
2615·7
(2454·6 to 2740·8)
6·8
(2·2 to 11·6)*
47·3
(45·7 to 48·7)
39·0
(36·7 to 40·9)
–17·5
(–21·0 to –13·8)*
Pancreatic cancer
6528·1
(6433·9 to 6630·7)
8236·6
(8064·7 to 8420·0)
26·2
(23·3 to 29·0)*
125·2
(123·4 to 127·0)
121·8
(119·3 to 124·4)
–2·7
(–4·8 to –0·6)*
Larynx cancer
2364·1
(2290·8 to 2443·5)
2608·5
(2518·3 to 2705·0)
10·3
(7·1 to 13·9)*
44·0
(42·7 to 45·5)
37·6
(36·3 to 39·0)
–14·5
(–17·0 to –11·8)*
Tracheal, bronchus, and lung 
cancer
31 802·0
(31 117·2 to 32 516·2)
36 419·5
(35 356·6 to 37 615·6)
14·5
(11·0 to 19·1)*
604·5
(591·8 to 617·4)
535·9
(520·3 to 553·1)
–11·3
(–14·0 to –7·9)*
Malignant skin melanoma
1304·0
(1086·8 to 1655·2)
1596·3
(1293·4 to 1982·7)
22·4
(15·6 to 27·5)*
23·3
(19·4 to 29·6)
22·8
(18·4 to 28·3)
–2·3
(–7·7 to 1·7)
Non-melanoma skin cancer
794·3
(764·9 to 828·0)
1088·8
(1028·3 to 1150·1)
37·1
(32·0 to 41·9)*
15·2
(14·7 to 15·9)
16·3
(15·4 to 17·2)
6·8
(2·8 to 10·6)*
Non-melanoma skin cancer 
(squamous-cell carcinoma)
789·6
(761·2 to 822·3)
1082·9
(1025·0 to 1142·0)
37·1
(32·0 to 42·0)*
15·1
(14·6 to 15·8)
16·2
(15·3 to 17·1)
6·9
(2·9 to 10·6)*
Non-melanoma skin cancer 
(basal-cell carcinoma)
4·7
(2·2 to 8·7)
6·0
(2·8 to 11·1)
26·9
(23·4 to 30·2)*
0·1
(0·0 to 0·2)
0·1
(0·0 to 0·2)
–3·8
(–6·5 to –1·2)*
(Table 1 continues on next page)
 Articles
1612 
www.thelancet.com   Vol 388   October 8, 2016
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Breast cancer
12 939·2
(12 181·7 to 13 828·7)
15 410·6
(14 415·5 to 16 217·8)
19·1
(11·6 to 25·8)*
231·4
(218·3 to 246·9)
217·1
(203·2 to 228·7)
–6·2
(–11·9 to –1·1)*
Cervical cancer
6819·2
(6393·4 to 7236·4)
6963·0
(6526·2 to 7408·0)
2·1
(–4·5 to 10·5)
118·9
(111·8 to 126·1)
96·7
(90·7 to 102·7)
–18·7
(–23·9 to –12·2)*
Uterine cancer
2077·7
(1963·6 to 2201·8)
2230·7
(2098·3 to 2386·9)
7·4
(0·3 to 15·8)*
38·7
(36·6 to 40·9)
32·2
(30·3 to 34·5)
–16·6
(–22·0 to –10·1)*
Ovarian cancer
3496·3
(3401·0 to 3660·5)
4135·9
(3992·4 to 4298·0)
18·3
(13·4 to 23·1)*
63·2
(61·5 to 66·0)
58·6
(56·6 to 60·8)
–7·3
(–11·0 to –3·8)*
Prostate cancer
4793·4
(3992·1 to 6079·2)
6281·2
(5233·9 to 7904·2)
31·0
(26·9 to 35·2)*
100·0
(83·5 to 126·8)
99·6
(83·0 to 125·7)
–0·4
(–3·5 to 2·6)
Testicular cancer
411·3
(390·2 to 435·8)
442·6
(413·1 to 473·3)
7·6
(0·3 to 13·6)*
6·3
(6·0 to 6·7)
5·9
(5·5 to 6·3)
–6·4
(–12·6 to –1·2)*
Kidney cancer
2649·3
(2539·2 to 2779·3)
3340·3
(3189·6 to 3513·2)
26·1
(21·2 to 30·6)*
48·5
(46·8 to 50·6)
48·4
(46·2 to 50·8)
–0·3
(–3·8 to 3·0)
Bladder cancer
2832·7
(2754·6 to 2908·1)
3368·8
(3251·3 to 3496·5)
18·9
(15·4 to 22·4)*
56·3
(54·8 to 57·8)
51·3
(49·5 to 53·2)
–8·8
(–11·5 to –6·2)*
Brain and nervous system cancer
6738·3
(6079·6 to 7270·6)
7624·4
(6975·3 to 8218·8)
13·2
(5·0 to 21·0)*
111·4
(100·8 to 119·7)
105·6
(96·7 to 113·7)
–5·2
(–11·7 to 1·2)
Thyroid cancer
649·6
(605·3 to 707·6)
846·3
(754·1 to 929·0)
30·3
(19·2 to 37·4)*
12·1
(11·3 to 13·2)
12·4
(11·1 to 13·6)
2·2
(–6·2 to 7·8)
Mesothelioma
544·9
(529·2 to 560·6)
701·9
(678·8 to 722·2)
28·8
(24·3 to 33·3)*
10·1
(9·8 to 10·3)
10·3
(9·9 to 10·5)
2·0
(–1·5 to 5·4)
Hodgkin’s lymphoma
949·3
(837·3 to 1120·9)
845·6
(758·4 to 1031·7)
–10·9
(–14·9 to –6·7)*
15·5
(13·7 to 18·3)
11·6
(10·5 to 14·2)
–24·7
(–28·2 to –21·1)*
Non-Hodgkin lymphoma
5063·1
(4581·8 to 5581·3)
6283·8
(5449·8 to 6632·3)
24·1
(11·5 to 31·7)*
88·3
(79·7 to 96·6)
89·5
(77·5 to 94·3)
1·3
(–8·5 to 7·0)
Multiple myeloma
1694·3
(1646·6 to 1751·4)
2182·4
(2096·5 to 2255·8)
28·8
(23·8 to 33·2)*
32·2
(31·2 to 33·2)
32·1
(30·8 to 33·1)
–0·4
(–4·1 to 2·9)
Leukaemia
11 272·2
(10 956·3 to 11 683·7)
12 040·4
(11 609·8 to 12 499·3)
6·8
(2·9 to 10·5)*
181·6
(176·6 to 187·8)
167·7
(161·8 to 173·9)
–7·6
(–10·8 to –4·6)*
Acute lymphoid leukaemia
4857·0
(4505·3 to 5452·8)
5057·8
(4658·4 to 5507·7)
4·1
(–1·7 to 9·9)
73·6
(68·3 to 82·4)
69·1
(63·6 to 75·2)
–6·1
(–11·3 to –1·0)*
Chronic lymphoid leukaemia
1183·2
(1107·9 to 1256·6)
1268·6
(1194·2 to 1349·3)
7·2
(1·8 to 12·8)*
21·8
(20·5 to 23·1)
18·7
(17·7 to 19·9)
–14·1
(–18·3 to –10·0)*
Acute myeloid leukaemia
4199·7
(3770·1 to 4553·5)
4769·0
(4345·7 to 5193·7)
13·6
(8·2 to 18·5)*
68·5
(62·1 to 74·0)
66·6
(60·8 to 72·5)
–2·8
(–7·0 to 1·1)
Chronic myeloid leukaemia
1032·3
(957·8 to 1131·8)
945·1
(885·8 to 1032·9)
–8·5
(–12·3 to –3·8)*
17·7
(16·5 to 19·3)
13·3
(12·5 to 14·5)
–24·8
(–27·8 to –21·2)*
Other neoplasms
9825·9
(9023·1 to 10 351·7)
11 789·9
(10 528·0 to 12 616·2)
20·0
(13·4 to 25·7)*
163·3
(150·1 to 171·6)
164·6
(146·8 to 175·8)
0·8
(–4·5 to 5·5)
Cardiovascular diseases
326 252·4
(318 365·8 to 334 285·8)
347 528·9
(337 220·3 to 358 093·5)
6·5
(4·1 to 8·7)*
6231·9
(6086·8 to 6378·1)
5179·7
(5026·3 to 5334·2)
–16·9
(–18·7 to –15·3)*
Rheumatic heart disease
11 594·7
(10 668·9 to 12 707·4)
10 513·2
(9 611·0 to 11 514·5)
–9·3
(–13·3 to –5·7)*
193·6
(178·4 to 210·6)
146·6
(134·2 to 160·1)
–24·3
(–27·5 to –21·3)*
Ischaemic heart disease
147 780·0
(144 845·9 to 151 651·5)
164 020·4
(159 621·3 to 169 088·2)
11·0
(8·3 to 13·3)*
2860·0
(2805·1 to 2927·3)
2452·6
(2388·9 to 2526·8)
–14·2
(–16·2 to –12·5)*
Cerebrovascular disease
118 566·2
(115 776·1 to 121 419·2)
118 626·7
(114 862·4 to 122 627·0)
0·1
(–2·5 to 2·7)
2283·2
(2230·3 to 2335·8)
1776·6
(1721·1 to 1834·8)
–22·2
(–24·1 to –20·1)*
Ischaemic stroke
44 104·6
(42 363·3 to 45 822·3)
45 208·5
(43 150·2 to 47 386·8)
2·5
(–0·4 to 5·2)
903·6
(869·6 to 936·9)
706·2
(675·6 to 739·0)
–21·8
(–24·0 to –19·8)*
Haemorrhagic stroke
74 461·5
(72 176·9 to 76 874·3)
73 418·2
(70 737·2 to 76 596·4)
–1·4
(–4·6 to 2·1)
1379·6
(1337·6 to 1423·6)
1070·4
(1032·1 to 1116·3)
–22·4
(–25·0 to –19·6)*
Hypertensive heart disease
14 852·4
(13 919·4 to 16 052·6)
17 484·6
(16 286·9 to 18 593·6)
17·7
(11·6 to 22·9)*
286·5
(268·8 to 309·8)
262·2
(243·2 to 279·1)
–8·5
(–13·4 to –4·5)*
(Table 1 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1613
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Cardiomyopathy and 
myocarditis
9619·8
(9134·6 to 9993·7)
9220·3
(8765·6 to 9706·0)
–4·2
(–8·3 to –0·1)*
163·4
(155·8 to 169·5)
130·0
(123·7 to 136·7)
–20·5
(–23·7 to –17·2)*
Atrial fi
 brillation and fl
 utter
3463·2
(2764·5 to 4281·3)
4433·7
(3541·7 to 5489·1)
28·0
(26·6 to 29·3)*
73·8
(59·3 to 90·5)
70·6
(56·5 to 86·9)
–4·2
(–5·3 to –3·3)*
Aortic aneurysm
2468·0
(2403·2 to 2547·3)
2930·2
(2846·0 to 3007·0)
18·7
(12·9 to 22·6)*
47·6
(46·4 to 49·1)
43·8
(42·6 to 45·0)
–7·9
(–12·3 to –5·0)*
Peripheral vascular disease
913·0
(686·4 to 1279·3)
1198·8
(898·0 to 1682·6)
31·3
(27·7 to 35·2)*
19·3
(14·5 to 26·9)
19·1
(14·3 to 26·8)
–1·1
(–3·9 to 1·7)
Endocarditis
1962·3
(1616·0 to 2190·5)
2210·3
(1838·9 to 2421·3)
12·6
(6·3 to 18·8)*
33·0
(27·7 to 36·7)
31·2
(26·1 to 34·2)
–5·5
(–10·2 to –0·9)*
Other cardiovascular and 
circulatory diseases
15 032·7
(13 427·8 to 16 820·7)
16 890·7
(14 824·7 to 19 104·2)
12·4
(8·4 to 15·6)*
271·6
(243·4 to 303·7)
247·0
(217·2 to 279·2)
–9·0
(–12·1 to –6·5)*
Chronic respiratory diseases
97 356·3
(90 607·8 to 104 559·9)
97 451·8
(89 829·7 to 105 527·6)
0·1
(–2·4 to 2·6)
1802·0
(1694·4 to 1915·3)
1443·4
(1336·9 to 1556·8)
–19·9
(–22·2 to –17·8)*
Chronic obstructive pulmonary 
disease
63 773·8
(60 981·4 to 66 186·6)
63 850·4
(61 215·3 to 66 288·6)
0·1
(–3·1 to 3·8)
1246·9
(1195·2 to 1291·9)
971·1
(932·7 to 1 007·6)
–22·1
(–24·6 to –19·2)*
Pneumoconiosis
976·7
(816·2 to 1 168·6)
1 099·6
(902·7 to 1 314·7)
12·6
(6·9 to 18·9)*
17·8
(15·0 to 21·1)
16·0
(13·2 to 19·1)
–9·9
(–14·8 to –4·7)*
Silicosis
271·5
(240·1 to 308·1)
270·2
(235·8 to 310·1)
–0·5
(–10·1 to 11·5)
5·0
(4·5 to 5·7)
4·0
(3·5 to 4·5)
–21·3
(–28·7 to –12·0)*
Asbestosis
76·3
(63·0 to 87·9)
92·0
(75·3 to 107·2)
20·5
(13·7 to 27·8)*
1·4
(1·2 to 1·6)
1·4
(1·1 to 1·6)
–3·8
(–8·9 to 1·7)
Coal worker’s pneumoconiosis
59·7
(52·8 to 67·4)
57·5
(49·0 to 67·2)
–3·6
(–17·4 to 9·4)
1·2
(1·0 to 1·3)
0·9
(0·7 to 1·0)
–25·1
(–35·6 to –15·1)*
Other pneumoconiosis
569·3
(440·2 to 715·7)
680·0
(526·2 to 855·9)
19·5
(13·4 to 25·9)*
10·2
(8·0 to 12·7)
9·8
(7·6 to 12·3)
–3·4
(–9·0 to 2·3)
Asthma
26 859·7
(21 268·1 to 33 122·5)
26 168·8
(20 501·4 to 32 583·0)
–2·6
(–9·2 to 4·2)
439·8
(351·4 to 537·5)
365·6
(287·5 to 453·5)
–16·9
(–23·5 to –10·3)*
Interstitial lung disease and 
pulmonary sarcoidosis
1672·3
(1351·2 to 1954·1)
2352·6
(1933·8 to 2618·7)
40·7
(29·2 to 48·8)*
32·0
(25·7 to 37·2)
35·4
(28·9 to 39·3)
10·3
(1·5 to 16·7)*
Other chronic respiratory 
diseases
4073·7
(3295·2 to 4805·9)
3980·4
(3225·6 to 4569·7)
–2·3
(–11·0 to 7·3)
65·5
(53·3 to 76·6)
55·4
(44·9 to 63·5)
–15·3
(–22·4 to –7·5)*
Cirrhosis and other chronic liver 
diseases
37 101·5
(35 722·1 to 39 385·8)
38 973·3
(37 202·0 to 41 702·9)
5·0
(1·6 to 8·7)*
632·5
(609·4 to 669·2)
539·6
(515·4 to 576·8)
–14·7
(–17·4 to –11·8)*
Cirrhosis and other chronic liver 
diseases due to hepatitis B
10 297·6
(9 495·9 to 11 233·5)
10 754·7
(9 876·8 to 11 957·6)
4·4
(0·2 to 8·6)*
178·0
(164·1 to 194·8)
149·5
(137·3 to 165·9)
–16·0
(–19·2 to –12·7)*
Cirrhosis and other chronic liver 
diseases due to hepatitis C
8408·4
(7768·6 to 9069·5)
9161·7
(8443·3 to 9968·2)
9·0
(5·7 to 12·3)*
146·5
(135·6 to 157·9)
127·4
(117·6 to 138·4)
–13·0
(–15·6 to –10·4)*
Cirrhosis and other chronic liver 
diseases due to alcohol use
10 093·5
(9 424·0 to 10 841·4)
10 997·4
(10 197·4 to 11 875·1)
9·0
(5·0 to 13·7)*
171·9
(160·5 to 184·3)
150·7
(139·7 to 162·6)
–12·3
(–15·5 to –8·6)*
Cirrhosis and other chronic liver 
diseases due to other causes
8302·1
(7741·5 to 9165·9)
8059·5
(7452·2 to 8977·7)
–2·9
(–6·5 to 1·3)
136·1
(126·8 to 149·9)
112·0
(103·6 to 124·7)
–17·7
(–20·6 to –14·3)*
Digestive diseases
41 351·8
(37 701·8 to 45 778·3)
42 189·1
(38 101·1 to 47 087·5)
2·0
(–2·7 to 6·2)
716·3
(653·0 to 793·4)
600·3
(542·1 to 670·1)
–16·2
(–19·7 to –12·9)*
Peptic ulcer disease
10 164·0
(9220·6 to 11 279·2)
8894·4
(7950·0 to 10 039·2)
–12·5
(–17·7 to –5·9)*
180·8
(163·9 to 201·3)
128·5
(114·6 to 145·3)
–28·9
(–33·2 to –23·6)*
Gastritis and duodenitis
5757·0
(4331·9 to 7638·9)
6145·5
(4517·3 to 8251·9)
6·7
(2·5 to 11·1)*
100·9
(76·0 to 134·0)
87·8
(64·6 to 118·0)
–13·1
(–16·4 to –9·7)*
Appendicitis
2197·3
(1823·7 to 2661·6)
2015·9
(1631·6 to 2381·2)
–8·3
(–21·5 to 6·4)
34·4
(28·7 to 41·2)
27·6
(22·4 to 32·6)
–19·6
(–30·7 to –6·8)*
Paralytic ileus and intestinal 
obstruction
6957·0
(6123·4 to 8236·1)
7135·5
(6464·3 to 8502·6)
2·6
(–5·5 to 11·2)
117·3
(104·1 to 138·5)
100·7
(91·4 to 119·7)
–14·2
(–20·1 to –7·5)*
Inguinal  femoral  and abdominal 
hernia
1689·6
(1147·1 to 1996·2)
1645·7
(1089·7 to 1969·1)
–2·6
(–9·8 to 7·0)
29·2
(20·1 to 34·2)
23·4
(15·6 to 27·9)
–19·7
(–26·1 to –11·8)*
(Table 1 continues on next page)
 Articles
1614 
www.thelancet.com   Vol 388   October 8, 2016
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Infl
 ammatory bowel disease
3222·5
(2514·5 to 4041·9)
3588·0
(2797·3 to 4483·0)
11·3
(5·1 to 15·4)*
53·8
(42·3 to 67·1)
49·8
(39·0 to 62·0)
–7·5
(–12·2 to –4·3)*
Vascular intestinal disorders
1475·6
(1358·6 to 1619·3)
1741·6
(1607·3 to 1903·4)
18·0
(12·8 to 23·7)*
28·8
(26·6 to 31·5)
26·5
(24·5 to 28·8)
–8·2
(–12·2 to –3·9)*
Gallbladder and biliary diseases
2706·6
(2459·3 to 2994·3)
2878·7
(2597·4 to 3161·8)
6·4
(–0·2 to 11·9)
48·3
(44·1 to 53·0)
41·6
(37·6 to 45·6)
–13·8
(–18·7 to –9·6)*
Pancreatitis
3765·2
(3501·1 to 4071·3)
4373·2
(4000·1 to 4766·0)
16·1
(9·2 to 23·2)*
62·8
(58·5 to 67·8)
60·2
(55·1 to 65·5)
–4·1
(–9·6 to 1·6)
Other digestive diseases
3417·0
(2883·7 to 4228·0)
3770·5
(3180·0 to 4438·8)
10·3
(–0·1 to 22·2)
60·0
(51·0 to 73·9)
54·2
(45·9 to 63·7)
–9·7
(–18·0 to –0·4)*
Neurological disorders
74 456·9
(58 081·0 to 93 693·7)
87 082·1
(67 962·4 to 109 039·4)
17·0
(15·5 to 18·5)*
1291·0
(1025·5 to 1596·9)
1252·4
(987·9 to 1556·6)
–3·0
(–4·2 to –2·0)*
Alzheimer’s disease and other 
dementias
17 905·9
(15 147·4 to 20 849·2)
23 779·2
(20 118·0 to 27 886·0)
32·8
(31·2 to 34·4)*
409·6
(348·0 to 479·2)
395·6
(333·5 to 463·8)
–3·4
(–4·4 to –2·5)*
Parkinson’s disease
1548·9
(1381·7 to 1747·5)
2059·3
(1831·8 to 2320·9)
32·9
(29·7 to 35·7)*
32·8
(29·4 to 36·8)
33·1
(29·5 to 37·2)
1·1
(–1·3 to 3·1)
Epilepsy
12 892·1
(10 694·5 to 15 020·3)
12 417·9
(10 438·3 to 14 478·8)
–3·7
(–8·6 to 1·3)
194·1
(160·8 to 226·1)
167·6
(140·8 to 195·3)
–13·7
(–17·9 to –9·3)*
Multiple sclerosis
1076·7
(913·9 to 1248·8)
1233·7
(1033·4 to 1436·9)
14·6
(9·9 to 18·4)*
18·1
(15·4 to 21·0)
16·9
(14·2 to 19·7)
–6·6
(–10·3 to –3·6)*
Motor neuron disease
759·2
(728·7 to 806·3)
910·0
(872·2 to 958·5)
19·9
(13·6 to 23·2)*
13·6
(13·1 to 14·4)
13·1
(12·5 to 13·8)
–3·9
(–9·0 to –1·3)*
Migraine
28 538·7
(17 584·9 to 42 479·8)
32 898·8
(20 294·8 to 48 945·4)
15·3
(14·0 to 16·6)*
435·2
(268·4 to 647·8)
438·7
(271·0 to 653·8)
0·8
(–0·1 to 1·8)
Tension-type headache
1961·3
(915·9 to 3647·4)
2260·5
(1054·6 to 4193·3)
15·3
(14·0 to 16·7)*
30·0
(14·0 to 55·5)
30·2
(14·1 to 56·0)
0·6
(–0·1 to 1·3)
Medication overuse headache
7705·4
(5100·2 to 10997·3)
9164·7
(6089·3 to 13080·8)
18·9
(15·4 to 22·8)*
123·0
(82·3 to 175·3)
123·7
(82·2 to 177·0)
0·6
(–2·3 to 3·5)
Other neurological disorders
2070·4
(1941·6 to 2302·3)
2359·5
(2216·5 to 2565·4)
14·0
(9·4 to 17·5)*
34·6
(32·2 to 38·0)
33·6
(31·3 to 36·4)
–3·1
(–6·4 to –0·4)*
Mental and substance use 
disorders
141 375·1
(105 843·7 to 178 447·3)
162 442·3
(121 032·0 to 205 579·7)
14·9
(14·1 to 15·7)*
2189·2
(1646·0 to 2762·8)
2183·3
(1627·1 to 2766·3)
–0·3
(–1·0 to 0·3)
Schizophrenia
13 185·0
(9 635·3 to 16 203·0)
15 516·1
(11 279·2 to 19 137·0)
17·7
(16·5 to 18·8)*
210·4
(154·7 to 258·4)
207·5
(151·1 to 255·5)
–1·4
(–2·4 to –0·5)*
Alcohol use disorders
11 566·7
(9 617·6 to 13 834·9)
11 194·3
(9 136·5 to 13 870·9)
–3·2
(–7·0 to 0·6)
183·4
(153·5 to 218·3)
149·4
(122·1 to 184·8)
–18·5
(–22·0 to –15·1)*
Drug use disorders
13 671·4
(11 292·6 to 16 046·0)
16 909·5
(14 037·6 to 19 871·6)
23·7
(18·6 to 27·2)*
207·2
(171·5 to 242·7)
223·5
(185·8 to 262·2)
7·9
(3·5 to 10·9)*
Opioid use disorders
9864·0
(8127·4 to 11516·8)
12 068·1
(9 878·0 to 14 145·1)
22·3
(17·5 to 26·1)*
150·2
(123·7 to 175·3)
159·3
(130·7 to 186·6)
6·0
(1·8 to 9·2)*
Cocaine use disorders
729·3
(558·4 to 902·4)
999·3
(773·5 to 1 233·9)
37·0
(29·2 to 47·0)*
11·3
(8·7 to 14·0)
13·4
(10·4 to 16·6)
18·7
(12·1 to 27·3)*
Amphetamine use disorders
1001·3
(706·2 to 1348·3)
1402·6
(1025·2 to 1846·9)
40·1
(26·1 to 55·2)*
14·6
(10·4 to 19·6)
18·4
(13·5 to 24·2)
25·8
(13·3 to 39·4)*
Cannabis use disorders
548·1
(351·9 to 780·7)
577·2
(371·8 to 817·6)
5·3
(3·7 to 7·1)*
7·9
(5·0 to 11·2)
7·6
(4·9 to 10·7)
–3·7
(–5·0 to –2·3)*
Other drug use disorders
1528·7
(1245·5 to 1861·2)
1862·2
(1501·6 to 2274·2)
21·8
(15·7 to 27·5)*
23·1
(19·0 to 28·0)
24·8
(20·0 to 30·2)
7·1
(1·7 to 12·0)*
Depressive disorders
45 916·0
(31 684·6 to 61 591·2)
54 255·4
(37 513·6 to 72 968·9)
18·2
(17·2 to 19·2)*
726·9
(503·8 to 975·9)
734·2
(508·2 to 986·9)
1·0
(0·5 to 1·5)*
Major depressive disorder
37 544·8
(24 983·0 to 51 134·6)
44 224·4
(29 542·6 to 60 430·5)
17·8
(16·6 to 19·0)*
590·9
(395·0 to 804·5)
597·2
(399·6 to 816·6)
1·1
(0·5 to 1·7)*
Dysthymia
8 371·3
(5 537·6 to 11 983·7)
10 031·0
(6 604·4 to 14 289·3)
19·8
(18·3 to 21·5)*
136·1
(89·8 to 194·6)
137·0
(90·0 to 195·3)
0·7
(–0·2 to 1·6)
(Table 1 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1615
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Bipolar disorder
7838·8
(4787·8 to 11674·9)
9004·7
(5501·3 to 13396·4)
14·9
(13·9 to 15·9)*
119·0
(72·8 to 176·9)
119·6
(73·2 to 177·8)
0·5
(0·0 to 0·9)
Anxiety disorders
21 474·8
(14 666·7 to 29 339·6)
24 643·0
(16 799·8 to 33 714·1)
14·8
(12·8 to 16·6)*
329·2
(225·4 to 448·4)
332·4
(227·0 to 453·8)
1·0
(–0·4 to 2·3)
Eating disorders
1198·1
(806·7 to 1669·8)
1 421·7
(950·5 to 1 978·6)
18·7
(16·5 to 20·8)*
17·1
(11·5 to 23·7)
18·7
(12·5 to 26·0)
9·6
(7·7 to 11·4)*
Anorexia nervosa
584·9
(396·7 to 829·1)
653·0
(439·3 to 929·4)
11·7
(8·7 to 14·6)*
8·2
(5·6 to 11·6)
8·6
(5·8 to 12·2)
4·6
(1·8 to 7·4)*
Bulimia nervosa
613·3
(394·9 to 892·6)
768·7
(493·0 to 1113·8)
25·3
(23·2 to 27·6)*
8·8
(5·7 to 12·9)
10·1
(6·5 to 14·6)
14·2
(12·2 to 16·2)*
Autistic spectrum disorders
8949·8
(5978·1 to 12 300·4)
10 051·5
(6718·9 to 13 804·4)
12·3
(11·9 to 12·8)*
134·7
(90·1 to 185·0)
135·5
(90·6 to 186·0)
0·6
(0·2 to 0·9)*
Autism
5632·7
(3617·2 to 7920·0)
6335·9
(4070·1 to 8919·0)
12·5
(11·9 to 13·1)*
84·8
(54·5 to 119·2)
85·4
(54·9 to 120·3)
0·7
(0·2 to 1·2)*
Asperger syndrome and other 
autistic spectrum disorders
3317·1
(2204·2 to 4849·0)
3715·6
(2467·7 to 5435·2)
12·0
(11·5 to 12·5)*
49·9
(33·2 to 72·9)
50·1
(33·3 to 73·2)
0·3
(–0·1 to 0·7)
Attention-defi
 cit hyperactivity 
disorder
617·9
(368·9 to 946·0)
620·1
(369·8 to 948·7)
0·4
(–0·6 to 1·2)
8·6
(5·1 to 13·2)
8·3
(5·0 to 12·7)
–3·5
(–4·4 to –2·8)*
Conduct disorder
5740·5
(3459·2 to 8923·4)
5770·5
(3471·8 to 8956·9)
0·5
(–0·3 to 1·4)
78·2
(47·2 to 121·3)
79·3
(47·7 to 123·1)
1·4
(0·7 to 2·0)*
Idiopathic developmental 
intellectual disability
3119·9
(1386·3 to 5416·5)
3442·1
(1503·1 to 5999·6)
10·3
(8·2 to 11·4)*
46·0
(20·4 to 80·0)
46·2
(20·1 to 80·5)
0·2
(–1·5 to 1·2)
Other mental and substance use 
disorders
8095·9
(5632·9 to 10919·3)
9613·4
(6698·4 to 12966·0)
18·7
(17·7 to 19·8)*
128·4
(89·5 to 172·8)
128·8
(89·8 to 173·6)
0·3
(–0·6 to 1·1)
Diabetes, urogenital, blood, and 
endocrine diseases
122 917·1
(106 347·2 to 142 775·0)
146 780·6
(126 480·8 to 171 189·3)
19·4
(16·4 to 22·5)*
2123·6
(1847·2 to 2453·9)
2086·8
(1803·2 to 2422·8)
–1·7
(–4·0 to 0·6)
Diabetes mellitus
49 724·5
(41 868·2 to 58 982·1)
64 134·5
(53 489·7 to 76 112·8)
29·0
(26·2 to 31·7)*
911·2
(772·1 to 1 076·0)
925·8
(776·1 to 1 096·3)
1·6
(–0·5 to 3·7)
Acute glomerulonephritis
412·3
(321·1 to 459·3)
337·9
(228·4 to 378·2)
–18·1
(–31·7 to –10·4)*
6·9
(5·4 to 7·7)
4·8
(3·2 to 5·3)
–30·6
(–42·4 to –24·1)*
Chronic kidney disease
29 488·3
(26 950·4 to 31 604·2)
35 259·7
(32 008·1 to 37 763·0)
19·6
(16·0 to 23·2)*
524·4
(482·1 to 561·0)
508·8
(462·1 to 545·1)
–3·0
(–5·8 to –0·1)*
Chronic kidney disease due to 
diabetes mellitus
8713·0
(7991·5 to 9466·3)
11 258·0
(10 302·9 to 12 225·2)
29·2
(25·9 to 32·5)*
159·0
(146·2 to 172·6)
163·3
(149·6 to 177·1)
2·7
(0·2 to 5·3)*
Chronic kidney disease due to 
hypertension
10 366·1
(9 400·8 to 10 985·1)
12 737·4
(11 488·7 to 13 553·9)
22·9
(18·6 to 27·4)*
188·4
(172·1 to 199·7)
186·1
(168·1 to 197·9)
–1·2
(–4·6 to 2·3)
Chronic kidney disease due to 
glomerulonephritis
7720·0
(6930·5 to 8332·1)
8136·0
(7294·2 to 8861·4)
5·4
(1·3 to 9·3)*
130·7
(117·3 to 140·8)
114·6
(103·0 to 124·6)
–12·3
(–15·6 to –9·0)*
Chronic kidney disease due to 
other causes
2689·3
(2208·6 to 3237·9)
3128·3
(2517·9 to 3802·9)
16·3
(13·1 to 19·2)*
46·3
(37·7 to 55·8)
44·7
(36·0 to 54·1)
–3·4
(–5·6 to –1·5)*
Urinary diseases and male 
infertility
7958·9
(6720·4 to 9447·1)
9653·3
(8096·4 to 11537·2)
21·3
(17·2 to 24·8)*
147·3
(123·4 to 175·7)
142·5
(119·0 to 170·6)
–3·3
(–6·3 to –0·5)*
Interstitial nephritis and 
urinary tract infections
3399·6
(3134·3 to 3743·4)
3950·3
(3625·0 to 4408·2)
16·2
(11·4 to 21·5)*
60·6
(56·1 to 66·3)
57·6
(52·8 to 63·9)
–5·0
(–9·0 to –0·3)*
Urolithiasis
448·5
(382·6 to 535·4)
456·1
(398·9 to 568·2)
1·7
(–4·7 to 10·8)
7·9
(6·7 to 9·4)
6·5
(5·7 to 8·1)
–17·3
(–22·5 to –9·6)*
Benign prostatic hyperplasia
2922·0
(1867·0 to 4187·6)
3792·7
(2419·5 to 5453·5)
29·8
(27·6 to 32·2)*
58·6
(37·5 to 84·1)
57·9
(37·1 to 82·9)
–1·3
(–2·8 to 0·3)
Male infertility
141·8
(57·7 to 293·6)
173·9
(69·7 to 365·9)
22·7
(19·2 to 25·9)*
2·1
(0·8 to 4·3)
2·3
(0·9 to 4·8)
9·8
(6·9 to 12·5)*
Other urinary diseases
1047·1
(861·6 to 1213·3)
1280·2
(1044·9 to 1424·5)
22·3
(10·3 to 36·4)*
18·2
(15·1 to 21·1)
18·2
(14·9 to 20·2)
0·2
(–9·9 to 11·5)
Gynaecological diseases
9292·8
(6396·3 to 13190·5)
10 255·1
(7 041·0 to 14 603·3)
10·4
(9·0 to 11·7)*
140·3
(96·5 to 199·6)
134·9
(92·6 to 192·2)
–3·8
(–4·9 to –2·8)*
(Table 1 continues on next page)
 Articles
1616 
www.thelancet.com   Vol 388   October 8, 2016
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Uterine fi
 broids
2212·2
(1393·2 to 3481·1)
2452·6
(1514·9 to 3914·8)
10·9
(8·3 to 13·1)*
34·6
(21·7 to 54·4)
32·4
(20·0 to 51·8)
–6·1
(–8·1 to –4·4)*
Polycystic ovarian syndrome
514·7
(245·2 to 972·0)
560·0
(263·4 to 1068·1)
8·8
(4·8 to 10·9)*
7·5
(3·6 to 14·2)
7·4
(3·5 to 14·0)
–2·6
(–6·5 to –0·6)*
Female infertility
275·6
(106·1 to 606·6)
344·5
(133·4 to 748·2)
25·0
(19·7 to 30·1)*
4·0
(1·6 to 8·9)
4·5
(1·7 to 9·8)
11·7
(7·2 to 16·2)*
Endometriosis
894·2
(580·2 to 1240·9)
999·0
(649·1 to 1390·3)
11·7
(10·4 to 12·9)*
13·4
(8·7 to 18·6)
13·0
(8·5 to 18·2)
–2·4
(–3·4 to –1·5)*
Genital prolapse
449·1
(228·1 to 794·4)
519·3
(258·8 to 921·5)
15·6
(11·7 to 18·4)*
8·0
(4·1 to 14·0)
7·3
(3·6 to 12·9)
–8·4
(–11·8 to –5·9)*
Premenstrual syndrome
3287·8
(2048·5 to 4917·5)
3621·6
(2248·2 to 5435·6)
10·2
(8·0 to 12·0)*
48·3
(30·1 to 72·2)
47·3
(29·4 to 71·0)
–2·0
(–3·9 to –0·4)*
Other gynaecological diseases
1659·3
(1213·1 to 2208·2)
1758·0
(1278·9 to 2342·6)
6·0
(4·0 to 8·1)*
24·6
(18·0 to 32·6)
23·0
(16·8 to 30·6)
–6·3
(–8·1 to –4·5)*
Haemoglobinopathies and 
haemolytic anaemias
20 211·2
(16 303·9 to 25 551·6)
20 604·4
(16 002·3 to 27 392·4)
1·9
(–11·4 to 19·6)
301·0
(243·6 to 378·6)
279·3
(217·4 to 370·5)
–7·2
(–18·9 to 8·7)
Thalassaemias
1366·6
(1131·0 to 1683·8)
1034·6
(839·9 to 1272·9)
–24·3
(–39·0 to –2·4)*
19·8
(16·4 to 24·3)
14·0
(11·4 to 17·2)
–29·0
(–42·6 to –9·0)*
Thalassaemias trait
3696·4
(2473·4 to 5333·5)
3922·2
(2605·5 to 5657·2)
6·1
(4·8 to 7·4)*
55·2
(36·9 to 79·6)
53·2
(35·3 to 76·7)
–3·6
(–4·7 to –2·6)*
Sickle cell disorders
8662·7
(6150·3 to 13061·9)
8973·8
(5936·8 to 14752·8)
3·6
(–23·4 to 40·6)
124·4
(88·4 to 187·0)
120·3
(79·7 to 197·7)
–3·3
(–28·4 to 31·4)
Sickle cell trait
1552·9
(1049·6 to 2211·1)
1720·3
(1153·9 to 2463·9)
10·8
(7·3 to 13·4)*
23·0
(15·5 to 32·7)
23·3
(15·6 to 33·4)
1·4
(–1·9 to 3·6)
G6PD defi
 ciency
1284·4
(1105·7 to 1525·4)
1440·5
(1225·4 to 1706·3)
12·1
(5·3 to 21·5)*
19·8
(17·0 to 23·4)
19·3
(16·4 to 22·9)
–2·4
(–8·4 to 5·3)
G6PD trait
26·9
(18·4 to 37·1)
28·0
(19·2 to 38·9)
4·3
(0·1 to 8·8)*
0·4
(0·3 to 0·6)
0·4
(0·3 to 0·5)
–5·3
(–9·0 to –1·2)*
Other haemoglobinopathies 
and haemolytic anaemias
3621·4
(2874·6 to 4634·1)
3485·1
(2770·9 to 4426·5)
–3·8
(–6·2 to –1·0)*
58·5
(47·2 to 73·7)
48·8
(39·1 to 61·7)
–16·5
(–19·2 to –13·8)*
Endocrine, metabolic, blood, 
and immune disorders
5829·0
(5157·9 to 6691·1)
6535·7
(5812·5 to 7435·2)
12·1
(7·6 to 17·0)*
92·6
(82·5 to 105·6)
90·7
(80·9 to 103·0)
–2·1
(–5·8 to 1·7)
Musculoskeletal disorders
123 801·0
(90 494·0 to 163 616·5)
148 986·5
(108 880·7 to 197 118·2)
20·3
(19·4 to 21·3)*
2082·9
(1530·5 to 2750·7)
2065·1
(1510·9 to 2730·7)
–0·9
(–1·5 to –0·2)*
Rheumatoid arthritis
5204·7
(3777·3 to 6833·5)
6333·4
(4574·6 to 8332·9)
21·7
(18·7 to 24·7)*
90·9
(66·3 to 118·9)
89·7
(65·0 to 117·6)
–1·3
(–3·6 to 1·2)
Osteoarthritis
9562·5
(6666·3 to 13 106·3)
12 886·2
(8 990·3 to 17 634·2)
34·8
(33·6 to 36·0)*
180·4
(125·9 to 247·2)
187·4
(130·8 to 256·4)
3·9
(3·0 to 4·8)*
Low back and neck pain
80 053·5
(57 147·1 to 108 282·6)
94 941·5
(67 745·5 to 128 118·6)
18·6
(17·6 to 19·6)*
1337·3
(958·3 to 1802·5)
1309·7
(936·1 to 1765·1)
–2·1
(–2·7 to –1·4)*
Low back pain
51 243·0
(36 375·0 to 70 714·6)
60 074·8
(42 682·1 to 82 419·2)
17·2
(16·4 to 18·1)*
852·0
(605·3 to 1 176·4)
829·5
(589·2 to 1 138·3)
–2·6
(–3·2 to –2·0)*
Neck pain
28 810·5
(19 224·7 to 39 466·1)
34 866·7
(23 343·7 to 47 754·3)
21·0
(18·9 to 23·2)*
485·3
(327·2 to 662·1)
480·2
(322·0 to 653·6)
–1·1
(–2·3 to 0·1)
Gout
1063·1
(719·2 to 1451·4)
1342·8
(908·5 to 1843·8)
26·3
(24·6 to 28·0)*
18·9
(12·9 to 25·8)
19·0
(12·9 to 26·1)
0·6
(–0·3 to 1·5)
Other musculoskeletal disorders
27 917·2
(19 404·3 to 38 408·8)
33 482·6
(23 135·4 to 45 865·5)
19·9
(16·7 to 23·0)*
455·4
(316·9 to 623·9)
459·2
(318·0 to 630·7)
0·8
(–1·5 to 3·2)
Other non-communicable 
diseases
170 032·0
(132 096·5 to 221 007·5)
192 712·9
(148 719·0 to 251 205·4)
13·3
(7·1 to 16·9)*
2726·4
(2098·4 to 3558·8)
2687·2
(2068·1 to 3508·3)
–1·4
(–6·1 to 1·4)
Congenital anomalies
57 594·6
(49 489·5 to 69 397·4)
58 355·3
(52 597·9 to 64 983·3)
1·3
(–12·2 to 11·2)
826·5
(711·2 to 994·5)
781·1
(704·2 to 869·9)
–5·5
(–17·9 to 3·5)
Neural tube defects
6925·7
(5218·4 to 9487·8)
5981·2
(4589·5 to 7574·7)
–13·6
(–32·7 to 5·7)
98·3
(74·1 to 134·8)
79·9
(61·3 to 101·2)
–18·8
(–36·7 to –0·6)*
Congenital heart anomalies
26 778·2
(22 186·7 to 31 821·1)
25 706·4
(22 612·9 to 28 639·2)
–4·0
(–18·1 to 7·6)
382·7
(316·9 to 454·7)
343·9
(302·5 to 383·1)
–10·2
(–23·3 to 0·4)
(Table 1 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1617
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Cleft lip and cleft palate
355·3
(288·5 to 424·1)
196·0
(150·8 to 259·3)
–44·8
(–54·9 to –33·7)*
5·1
(4·1 to 6·1)
2·6
(2·0 to 3·5)
–48·3
(–57·6 to –38·1)*
Down’s syndrome
2379·1
(1571·3 to 3712·7)
2 401·1
(1 739·7 to 3 291·8)
0·9
(–23·2 to 29·4)
34·8
(23·1 to 53·9)
32·2
(23·3 to 44·0)
–7·5
(–29·2 to 17·8)
Turner’s syndrome
6·0
(2·1 to 12·9)
6·6
(2·4 to 14·4)
11·4
(8·7 to 14·0)*
0·1
(0·0 to 0·2)
0·1
(0·0 to 0·2)
–0·1
(–2·4 to 2·3)
Klinefelter’s syndrome
1·2
(0·4 to 2·8)
1·3
(0·5 to 3·2)
13·5
(10·6 to 15·6)*
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
0·2
(–2·2 to 2·0)
Other chromosomal 
abnormalities
2110·0
(1124·3 to 4575·8)
2354·5
(1418·6 to 3905·9)
11·6
(–19·2 to 35·1)
30·4
(16·4 to 65·4)
31·5
(19·0 to 52·2)
3·6
(–24·3 to 25·0)
Other congenital anomalies
19 039·2
(16 026·4 to 23 290·1)
21 708·1
(18 750·6 to 25 714·7)
14·0
(0·3 to 26·3)*
275·0
(231·4 to 336·5)
291·0
(251·2 to 344·6)
5·8
(–6·6 to 16·7)
Skin and subcutaneous diseases
42 069·1
(27 826·1 to 62 299·6)
47 222·7
(31 372·1 to 69 571·8)
12·3
(11·5 to 13·2)*
639·6
(426·1 to 942·5)
643·4
(428·2 to 946·7)
0·6
(0·1 to 1·2)*
Dermatitis
7733·8
(5244·5 to 10760·5)
8788·0
(5957·2 to 12275·5)
13·6
(12·9 to 14·4)*
117·8
(80·2 to 164·1)
119·7
(81·3 to 166·6)
1·6
(1·0 to 2·2)*
Psoriasis
5478·8
(3816·1 to 7443·3)
6438·3
(4487·4 to 8755·9)
17·5
(16·6 to 18·4)*
87·4
(60·9 to 118·7)
87·9
(61·3 to 119·5)
0·6
(0·0 to 1·2)
Cellulitis
406·1
(251·0 to 550·4)
498·2
(315·1 to 692·8)
22·7
(11·9 to 34·6)*
6·9
(4·3 to 9·4)
7·0
(4·5 to 9·8)
1·6
(–7·4 to 11·6)
Pyoderma
1070·5
(714·3 to 1585·5)
1361·7
(932·3 to 2020·6)
27·2
(17·0 to 38·8)*
17·5
(11·7 to 25·6)
19·1
(13·1 to 28·2)
9·2
(0·6 to 18·9)*
Scabies
4944·3
(2786·4 to 8050·4)
5268·9
(2947·0 to 8616·4)
6·6
(3·8 to 9·5)*
73·0
(41·2 to 118·8)
71·1
(39·8 to 116·0)
–2·5
(–4·5 to –0·5)*
Fungal skin diseases
2457·6
(976·3 to 5214·9)
2783·3
(1101·3 to 5914·6)
13·3
(12·4 to 14·1)*
37·2
(14·7 to 79·0)
37·8
(15·0 to 80·3)
1·7
(1·4 to 2·0)*
Viral skin diseases
4977·3
(3147·1 to 7362·6)
5396·9
(3412·0 to 7962·7)
8·4
(7·9 to 9·0)*
73·7
(46·7 to 109·3)
73·0
(46·2 to 107·9)
–1·0
(–1·4 to –0·6)*
Acne vulgaris
6553·4
(3137·7 to 12159·0)
6854·0
(3271·3 to 12744·4)
4·6
(3·5 to 5·7)*
91·1
(43·7 to 169·0)
91·9
(43·9 to 171·0)
0·8
(–0·1 to 1·8)
Alopecia areata
610·5
(376·1 to 911·7)
695·6
(427·5 to 1035·9)
13·9
(13·1 to 14·7)*
9·4
(5·8 to 14·0)
9·3
(5·7 to 13·8)
–1·0
(–1·7 to –0·4)*
Pruritus
631·4
(306·3 to 1152·1)
741·6
(359·8 to 1349·6)
17·5
(15·5 to 19·4)*
10·1
(4·9 to 18·5)
10·2
(4·9 to 18·6)
0·5
(–0·7 to 1·7)
Urticaria
3718·5
(2297·3 to 5286·3)
4115·7
(2560·6 to 5836·2)
10·7
(9·5 to 12·0)*
55·5
(34·5 to 78·7)
55·5
(34·6 to 78·7)
0·0
(–0·5 to 0·4)
Decubitus ulcer
494·1
(328·7 to 602·5)
609·1
(415·1 to 738·7)
23·3
(17·3 to 33·2)*
9·8
(6·5 to 11·9)
9·4
(6·4 to 11·3)
–4·3
(–8·9 to 3·7)*
Other skin and subcutaneous 
diseases
2992·7
(1486·8 to 5413·5)
3671·3
(1817·7 to 6638·7)
22·7
(21·9 to 23·5)*
50·2
(24·9 to 90·8)
51·5
(25·5 to 93·2)
2·6
(2·1 to 3·3)*
Sense organ diseases
54 708·4
(38 076·6 to 75 346·3)
68 515·2
(47 752·5 to 94 246·6)
25·2
(24·2 to 26·4)*
993·6
(694·9 to 1 361·8)
999·9
(697·1 to 1 370·3)
0·6
(–0·1 to 1·3)
Glaucoma
388·4
(268·1 to 538·9)
541·3
(369·5 to 748·0)
39·4
(37·0 to 41·9)*
8·0
(5·5 to 11·2)
8·4
(5·7 to 11·6)
4·3
(2·6 to 5·8)*
Cataract
3091·3
(2213·8 to 4152·6)
3879·7
(2766·1 to 5232·4)
25·5
(24·1 to 26·9)*
62·9
(45·1 to 84·3)
60·3
(43·0 to 81·0)
–4·2
(–5·2 to –3·2)*
Macular degeneration
313·2
(219·5 to 429·6)
462·4
(327·4 to 633·5)
47·7
(45·2 to 49·9)*
6·9
(4·9 to 9·5)
7·4
(5·2 to 10·1)
6·9
(5·3 to 8·6)*
Refraction and 
accommodation disorders
12 046·9
(7737·6 to 18 905·4)
14 593·8
(9388·5 to 22 942·4)
21·1
(20·2 to 22·1)*
207·8
(133·9 to 326·0)
207·3
(133·7 to 324·8)
–0·3
(–0·9 to 0·4)
Age-related and other hearing 
loss
32 119·0
(21 992·4 to 44 438·1)
40 596·8
(27 842·2 to 56 168·9)
26·4
(24·6 to 28·3)*
589·4
(405·6 to 817·1)
595·9
(409·6 to 825·0)
1·1
(0·0 to 2·1)
Other vision loss
1352·0
(957·1 to 1852·2)
1756·4
(1247·4 to 2393·6)
29·9
(27·8 to 32·1)*
23·9
(17·0 to 32·5)
25·2
(17·9 to 34·1)
5·6
(4·3 to 6·7)*
Other sense organ diseases
5397·7
(3358·7 to 7841·8)
6684·7
(4178·4 to 9722·8)
23·8
(22·9 to 24·8)*
94·7
(59·3 to 137·2)
95·5
(59·9 to 138·6)
0·9
(0·2 to 1·5)*
(Table 1 continues on next page)
 Articles
1618 
www.thelancet.com   Vol 388   October 8, 2016
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Oral disorders
13 868·2
(8387·2 to 21 285·6)
16 969·6
(10 280·0 to 26 059·7)
22·4
(21·6 to 23·2)*
241·3
(147·2 to 367·9)
240·8
(146·9 to 367·8)
–0·2
(–0·5 to 0·1)
Deciduous caries
141·4
(61·3 to 279·6)
147·2
(62·8 to 292·3)
4·1
(1·6 to 5·9)*
2·1
(0·9 to 4·1)
2·0
(0·9 to 4·0)
–2·7
(–4·9 to –0·8)*
Permanent caries
1536·3
(681·5 to 2960·1)
1743·4
(773·5 to 3358·0)
13·5
(12·6 to 14·4)*
23·7
(10·5 to 45·7)
23·6
(10·5 to 45·5)
–0·4
(–1·2 to 0·4)
Periodontal diseases
2808·4
(1084·9 to 5841·7)
3520·7
(1357·6 to 7337·3)
25·4
(24·1 to 26·5)*
48·0
(18·6 to 100·0)
48·6
(18·8 to 101·2)
1·2
(0·6 to 1·8)*
Edentulism and severe tooth 
loss
5999·5
(4012·3 to 8293·2)
7640·3
(5092·8 to 10572·8)
27·3
(26·9 to 27·7)*
114·6
(76·7 to 158·5)
113·6
(76·0 to 157·3)
–0·8
(–1·1 to –0·6)*
Other oral disorders
3382·7
(2093·2 to 5085·7)
3918·1
(2423·4 to 5894·1)
15·8
(15·3 to 16·4)*
53·0
(32·8 to 79·5)
53·0
(32·8 to 79·6)
0·0
(–0·2 to 0·3)
Sudden infant death syndrome
1791·7
(1458·5 to 2904·4)
1650·1
(1366·4 to 2367·7)
–7·9
(–23·0 to 8·9)
25·5
(20·7 to 41·3)
22·0
(18·2 to 31·6)
–13·5
(–27·7 to 2·3)
Injuries
263 084·3
(245 566·5 to 278 621·5)
249 791·3
(231 409·2 to 266 419·2)
–5·1
(–8·5 to –0·9)*
4044·0
(3764·8 to 4300·1)
3376·1
(3120·8 to 3607·0)
–16·5
(–19·4 to –13·0)*
Transport injuries
77 146·4
(73 768·7 to 80 734·9)
72 365·5
(68 372·4 to 76 237·9)
–6·2
(–11·1 to –1·8)*
1175·5
(1121·9 to 1231·3)
971·4
(917·0 to 1024·0)
–17·4
(–21·6 to –13·5)*
Road injuries
71 941·1
(68 596·1 to 75 312·5)
67 270·4
(63 538·6 to 70 859·9)
–6·5
(–11·4 to –2·2)*
1095·3
(1042·8 to 1145·8)
903·0
(854·0 to 951·5)
–17·6
(–21·8 to –13·8)*
Pedestrian road injuries
27 185·9
(25 567·5 to 29 487·1)
24 491·1
(22 747·9 to 26 770·6)
–9·9
(–16·4 to –3·8)*
417·2
(392·7 to 452·1)
330·1
(307·3 to 360·7)
–20·9
(–26·5 to –15·5)*
Cyclist road injuries
3721·2
(3357·8 to 4119·6)
3399·8
(3022·9 to 3807·0)
–8·6
(–15·1 to –2·1)*
58·5
(52·7 to 65·1)
46·3
(41·1 to 52·0)
–20·9
(–26·3 to –15·4)*
Motorcyclist road injuries
13 655·4
(12 181·3 to 14 651·4)
13 686·2
(12 440·3 to 15 369·7)
0·2
(–7·8 to 10·6)
204·9
(182·3 to 219·9)
182·4
(165·7 to 204·3)
–10·9
(–17·9 to –1·7)*
Motor vehicle road injuries
26 257·7
(24 307·0 to 28 943·8)
24 460·3
(22 362·4 to 26 719·4)
–6·8
(–11·6 to –1·8)*
397·6
(368·7 to 437·0)
327·5
(299·3 to 357·3)
–17·6
(–21·8 to –13·2)*
Other road injuries
1120·9
(782·6 to 1331·6)
1233·1
(858·6 to 1446·6)
10·0
(–5·2 to 31·3)
17·1
(12·1 to 20·2)
16·6
(11·6 to 19·4)
–2·9
(–16·0 to 15·4)
Other transport injuries
5205·3
(4772·9 to 5728·4)
5095·1
(4507·0 to 5967·9)
–2·1
(–10·5 to 7·5)
80·2
(73·6 to 88·4)
68·4
(60·6 to 80·2)
–14·7
(–21·8 to –6·7)*
Unintentional injuries
118 001·9 
(105 534·5 to 129 998·5)
107 990·9
(95 660·4 to 120 900·3)
–8·5 
(–11·9 to –3·4)*
1840·5
(1642·4 to 2033·1)
1481·0
(1310·3 to 1660·5)
–19·5 (–22·2 
to –15·3)*
Falls
23 912·3
(20 767·3 to 27 587·9)
26 101·6
(22 363·6 to 30 779·5)
9·2
(3·6 to 14·6)*
403·3
(349·6 to 467·0)
368·3
(315·1 to 435·0)
–8·7
(–13·1 to –4·4)*
Drowning
24 207·3
(20 715·5 to 25 812·8)
17 864·3
(15 792·7 to 19 306·8)
–26·2
(–30·6 to –20·0)*
356·2
(305·1 to 379·5)
241·1
(213·0 to 260·6)
–32·3
(–36·3 to –26·7)*
Fire, heat, and hot substances
11 737·6
(9 928·4 to 12 948·0)
10 274·1
(8 701·9 to 11 443·4)
–12·5
(–17·4 to –5·1)*
179·7
(153·4 to 198·0)
139·0
(117·7 to 155·0)
–22·6
(–26·8 to –16·6)*
Poisonings
5746·4
(3978·7 to 7215·7)
4866·9
(3240·1 to 6070·3)
–15·3
(–28·9 to 3·6)
86·6
(60·4 to 107·8)
65·5
(43·6 to 81·5)
–24·4
(–36·0 to –7·5)*
Exposure to mechanical forces
13 753·4
(12 020·2 to 15 236·7)
13 118·4
(10 878·2 to 14 847·6)
–4·6
(–11·8 to 1·7)
210·2
(183·6 to 234·3)
177·4
(146·9 to 201·3)
–15·6
(–21·7 to –10·2)*
Unintentional fi
 rearm injuries
1655·9
(1188·2 to 1837·5)
1546·4
(1101·5 to 1727·2)
–6·6
(–11·9 to –0·6)*
24·9
(18·0 to 27·6)
20·7
(14·8 to 23·1)
–16·8
(–21·4 to –11·8)*
Unintentional suff
 ocation
2647·9
(2075·2 to 3023·5)
2495·6
(1885·3 to 2883·4)
–5·8
(–17·6 to 7·8)
39·3
(30·8 to 44·8)
33·9
(25·7 to 39·1)
–13·7
(–24·3 to –1·8)*
Other exposure to mechanical 
forces
9449·6
(8051·7 to 10717·9)
9076·5
(7327·9 to 10524·0)
–3·9
(–11·4 to 3·1)
146·0
(124·4 to 166·3)
122·8
(99·1 to 142·7)
–15·9
(–22·2 to –10·1)*
Adverse eff
 ects of medical 
treatment
5671·1
(4245·4 to 6758·2)
5384·9
(4213·4 to 6360·5)
–5·0
(–10·5 to 2·7)
89·8
(67·8 to 106·9)
74·1
(58·2 to 87·7)
–17·4
(–21·6 to –11·7)*
Animal contact
6453·3
(4501·0 to 7223·6)
5661·2
(3760·0 to 7514·8)
–12·3
(–19·9 to 10·9)
97·6
(68·4 to 109·2)
76·6
(50·8 to 101·5)
–21·5
(–28·2 to –0·7)*
Venomous animal contact
5306·6
(3504·8 to 5989·8)
4648·0
(2901·8 to 6463·8)
–12·4
(–20·6 to 12·9)
80·1
(53·1 to 90·4)
62·8
(39·2 to 87·3)
–21·6
(–29·0 to 1·1)
(Table 1 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1619
with each recording large increases in burden from 1990 
to 2005, but by 2015, all measures of DALYs and relative 
ranks for malaria and HIV
/AIDS had fallen markedly. 
Trends for NCDs and injuries, both in terms of ranks and 
changes in disease burden, were more varied. Between 
1990 and 2005, total DALYs and all-age DALY rates 
signifi
 cantly increased for many NCDs, including 
ischaemic heart disease, low back and neck pain, lung 
cancer, chronic kidney disease, and migraine. For these 
NCDs, their relative ranks also climbed by 2005, yet their 
age-standardised DALY rates either signifi
 cantly decreased 
or remained relatively unchanged, refl
 ecting the eff
 ects of 
changes in population age structure. This pattern 
continued through 2015 for many NCDs, and was further 
exemplifi
 ed by Alzheimer’s disease and other dementias 
as it rose to the 29th leading cause of global DALYs amid a 
signifi
 cant decrease in age-standardised DALY rates. From 
1990 to 2005, all three measures of DALYs signifi
 cantly 
increased for a subset of NCDs (ie, sense organ diseases, 
diabetes, depressive disorders, and other musculoskeletal 
disorders), which contributed to their rises in relative 
ranking. More heterogeneous patterns emerged for 
injuries; for instance, road injuries and interpersonal 
violence each rose in refl
 ective ranks from 2005 to 2015, 
despite signifi
 cant reductions in total DALYs, all-age DALY 
rates, and age-standardised DALY rates from each cause.
For at least one of their leading causes of DALYs in 2015, 
most age groups under 40 years old had a more than 31% 
decrease in total burden (fi
 gure 3). The causes for which 
DALYs largely declined included lower respiratory 
infections, diarrhoeal diseases, malaria, preterm birth 
complications, and drowning among children younger 
than 5 years, and HIV
/AIDS and malaria for people 
between the ages of 5 years and 40 years. Increases in 
cause-specifi
 c DALYs varied more by age, with rising 
DALYs due to depressive disorders and drug use disorders 
for populations at age 20–30 years. DALYs from low back 
and neck pain increased since 2005 for many age groups. 
All-age DALYs (thousands)
Age-standardised rate (per 100 000)
2005
2015
Percentage 
change,
2005–15
2005
2015
Percentage 
change,
2005–15
(Continued from previous page)
Non-venomous animal 
contact
1146·7
(920·0 to 1358·6)
1013·2
(840·1 to 1180·4)
–11·6
(–20·1 to 5·0)
17·5
(14·1 to 20·6)
13·8
(11·4 to 16·1)
–21·2
(–28·5 to –6·9)*
Foreign body
8668·4
(6684·4 to 10942·0)
8244·8
(6786·9 to 9635·2)
–4·9
(–14·1 to 4·8)
132·2
(103·4 to 165·2)
112·4
(92·8 to 131·1)
–15·0
(–22·5 to –7·3)*
Pulmonary aspiration and 
foreign body in airway
6632·4
(4907·7 to 8950·1)
6321·8
(5088·3 to 7704·2)
–4·7
(–15·7 to 6·1)
101·0
(76·1 to 134·5)
86·2
(69·6 to 104·7)
–14·7
(–23·9 to –6·2)*
Foreign body in eyes
48·8
(20·8 to 87·9)
56·2
(24·0 to 101·1)
15·2
(13·8 to 16·7)*
0·8
(0·3 to 1·4)
0·8
(0·3 to 1·4)
0·5
(–0·9 to 1·3)
Foreign body in other body 
part
1987·3
(1331·1 to 2717·2)
1866·9
(1394·9 to 2247·3)
–6·1
(–19·8 to 6·4)
30·4
(20·8 to 41·4)
25·4
(19·1 to 30·6)
–16·4
(–28·8 to –6·5)*
Environmental heat and cold 
exposure
4503·5
(3641·3 to 5457·2)
4234·7
(3350·6 to 5294·9)
–6·0
(–10·1 to –1·4)*
74·1
(59·9 to 89·9)
58·7
(46·4 to 73·6)
–20·7
(–24·0 to –17·1)*
Other unintentional injuries
13 348·6
(11 406·7 to 15 619·1)
12 240·0
(10 234·9 to 14 692·0)
–8·3
(–12·9 to –3·8)*
210·9
(178·2 to 249·5)
167·9
(139·9 to 202·4)
–20·4
(–24·1 to –16·6)*
Self-harm and interpersonal 
violence
58 615·7
(52 794·8 to 60 379·5)
55 719·4
(50 909·8 to 58 127·7)
–4·9
(–9·0 to –0·8)*
889·6
(801·0 to 916·0)
741·1
(676·7 to 773·2)
–16·7
(–20·3 to –13·0)*
Self-harm
35 819·1
(31 467·1 to 37 112·4)
34 260·9
(30 852·1 to 36 042·4)
–4·4
(–10·4 to 1·6)
551·9
(484·7 to 571·2)
457·9
(412·2 to 481·5)
–17·0
(–22·3 to –11·9)*
Interpersonal violence
22 796·5
(20 747·8 to 23 566·7)
21 458·5
(19 354·8 to 22 540·1)
–5·9
(–9·0 to –2·0)*
337·6
(308·1 to 349·1)
283·3
(255·6 to 297·4)
–16·1
(–18·8 to –12·7)*
Assault by fi
 rearm
8856·3
(7747·9 to 9172·1)
9188·1
(7854·5 to 9689·2)
3·7
(0·0 to 8·2)
129·0
(113·0 to 133·6)
120·7
(103·2 to 127·3)
–6·4
(–9·9 to –2·4)*
Assault by sharp object
5425·2
(5050·4 to 5731·6)
4546·1
(4223·1 to 4937·8)
–16·2
(–20·6 to –11·2)*
80·5
(75·1 to 85·0)
59·9
(55·6 to 65·0)
–25·6
(–29·6 to –21·2)*
Assault by other means
8515·1
(7723·3 to 9065·4)
7724·3
(6927·0 to 8395·8)
–9·3
(–14·2 to –2·7)*
128·2
(116·6 to 136·2)
102·7
(92·2 to 111·6)
–19·8
(–24·2 to –14·1)*
Forces of nature, war, and legal 
intervention
9320·3
(6951·1 to 11 778·4)
13 715·5
(8561·9 to 18 537·5)
47·2
(–1·9 to 100·5)
138·4
(103·8 to 174·8)
182·6
(114·4 to 246·3)
31·9
(–11·6 to 79·5)
Exposure to forces of nature
6203·9
(4037·7 to 8412·0)
1435·5
(1092·6 to 1846·4)
–76·9
(–81·2 to –69·4)*
91·9
(60·2 to 124·2)
19·6
(14·9 to 25·2)
–78·7
(–82·7 to –72·0)*
Collective violence and legal 
intervention
3116·4
(2504·2 to 3760·8)
12 279·9
(7208·0 to 17 075·2)
294·0
(175·8 to 394·3)*
46·5
(37·4 to 56·1)
163·0
(95·9 to 226·4)
250·5
(144·1 to 341·2)*
Data in parentheses are 95% uncertainty intervals. DALYs=disability-adjusted life-years. G6PD=glucose-6-phosphate dehydrogenase. *Percentage changes that are statistically signifi
 cant.
Table 1: Global all-age DALYs and age-standardised DALY rates in 2005 and 2015 with median percentage change between 2005 and 2015 for all causes
 Articles
1620 
www.thelancet.com   Vol 388   October 8, 2016
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Global
70·73
(70·48–
70·96)
61·37
(58·61–
63·76)
65·69
(65.45–
65·93)
57·96
(55·69–
59·98)
74·83
(74·39–
75·25)
64·88
(61·96–
67·46)
69·04
(68·63–
69·42)
60·91
(58·55–
63·01)
18·46
(18·31–
18·61)
14·19
(12·98–
15·28)
15·45
(15·31–
15·59)
11·90
(10·89–
12·81)
High SDI
80·26
(80·23–
80·28)
69·62
(66·53–
72·30)
73·25
(73·20–
73·29)
64·82
(62·36–
66·96)
82·34
(82·26–
82·41)
71·33
(68·13–
74·13)
76·21
(76·10–
76·31)
67·27
(64·70–
69·54)
20·96
(20·92–
21·01)
16·18
(14·83–
17·38)
17·66
(17·62–
17·70)
13·55
(12·38–
14·58)
High-middle SDI
75·26
(75·02–
75·51)
65·85
(63·11–
68·23)
69·26
(68·96–
69·53)
61·50
(59·22–
63·59)
79·13
(78·80–
79·43)
69·09
(66·18–
71·63)
72·69
(72·25–
73·10)
64·46
(62·01–
66·60)
19·20
(19·01–
19·40)
14·90 
(13·69–
16·00)
15·81
(15·58–
16·01)
12·30
(11·29–
13·21)
Middle SDI
71·83
(71·49–
72·19)
62·72
(60·08–
65·04)
66·80
(66·43–
67·19)
59·31
(57·11–
61·26)
75·71
(75·21–
76·19)
66·02
(63·24–
68·52)
69·55
(68·99–
70·14)
61·74
(59·46–
63·75)
17·33
(17·03–
17·62)
13·36
(12·19–
14·40)
14·30
(14·01–
14·59)
11·13
(10·24–
11·95)
Low-middle SDI
62·59
(61·97–
63·21)
53·65
(51·01–
56·01)
60·30
(59·69–
60·86)
52·55
(50·22–
54·66)
67·72
(66·80–
68·61)
58·18
(55·33–
60·84)
63·83
(62·99–
64·62)
55·85
(53·44–
58·01)
14·75
(14·34–
15·16)
11·00
(9·95–
12·05)
13·39
(13·06–
13·70)
10·09
(9·18–
10·94)
Low SDI
56·19
(55·16–
57·24)
48·18
(45·46–
50·55)
54·49
(53·52–
55·45)
47·34
(45·02–
49·45)
62·30
(60·22–
64·27)
53·64
(50·41–
56·49)
59·13
(56·85–
61·28)
51·66
(48·91–
54·31)
13·35
(12·36–
14·29)
9·88
(8·61–
11·06)
12·78
(11·77–
13·68)
9·55
(8·41–
10·63)
High-income
82·09
(82·07–
82·11)
71·13
(67·95–
73·87)
76·35
(76·33–
76·37)
67·48
(64·90–
69·75)
83·42
(83·38–
83·46)
72·21
(68·97–
75·02)
78·10 
(78·05–
78·15)
68·91
(66·27–
71·25)
21·68
(21·65–
21·70)
16·78
(15·39–
18·00)
18·24
(18·22–
18·27)
14·03
(12·82–
15·09)
High-income North 
America
80·43
(80·39–
80·47)
68·84
(65·64–
71·64)
75·33
(75·28–
75·37)
65·86
(63·17–
68·24)
81·75
(81·68–
81·82)
69·80
(66·51–
72·75)
77·02
(76·95–
77·10)
67·11
(64·32–
69·65)
20·80
(20·74–
20·86)
15·56
(14·12–
16·84)
18·17
(18·12–
18·21)
13·50
(12·21–
14·67)
Canada
82·53
(82·48–
82·60)
71·39
(68·19–
74·21)
77·81
(77·75–
77·86)
68·29
(65·47–
70·74)
83·86
(83·66–
84·08)
72·49
(69·32–
75·37)
79·50 
(79·28–
79·72)
69·64
(66·80–
72·16)
21·87
(21·72–
22·02)
16·77
(15·33–
18·04)
18·81
(18·68–
18·94)
14·29
(13·00–
15·44)
Greenland
71·07
(70·24–
71·91)
61·63
(59·00–
64·06)
67·44
(66·72–
68·12)
59·74
(57·50–
61·80)
74·90
(73·77–
75·71)
64·81
(61·93–
67·47)
70·00
(69·06–
70·94)
61·90
(59·46–
64·13)
16·76
(16·23–
17·09)
12·65
(11·46–
13·71)
14·26
(14·01–
14·52)
10·79
(9·82–
11·66)
USA
80·21
(80·17–
80·25)
68·57
(65·38–
71·38)
75·06
(75·00–
75·11)
65·60
(62·93–
67·96)
81·52
(81·44–
81·60)
69·50 
(66·21–
72·47)
76·74
(76·66–
76·83)
66·82
(64·05–
69·35)
20·68
(20·62–
20·74)
15·42
(13·99–
16·71)
18·09
(18·04–
18·14)
13·41
(12·12–
14·58)
Australasia
83·25
(83·20–
83·31)
71·66
(68·37–
74·50)
78·57
(78·52–
78·62)
68·83
(66·11–
71·26)
84·32
(84·21–
84·44)
72·57
(69·31–
75·54)
80·09
(79·98–
80·20)
70·08
(67·24–
72·60)
22·01
(21·93–
22·09)
17·06
(15·65–
18·29)
19·11
(19·05–
19·18)
14·66
(13·42–
15·79)
Australia
83·55
(83·49–
83·61)
71·88
(68·59–
74·74)
78·76
(78·70–
78·82)
68·94
(66·19–
71·38)
84·52
(84·41–
84·65)
72·72
(69·43–
75·71)
80·19
(80·08–
80·31)
70·12
(67·25–
72·66)
22·13
(22·04–
22·22)
17·15
(15·75–
18·40)
19·16
(19·08–
19·23)
14·67
(13·43–
15·82)
New Zealand
81·80
(81·67–
81·93)
70·59
(67·45–
73·42)
77·61
(77·48–
77·73)
68·32
(65·64–
70·68)
83·29
(83·03–
83·53)
71·83
(68·60–
74·82)
79·58
(79·30–
79·88)
69·94
(67·20–
72·40)
21·39
(21·20–
21·55)
16·57
(15·20–
17·82)
18·89
(18·74–
19·06)
14·59
(13·37–
15·68)
High-income Asia 
Pacifi
 c
84·71
(84·67–
84·76)
74·76
(71·79–
77·29)
77·77
(77·70–
77·83)
69·68
(67·35–
71·75)
85·95
(85·85–
86·05)
75·82
(72·83–
78·39)
79·39
(79·24–
79·53)
71·05
(68·64–
73·16)
23·39
(23·32–
23·46)
18·66
(17·29–
19·85)
18·67
(18·61–
18·73)
14·63
(13·48–
15·62)
Brunei
78·95
(78·49–
79·31)
69·48
(66·76–
72·02)
74·80
(74·36–
75·15)
66·88
(64·59–
69·00)
79·36
(78·84–
79·87)
69·96
(67·21–
72·39)
75·13
(74·43–
75·87)
67·20
(64·83–
69·39)
18·77
(18·50–
19·01)
14·81
(13·69–
15·83)
15·96
(15·61–
16·33)
12·45
(11·43–
13·43)
Japan
85·34
(85·31–
85·37)
75·43
(72·48–
77·97)
78·46
(78·44–
78·49)
70·32
(67·99–
72·38)
86·35
(86·28–
86·41)
76·28
(73·33–
78·85)
79·94
(79·88–
80·00)
71·54
(69·14–
73·67)
23·78
(23·73–
23·84)
19·04
(17·65–
20·25)
18·94
(18·91–
18·98)
14·85
(13·69–
15·88)
Singapore
82·17
(81·99–
82·35)
73·34
(70·67–
75·64)
77·88
(77·70–
78·05)
70·62
(68·52–
72·48)
83·99
(83·69–
84·35)
75·02
(72·28–
77·44)
79·83
(79·45–
80·18)
72·31
(70·06–
74·21)
21·19
(20·97–
21·46)
17·24
(16·02–
18·32)
18·19
(17·94–
18·42)
14·75
(13·69–
15·65)
South Korea
81·97
(81·79–
82·15)
71·92
(68·98–
74·42)
75·22
(74·95–
75·50)
67·35
(65·02–
69·41)
84·28
(83·91–
84·64)
73·97
(70·91–
76·61)
77·53
(76·98–
78·05)
69·38
(66·95–
71·51)
21·66
(21·39–
21·91)
16·97
(15·58–
18·18)
17·33
(17·02–
17·62)
13·49
(12·34–
14·50)
(Table 2 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1621
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Western Europe
82·60
(82·59–
82·62)
71·55
(68·33–
74·39)
76·99
(76·98–
77·01)
68·13
(65·50–
70·42)
83·97
(83·91–
84·03)
72·75
(69·44–
75·62)
78·93
(78·87–
79·00)
69·82
(67·16–
72·15)
21·64
(21·60–
21·67)
16·79
(15·38–
18·01)
18·29
(18·25–
18·32)
14·20 
(12·99–
15·23)
Andorra
87·91
(87·62–
88·21)
75·88
(72·38–
78·96)
80·38
(79·98–
80·77)
70·89
(68·11–
73·38)
88·44
(88·12–
88·73)
76·30 
(72·75–
79·42)
81·20
(80·80–
81·57)
71·57
(68·74–
74·03)
24·99
(24·73–
25·23)
19·38
(17·77–
20·82)
19·53
(19·32–
19·74)
15·16
(13·88–
16·31)
Austria
82·22
(82·15–
82·30)
71·19
(67·98–
74·02)
76·63
(76·55–
76·71)
67·65
(65·05–
69·96)
83·66
(83·52–
83·79)
72·42
(69·15–
75·31)
78·81
(78·66–
78·95)
69·59
(66·86–
71·97)
21·34
(21·25–
21·43)
16·56
(15·16–
17·79)
18·21
(18·13–
18·29)
14·12
(12·93–
15·18)
Belgium
81·97
(81·87–
82·07)
70·88
(67·69–
73·65)
76·18
(76·08–
76·29)
67·18
(64·52–
69·46)
83·19
(82·82–
83·56)
71·96
(68·66–
74·88)
77·83
(77·37–
78·27)
68·62
(65·99–
71·05)
21·22
(20·97–
21·49)
16·29
(14·84–
17·59)
17·62
(17·36–
17·88)
13·47
(12·27–
14·58)
Cyprus
82·15
(81·97–
82·33)
71·02
(67·78–
73·89)
75·90
(75·73–
76·07)
67·09
(64·50–
69·34)
85·05
(84·80–
85·29)
73·41
(69·97–
76·38)
78·69
(78·38–
78·99)
69·38
(66·65–
71·82)
22·49
(22·31–
22·66)
17·33
(15·81–
18·67)
17·95
(17·77–
18·13)
13·78
(12·58–
14·90)
Denmark
80·50
(80·39–
80·62)
69·73
(66·63–
72·49)
76·08
(75·98–
76·19)
67·24
(64·67–
69·51)
82·44
(82·15–
82·72)
71·39
(68·26–
74·21)
78·31
(78·03–
78·60)
69·21
(66·59–
71·56)
20·43
(20·24–
20·62)
15·83
(14·49–
17·01)
17·64
(17·47–
17·80)
13·74
(12·63–
14·71)
Finland
82·43
(82·30–
82·55)
71·05
(67·72–
74·00)
75·55
(75·41–
75·68)
66·44
(63·69–
68·82)
83·87
(83·60–
84·15)
72·37
(68·92–
75·31)
77·97
(77·62–
78·32)
68·59
(65·86–
70·98)
21·57
(21·39–
21·76)
16·59
(15·12–
17·84)
17·97
(17·79–
18·16)
13·83
(12·60–
14·90)
France
83·90 
(83·87–
83·94)
72·66
(69·29–
75·57)
76·81
(76·78–
76·84)
68·01
(65·38–
70·31)
85·17
(85·01–
85·33)
73·83
(70·44–
76·73)
78·39
(78·17–
78·60)
69·30 
(66·55–
71·64)
23·00
(22·89–
23·11)
17·91
(16·38–
19·21)
18·69
(18·58–
18·80)
14·32
(12·99–
15·43)
Germany
82·06
(82·03–
82·10)
70·86
(67·65–
73·74)
76·58
(76·54–
76·61)
67·72
(65·12–
70·01)
83·19
(83·07–
83·30)
71·85
(68·59–
74·75)
78·36
(78·23–
78·49)
69·31
(66·67–
71·65)
20·95
(20·88–
21·03)
16·23
(14·87–
17·40)
17·80
(17·73–
17·87)
13·88
(12·74–
14·88)
Greece
82·34
(82·25–
82·43)
71·62
(68·49–
74·37)
76·82
(76·73–
76·92)
68·22
(65·71–
70·46)
83·49
(83·25–
83·74)
72·64
(69·46–
75·42)
78·42
(78·10–
78·72)
69·60 
(67·00–
71·88)
20·96
(20·78–
21·14)
16·38
(15·01–
17·54)
18·30
(18·12–
18·47)
14·30 
(13·13–
15·34)
Iceland
83·64
(83·28–
84·06)
72·37
(69·13–
75·24)
79·65
(79·44–
79·92)
70·50
(67·82–
72·89)
85·82
(85·38–
86·30)
74·35
(70·99–
77·33)
80·93
(80·60–
81·25)
71·60 
(68·91–
73·99)
23·00
(22·63–
23·43)
17·83
(16·29–
19·21)
19·25
(19·07–
19·43)
14·93
(13·69–
16·05)
Ireland
81·77
(81·49–
82·11)
70·80
(67·53–
73·65)
77·65
(77·39–
77·86)
68·43
(65·76–
70·81)
84·31
(83·60–
85·02)
72·94
(69·60–
76·00)
79·18
(78·94–
79·51)
69·74
(66·95–
72·16)
21·98
(21·36–
22·66)
17·09
(15·66–
18·46)
18·30
(18·08–
18·61)
14·14
(12·92–
15·20)
Israel
81·73
(81·57–
81·87)
70·97
(67·90–
73·67)
77·63
(77·46–
77·77)
68·60
(65·94–
70·92)
83·82
(83·55–
84·07)
72·69
(69·47–
75·47)
80·18
(79·92–
80·47)
70·72
(67·94–
73·16)
21·29
(21·09–
21·47)
16·44
(15·05–
17·64)
19·10
(18·93–
19·28)
14·72
(13·43–
15·83)
Italy
83·73
(83·69–
83·77)
72·34
(69·02–
75·27)
78·29
(78·26–
78·33)
69·36
(66·72–
71·67)
84·57
(84·44–
84·71)
73·10
(69·76–
76·01)
79·64
(79·48–
79·78)
70·58
(67·86–
72·95)
21·90
(21·80–
21·99)
16·87
(15·44–
18·12)
18·37
(18·27–
18·45)
14·27
(13·05–
15·31)
Luxembourg
82·51
(82·32–
82·73)
70·98
(67·62–
73·95)
77·24
(77·03–
77·44)
67·78
(64·99–
70·19)
84·29
(84·01–
84·62)
72·47
(69·05–
75·42)
79·86
(79·60–
80·12)
70·09
(67·20–
72·60)
21·79
(21·59–
22·05)
16·67
(15·16–
17·96)
18·69
(18·54–
18·83)
14·31
(13·05–
15·45)
Malta
82·73
(82·33–
83·10)
71·52
(68·23–
74·41)
78·32
(77·92–
78·69)
69·06
(66·33–
71·43)
84·48
(84·15–
84·84)
72·97
(69·61–
75·95)
79·65
(79·26–
80·06)
70·17
(67·29–
72·59)
22·05
(21·80–
22·33)
17·03
(15·60–
18·34)
18·67
(18·43–
18·92)
14·48
(13·25–
15·55)
Netherlands
81·63
(81·53–
81·73)
70·43
(67·22–
73·29)
77·33
(77·24–
77·42)
68·31
(65·65–
70·67)
83·40 
(83·08–
83·72)
71·93
(68·64–
74·87)
79·17
(78·86–
79·52)
69·89
(67·22–
72·30)
21·22
(21·02–
21·47)
16·28
(14·85–
17·52)
17·78
(17·59–
18·00)
13·75
(12·58–
14·80)
Norway
82·42
(82·27–
82·58)
70·96
(67·71–
73·85)
77·81
(77·66–
77·95)
68·50 
(65·80–
70·87)
84·08
(83·81–
84·34)
72·56
(69·27–
75·55)
79·94
(79·68–
80·21)
70·40 
(67·62–
72·90)
21·54
(21·35–
21·73)
16·65
(15·28–
17·91)
18·57
(18·41–
18·74)
14·36
(13·14–
15·48)
Portugal
81·74
(81·66–
81·83)
70·60
(67·34–
73·41)
75·06
(74·96–
75·14)
66·36
(63·75–
68·59)
83·86
(83·69–
84·02)
72·40
(69·05–
75·36)
77·65
(77·47–
77·83)
68·61
(65·93–
70·95)
21·38
(21·26–
21·49)
16·48
(15·07–
17·73)
17·71
(17·62–
17·81)
13·72
(12·59–
14·76)
(Table 2 continues on next page)
 Articles
1622 
www.thelancet.com   Vol 388   October 8, 2016
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Spain
83·63
(83·59–
83·67)
72·81
(69·58–
75·61)
76·91
(76·87–
76·95)
68·29
(65·70–
70·55)
85·27
(85·17–
85·38)
74·27
(70·99–
77·13)
79·84
(79·72–
79·96)
70·91
(68·26–
73·23)
22·50 
(22·42–
22·58)
17·58
(16·12–
18·83)
18·86
(18·79–
18·92)
14·72
(13·49–
15·77)
Sweden
82·61
(82·50–
82·73)
71·97
(68·89–
74·70)
78·42
(78·30–
78·54)
69·24
(66·58–
71·58)
83·98
(83·74–
84·25)
73·04
(69·93–
75·82)
80·25
(80·01–
80·48)
70·70
(67·98–
73·16)
21·39
(21·22–
21·59)
16·59
(15·24–
17·78)
18·72
(18·57–
18·86)
14·36
(13·13–
15·47)
Switzerland
83·72
(83·59–
83·85)
72·15
(68·81–
75·09)
78·67
(78·54–
78·80)
69·23
(66·47–
71·66)
85·18
(84·89–
85·50)
73·55
(70·15–
76·54)
80·65
(80·33–
81·01)
71·16
(68·40–
73·63)
22·52
(22·31–
22·74)
17·40
(15·85–
18·73)
19·25
(19·06–
19·47)
14·99
(13·77–
16·09)
UK
81·14
(81·11–
81·18)
70·63
(67·46–
73·34)
76·73
(76·70–
76·77)
67·86
(65·24–
70·12)
82·81
(82·71–
82·93)
72·09
(68·88–
74·81)
79·03
(78·94–
79·13)
69·86
(67·26–
72·19)
20·85
(20·77–
20·95)
16·41
(15·13–
17·54)
18·35
(18·28–
18·41)
14·38
(13·28–
15·39)
England
81·38
(81·34–
81·41)
70·91
(67·74–
73·60)
77·05
(77·02–
77·09)
68·20
(65·59–
70·47)
83·05
(82·94–
83·16)
72·37
(69·18–
75·11)
79·34
(79·24–
79·44)
70·19
(67·61–
72·53)
21·01
(20·92–
21·10)
16·57
(15·29–
17·71)
18·51
(18·44–
18·58)
14·54
(13·43–
15·54)
Northern Ireland
80·78
(80·57–
80·97)
70·40
(67·34–
73·09)
75·84
(75·64–
76·04)
67·11
(64·54–
69·40)
82·30
(81·91–
82·68)
71·74
(68·69–
74·38)
77·94
(77·50–
78·37)
68·98
(66·37–
71·31)
20·55
(20·27–
20·82)
16·17
(14·89–
17·30)
17·67
(17·45–
17·89)
13·82
(12·71–
14·82)
Scotland
79·48
(79·35–
79·61)
68·60
(65·44–
71·42)
74·35
(74·23–
74·47)
65·43
(62·83–
67·70)
81·22
(80·86–
81·62)
70·03
(66·77–
72·90)
77·15
(76·79–
77·50)
67·83
(65·20–
70·28)
19·81
(19·57–
20·06)
15·35
(14·05–
16·49)
17·46
(17·28–
17·65)
13·54
(12·45–
14·58)
Wales
80·66
(80·53–
80·79)
69·95
(66·78–
72·73)
76·19
(76·06–
76·31)
66·91
(64·19–
69·30)
82·16
(81·86–
82·46)
71·20
(67·94–
74·08)
77·98
(77·69–
78·28)
68·39
(65·59–
70·88)
20·38
(20·18–
20·58)
15·88
(14·57–
17·06)
17·63
(17·47–
17·79)
13·62
(12·50–
14·65)
Southern Latin 
America
79·29
(79·23–
79·34)
69·60 
(66·74–
72·09)
72·64
(72·58–
72·69)
64·83
(62·54–
66·87)
80·41
(80·19–
80·63)
70·54
(67·61–
73·11)
73·98
(73·74–
74·23)
66·02
(63·62–
68·10)
19·81
(19·67–
19·94)
15·78
(14·59–
16·82)
15·83
(15·71–
15·95)
12·47
(11·47–
13·33)
Argentina
78·69
(78·61–
78·76)
69·07
(66·24–
71·55)
71·78
(71·71–
71·85)
64·04
(61·79–
66·07)
79·76
(79·51–
80·01)
70·00
(67·06–
72·53)
73·05
(72·77–
73·31)
65·20 
(62·88–
67·28)
19·55
(19·40–
19·69)
15·58
(14·41–
16·62)
15·37
(15·23–
15·50)
12·10
(11·12–
12·94)
Chile
80·97
(80·87–
81·08)
71·07
(68·14–
73·59)
75·36
(75·26–
75·47)
67·21
(64·82–
69·31)
82·04
(81·53–
82·54)
71·91
(69·01–
74·53)
76·56
(75·93–
77·19)
68·28
(65·76–
70·51)
20·50 
(20·15–
20·84)
16·30 
(15·06–
17·39)
17·22
(16·88–
17·57)
13·59
(12·47–
14·60)
Uruguay
79·15
(78·98–
79·31)
69·51
(66·62–
71·93)
71·80 
(71·65–
71·96)
64·33
(62·09–
66·28)
80·51
(80·15–
80·90)
70·65
(67·77–
73·25)
72·93
(72·50–
73·37)
65·30 
(62·97–
67·25)
19·85
(19·65–
20·05)
15·80 
(14·63–
16·86)
15·05
(14·85–
15·24)
11·86
(10·90–
12·68)
Central Europe, 
eastern Europe, and 
central Asia
73·64
(73·53–
73·75)
64·25
(61·48–
66·73)
62·93
(62·80–
63·06)
55·92
(53·84–
57·72)
77·31
(77·09–
77·50)
67·31
(64·36–
69·91)
67·95
(67·71–
68·21)
60·13
(57·76–
62·14)
17·86
(17·77–
17·94)
13·74
(12·56–
14·77)
13·97
(13·90–
14·04)
10·57
(9·60–
11·43)
Eastern Europe
72·72
(72·63–
72·80)
63·16
(60·37–
65·68)
59·78
(59·65–
59·91)
53·18
(51·24–
54·89)
76·70
(76·44–
76·94)
66·44
(63·45–
69·08)
65·73
(65·39–
66·05)
58·15
(55·84–
60·13)
17·40
(17·27–
17·52)
13·30
(12·12–
14·33)
13·10
(12·98–
13·22)
9·84
(8·90–
10·68)
Belarus
74·89
(74·62–
75·15)
65·58
(62·91–
68·05)
62·76
(62·41–
63·09)
55·92
(53·92–
57·70)
77·07
(76·58–
77·58)
67·38
(64·53–
69·96)
65·02
(64·33–
65·74)
57·85
(55·63–
59·94)
17·05
(16·77–
17·32)
13·19
(12·06–
14·23)
11·75
(11·47–
12·04)
8·86
(8·00–
9·68)
Estonia
77·67
(77·51–
77·84)
67·79
(64·90–
70·36)
67·12
(66·93–
67·29)
59·50
(57·27–
61·47)
81·43
(80·99–
81·88)
71·08
(68·17–
73·78)
73·44
(73·07–
73·83)
64·89
(62·39–
67·14)
19·70
(19·35–
20·07)
15·32
(14·07–
16·50)
15·61
(15·39–
15·85)
11·87
(10·77–
12·85)
Latvia
76·63
(76·48–
76·78)
66·98
(64·16–
69·53)
65·47
(65·32–
65·62)
58·12
(55·95–
60·04)
79·73
(79·34–
80·06)
69·63
(66·64–
72·23)
70·59
(70·17–
70·99)
62·48
(60·12–
64·65)
19·01
(18·79–
19·20)
14·70
(13·42–
15·80)
14·55
(14·37–
14·72)
10·99
(9·97–
11·90)
Lithuania
77·71
(77·60–
77·82)
67·74
(64·85–
70·37)
65·71
(65·60–
65·82)
58·22
(55·95–
60·15)
80·39
(80·16–
80·61)
70·02
(67·03–
72·76)
69·72
(69·47–
70·02)
61·55
(59·11–
63·70)
19·63
(19·49–
19·76)
15·11
(13·80–
16·26)
14·75
(14·64–
14·87)
10·97
(9·87–
11·94)
Moldova
73·43
(73·13–
73·69)
64·40
(61·73–
66·76)
65·55
(65·21–
65·82)
58·37
(56·23–
60·27)
77·70
(77·29–
78·06)
67·96
(65·13–
70·54)
69·93
(69·47–
70·35)
62·06
(59·81–
64·18)
17·39
(17·21–
17·58)
13·53
(12·39–
14·53)
14·04
(13·91–
14·18)
10·71
(9·76–
11·57)
(Table 2 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1623
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Russia
72·21
(72·11–
72·30)
62·43
(59·56–
64·98)
58·71
(58·54–
58·87)
52·21
(50·31–
53·88)
76·57
(76·22–
76·90)
66·02
(62·89–
68·71)
65·30
(64·85–
65·77)
57·71
(55·43–
59·76)
17·48
(17·29–
17·64)
13·26
(12·03–
14·31)
13·12
(12·95–
13·30)
9·83
(8·86–
10·68)
Ukraine
73·16
(72·91–
73·37)
64·21
(61·62–
66·53)
61·36
(61·08–
61·60)
54·64
(52·67–
56·37)
76·45
(75·94–
76·93)
66·93
(64·21–
69·44)
66·26
(65·56–
66·93)
58·71
(56·38–
60·69)
16·95
(16·73–
17·18)
13·15
(12·05–
14·14)
12·97
(12·77–
13·18)
9·82
(8·90–
10·63)
Central Europe
77·90
(77·86–
77·94)
68·36
(65·55–
70·83)
70·48
(70·44–
70·52)
62·43
(60·05–
64·51)
80·45
(80·31–
80·58)
70·52
(67·59–
73·06)
73·43
(73·25–
73·59)
64·92
(62·42–
67·13)
19·05
(18·98–
19·11)
14·80
(13·54–
15·90)
15·33
(15·26–
15·39)
11·65
(10·59–
12·59)
Albania
79·08
(78·63–
79·52)
69·12
(66·18–
71·74)
73·49
(72·96–
74·00)
64·65
(62·01–
66·95)
81·32
(80·71–
81·95)
71·17
(68·10–
73·74)
74·98
(74·10–
75·87)
66·20
(63·43–
68·64)
20·06
(19·65–
20·47)
15·65
(14·28–
16·89)
16·09
(15·36–
16·99)
12·34
(11·10–
13·63)
Bosnia and 
Herzegovina
79·89
(79·75–
80·05)
69·96
(67·03–
72·56)
74·05
(73·91–
74·23)
65·08
(62·52–
67·36)
81·82
(81·45–
82·21)
71·51
(68·53–
74·24)
76·00
(75·72–
76·30)
66·69
(64·02–
69·04)
20·09
(19·81–
20·38)
15·56
(14·25–
16·76)
16·64
(16·51–
16·81)
12·59
(11·45–
13·61)
Bulgaria
76·22
(76·11–
76·34)
67·07
(64·38–
69·46)
69·07
(68·95–
69·17)
61·35
(59·08–
63·34)
78·36
(77·90–
78·80)
68·88
(66·09–
71·34)
71·37
(70·84–
71·87)
63·34
(60·91–
65·43)
17·54
(17·26–
17·79)
13·67
(12·53–
14·68)
14·14
(13·91–
14·37)
10·78
(9·80–
11·69)
Croatia
79·21
(79·07–
79·35)
69·34
(66·46–
71·92)
72·01
(71·89–
72·12)
63·67
(61·24–
65·84)
80·92
(80·61–
81·26)
70·74
(67·69–
73·39)
74·65
(74·31–
75·00)
65·87
(63·30–
68·12)
18·92
(18·71–
19·15)
14·64
(13·35–
15·72)
15·39
(15·20–
15·58)
11·70
(10·64–
12·64)
Czech Republic
79·37
(79·28–
79·47)
69·51
(66·58–
72·10)
72·98
(72·90–
73·06)
64·55
(62·06–
66·73)
81·65
(81·47–
81·83)
71·41
(68·37–
74·06)
75·92
(75·73–
76·11)
66·94
(64·35–
69·27)
19·46
(19·33–
19·59)
15·05
(13·78–
16·19)
16·06
(15·96–
16·17)
12·13
(11·00–
13·14)
Hungary
77·25
(77·14–
77·34)
67·48
(64·65–
70·00)
68·82
(68·73–
68·91)
61·06
(58·81–
63·06)
79·95
(79·55–
80·34)
69·76
(66·77–
72·32)
73·22
(72·78–
73·68)
64·71
(62·24–
66·94)
19·00
(18·75–
19·23)
14·59
(13·27–
15·70)
15·41
(15·20–
15·63)
11·65
(10·56–
12·61)
Macedonia
76·41
(76·25–
76·57)
67·48
(64·89–
69·82)
71·36
(71·20–
71·51)
63·45
(61·07–
65·54)
79·14
(78·63–
79·65)
69·66
(66·84–
72·23)
73·92
(73·30–
74·51)
65·54
(63·08–
67·75)
17·94
(17·65–
18·28)
13·95
(12·78–
15·05)
15·06
(14·67–
15·47)
11·50
(10·47–
12·50)
Montenegro
77·96
(77·70–
78·22)
68·56
(65·82–
71·10)
71·99
(71·77–
72·22)
63·70
(61·25–
65·88)
80·18
(79·69–
80·68)
70·44
(67·53–
73·02)
74·21
(73·61–
74·86)
65·59
(63·03–
67·89)
18·94
(18·63–
19·25)
14·76
(13·53–
15·90)
15·64
(15·26–
16·09)
11·95
(10·83–
12·96)
Poland
79·36
(79·31–
79·41)
69·57
(66·70–
72·07)
70·78
(70·73–
70·83)
62·67
(60·24–
64·74)
81·61
(81·39–
81·81)
71·53
(68·56–
74·11)
73·45
(73·23–
73·69)
64·96
(62·44–
67·15)
19·98
(19·86–
20·10)
15·51
(14·22–
16·67)
15·56
(15·46–
15·66)
11·82
(10·74–
12·79)
Romania
76·08
(76·00–
76·17)
66·92
(64·24–
69·30)
68·82
(68·75–
68·90)
61·04
(58·74–
63·06)
78·99
(78·59–
79·36)
69·44
(66·68–
71·90)
71·52
(71·03–
72·00)
63·40
(60·98–
65·54)
18·15
(17·92–
18·37)
14·25
(13·12–
15·26)
14·55
(14·34–
14·77)
11·14
(10·15–
12·04)
Serbia
75·94
(75·71–
76·15)
66·88
(64·26–
69·26)
70·58
(70·36–
70·80)
62·59
(60·22–
64·67)
78·87
(78·69–
79·05)
69·23
(66·44–
71·75)
73·48
(73·20–
73·71)
64·90
(62·35–
67·11)
17·88
(17·77–
17·99)
13·85
(12·68–
14·89)
15·18
(15·02–
15·31)
11·52
(10·46–
12·47)
Slovakia
78·18
(78·06–
78·30)
68·72
(65·92–
71·18)
70·28
(70·16–
70·39)
62·14
(59·72–
64·26)
80·92
(80·69–
81·14)
70·92
(68·01–
73·52)
73·98
(73·74–
74·21)
65·21
(62·65–
67·47)
19·18
(19·03–
19·33)
14·90
(13·67–
16·05)
15·38
(15·26–
15·49)
11·60
(10·53–
12·55)
Slovenia
81·07
(80·92–
81·20)
70·80
(67·77–
73·46)
73·89
(73·76–
74·01)
65·25
(62·75–
67·47)
83·84
(83·62–
84·05)
73·21
(70·12–
75·94)
77·94
(77·71–
78·18)
68·66
(65·91–
71·09)
21·31
(21·16–
21·47)
16·54
(15·13–
17·77)
17·55
(17·42–
17·68)
13·39
(12·17–
14·47)
Central Asia
71·47
(71·12–
71·80)
62·79
(60·19–
65·08)
63·62
(63·27–
63·98)
56·73
(54·69–
58·52)
75·30 
(74·77–
75·76)
65·96
(63·27–
68·44)
67·41
(66·85–
67·91)
59·93
(57·71–
61·94)
16·95
(16·75–
17·17)
13·14
(12·03–
14·15)
13·48
(13·32–
13·66)
10·35
(9·44–
11·16)
Armenia
75·32
(74·82–
75·77)
65·81
(63·07–
68·24)
68·18
(67·64–
68·75)
60·65
(58·47–
62·68)
78·37
(77·89–
78·95)
68·40
(65·51–
70·99)
70·75
(70·05–
71·47)
62·84
(60·47–
65·01)
18·06
(17·85–
18·44)
13·83
(12·63–
14·95)
14·37
(14·13–
14·66)
10·99
(9·99–
11·87)
Azerbaijan
71·39
(70·61–
72·13)
62·63
(59·91–
65·16)
65·10
(64·27–
65·92)
58·10
(55·95–
60·12)
76·32
(75·59–
77·07)
66·67
(63·73–
69·41)
69·57
(68·51–
70·58)
61·78
(59·33–
63·98)
17·57
(17·25–
17·90)
13·56
(12·32–
14·64)
14·46
(13·77–
14·96)
11·12
(10·05–
12·10)
(Table 2 continues on next page)
 Articles
1624 
www.thelancet.com   Vol 388   October 8, 2016
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Georgia
76·02
(75·39–
76·63)
67·04
(64·39–
69·40)
67·40
(66·60–
68·21)
60·26
(58·09–
62·26)
78·04
(77·27–
78·74)
68·48
(65·63–
71·10)
67·86
(66·87–
69·05)
60·52
(58·23–
62·66)
18·13
(17·73–
18·55)
14·12
(12·89–
15·23)
13·23
(12·89–
13·73)
10·15
(9·21–
11·06)
Kazakhstan
71·06
(70·70–
71·40)
62·23
(59·70–
64·57)
59·79
(59·41–
60·14)
53·24
(51·28–
54·98)
75·03
(74·05–
75·95)
65·52
(62·54–
68·31)
65·29
(64·11–
66·49)
57·91
(55·58–
60·11)
16·49
(16·00–
16·99)
12·70 
(11·53–
13·82)
12·66
(12·21–
13·13)
9·60
(8·68–
10·47)
Kyrgyzstan
70·68
(70·16–
71·20)
62·06
(59·52–
64·39)
62·56
(61·96–
63·23)
55·92
(53·99–
57·76)
74·10
(73·44–
74·71)
64·92
(62·25–
67·31)
65·60
(64·83–
66·41)
58·62
(56·46–
60·57)
16·13
(15·81–
16·47)
12·55
(11·47–
13·49)
12·64
(12·31–
12·98)
9·79
(8·91–
10·58)
Mongolia
67·72
(67·00–
68·42)
60·10
(57·87–
62·07)
59·95
(59·16–
60·71)
53·54
(51·58–
55·43)
71·87
(71·03–
72·67)
63·55
(61·09–
65·93)
62·78
(61·90–
63·63)
55·92
(53·79–
57·96)
15·12
(14·80–
15·43)
11·73
(10·76–
12·66)
11·78
(11·55–
12·05)
8·94
(8·13–
9·73)
Tajikistan
70·16
(69·42–
70·88)
61·79
(59·20–
64·06)
65·92
(65·24–
66·65)
58·68
(56·48–
60·63)
74·80
(73·94–
75·53)
65·67
(63·00–
68·18)
70·12
(69·20–
70·96)
62·17
(59·71–
64·38)
16·91
(16·48–
17·22)
13·20
(12·13–
14·21)
15·04
(14·71–
15·31)
11·61
(10·61–
12·52)
Turkmenistan
69·51
(68·21–
70·74)
61·31
(58·75–
63·67)
62·12
(60·77–
63·27)
55·49
(53·35–
57·52)
73·69
(72·71–
74·46)
64·83
(62·09–
67·28)
66·33
(65·35–
67·15)
59·11
(56·86–
61·15)
16·78
(16·53–
17·01)
13·09
(11·99–
14·06)
13·57
(13·32–
13·79)
10·47
(9·58–
11·31)
Uzbekistan
71·50
(70·65–
72·29)
62·93
(60·29–
65·29)
65·48
(64·61–
66·40)
58·39
(56·15–
60·45)
75·20
(74·34–
76·03)
66·03
(63·32–
68·49)
68·37
(67·51–
69·27)
60·85
(58·49–
63·00)
16·77
(16·40–
17·33)
13·10
(11·98–
14·12)
13·69
(13·42–
14·00)
10·59
(9·67–
11·42)
Latin America and 
Caribbean
76·49
(76·28–
76·69)
66·42
(63·49–
69·02)
70·45
(70·24–
70·68)
62·25
(59·82–
64·38)
78·25
(77·87–
78·62)
67·88
(64·80–
70·50)
72·20
(71·73–
72·62)
63·76
(61·28–
65·91)
18·85
(18·69–
19·02)
14·38
(13·08–
15·51)
16·25
(16·11–
16·40)
12·45
(11·37–
13·42)
Central Latin 
America
77·58
(77·40–
77·75)
67·68
(64·81–
70·20)
71·92
(71·72–
72·11)
63·73
(61·30–
65·83)
78·81
(78·44–
79·15)
68·69
(65·67–
71·26)
73·28
(72·84–
73·72)
64·88
(62·36–
67·07)
19·06
(18·95–
19·19)
14·51
(13·21–
15·68)
16·97
(16·86–
17·09)
13·05
(11·91–
14·05)
Colombia
78·26
(78·06–
78·46)
68·20
(65·23–
70·78)
72·02
(71·80–
72·23)
64·05
(61·65–
66·08)
80·80
(80·35–
81·25)
70·21
(67·06–
72·90)
75·15
(74·58–
75·65)
66·65
(64·15–
68·88)
20·06
(19·85–
20·28)
15·33
(13·95–
16·52)
17·46
(17·28–
17·64)
13·55
(12·44–
14·57)
Costa Rica
81·47
(81·22–
81·69)
70·96
(67·85–
73·65)
76·56
(76·27–
76·80)
67·84
(65·19–
70·12)
82·60
(82·12–
83·05)
71·84
(68·61–
74·60)
78·08
(77·50–
78·58)
69·11
(66·46–
71·44)
21·24
(20·99–
21·51)
16·24
(14·85–
17·48)
18·90 
(18·66–
19·12)
14·67
(13·44–
15·77)
El Salvador
77·02
(76·56–
77·45)
66·63
(63·59–
69·35)
68·79
(68·07–
69·49)
60·84
(58·45–
62·88)
78·94
(78·06–
79·85)
68·24
(64·99–
71·16)
70·57
(69·32–
71·94)
62·56
(60·03–
64·95)
19·55
(19·10–
20·06)
14·80
(13·36–
16·08)
17·79
(17·33–
18·24)
13·74
(12·56–
14·87)
Guatemala
73·16
(72·79–
73·54)
63·27
(60·37–
65·90)
66·41
(66·08–
66·75)
58·31
(55·91–
60·44)
75·20
(73·54–
77·05)
65·09
(61·95–
68·07)
69·81
(67·75–
71·79)
61·33
(58·45–
64·12)
17·38
(16·41–
18·60)
13·02
(11·59–
14·44)
17·18
(16·45–
17·95)
13·09
(11·85–
14·29)
Honduras
72·00
(69·46–
74·83)
63·00
(59·75–
66·13)
70·45
(67·22–
72·91)
62·58
(59·11–
65·60)
73·95
(71·41–
76·68)
64·71
(61·55–
68·01)
72·09
(68·69–
74·71)
64·07
(60·73–
67·10)
16·30
(15·18–
17·86)
12·48
(11·19–
13·99)
16·08
(14·54–
17·25)
12·49
(11·04–
13·84)
Mexico
77·72
(77·45–
77·95)
68·16
(65·42–
70·62)
72·54
(72·25–
72·81)
64·56
(62·22–
66·64)
78·32
(77·98–
78·60)
68·64
(65·82–
71·11)
73·43
(73·04–
73·75)
65·26
(62·82–
67·38)
18·65
(18·59–
18·70)
14·24
(12·98–
15·37)
16·78
(16·74–
16·83)
12·91
(11·78–
13·91)
Nicaragua
79·26
(78·69–
79·76)
69·03
(65·97–
71·74)
73·74
(73·07–
74·37)
65·25
(62·65–
67·57)
80·76
(79·93–
81·68)
70·31
(67·22–
73·07)
75·01
(73·80–
76·26)
66·47
(63·72–
69·01)
20·76
(20·25–
21·30)
15·88
(14·42–
17·17)
18·30
(17·75–
18·85)
14·19
(12·90–
15·41)
Panama
79·72
(79·09–
80·35)
69·27
(66·25–
72·03)
74·77
(73·98–
75·48)
66·08
(63·42–
68·38)
81·01
(79·82–
82·22)
70·21
(66·90–
73·23)
75·48
(73·89–
76·95)
66·63
(63·75–
69·40)
20·93
(20·19–
21·70)
15·90
(14·35–
17·37)
18·34
(17·55–
19·16)
14·11
(12·76–
15·39)
Venezuela
78·22
(78·11–
78·32)
67·39
(64·28–
70·19)
71·17
(71·06–
71·27)
61·93
(59·15–
64·31)
79·16
(78·00–
80·36)
68·14
(64·68–
71·24)
70·69
(69·02–
72·41)
61·62
(58·62–
64·44)
19·37
(18·64–
20·13)
14·58
(13·09–
15·96)
16·05
(15·37–
16·77)
12·05
(10·85–
13·25)
Andean Latin 
America
76·76
(76·30–
77·23)
66·92
(64·06–
69·48)
73·09
(72·59–
73·57)
64·22
(61·57–
66·57)
79·01
(78·22–
79·82)
68·86
(65·87–
71·66)
75·40 
(74·51–
76·28)
66·26
(63·43–
68·85)
19·24
(18·74–
19·76)
14·90
(13·63–
16·14)
17·61
(17·15–
18·06)
13·44
(12·14–
14·60)
(Table 2 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1625
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Bolivia
71·40
(69·86–
72·67)
62·29
(59·64–
64·88)
69·02
(67·91–
70·15)
60·74
(58·14–
63·17)
74·22
(72·07–
76·43)
64·65
(61·20–
67·81)
72·11
(69·61–
74·23)
63·35
(60·22–
66·40)
16·64
(15·46–
18·07)
12·80 
(11·36–
14·26)
16·33
(15·07–
17·17)
12·41
(11·10–
13·67)
Ecuador
76·85
(76·33–
77·36)
66·94
(63·96–
69·56)
71·53
(70·79–
72·19)
62·95
(60·31–
65·29)
78·56
(77·59–
79·50)
68·39
(65·41–
71·20)
73·35
(72·06–
74·39)
64·57
(61·56–
67·16)
18·94
(18·40–
19·46)
14·57
(13·33–
15·81)
16·49
(15·80–
17·02)
12·48
(11·14–
13·66)
Peru
78·80
(78·19–
79·39)
68·71
(65·77–
71·33)
75·55
(74·73–
76·36)
66·30
(63·53–
68·76)
81·10
(80·01–
82·23)
70·74
(67·67–
73·66)
77·85
(76·38–
79·13)
68·37
(65·44–
71·13)
20·44
(19·71–
21·22)
15·93
(14·52–
17·30)
18·78
(18·02–
19·53)
14·42
(13·06–
15·70)
Caribbean
72·72
(71·92–
73·44)
63·17
(60·25–
65·76)
69·08
(68·51–
69·68)
60·88
(58·42–
63·12)
75·21
(73·88–
76·31)
65·16
(61·96–
67·91)
70·92
(69·92–
71·88)
62·43
(59·83–
64·66)
18·22
(17·84–
18·59)
14·04
(12·77–
15·10)
16·18
(15·97–
16·43)
12·47
(11·39–
13·43)
Antigua and 
Barbuda
77·20
(76·51–
78·00)
67·21
(64·20–
69·87)
72·45
(71·58–
73·41)
63·69
(61·07–
66·03)
78·85
(78·10–
79·78)
68·54
(65·44–
71·37)
73·78
(72·68–
75·33)
64·92
(62·16–
67·47)
18·43
(18·03–
19·10)
14·28
(13·02–
15·46)
15·57
(14·73–
16·84)
11·90
(10·54–
13·37)
The Bahamas
74·43
(73·70–
75·22)
64·60 
(61·75–
67·14)
68·91
(67·92–
69·86)
60·65
(58·19–
62·97)
76·41
(75·13–
77·73)
66·24
(63·14–
69·13)
70·87
(69·42–
72·31)
62·47
(59·69–
65·04)
17·58
(16·97–
18·24)
13·49
(12·26–
14·70)
15·42
(14·86–
16·14)
11·79
(10·61–
12·96)
Barbados
76·96
(76·19–
77·73)
66·70
(63·63–
69·54)
72·90 
(72·17–
73·53)
64·11
(61·48–
66·54)
77·56
(76·24–
78·67)
67·12
(63·92–
69·93)
73·63
(72·28–
74·85)
64·84
(62·02–
67·46)
18·05
(17·34–
18·64)
13·81
(12·54–
15·06)
16·09
(15·12–
16·78)
12·29
(10·96–
13·53)
Belize
73·08
(72·37–
73·77)
63·66
(60·85–
66·10)
67·27
(66·44–
68·11)
59·58
(57·17–
61·66)
74·73
(73·67–
75·77)
65·00
(62·11–
67·76)
69·05
(67·70–
70·29)
61·18
(58·61–
63·64)
16·75
(16·23–
17·30)
12·97
(11·80–
14·04)
14·44
(13·90–
15·11)
11·19
(10·17–
12·20)
Bermuda
79·60 
(79·07–
80·17)
69·18
(66·21–
72·01)
73·35
(72·73–
74·01)
64·74
(62·22–
67·06)
82·23
(81·24–
83·29)
71·28
(68·14–
74·12)
75·00
(73·93–
75·97)
66·15
(63·61–
68·57)
20·38
(19·75–
21·11)
15·80
(14·45–
17·03)
16·27
(15·84–
16·62)
12·53
(11·43–
13·52)
Cuba
79·14
(79·04–
79·22)
68·94
(65·93–
71·55)
75·19
(75·09–
75·27)
66·68
(64·14–
68·92)
80·60 
(80·24–
80·97)
70·06
(66·98–
72·80)
75·87
(75·52–
76·25)
67·22
(64·76–
69·45)
19·56
(19·34–
19·79)
15·16
(13·88–
16·31)
16·68
(16·50–
16·87)
13·01
(11·96–
13·95)
Dominica
77·15
(76·26–
77·93)
66·87
(63·91–
69·60)
71·36
(70·25–
72·27)
62·42
(59·76–
64·84)
76·81
(75·46–
78·06)
66·52
(63·28–
69·40)
69·71
(67·83–
71·50)
61·07
(58·09–
63·74)
18·29
(17·55–
18·86)
14·04
(12·66–
15·26)
14·93
(14·01–
15·94)
11·25
(9·97–
12·50)
Dominican 
Republic
76·16
(75·51–
76·65)
66·32
(63·46–
68·91)
70·75
(70·04–
71·40)
62·43
(59·94–
64·68)
77·93
(77·41–
78·30)
67·89
(64·83–
70·38)
72·82
(71·86–
73·45)
64·36
(61·78–
66·67)
19·04
(18·91–
19·11)
14·78
(13·55–
15·85)
16·79
(16·51–
16·90)
12·99
(11·86–
13·96)
Grenada
73·36
(72·61–
74·08)
63·76
(60·97–
66·16)
67·21
(66·38–
67·95)
59·21
(56·81–
61·43)
74·28
(72·93–
75·36)
64·40
(61·31–
67·09)
68·78
(67·50–
70·02)
60·56
(57·89–
62·93)
16·30
(15·74–
16·82)
12·50
(11·33–
13·54)
13·99
(13·53–
14·41)
10·61
(9·51–
11·52)
Guyana
67·83
(66·96–
68·68)
58·96
(56·30–
61·42)
61·28
(60·22–
62·33)
54·11
(51·88–
56·20)
70·47
(68·95–
71·86)
61·22
(58·26–
64·03)
63·47
(61·70–
65·26)
56·08
(53·43–
58·62)
14·88
(14·21–
15·47)
11·43
(10·35–
12·47)
12·55
(12·03–
13·14)
9·57
(8·67–
10·50)
Haiti
59·86
(57·33–
62·32)
51·93
(48·83–
54·97)
60·30
(58·18–
62·80)
52·84
(50·10–
55·64)
64·74
(61·22–
68·20)
55·81
(51·95–
59·24)
63·91
(60·58–
67·20)
55·75
(52·32–
59·08)
13·37
(11·94–
15·07)
10·09
(8·77–
11·46)
14·01
(12·88–
15·32)
10·54
(9·30–
11·84)
Jamaica
76·72
(75·84–
77·43)
66·45
(63·40–
69·28)
73·96
(72·94–
74·84)
64·93
(62·19–
67·48)
76·97
(75·72–
78·20)
66·55
(63·15–
69·48)
73·03
(71·74–
74·36)
64·18
(61·35–
66·78)
18·00
(17·35–
18·77)
13·85
(12·48–
15·08)
16·43
(15·55–
17·11)
12·65
(11·39–
13·78)
Puerto Rico
80·24
(80·07–
80·41)
69·47
(66·33–
72·22)
72·85
(72·67–
73·00)
63·94
(61·31–
66·24)
81·77
(81·16–
82·37)
70·70
(67·45–
73·61)
75·03
(74·35–
75·73)
65·70
(62·92–
68·26)
20·43
(20·03–
20·83)
15·71
(14·34–
16·94)
17·42
(17·11–
17·72)
13·17
(11·95–
14·31)
Saint Lucia
76·14
(75·26–
77·06)
66·13
(63·23–
68·75)
70·19
(69·24–
71·13)
61·74
(59·30–
63·99)
77·09
(75·75–
78·29)
66·91
(63·83–
69·68)
72·52
(71·02–
73·92)
63·78
(61·01–
66·41)
17·82
(17·13–
18·53)
13·74
(12·49–
14·93)
16·08
(15·41–
16·73)
12·35
(11·12–
13·45)
Saint Vincent 
and the 
Grenadines
73·00
(72·20–
73·75)
63·48
(60·67–
65·95)
68·03
(67·29–
68·71)
59·90
(57·52–
62·10)
73·95
(72·82–
75·00)
64·26
(61·26–
66·93)
68·77
(67·61–
69·89)
60·59
(58·00–
62·87)
16·11
(15·64–
16·62)
12·39
(11·28–
13·41)
14·09
(13·51–
14·61)
10·71
(9·59–
11·71)
(Table 2 continues on next page)
 Articles
1626 
www.thelancet.com   Vol 388   October 8, 2016
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Suriname
72·74
(71·94–
73·56)
63·29
(60·51–
65·80)
67·08
(66·13–
68·21)
59·30
(56·87–
61·54)
75·34
(73·89–
76·55)
65·50
(62·51–
68·45)
68·82
(67·09–
70·46)
60·87
(58·15–
63·47)
17·81
(16·90–
18·46)
13·79
(12·48–
15·07)
14·97
(13·93–
15·94)
11·60
(10·37–
12·83)
Trinidad and 
Tobago
74·55
(74·07–
74·94)
64·63
(61·71–
67·22)
67·83
(67·34–
68·24)
59·72
(57·26–
61·89)
76·11
(74·90–
77·24)
65·86
(62·82–
68·63)
68·88
(67·40–
70·26)
60·56
(57·82–
63·02)
17·70
(17·11–
18·26)
13·58
(12·32–
14·73)
14·01
(13·42–
14·55)
10·64
(9·59–
11·68)
Virgin Islands 
78·01
(77·51–
78·52)
67·81
(64·87–
70·40)
70·91
(70·26–
71·53)
62·41
(59·95–
64·67)
78·72
(77·88–
79·47)
68·35
(65·40–
71·18)
70·34
(68·90–
71·64)
62·04
(59·52–
64·54)
18·47
(18·11–
18·79)
14·26
(13·03–
15·36)
14·52
(13·95–
15·13)
11·03
(10·04–
12·07)
Tropical Latin 
America
76·21
(75·81–
76·58)
65·73
(62·71–
68·45)
68·77
(68·38–
69·19)
60·66
(58·25–
62·82)
78·18
(77·61–
78·70)
67·36
(64·20–
70·06)
70·75
(70·08–
71·38)
62·38
(59·89–
64·58)
18·72
(18·37–
19·08)
14·21
(12·88–
15·37)
15·33
(15·06–
15·65)
11·70
(10·66–
12·65)
Brazil
76·21
(75·81–
76·59)
65·73
(62·70–
68·46)
68·69
(68·28–
69·12)
60·58
(58·18–
62·74)
78·21
(77·63–
78·74)
67·38
(64·24–
70·09)
70·72
(70·02–
71·35)
62·35
(59·87–
64·54)
18·74
(18·38–
19·11)
14·23
(12·89–
15·40)
15·32
(15·05–
15·65)
11·70
(10·65–
12·65)
Paraguay
76·10
(75·16–
77·01)
65·86
(62·81–
68·66)
72·03
(71·11–
72·86)
63·47
(60·86–
65·87)
76·95
(75·54–
78·38)
66·44
(63·14–
69·64)
72·09
(70·20–
73·79)
63·54
(60·38–
66·19)
17·79
(17·02–
18·72)
13·48
(12·10–
14·92)
15·74
(14·84–
16·55)
12·01
(10·72–
13·22)
Southeast Asia, east 
Asia, and Oceania
73·95
(73·58–
74·33)
65·33
(62·87–
67·58)
68·52
(68·12–
68·95)
61·40
(59·27–
63·32)
78·38
(77·84–
78·93)
69·11
(66·39–
71·55)
71·90
(71·26–
72·50)
64·36
(62·09–
66·41)
18·48
(18·12–
18·87)
14·53
(13·45–
15·60)
14·95
(14·63–
15·29)
11·86
(10·97–
12·70)
East Asia
74·94
(74·46–
75·43)
66·54
(64·09–
68·73)
69·38
(68·86–
69·89)
62·44
(60·36–
64·35)
79·83
(79·19–
80·49)
70·71
(67·99–
73·12)
73·17
(72·45–
73·88)
65·74
(63·45–
67·78)
18·99
(18·51–
19·50)
15·07
(13·98–
16·18)
15·13
(14·73–
15·54)
12·09
(11·18–
12·92)
China
74·90
(74·41–
75·40)
66·53
(64·05–
68·73)
69·33
(68·82–
69·86)
62·40
(60·32–
64·31)
79·89
(79·24–
80·56)
70·78
(68·07–
73·23)
73·19
(72·44–
73·91)
65·75
(63·43–
67·77)
19·01
(18·52–
19·57)
15·11
(14·00–
16·22)
15·10
(14·68–
15·50)
12·07
(11·16–
12·90)
North Korea
72·55
(69·82–
75·12)
64·12
(60·50–
67·12)
67·53
(64·35–
71·01)
60·93
(57·56–
64·20)
74·89
(72·19–
77·52)
66·20
(62·62–
69·50)
68·94
(65·72–
71·93)
62·22
(58·78–
65·27)
16·59
(15·35–
17·90)
13·02
(11·60–
14·42)
13·94
(12·91–
15·25)
11·14
(10·00–
12·41)
Taiwan 
(province of 
China)
80·69
(80·57–
80·81)
70·76
(67·85–
73·30)
74·48
(74·38–
74·60)
66·78
(64·52–
68·76)
82·50
(81·18–
83·87)
72·18
(68·93–
75·14)
76·64
(75·07–
78·27)
68·54
(65·66–
71·16)
20·75
(19·81–
21·71)
16·11
(14·63–
17·56)
17·83
(17·04–
18·69)
14·14
(12·85–
15·40)
Southeast Asia
72·16
(71·46–
72·89)
62·99
(60·28–
65·42)
67·08
(66·24–
68·00)
59·39
(57·12–
61·51)
75·32
(74·30–
76·32)
65·77
(63·04–
68·45)
69·18
(67·96–
70·46)
61·37
(58·95–
63·67)
17·10
(16·64–
17·58)
13·05
(11·88–
14·14)
14·32
(13·85–
14·99)
11·02
(10·03–
12·01)
Cambodia
66·24
(65·34–
67·27)
57·67
(55·12–
60·05)
61·53
(60·48–
62·59)
54·41
(52·18–
56·48)
72·44
(70·47–
74·65)
63·20
(60·14–
66·32)
66·21
(64·31–
68·00)
58·76
(56·24–
61·37)
15·49
(14·72–
16·72)
11·80 
(10·60–
13·12)
13·09
(12·36–
13·71)
10·05
(9·12–
11·01)
Indonesia
70·11
(69·16–
71·14)
61·40
(58·93–
63·80)
67·35
(66·18–
68·63)
59·63
(57·19–
61·78)
73·29
(71·23–
75·39)
64·06
(61·07–
66·97)
69·01
(66·64–
71·91)
61·21
(58·27–
64·28)
15·80
(15·03–
16·90)
11·97
(10·81–
13·15)
14·17
(13·25–
15·79)
10·88
(9·66–
12·36)
Laos
62·05
(60·33–
63·86)
54·26
(51·70–
56·65)
58·08
(56·59–
59·47)
51·31
(49·04–
53·42)
69·48
(66·71–
72·17)
60·75
(57·56–
63·91)
64·73
(62·17–
67·51)
57·20 
(54·14–
60·31)
15·26
(13·95–
16·63)
11·60
(10·20–
13·00)
13·78
(12·78–
14·71)
10·49
(9·37–
11·60)
Malaysia
76·30
(76·22–
76·37)
66·76
(64·04–
69·16)
72·35
(72·27–
72·44)
64·08
(61·75–
66·23)
78·62
(77·72–
79·60)
68·60 
(65·64–
71·42)
72·39
(70·75–
74·04)
64·21
(61·50–
66·73)
17·89
(17·46–
18·39)
13·71
(12·45–
14·86)
15·16
(14·29–
16·00)
11·79
(10·61–
12·90)
Maldives
78·22
(77·80–
78·65)
67·35
(64·31–
70·02)
75·73
(75·17–
76·25)
66·24
(63·45–
68·64)
82·26
(81·00–
83·52)
71·20
(68·08–
74·17)
78·06
(76·40–
79·63)
68·79
(65·73–
71·60)
20·80 
(19·93–
21·72)
15·90 
(14·43–
17·29)
18·29
(17·22–
19·27)
14·17
(12·75–
15·45)
Mauritius
75·67
(75·40–
75·92)
66·47
(63·85–
68·76)
69·17
(68·91–
69·42)
61·68
(59·50–
63·58)
77·70
(77·09–
78·26)
67·92
(65·14–
70·41)
71·40 
(70·82–
72·07)
63·38
(60·98–
65·51)
17·89
(17·56–
18·24)
13·70 
(12·52–
14·77)
14·77
(14·50–
15·10)
11·39
(10·39–
12·27)
Myanmar
66·02
(61·76–
70·84)
57·67
(53·57–
61·94)
60·74
(56·24–
65·94)
53·78
(49·53–
58·22)
71·20
(66·85–
75·28)
62·24
(58·07–
66·28)
64·92
(60·29–
69·96)
57·56
(53·22–
61·91)
15·05
(13·25–
17·14)
11·36
(9·68–
13·07)
12·90
(11·42–
15·11)
9·82
(8·39–
11·59)
(Table 2 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1627
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Philippines
73·03
(72·88–
73·18)
63·05
(60·16–
65·57)
65·43
(65·27–
65·58)
57·69
(55·43–
59·66)
74·41
(73·36–
75·31)
64·43
(61·55–
67·10)
67·71
(66·63–
68·76)
59·82
(57·37–
61·95)
16·55
(16·00–
17·05)
12·50 
(11·34–
13·58)
13·19
(12·72–
13·67)
10·03
(9·09–
10·89)
Sri Lanka
77·97
(77·72–
78·23)
68·07
(65·20–
70·58)
70·10 
(69·85–
70·36)
62·08
(59·74–
64·13)
81·19
(79·06–
83·24)
70·84
(67·31–
73·92)
74·05
(71·09–
76·93)
65·47
(61·81–
68·87)
19·88
(18·47–
21·33)
15·31
(13·60–
16·89)
16·64
(15·29–
18·11)
12·85
(11·28–
14·39)
Seychelles
75·88
(75·41–
76·46)
66·68
(64·02–
69·12)
68·23
(67·63–
68·81)
60·74
(58·52–
62·75)
77·93
(76·78–
78·97)
68·29
(65·52–
70·95)
70·55
(68·82–
72·14)
62·77
(60·08–
65·25)
17·98
(17·48–
18·44)
13·81
(12·63–
14·94)
14·50
(13·82–
15·26)
11·13
(10·05–
12·20)
Thailand
76·50
(75·95–
77·06)
66·91
(64·21–
69·39)
69·77
(68·82–
70·76)
61·78
(59·27–
64·01)
78·98
(77·47–
80·46)
69·11
(66·04–
72·23)
70·81
(68·74–
73·24)
62·92
(60·29–
65·67)
18·77
(18·08–
19·63)
14·48
(13·16–
15·80)
14·97
(14·25–
16·20)
11·59
(10·51–
12·79)
Timor-Leste
68·04
(66·22–
69·89)
59·73
(57·05–
62·44)
66·97
(65·35–
68·64)
58·74
(55·92–
61·30)
72·96
(70·01–
75·75)
64·02
(60·49–
67·35)
71·98
(68·85–
75·12)
63·08
(59·32–
66·79)
16·40
(14·96–
17·76)
12·60
(11·07–
14·05)
16·61
(15·28–
18·13)
12·61
(11·10–
14·17)
Vietnam
76·96
(74·35–
79·23)
67·23
(63·76–
70·40)
69·45
(66·39–
72·95)
61·89
(58·50–
65·51)
79·38
(77·02–
82·25)
69·76
(66·41–
73·20)
71·31
(67·83–
74·84)
63·80 
(60·25–
67·14)
18·83
(17·64–
20·57)
14·65
(13·11–
16·41)
14·75
(13·69–
16·34)
11·58
(10·33–
13·06)
Oceania
60·94
(56·86–
65·01)
52·15
(48·22–
56·06)
59·03
(55·23–
63·02)
52·11
(48·32–
55·82)
63·72
(58·96–
67·73)
54·48
(49·99–
58·41)
61·42
(57·02–
65·32)
54·24
(50·11–
57·86)
11·91
(10·33–
13·38)
8·73
(7·39–
10·01)
11·74
(10·65–
12·99)
8·86
(7·77–
10·03)
American 
Samoa
74·63
(72·98–
75·91)
64·66
(61·63–
67·36)
69·55
(67·93–
71·11)
61·14
(58·40–
63·76)
74·85
(72·39–
77·07)
64·86
(61·72–
68·10)
70·87
(68·59–
73·17)
62·33
(59·32–
65·44)
16·17
(14·98–
17·31)
12·17
(10·85–
13·56)
14·46
(13·64–
15·44)
10·94
(9·80–
12·13)
Federated States 
of Micronesia
69·93
(64·32–
74·51)
61·17
(55·63–
65·47)
65·36
(60·00–
70·18)
58·15
(52·88–
62·29)
71·54
(65·30–
75·82)
62·52
(56·78–
66·79)
66·52
(60·42–
70·80)
59·17
(53·52–
63·30)
14·60
(11·87–
16·79)
11·12
(8·75–
13·02)
12·96
(10·83–
14·41)
9·94
(8·07–
11·30)
Fiji
67·13
(65·42–
68·78)
58·07
(55·19–
60·77)
62·69
(60·85–
64·52)
55·18
(52·48–
57·81)
68·13
(65·45–
70·87)
58·97
(55·62–
62·18)
63·69
(60·77–
66·48)
56·19
(53·06–
59·16)
13·44
(12·28–
14·61)
10·05
(8·82–
11·33)
11·87
(10·99–
12·73)
8·97
(7·99–
10·00)
Guam
76·52
(75·37–
77·64)
65·90
(62·55–
68·94)
70·07
(68·71–
71·26)
62·30
(60·02–
64·56)
75·31
(73·53–
77·29)
64·87
(61·61–
67·99)
68·49
(66·20–
70·79)
60·87
(58·19–
63·57)
16·69
(15·95–
17·72)
12·55
(11·35–
13·79)
13·65
(12·85–
14·37)
10·52
(9·51–
11·52)
Kiribati
64·94
(62·65–
67·10)
56·02
(52·94–
58·91)
56·94
(54·59–
59·28)
50·14
(47·27–
52·89)
67·44
(64·55–
70·21)
58·34
(54·91–
61·62)
58·85
(55·69–
61·78)
52·04
(48·74–
55·23)
13·39
(12·31–
14·42)
10·04
(8·86–
11·15)
10·74
(9·94–
11·52)
8·13
(7·19–
9·08)
Marshall Islands
66·83
(64·59–
68·99)
57·26
(54·03–
60·39)
62·73
(60·79–
64·89)
54·83
(52·07–
57·66)
69·50 
(66·96–
71·91)
59·42
(55·77–
62·90)
64·57
(61·96–
67·29)
56·37
(53·19–
59·53)
13·79
(12·65–
14·83)
10·12
(8·77–
11·43)
12·42
(11·59–
13·18)
9·23
(8·14–
10·25)
Northern 
Mariana Islands
77·39
(76·65–
78·14)
67·32
(64·34–
69·95)
74·55
(73·60–
75·36)
65·91
(63·22–
68·16)
78·47
(77·15–
79·64)
68·26
(65·13–
71·21)
74·17
(72·71–
75·49)
65·64
(62·87–
68·11)
18·21
(17·55–
18·80)
13·88
(12·59–
15·11)
15·92
(15·26–
16·49)
12·28
(11·15–
13·36)
Papua New 
Guinea
58·54
(53·42–
63·88)
49·82
(45·14–
54·61)
57·25
(52·39–
62·71)
50·55
(45·95–
55·57)
61·85
(55·97–
67·04)
52·62
(47·33–
57·26)
60·13
(54·55–
65·30)
53·11
(47·99–
57·67)
11·07
(9·04–
13·12)
8·02
(6·41–
9·61)
11·34
(9·73–
13·22)
8·52
(7·14–
10·11)
Samoa
73·70
(71·66–
75·83)
64·10
(60·84–
67·21)
70·00
(67·91–
71·97)
61·81
(58·87–
64·79)
74·22
(71·79–
76·62)
64·45
(60·99–
67·91)
72·23
(69·74–
74·55)
63·58
(60·54–
66·60)
15·96
(14·76–
17·15)
12·06
(10·65–
13·56)
15·02
(14·00–
16·06)
11·45
(10·19–
12·72)
Solomon Islands
62·69
(57·49–
68·21)
54·94
(50·49–
59·82)
60·93
(56·04–
65·96)
54·44
(50·20–
58·93)
65·12
(59·19–
70·81)
56·98
(51·74–
61·79)
62·86
(56·96–
68·13)
56·07
(51·03–
60·69)
11·78
(9·54–
14·16)
8·95
(7·07–
10·81)
11·83
(9·87–
13·36)
9·10
(7·53–
10·52)
Tonga
72·70
(71·27–
73·99)
62·79
(59·60–
65·53)
67·29
(65·66–
68·82)
59·53
(56·92–
61·95)
74·68
(72·19–
77·07)
64·43
(60·83–
67·76)
68·40 
(65·44–
71·10)
60·50 
(57·30–
63·51)
16·40 
(15·33–
17·46)
12·25
(10·86–
13·62)
13·64
(12·69–
14·66)
10·39
(9·31–
11·55)
Vanuatu
64·21
(59·00–
69·19)
56·64
(51·85–
61·42)
61·37
(56·42–
66·39)
54·95
(50·36–
59·62)
66·64
(61·23–
70·86)
58·58
(53·61–
62·91)
63·22
(58·12–
67·35)
56·41
(51·72–
60·55)
12·72
(10·52–
14·57)
9·79
(7·92–
11·44)
12·03
(10·43–
13·29)
9·32
(7·90–
10·69)
(Table 2 continues on next page)
 Articles
1628 
www.thelancet.com   Vol 388   October 8, 2016
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
North Africa and 
Middle East
72·55
(71·85–
73·21)
62·33
(59·42–
65·02)
68·64
(67·98–
69·34)
59·98
(57·44–
62·33)
74·94
(74·12–
75·69)
64·29
(61·31–
67·14)
70·07
(69·16–
70·94)
61·16
(58·55–
63·62)
17·58
(17·28–
17·87)
13·07
(11·80–
14·25)
15·37
(15·08–
15·65)
11·55
(10·45–
12·57)
Afghanistan
51·40
(47·39–
55·64)
44·45
(40·62–
48·10)
52·67
(48·93–
56·74)
45·55
(42·13–
49·21)
54·46
(50·19–
58·82)
47·11
(43·28–
51·24)
53·34
(49·22–
57·70)
46·27
(42·42–
50·19)
9·41
(8·21–
10·93)
6·91
(5·82–
8·22)
10·57
(9·49–
12·37)
7·68
(6·52–
9·09)
Algeria
76·07
(74·93–
77·12)
65·55
(62·46–
68·52)
73·51
(72·29–
74·79)
64·39
(61·45–
67·02)
77·44
(76·01–
78·52)
66·66
(63·44–
69·65)
75·37
(74·13–
76·79)
65·91
(63·15–
68·58)
18·29
(17·47–
18·76)
13·73
(12·34–
15·01)
17·48
(16·90–
18·23)
13·26
(11·99–
14·47)
Bahrain
78·06
(77·24–
78·93)
66·10
(62·55–
69·30)
74·63
(73·80–
75·59)
64·92
(62·04–
67·48)
80·34
(78·92–
81·83)
67·98
(64·36–
71·35)
78·21
(76·45–
79·99)
67·89
(64·67–
71·12)
19·23
(18·60–
20·06)
14·00
(12·51–
15·46)
17·76
(16·79–
18·90)
13·22
(11·71–
14·75)
Egypt
72·64
(72·38–
72·87)
62·41
(59·38–
65·08)
67·69
(67·45–
67·94)
59·42
(57·08–
61·59)
74·45
(73·88–
74·95)
63·84
(60·71–
66·58)
68·71
(68·13–
69·28)
60·23
(57·62–
62·46)
16·42
(16·23–
16·61)
12·16
(10·97–
13·28)
13·50
(13·34–
13·66)
10·12
(9·16–
11·03)
Iran
74·58
(72·51–
76·50)
64·28
(61·12–
67·51)
69·64
(67·24–
71·98)
60·98
(57·86–
64·21)
77·98
(75·87–
80·02)
67·13
(63·56–
70·62)
71·85
(69·18–
74·18)
62·99
(59·82–
66·40)
17·85
(16·78–
19·04)
13·34
(11·86–
14·92)
15·06
(14·08–
16·17)
11·40
(10·11–
12·80)
Iraq
68·24
(65·65–
70·65)
58·57
(55·18–
61·60)
63·26
(59·95–
66·53)
54·71
(51·15–
58·09)
70·66
(67·52–
73·64)
60·53
(56·47–
63·92)
64·33
(60·79–
68·46)
55·65
(51·90–
59·50)
14·80
(13·47–
16·11)
10·88
(9·40–
12·25)
13·05
(11·96–
15·04)
9·55
(8·38–
10·94)
Jordan
74·44
(73·52–
75·33)
63·69
(60·58–
66·46)
74·66
(73·91–
75·44)
65·14
(62·30–
67·75)
80·69
(79·65–
81·78)
68·76
(65·18–
72·06)
76·46
(75·09–
77·61)
66·68
(63·79–
69·52)
19·84
(19·18–
20·58)
14·67
(13·09–
16·13)
17·46
(16·64–
18·17)
13·12
(11·76–
14·44)
Kuwait
80·19
(79·91–
80·52)
68·91
(65·71–
71·77)
76·27
(75·99–
76·54)
66·90
(64·25–
69·36)
81·55
(80·47–
82·71)
70·19
(66·81–
73·29)
79·43
(77·94–
80·67)
69·56
(66·56–
72·40)
19·18
(18·38–
20·06)
14·41
(12·88–
15·84)
18·94
(18·09–
19·69)
14·40
(12·97–
15·80)
Lebanon
77·64
(75·78–
79·42)
65·80
(62·25–
69·26)
77·03
(74·16–
79·60)
65·45
(61·58–
69·00)
79·87
(77·76–
82·32)
68·01
(64·42–
71·62)
77·90 
(75·08–
80·86)
66·81
(62·93–
70·47)
19·01
(18·09–
20·31)
14·11
(12·60–
15·68)
17·80
(16·14–
19·72)
13·07
(11·28–
15·01)
Libya
76·92
(76·07–
77·62)
66·28
(63·11–
69·04)
73·91
(73·06–
74·78)
64·74
(61·95–
67·21)
76·86
(75·26–
78·22)
66·09
(62·84–
69·25)
71·41
(68·93–
73·78)
62·45
(59·39–
65·54)
17·84
(16·99–
18·55)
13·34
(11·96–
14·72)
15·90
(14·76–
16·92)
11·99
(10·61–
13·33)
Morocco
73·80
(70·89–
76·16)
63·24
(59·71–
66·72)
71·62
(68·72–
74·08)
61·88
(58·64–
65·13)
75·83
(72·69–
79·05)
64·92
(61·12–
68·62)
73·32
(69·45–
76·58)
63·37
(59·35–
66·89)
17·20
(15·61–
19·00)
12·70
(11·04–
14·44)
16·39
(14·35–
18·01)
12·13
(10·31–
13·70)
Palestine
77·34
(76·55–
78·10)
66·84
(63·82–
69·70)
72·06
(70·51–
73·06)
62·49
(59·81–
65·14)
77·90
(75·78–
79·78)
67·44
(63·98–
70·52)
71·60
(68·64–
74·52)
62·50
(59·06–
65·67)
18·17
(17·04–
19·22)
13·84
(12·39–
15·21)
15·01
(13·92–
16·52)
11·35
(9·94–
12·77)
Oman
78·38
(77·34–
79·32)
66·81
(63·47–
69·91)
74·07
(72·92–
75·18)
64·15
(61·29–
66·85)
79·64
(78·29–
81·14)
67·75
(64·31–
71·05)
75·71
(74·05–
77·69)
65·38
(62·24–
68·65)
18·79
(18·11–
19·71)
13·71
(12·25–
15·17)
16·32
(15·48–
17·55)
12·03
(10·70–
13·57)
Qatar
78·31
(77·49–
79·11)
67·01
(63·71–
70·07)
75·24
(73·63–
76·87)
65·43
(62·30–
68·46)
81·20
(79·43–
82·88)
69·31
(65·82–
72·71)
79·11
(76·93–
81·25)
68·57
(64·92–
71·83)
19·76
(18·65–
20·98)
14·58
(12·92–
16·27)
18·59
(17·07–
19·91)
13·80 
(12·07–
15·51)
Saudi Arabia
80·00
(79·43–
80·55)
68·99
(65·85–
71·89)
75·95
(75·29–
76·58)
66·78
(64·09–
69·25)
82·21
(81·29–
83·09)
70·87
(67·53–
74·08)
77·45
(76·34–
78·53)
68·15
(65·33–
70·73)
20·68
(19·98–
21·46)
15·72
(14·25–
17·18)
17·77
(16·98–
18·51)
13·67
(12·41–
14·90)
Sudan
66·07
(62·29–
70·01)
56·47
(52·50–
60·70)
63·09
(59·34–
67·21)
54·72
(50·75–
58·67)
69·27
(65·38–
73·59)
59·38
(55·50–
63·72)
65·81
(61·55–
69·91)
57·16
(53·08–
61·35)
15·03
(13·32–
17·27)
11·20
(9·59–
13·17)
14·27
(12·39–
15·93)
10·56
(8·92–
12·10)
Syria
77·37
(76·74–
77·97)
67·20
(64·25–
69·78)
73·85
(73·09–
74·68)
65·31
(62·81–
67·63)
74·81
(72·12–
77·75)
63·82
(59·86–
67·73)
62·58
(56·48–
70·19)
54·17
(48·63–
61·05)
17·98
(17·37–
18·82)
13·46
(12·11–
14·74)
15·47
(14·56–
16·66)
11·74
(10·46–
12·98)
Tunisia
78·95
(77·45–
80·46)
68·16
(64·92–
71·20)
73·66
(71·83–
75·41)
64·38
(61·36–
67·24)
80·73
(78·82–
82·71)
69·61
(66·03–
72·89)
74·63
(72·03–
77·02)
65·26
(61·88–
68·39)
19·77
(18·50–
21·22)
14·95
(13·25–
16·56)
16·18
(14·85–
17·69)
12·24
(10·67–
13·82)
(Table 2 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1629
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Turkey
79·52
(78·90–
80·10)
68·04
(64·90–
70·99)
72·91
(72·25–
73·57)
64·01
(61·39–
66·35)
82·37
(81·82–
82·94)
70·49
(66·94–
73·59)
75·90 
(75·25–
76·55)
66·61
(63·86–
69·04)
21·21
(20·91–
21·55)
15·75
(14·19–
17·16)
17·35
(16·89–
17·67)
13·17
(11·92–
14·27)
United Arab 
Emirates
77·32
(76·47–
78·00)
66·22
(63·07–
69·16)
74·16
(73·26–
74·93)
64·47
(61·53–
67·14)
78·02
(75·54–
79·89)
67·00
(63·40–
70·34)
74·52
(71·82–
77·08)
65·04
(61·38–
68·31)
17·99
(16·84–
18·95)
13·46
(11·93–
14·80)
15·92
(14·70–
17·04)
11·98
(10·50–
13·33)
Yemen
64·72
(59·58–
70·44)
56·24
(51·57–
61·26)
64·41
(59·19–
69·89)
56·78
(52·15–
61·46)
66·57
(60·83–
71·63)
57·71
(52·65–
62·10)
65·39
(59·70–
70·23)
57·40
(52·34–
61·68)
13·55
(11·14–
16·14)
10·28
(8·32–
12·21)
14·03
(11·65–
16·29)
10·71
(8·75–
12·50)
South Asia
65·22
(64·66–
65·79)
55·61
(52·88–
58·11)
62·43
(61·92–
62·97)
54·26
(51·89–
56·37)
69·56
(68·83–
70·27)
59·52
(56·53–
62·18)
65·42
(64·74–
66·10)
57·15
(54·76–
59·35)
15·10
(14·74–
15·47)
11·19
(10·11–
12·26)
13·39
(13·11–
13·69)
10·04
(9·15–
10·90)
Bangladesh
68·70
(67·58–
69·89)
58·62
(55·71–
61·43)
65·67
(64·60–
66·76)
57·34
(54·71–
59·68)
72·52
(70·56–
74·46)
62·18
(58·79–
65·30)
68·52
(66·50–
70·35)
60·06
(57·26–
62·74)
16·16
(14·93–
17·32)
12·13
(10·66–
13·46)
14·58
(13·76–
15·33)
11·12
(10·01–
12·19)
Bhutan
70·15
(67·77–
72·32)
59·82
(56·53–
63·05)
68·68
(66·42–
70·67)
59·58
(56·50–
62·30)
74·26
(71·54–
76·54)
63·08
(59·42–
66·49)
71·50
(69·05–
74·20)
61·95
(58·52–
65·20)
17·80
(16·35–
19·13)
13·11
(11·52–
14·60)
16·35
(15·06–
17·75)
12·22
(10·73–
13·75)
India
65·03
(64·41–
65·66)
55·38
(52·60–
57·89)
62·22
(61·65–
62·83)
54·01
(51·64–
56·15)
69·53
(68·68–
70·43)
59·44
(56·46–
62·17)
65·24
(64·46–
66·00)
56·97
(54·53–
59·20)
15·06
(14·65–
15·51)
11·14
(10·03–
12·17)
13·21
(12·89–
13·53)
9·89
(9·00–
10·75)
Nepal
68·83
(66·99–
70·57)
59·54
(56·41–
62·32)
65·96
(64·42–
67·66)
57·63
(54·90–
60·03)
71·23
(68·75–
73·92)
61·58
(58·13–
64·95)
68·09
(65·20–
70·91)
59·53
(56·39–
62·74)
15·56
(14·22–
17·16)
11·81
(10·30–
13·35)
14·76
(13·48–
16·01)
11·25
(9·97–
12·59)
Pakistan
63·24
(61·42–
65·05)
54·31
(51·48–
57·18)
61·29
(59·54–
63·19)
53·51
(50·86–
55·94)
67·32
(65·22–
69·82)
57·93
(54·76–
61·01)
64·54
(62·22–
66·49)
56·40 
(53·59–
59·28)
14·39
(13·34–
15·78)
10·73
(9·41–
12·06)
13·59
(12·72–
14·32)
10·21
(9·14–
11·34)
Sub-Saharan Africa
55·92
(55·05–
56·74)
47·94
(45·32–
50·16)
54·26
(53·46–
55·10)
47·13
(44·90–
49·12)
63·61
(61·83–
65·17)
54·63
(51·52–
57·44)
60·02
(58·35–
61·58)
52·35
(49·72–
54·90)
14·28
(13·44–
15·06)
10·57
(9·31–
11·69)
13·33
(12·62–
13·99)
9·96
(8·86–
10·99)
Southern sub-
Saharan Africa
51·80 
(50·49–
53·23)
44·71
(42·42–
46·86)
49·85
(48·74–
51·12)
43·62
(41·66–
45·44)
63·21
(61·67–
64·69)
54·06
(51·28–
56·71)
57·51
(56·00–
58·95)
50·14
(47·75–
52·40)
14·81
(14·01–
15·56)
10·80 
(9·59–
11·98)
12·35
(11·68–
13·03)
9·05
(8·05–
9·98)
Botswana
50·78
(39·38–
64·33)
44·97
(34·78–
54·50)
47·92
(38·74–
60·22)
42·81
(34·01–
51·74)
62·01
(47·70–
72·30)
53·95
(41·57–
61·73)
55·78
(43·89–
66·62)
49·39
(39·01–
57·39)
13·82
(7·51–
18·54)
10·57
(5·57–
13·91)
12·01
(7·31–
16·37)
9·10
(5·40–
12·22)
Lesotho
44·77
(41·20–
48·58)
38·92
(35·56–
42·30)
41·21
(38·65–
44·59)
36·45
(34·07–
39·63)
50·41
(43·61–
58·50)
43·83
(37·87–
49·81)
44·11
(38·61–
51·77)
39·13
(34·27–
44·74)
11·49
(8·12–
15·20)
8·57
(5·97–
11·17)
9·26
(7·16–
12·77)
6·87
(5·22–
9·42)
Namibia
55·05
(51·33–
59·06)
47·65
(43·90–
51·40)
51·07
(48·07–
54·29)
44·91
(41·85–
48·01)
68·44
(61·62–
73·04)
58·70 
(52·80–
63·47)
59·98
(53·61–
66·28)
52·56
(46·87–
58·13)
16·51
(12·83–
18·64)
12·31
(9·39–
14·52)
13·01
(10·40–
15·97)
9·79
(7·69–
12·19)
South Africa
53·62
(52·18–
55·38)
46·19
(43·83–
48·49)
51·67
(50·36–
53·14)
45·17
(43·09–
47·15)
63·99
(62·55–
65·18)
54·63
(51·81–
57·23)
58·64
(57·32–
59·91)
51·07
(48·74–
53·20)
14·97
(14·18–
15·69)
10·88
(9·65–
12·06)
12·56
(11·93–
13·21)
9·15
(8·16–
10·12)
Swaziland
43·17
(39·24–
47·45)
37·24
(33·86–
40·73)
41·68
(38·42–
45·84)
36·52
(33·44–
39·83)
54·87
(46·71–
63·97)
47·12
(40·22–
53·87)
48·96
(42·27–
58·26)
43·01
(37·10–
49·82)
12·24
(8·24–
16·65)
9·06
(5·84–
12·09)
10·36
(7·55–
14·68)
7·68
(5·39–
10·79)
Zimbabwe
45·56
(42·36–
49·34)
39·75
(36·90–
42·77)
44·61
(41·95–
48·39)
39·24
(36·79–
42·17)
62·54
(56·27–
68·35)
54·29
(48·68–
59·44)
56·28
(51·09–
62·63)
49·52
(44·79–
54·76)
14·81
(11·38–
18·26)
11·23
(8·38–
13·90)
12·20 
(10·09–
15·22)
9·24
(7·37–
11·68)
Western sub-
Saharan Africa
57·51
(56·07–
58·82)
49·35
(46·72–
51·71)
55·80 
(54·46–
57·19)
48·44
(46·03–
50·65)
64·15
(60·80–
66·47)
55·25
(51·81–
58·49)
60·97
(58·24–
62·97)
53·19
(50·17–
55·91)
14·98
(13·35–
16·06)
11·21
(9·74–
12·54)
14·16
(13·01–
15·00)
10·62
(9·32–
11·78)
Benin
60·97
(56·43–
65·32)
52·53
(48·15–
56·53)
56·21
(52·01–
61·29)
49·70 
(45·45–
53·99)
64·84
(55·71–
72·41)
56·44
(49·10–
62·89)
59·88
(51·34–
68·32)
53·59
(45·88–
60·42)
13·93
(10·08–
17·93)
10·67
(7·51–
13·80)
12·40 
(9·47–
15·93)
9·66
(7·11–
12·34)
(Table 2 continues on next page)
 Articles
1630 
www.thelancet.com   Vol 388   October 8, 2016
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Burkina Faso
56·63
(53·42–
59·73)
48·94
(45·56–
52·15)
55·04
(52·19–
58·27)
48·19
(44·89–
51·56)
61·85
(54·32–
68·96)
54·25
(47·62–
60·31)
60·01
(52·54–
66·03)
53·28
(47·34–
58·69)
13·59
(10·13–
17·19)
10·51
(7·72–
13·28)
13·54
(10·32–
16·35)
10·47
(7·98–
12·83)
Cameroon
55·92
(52·80–
59·52)
48·21
(44·66–
51·56)
53·84
(50·74–
57·25)
46·89
(43·74–
50·19)
61·20 
(53·95–
68·55)
53·35
(46·88–
59·61)
57·59
(50·44–
64·22)
50·85
(44·49–
56·32)
14·06
(10·39–
17·58)
10·68
(7·68–
13·40)
12·99
(9·83–
16·07)
9·86
(7·25–
12·30)
Cape Verde
76·02
(73·41–
76·91)
65·63
(62·25–
68·60)
63·22
(59·21–
68·01)
56·01
(52·27–
60·21)
76·55
(74·33–
77·59)
66·26
(62·96–
69·24)
69·13
(66·18–
71·78)
60·99
(57·64–
64·19)
18·09
(16·79–
18·64)
13·68
(12·17–
15·01)
14·85
(13·40–
16·22)
11·31
(9·78–
12·82)
Chad
54·49
(49·28–
60·02)
47·07
(42·17–
51·79)
51·52
(46·42–
57·50)
44·78
(40·30–
49·49)
58·88
(49·37–
67·61)
51·31
(43·16–
58·31)
55·92
(47·52–
63·60)
48·99
(41·63–
55·16)
13·57
(9·15–
18·17)
10·39
(6·83–
13·74)
12·82
(9·30–
16·41)
9·68
(6·76–
12·31)
Côte d’Ivoire
54·81
(51·77–
58·19)
47·31
(44·08–
50·42)
52·17
(49·40–
55·26)
45·74
(42·79–
48·69)
61·41
(55·01–
68·52)
53·25
(47·55–
58·86)
57·21
(49·99–
64·50)
50·62
(44·57–
56·49)
13·45
(10·36–
17·14)
10·18
(7·63–
12·89)
12·52
(9·58–
15·76)
9·58
(7·19–
12·09)
The Gambia
66·15
(63·52–
69·30)
57·47
(53·89–
60·95)
63·77
(60·62–
66·93)
56·24
(53·02–
59·47)
69·63
(64·33–
74·55)
60·60 
(55·53–
65·49)
66·65
(61·40–
70·72)
58·85
(53·84–
63·05)
15·20 
(12·74–
17·85)
11·66
(9·40–
13·93)
14·44
(12·06–
16·15)
11·12
(9·08–
12·84)
Ghana
62·22
(58·39–
66·35)
54·17
(50·38–
58·28)
59·44
(55·06–
63·57)
52·58
(48·64–
56·59)
67·55
(59·65–
74·25)
59·26
(52·16–
65·27)
63·06
(54·99–
69·81)
56·43
(49·27–
62·23)
14·65
(11·01–
18·42)
11·43
(8·29–
14·33)
13·26
(10·33–
16·14)
10·37
(7·79–
12·80)
Guinea
56·87
(54·19–
59·83)
49·13
(46·04–
52·16)
55·17
(52·35–
58·20)
48·39
(45·37–
51·39)
60·49
(54·52–
67·09)
52·65
(47·07–
58·36)
57·81
(50·80–
64·49)
51·10 
(45·32–
56·48)
13·11
(10·29–
16·46)
10·04
(7·59–
12·67)
12·74
(9·77–
15·74)
9·76
(7·38–
12·08)
Guinea-Bissau
53·45
(41·87–
65·17)
47·62
(37·00–
56·49)
52·32
(41·45–
61·55)
46·95
(36·92–
54·28)
56·44
(42·35–
67·69)
50·29
(37·66–
58·94)
54·86
(41·87–
63·97)
49·30 
(37·55–
56·40)
12·49
(7·38–
18·14)
9·86
(5·56–
13·75)
12·60 
(7·97–
16·67)
9·81
(6·01–
12·82)
Liberia
58·41
(55·78–
61·50)
49·34
(45·91–
52·69)
58·42
(55·80–
61·11)
49·59
(46·21–
52·76)
63·41
(57·41–
69·44)
54·28
(49·06–
59·54)
63·08
(57·54–
67·67)
54·32
(49·25–
58·93)
13·46
(10·70–
16·61)
9·89
(7·64–
12·38)
14·11
(11·59–
16·32)
10·32
(8·27–
12·33)
Mali
57·10 
(54·19–
59·62)
48·99
(45·63–
52·25)
56·70 
(54·17–
59·25)
49·03
(45·80–
51·97)
60·44
(54·41–
66·68)
52·48
(46·95–
57·55)
60·04
(54·18–
64·35)
52·64
(47·53–
56·71)
13·86
(10·84–
16·93)
10·51
(8·06–
12·88)
14·63
(12·17–
16·71)
11·06
(8·94–
12·93)
Mauritania
66·08
(63·12–
68·95)
56·59
(53·00–
60·00)
66·76
(63·89–
69·70)
57·74
(54·26–
60·96)
69·81
(63·59–
75·57)
60·13
(54·58–
65·16)
69·83
(63·66–
75·84)
60·72
(55·13–
65·85)
15·43
(12·47–
18·74)
11·57
(9·08–
13·97)
16·23
(13·54–
19·71)
12·20 
(9·82–
14·85)
Niger
56·69
(53·93–
59·39)
49·23
(46·04–
52·19)
55·23
(52·52–
57·72)
48·42
(45·56–
51·12)
62·47
(56·63–
68·18)
54·62
(49·53–
59·73)
59·58
(52·81–
65·38)
52·71
(46·88–
57·41)
14·18
(11·30–
17·09)
10·82
(8·50–
13·07)
13·37
(10·41–
15·90)
10·20 
(7·88–
12·23)
Nigeria
57·27
(54·37–
59·89)
48·85
(45·55–
51·94)
56·32
(53·71–
59·05)
48·49
(45·46–
51·58)
66·33
(59·47–
70·32)
56·70 
(51·20–
61·03)
62·95
(57·35–
65·78)
54·38
(49·69–
57·95)
16·69
(13·14–
18·76)
12·42
(9·77–
14·48)
15·56
(13·16–
16·63)
11·54
(9·51–
13·09)
São Tomé and 
Príncipe
66·23
(62·95–
69·55)
57·52
(53·96–
60·98)
64·70 
(61·02–
68·11)
56·82
(53·12–
60·37)
68·81
(61·31–
75·85)
59·88
(53·33–
66·12)
67·19
(59·36–
74·84)
59·20 
(52·56–
65·53)
14·08
(10·84–
17·67)
10·72
(8·12–
13·39)
14·05
(11·23–
17·55)
10·75
(8·30–
13·43)
Senegal
63·34
(58·73–
68·24)
54·93
(50·49–
59·50)
60·96
(55·78–
65·54)
53·85
(49·19–
57·99)
66·70 
(58·22–
74·46)
58·42
(50·73–
64·76)
63·84
(54·36–
70·63)
56·97
(48·79–
63·01)
13·78
(10·12–
17·89)
10·62
(7·54–
13·61)
13·27
(9·98–
16·37)
10·37
(7·55–
12·81)
Sierra Leone
53·25
(51·13–
55·51)
45·84
(43·07–
48·53)
51·31
(49·15–
53·49)
44·43
(41·65–
46·90)
57·73
(51·98–
63·30)
50·57
(45·66–
55·39)
56·54
(50·98–
62·48)
49·86
(44·73–
54·86)
12·49
(9·78–
15·38)
9·48
(7·31–
11·79)
12·90 
(10·28–
15·60)
9·74
(7·58–
11·87)
Togo
59·02
(55·78–
62·50)
51·21
(47·63–
54·69)
54·59
(51·23–
58·28)
48·11
(44·83–
51·43)
64·61
(58·52–
70·49)
56·48
(50·97–
61·52)
58·47
(52·25–
65·69)
52·02
(46·39–
57·51)
14·56
(11·46–
17·65)
11·20 
(8·60–
13·65)
12·32
(9·91–
15·47)
9·53
(7·35–
11·85)
Eastern sub-
Saharan Africa
56·08
(54·83–
57·34)
48·45
(45·86–
50·76)
54·53
(53·31–
55·72)
47·61
(45·40–
49·71)
64·32
(61·38–
67·07)
55·84
(52·48–
58·99)
60·50 
(57·72–
63·16)
53·13
(50·12–
56·22)
13·98
(12·61–
15·37)
10·53
(9·15–
11·90)
13·06
(11·85–
14·21)
9·88
(8·61–
11·14)
(Table 2 continues on next page)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1631
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Burundi
55·27
(52·28–
58·06)
48·44
(45·16–
51·56)
54·16
(50·88–
57·52)
47·83
(44·43–
51·02)
62·69
(54·73–
70·23)
55·80 
(48·75–
62·27)
60·10 
(53·06–
67·68)
53·82
(47·80–
59·82)
12·82
(9·59–
16·50)
10·08
(7·37–
12·88)
12·63
(9·89–
15·75)
9·88
(7·68–
12·18)
Comoros
66·70 
(63·68–
69·99)
57·99
(54·66–
61·50)
65·33
(62·26–
68·60)
57·09
(53·78–
60·39)
69·29
(63·40–
75·47)
60·62
(54·98–
65·59)
66·88
(59·97–
73·41)
58·93
(52·88–
64·41)
14·53
(11·92–
17·65)
11·10 
(8·78–
13·54)
14·20 
(11·45–
17·21)
10·82
(8·68–
13·10)
Djibouti
63·91
(53·86–
71·72)
55·49
(47·06–
61·84)
57·84
(47·80–
66·54)
51·35
(42·10–
58·41)
66·98
(56·90–
74·05)
58·00 
(50·10–
64·10)
60·88
(50·23–
69·17)
53·93
(44·93–
60·78)
14·82
(10·34–
18·71)
11·17
(7·77–
13·99)
12·68
(9·03–
16·33)
9·67
(6·85–
12·37)
Eritrea
60·25
(51·43–
69·82)
52·69
(45·09–
59·93)
59·80 
(49·75–
67·61)
52·23
(44·29–
58·27)
61·27
(51·78–
71·86)
54·02
(45·38–
61·97)
60·30 
(50·84–
69·23)
53·13
(44·87–
60·06)
11·72
(8·22–
16·59)
9·11
(6·24–
12·36)
12·28
(9·13–
15·98)
9·37
(6·69–
12·12)
Ethiopia
56·14
(53·45–
58·72)
49·32
(46·48–
52·07)
56·04
(53·51–
58·96)
49·30 
(46·65–
52·30)
66·80 
(59·33–
73·42)
58·77
(52·50–
64·20)
63·57
(55·62–
69·63)
56·28
(49·52–
61·63)
14·27
(10·72–
17·84)
11·00 
(8·27–
13·63)
13·56
(10·54–
16·34)
10·42
(7·90–
12·58)
Kenya
58·53
(57·14–
59·88)
49·67
(46·13–
52·44)
55·96
(54·64–
57·25)
48·76
(46·34–
50·93)
67·57
(65·77–
69·31)
57·66
(53·64–
61·01)
62·82
(61·09–
64·62)
54·92
(52·29–
57·47)
15·31
(14·17–
16·53)
11·45
(9·89–
12·97)
13·87
(13·01–
14·77)
10·59
(9·37–
11·68)
Madagascar
62·33
(59·40–
65·25)
53·64
(50·13–
57·00)
60·13
(56·80–
62·98)
52·03
(48·41–
55·18)
65·04
(57·77–
72·35)
56·75
(50·52–
62·59)
61·91
(54·45–
69·95)
54·43
(48·02–
60·83)
13·15
(10·10–
16·69)
9·99
(7·55–
12·60)
12·64
(9·95–
15·97)
9·56
(7·46–
11·87)
Malawi
49·32
(46·27–
52·66)
42·60 
(39·74–
45·60)
47·72
(44·73–
51·41)
41·63
(38·71–
44·92)
62·98
(56·85–
68·70)
54·97
(49·46–
59·86)
58·15
(51·92–
63·72)
51·35
(46·05–
56·40)
14·81
(11·53–
17·83)
11·32
(8·60–
13·68)
13·51
(10·59–
16·30)
10·37
(7·97–
12·57)
Mozambique
54·79
(51·04–
58·72)
46·48
(42·43–
50·10)
50·88
(47·90–
54·71)
44·16
(41·06–
47·64)
59·86
(52·11–
67·28)
51·69
(45·15–
57·69)
54·28
(47·35–
61·94)
47·80 
(41·60–
53·86)
13·85
(9·99–
17·92)
10·32
(7·24–
13·27)
11·87
(9·20–
15·65)
8·84
(6·56–
11·72)
Rwanda
60·97
(58·02–
64·00)
52·57
(48·95–
56·16)
58·08
(55·32–
61·18)
50·39
(47·21–
53·62)
67·68
(60·39–
73·73)
59·11
(52·82–
64·58)
63·73
(56·40–
69·34)
56·16
(49·82–
61·32)
15·06
(11·69–
18·23)
11·56
(8·91–
14·25)
13·95
(10·78–
16·52)
10·74
(8·17–
12·89)
Somalia
52·51
(41·10–
66·66)
45·86
(35·54–
55·66)
51·66
(41·01–
63·08)
46·33
(36·49–
54·83)
54·98
(42·35–
67·96)
47·96
(37·04–
57·19)
53·40 
(41·87–
64·12)
47·76
(37·41–
55·73)
10·69
(7·12–
16·09)
8·10 
(5·21–
11·73)
11·26
(7·63–
15·67)
8·71
(5·75–
11·88)
South Sudan
55·74
(43·07–
67·56)
48·44
(37·79–
57·07)
54·87
(43·09–
64·34)
47·89
(37·96–
55·43)
56·87
(43·88–
68·72)
49·77
(38·27–
58·38)
55·45
(43·16–
64·87)
48·64
(38·05–
56·08)
11·97
(7·37–
17·66)
8·98
(5·34–
13·00)
12·33
(7·95–
16·51)
9·12
(5·83–
12·18)
Tanzania
57·17
(53·50–
60·79)
49·44
(46·06–
53·05)
57·12
(53·46–
60·80)
49·74
(46·17–
53·19)
65·47
(56·90–
72·65)
57·40 
(50·02–
63·49)
62·69
(54·76–
68·51)
55·32
(48·37–
60·49)
14·46
(10·45–
18·66)
11·18
(7·94–
14·12)
13·93
(10·64–
16·46)
10·71
(8·00–
12·82)
Uganda
55·34
(52·66–
58·44)
47·78
(44·69–
50·97)
51·71
(49·09–
54·57)
45·36
(42·49–
48·23)
64·35
(56·89–
71·57)
56·25
(49·89–
62·36)
58·36
(51·27–
66·03)
51·76
(45·44–
57·69)
14·11
(10·60–
18·08)
10·90 
(7·98–
13·80)
12·40 
(9·73–
15·74)
9·54
(7·25–
12·13)
Zambia
48·46
(45·68–
51·26)
42·41
(39·54–
45·15)
45·78
(43·60–
48·33)
40·36
(37·94–
42·72)
59·83
(53·63–
67·00)
52·38
(46·92–
58·21)
53·97
(48·48–
61·10)
47·77
(42·64–
53·66)
12·74
(9·89–
16·41)
9·81
(7·34–
12·57)
10·61
(8·78–
13·49)
8·07
(6·51–
10·38)
Central sub-
Saharan Africa
56·41
(52·60–
59·67)
46·71
(41·51–
50·81)
54·60 
(51·21–
57·42)
46·50 
(42·70–
49·68)
61·04
(55·98–
66·25)
50·71
(44·61–
55·69)
58·94
(53·90–
63·87)
50·56
(46·12–
54·91)
12·79
(10·79–
15·11)
8·87
(6·84–
10·89)
12·61
(10·67–
14·58)
9·12
(7·53–
10·85)
Angola
55·19
(43·52–
67·89)
47·66
(37·79–
56·61)
55·20 
(44·08–
64·69)
48·52
(38·95–
56·00)
59·75
(45·75–
71·66)
51·73
(39·66–
60·53)
59·55
(46·05–
68·63)
52·43
(41·43–
59·55)
12·10 
(7·38–
17·92)
8·97
(5·42–
12·88)
12·72
(8·13–
16·57)
9·57
(6·13–
12·44)
Central African 
Republic
47·63
(39·73–
57·62)
41·10 
(34·21–
48·26)
43·62
(37·13–
52·61)
38·33
(32·47–
45·21)
51·75
(42·48–
63·18)
45·12
(37·16–
53·72)
47·55
(39·54–
59·15)
42·15
(34·69–
50·66)
10·90 
(7·53–
16·52)
8·25
(5·45–
12·08)
9·75
(7·41–
14·86)
7·34
(5·32–
10·57)
Congo
55·61
(52·62–
58·83)
47·40 
(43·62–
50·61)
58·08
(54·72–
61·61)
50·39
(46·85–
54·00)
60·01
(52·72–
68·01)
51·32
(45·16–
57·62)
63·40 
(55·94–
68·74)
55·23
(48·88–
60·46)
11·54
(8·70–
15·25)
8·42
(6·22–
11·06)
14·00 
(11·01–
16·37)
10·51
(8·10–
12·58)
(Table 2 continues on next page)
 Articles
1632 
www.thelancet.com   Vol 388   October 8, 2016
For people 60 years and older, several causes, including 
ischaemic heart disease, chronic kidney disease, diabetes, 
hearing loss, and Alzheimer’s disease and other 
dementias, ranked among the leading causes of DALYs in 
2015 and caused more DALYs than in 2005. 
Regional and country-specifi
 c HALE
HALE at birth was highest for men in Singapore 
(72·3 years [95% UI 70·1–74·2]) and for women in 
Andorra (76·3 years [72·8–79·4]) in 2015. It was lowest in 
Lesotho for both men (39·1 years [34·3–44·7]) and women 
(43·8 years [37·9–49·8]; table 2; appendix p 12). HALE at 
birth in 2015 exceeded 70 years in only 14 geographies for 
men, while 59 countries and territories surpassed this 
threshold for women. 13 countries and territories had 
HALE lower than 50 years for either sex. Since 2005, 
121 countries and territories had signifi
 cant increases in 
HALE at birth for men and 139 for women, led in both 
cases by Zimbabwe, whereas HALE at birth worsened for 
two countries (Syria and Libya) driven mainly by decreases 
in life expectancy (table 2). HALE at age 65 years was 
highest in Andorra for both men (15·2 years 
[UI 13·9–16·3]) and women (19·4 years [17·8–20·8]) in 
2015, whereas the lowest HALE for men was in Lesotho 
(6·9 years [5·2–9·4]) and for women in Afghanistan 
(6·9 years [5·8–8·2]).
Epidemiological transition
HALE at birth increased continuously and in a largely 
linear manner with increasing SDI for both sexes 
(fi
 gure 4A). At a SDI of 0·20, average HALE was 46·2 years 
for men and 47·1 years for women; by a SDI of 0·90, 
average HALE was 69·8 years for men and 73·8 years for 
women. Among high SDI regions, North America was the 
furthest below expected HALE at birth for both sexes, 
whereas high-income Asia Pacifi
 c remained above 
expected HALE at birth for both sexes and over time. In 
Australasia, male HALE was consistently close to expected 
levels, whereas female HALE remained below expected 
levels since 1990. With the exception of the Caribbean in 
2010 (the year of the Haitian earthquake) HALE at birth 
throughout Latin America and the Caribbean was generally 
higher than expected for both sexes. HALE at birth also 
exceeded expectations in east Asia and north Africa and 
the Middle East. By contrast, Oceania steadily remained 
below expected levels of HALE, and all regions within the 
central Europe, eastern Europe, and central Asia GBD 
super-region had HALE lower than expected over time, 
particularly for men. HALE trends in sub-Saharan Africa 
were heavily infl
 uenced by the HIV
/AIDS epidemic, 
particularly in southern sub-Saharan Africa, where HALE 
was well below expected levels. Notably, after lagging below 
expected levels of HALE before 2005, eastern sub-Saharan 
Africa posted average HALE for women that exceeded 
expected levels. Less pronounced increases occurred for 
men in eastern sub-Saharan Africa, as HALE essentially 
equalled expected levels only around 2010 (fi
 gure 4A).
Years of functional health lost on average increased as 
countries developed (fi
 gure 4B). Among high-income 
regions, all regions except for high-income Asia Pacifi
 c 
consistently exceeded expected levels of functional health 
loss over time, and women generally experienced a 
higher gap than men. South Asia, north Africa and the 
Middle East, and central sub-Saharan Africa had 
generally higher-than-expected functional health loss, 
whereas a number of regions, including Oceania, 
southeast Asia, and east Asia, all recorded smaller gaps 
between life expectancy and HALE than was expected.
The ratio of years of functional health loss to life 
expectancy, the proportion of life expectancy spent with 
disability, declined slightly with increasing SDI (fi
 gure 4C). 
Among men and women, central sub-Saharan Africa had 
the highest proportion of life spent with disability in 2015, 
although high-income North America had the largest 
diff
 erence between observed and expected levels for that 
year. For both sexes, several regions showed higher-than-
expected proportions of life expectancy spent in ill health 
(eg, south Asia, north Africa and the Middle East, and 
2005, at birth
2015, at birth
2015, at age 65 years
Females
Males
Females
Males
Females
Males
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
Life 
expectancy
HALE
(Continued from previous page)
Democratic 
Republic of the 
Congo
57·64
(55·14–
60·61)
47·07
(40·13–
51·19)
55·25
(52·58–
57·86)
46·61
(42·75–
49·94)
62·14
(56·77–
68·11)
51·04
(43·96–
56·67)
59·37
(53·21–
65·66)
50·66
(45·33–
55·99)
13·20 
(10·70–
16·25)
9·04
(6·57–
11·48)
12·70 
(10·21–
15·37)
9·14
(7·12–
11·15)
Equatorial 
Guinea
56·51
(44·74–
67·67)
49·44
(38·84–
57·56)
55·55
(44·50–
63·43)
48·93
(39·34–
55·10)
61·90 
(48·89–
71·63)
53·99
(42·57–
61·32)
60·27
(48·44–
67·38)
53·03
(42·56–
58·90)
13·77
(8·32–
18·74)
10·47
(6·04–
13·86)
13·88
(9·07–
16·60)
10·47
(6·73–
12·86)
Gabon
61·28
(58·52–
64·16)
51·68
(47·81–
55·07)
59·26
(55·55–
63·45)
51·16
(47·61–
55·01)
68·45
(61·48–
74·32)
57·02
(50·37–
62·57)
63·58
(56·80–
69·02)
55·00 
(48·91–
60·04)
14·41
(11·30–
17·40)
10·16
(7·60–
12·55)
13·98
(11·11–
16·34)
10·34
(8·00–
12·41)
Data in parentheses are 95% uncertainty intervals. HALE=healthy life expe 
ctancy. SDI=Socio-demographic Index.
Table 2: Global, regional, and national or territory life expectancy and HALE at birth, by sex, in 2005 and 2015, and HALE at age 65, by sex, in 2015
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1633
Australasia), whereas others experienced lower-than-
expected levels over time (eg, southeast Asia, east Asia, 
eastern sub-Saharan Africa, and southern Latin America).
Expected 
age-standardised 
YLL 
rates 
for 
many 
communicable causes and neonatal conditions declined 
profoundly as SDI increased (fi
 gure 5A). At the same time, 
age-standardised YLD rates for the leading causes of YLDs 
such as mental and substance abuse disorders and 
musculoskeletal disorders demonstrate relatively little 
change. At higher SDIs, the composition of disease burden 
shifted toward YLDs as the primary driver of burden, 
mainly due to the diff
 erential pace of change. The combined 
eff
 ect of the change in age-specifi
 c rates and age-structure 
change that occur with development is shown in fi
 gure 5B, 
which provides expected all-age YLL and YLD rates for 
Level 2 causes. Demographic shifts in age-structure 
potentiate and accelerate the transition from Group 1 
conditions toward NCDs in terms of the composition of the 
burden of disease that health systems must handle. Of 
note, from an SDI of 0·8 onwards further declines in the 
age-standardised rates are matched or exceeded by 
increases in population age structure so that all-age rates 
for YLDs actually increase, as do YLL rates for some causes 
such as neurological conditions. These characterisations of 
the epidemiological transition demonstrate the double 
burden of communicable diseases and NCDs for 
populations with an SDI in the intermediate range.
Observed versus expected total and cause-specifi
 c burden
In 2015, the Maldives and Nicaragua had the lowest ratios 
of observed to expected all-ages DALY rates; many countries 
throughout Latin America also had lower-than-expected all-
ages DALY rates (fi
 gure 6). Other regions where observed 
all-ages DALY rates fell below expected levels, included 
western Europe (eg, Portugal, Spain, France, Italy, and 
Sweden); western sub-Saharan Africa (eg, Burkina Faso, 
Figure 2: Leading 30 Level 3 causes of global DALYs for both sexes combined, 1990, 2005, 2015, with percentage change in number of DALYs, and all-age, and age-standardised rates
Causes are connected by lines between time periods; solid lines are increases and dashed lines are decreases. For the time period of 1990 to 2005 and for 2005 to 2015, three measures of change are 
shown: percent change in the number of DALYs, percent change in the all-age DALY rate, and percent change in the age-standardised DALY rate. Statistically signifi
 cant changes are shown in bold. 
DALYs=disability-adjusted life-years. COPD=chronic obstructive pulmonary disease.
Leading causes 1990
Leading causes 2005
Leading causes 2015
% change,
number
of DALYs
1990–2005
% change,
all-age 
DALY rate 
1990–2005 
% change, age-
standardised
DALY rate
1990–2005
% change,
number
of DALYs
2005–15
% change,
all-age 
DALY rate 
2005–15 
% change, age-
standardised
DALY rate
2005–15
Communicable, maternal, 
neonatal, and nutritional
Non-communicable
Injuries
1 Lower respiratory infection
1 Ischaemic heart disease
1 Ischaemic heart disease
11·0
0·1
–23·8
18·6
–24·4
–27·2
25·2
–14·6
–6·5
–32·6
29·0
0·1
1·3
–38·3
18·2
–3·3
12·3
–19·0
14·5
19·6
–4·4
19·9
15·3
–0·2
–2·6
9·2
–10·6
14·8
32·8
–5·9
–1·8
–11·3
–32·6
4·9
–33·1
–35·7
9·9
–24·2
–17·1
–40·4
14·6
–11·5
–9·4
–45·0
4·5
–17·2
–0·7
–28·2
1·1
4·8
–15·4
6·0
2·0
–11·7
–13·9
–3·3
–21·4
1·5
17·4
–16·8
–14·2
–22·2
–31·0
–2·1
–28·6
–34·0
0·6
–19·2
–17·6
–40·3
1·6
–22·1
–5·5
–43·1
1·0
–11·3
0·6
–32·4
–11·3
–3·0
–17·0
0·8
0·8
–5·5
–16·9
–8·7
–17·8
1·0
–3·4
–16·1
26·3
–37·2
21·6
–37·9
584·8
–37·3
20·7
34·5
–2·4
11·8
–1·1
–13·1
39·4
13·8
–15·0
65·1
32·9
22·7
14·8
31·7
7·0
36·6
29·7
–23·9
51·5
–12·3
–36·1
–65·1
–38·0
6·0
2·7
–49·0
–1·0
–49·4
445·2
–49·0
–1·4
9·4
–20·4
–9·0
–19·6
–28·3
11·7
–10·0
–30·5
34·4
8·1
–0·2
–6·8
7·4
–12·9
10·0
5·6
–38·3
23·3
–28·7
–48·0
–71·8
–49·6
–13·7
–12·2
–37·5
–13·0
–36·1
446·8
–39·3
18·3
–1·8
0·3
–7·9
–27·7
–13·4
2·1
–1·3
–35·8
18·3
0·6
1·2
–10·9
–6·1
10·5
3·5
–0·3
–26·8
13·4
–31·2
–36·2
–64·6
–42·8
–15·4
2 Neonatal preterm birth
2 Lower respiratory infection
2 Cerebrovascular disease
3 Diarrhoeal diseases
3 Cerebrovascular disease
3 Lower respiratory infection
4 Ischaemic heart disease
4 Neonatal preterm birth
4 Low back and neck pain
5 Cerebrovascular disease
5 HIV/AIDS
5 Neonatal preterm birth
6 Neonatal encephalopathy
6 Diarrhoeal diseases
6 Diarrhoeal diseases
7 Malaria
7 Malaria
7 Sense organ diseases
8 Measles
8 Low back and neck pain
8 Neonatal encephalopathy
9 Congenital anomalies
9 Road injuries
10 COPD
10 Road injuries
10 HIV/AIDS
11 Road injuries
11 COPD
11 Diabetes
12 Low back and neck pain
12 Congenital anomalies
12 COPD
13 Tuberculosis
13 Sense organ diseases
13 Congenital anomalies
14 Iron-deficiency anaemia
14 Iron-deficiency anaemia
14 Malaria
15 Protein-energy malnutrition
15 Tuberculosis
15 Depressive disorders
16 Sense organ diseases
16 Diabetes
16 Iron-deficiency anaemia
17 Drowning
17 Depressive disorders
17 Skin diseases
18 Meningitis
18 Skin diseases
18 Tuberculosis
19 Depressive disorders
19 Self-harm
19 Lung cancer
20 Skin diseases
20 Lung cancer
20 Chronic kidney disease
21 Self-harm
21 Neonatal sepsis
21 Self-harm
22 Other neonatal
22 Chronic kidney disease
22 Other musculoskeletal
23 Asthma
23 Migraine
23 Migraine
24 Diabetes
24 Meningitis
24 Neonatal sepsis
25 Neonatal sepsis
25 Other musculoskeletal
25 Asthma
26 Tetanus
26 Asthma
26 Falls
27 Lung cancer
27 Protein-energy malnutrition
27 Meningitis
28 Falls
28 Measles
28 Anxiety disorders
29 Migraine
29 Drowning
29 Alzheimer’s disease
30 Chronic kidney disease
30 Falls
30 Interpersonal violence
31 Other neonatal
31 Interpersonal violence
31 Protein-energy malnutrition
32 Interpersonal violence
34 Other musculoskeletal
34 Other neonatal
33 Anxiety disorders
37 Anxiety disorders
35 Drowning
37 Alzheimer’s disease
42 HIV/AIDS
81 Measles
72 Tetanus
49 Alzheimer’s disease
100 Tetanus
9 Neonatal encephalopathy
 Articles
1634 
www.thelancet.com   Vol 388   October 8, 2016
Niger, and Senegal); eastern sub-Saharan Africa (eg, 
Burundi and Ethiopia); north Africa and the Middle East 
(eg, Jordan, Saudi Arabia, and Turkey); east Asia (eg, 
China); and a subset of countries in South and 
Southeast Asia (eg, Bangladesh, Sri Lanka, and Vietnam). 
By contrast, observed all-ages DALY rates exceeded expected 
levels in southern sub-Saharan Africa, much of central Asia 
and eastern Europe, and a number of countries in central 
sub-Saharan Africa. Notably, observed all-ages DALY rates 
surpassed expected levels in the USA.
Ischaemic heart disease and stroke were the leading two 
causes of DALYs worldwide in 2015, and 106 geographies 
also had one of these diseases as the leading cause of 
DALYs that year (fi
 gure 7). Four GBD super-regions 
showed deviations from this trend: Latin America and the 
Caribbean, where diabetes and interpersonal violence 
often resulted in the most DALYs; north Africa and the 
Middle East, where war was a primary cause of burden; 
south Asia, where neonatal disorders often ranked among 
the leading causes of DALYs; and sub-Saharan Africa, 
where HIV
/AIDS or malaria was the leading driver of 
disease burden in 29 geographies.
Stroke resulted in the most countries (94) having lower 
observed DALYs than expected based on their SDI. Other 
leading causes for which observed DALYs were well below 
expected 
levels 
included 
ischaemic 
heart 
disease 
particularly in Latin America, east Asia, and southeast 
Asia; road injuries in north Africa and the Middle East; 
and lower respiratory infections and diarrhoeal diseases in 
sub-Saharan Africa. Many high-income countries and 
territories also had lower-than-expected DALYs from 
ischaemic heart disease and Alzheimer’s disease and other 
dementias. Road injuries accounted for lower burden than 
expected in 52 countries and territories, especially in 
Colombia. Although many Group 1 causes remained 
among the leading causes of DALYs, observed levels were 
often lower than expected on the basis of SDI (eg, lower 
respiratory infections in Ethiopia, diarrhoeal diseases in 
Afghanistan, and preterm birth complications in Kenya).
By contrast, diabetes was a leading cause for which 
observed burden exceeded expected levels in many 
geographies, especially in Oceania and the Caribbean. 
Observed DALYs due to chronic obstructive pulmonary 
disease were higher than expected in 30 geographies, as 
were those due to liver cancer and lung cancer for a subset 
of countries and territories. Drug use disorders led to more 
observed DALYs than expected in many high-income 
countries in 2015, particularly in the USA and Australia. 
A similar pattern occurred for self-harm, cirrhosis, alcohol 
use disorders, and drug use disorders throughout eastern 
Europe, and most prominently in Russia. Interpersonal 
violence was among the leading two causes of DALYs for 
six of 11 countries in central and tropical Latin America 
(Brazil, Colombia, El Salvador, Guatemala, Honduras, and 
Figure 3: Leading ten Level 3 causes of global age-specifi
 c DALYs in 2015
Each cause is coloured by the percentage change in age-specifi
 c DALYs from 2005 to 2015. NN Preterm=neonatal preterm birth complications. NN Sepsis=neonatal sepsis and other neonatal infections. 
LRI=lower respiratory infections. Iron=iron-defi
 ciency anaemia. HIV=HIV/AIDS. Back & neck=low back and neck pain. IHD=ischaemic heart disease. NN Enceph=neonatal encephalopathy due to birth asphyxia 
and trauma. Diarrhoea=diarrhoeal diseases. Skin=skin and subcutaneous diseases. Depression=depressive disorders. Stroke=cerebrovascular disease. Congenital=congenital anomalies. Diabetes=diabetes 
mellitus. COPD=chronic obstructive pulmonary disease. Alzheimer’s=Alzheimer’s disease and other dementias. PEM=protein-energy malnutrition. Conduct=conduct disorder. Sense=sense organ diseases. 
Other NN=other neonatal disorders. Intest inf=intestinal infectious diseases. Violence=interpersonal violence. NN Haemol=haemolytic disease and other neonatal jaundice. Anxiety=anxiety disorders. 
TB=tuberculosis. Lung C= lung, bronchial, and tracheal cancers. STD=sexually transmitted diseases excluding HIV. Haemog=haemoglobinopathies and haemolytic anaemias. CKD=chronic kidney disease. 
Other MSK=other musculoskeletal disorders. Drugs=drug use disorders. Stomach C=stomach cancer. HTN HD=hypertensive heart disease. GBD=Global Burden of Disease. DALYs=disability-adjusted life-years. 
–0·56 to –0·31
–0·31 to –0·19
–0·19 to –0·09
–0·09 to –0·04
–0·04 to 0·01
0·01 to 0·08
0·08 to 0·15
0·15 to 0·23
0·23 to 0·32
0·32 to 0·57
1
2
3
4
5
6
7
8
9
10
Early neonatal (0–6 days)
Late neonatal (7–27 days)
Post-neonatal (28–364 days)
1–4 years
5–9 years
10–14 years
15–19 years
20–24 years
25–29 years
30–34 years
35–39 years
40–44 years
45–49 years
50–54 years
55–59 years
60–64 years
65–69 years
70–74 years
75–79 years
≥80 years
NN Preterm
NN Sepsis
LRI
Malaria 
 
Iron
Iron
Road injuries
Road injuries
Road injuries
HIV
HIV
Back & neck
IHD
IHD
IHD
IHD
IHD
IHD
IHD
IHD
NN Enceph
NN Preterm
Diarrhoea
Diarrhoea
Skin
Skin
Skin
Depression
HIV
Back & neck
Back & neck
HIV
Back & neck
Stroke
Stroke
Stroke
Stroke
Stroke
Stroke
Stroke
NN Sepsis
NN Enceph
Congenital
LRI
LRI
HIV
Depression
Self-harm
Back & neck
Road injuries
Road injuries
IHD
Stroke
Back & neck 
Back & neck
Diabetes
COPD
COPD
COPD
Alzheimer’s
Congenital
Congenital
Malaria
PEM
Diarrhoea
Conduct
Iron
Back & neck
Depression
Depression
Depression
Road injuries
Diabetes
Diabetes
Diabetes
Back & neck  
Diabetes 
Sense
Sense
COPD
Other NN
LRI
PEM
Iron
Intest inf
Asthma
Back & neck
Skin
Self-harm
Self-harm
IHD
Depression
HIV
Sense
Sense
COPD
Sense
Diabetes
Diabetes
Sense
LRI
Other NN
Meningitis
Congenital
Malaria
Road injuries
Self-harm
Violence
Migraine
Migraine
Migraine
Stroke
Depression
Depression
COPD
Sense
Back & neck
Back & neck
Alzheimer’s
LRI
NN Haemol
Diarrhoea
HIV
Meningitis
HIV
Anxiety
Migraine
HIV
Skin
IHD
TB
Diabetes
Road injuries
Lung C
Lung C
Lung C
Lung C
Lung C
Back & neck
Diabetes
STD
Meningitis
Haemog
Drowning
Asthma
Intest inf
Anxiety
Migraine
Violence
TB
Self-harm
Sense
Sense
COPD
Depression
CKD
CKD
LRI
LRI
CKD
Diarrhoea
Malaria
Iron
Skin
Road injuries
Migraine
Violence
Iron
TB
Skin
Stroke
TB
TB
Road injuries
TB
LRI
LRI
Alzheimer’s
Lung C
Back & neck
Meningitis
NN Haemol
NN Preterm
Haemog
Congenital
Haemog
HIV
Other MSK
Drugs
Violence
Other MSK
Migraine
Other MSK
TB
CKD
Depression
Stomach C
CKD
CKD
HTN HD
Rate of change 2005–15 (%)
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1635
Venezuela), and each had observed burden far surpassing 
expected levels. Throughout sub-Saharan Africa, HIV
/
AIDS and malaria resulted in far more DALYs than 
expected based on SDI.
Heterogeneous trends across and within regions 
emerged in terms of both leading causes of DALYs and 
ratios of observed to expected levels. For instance, south 
Asia’s disease burden landscape diverged from global 
patterns, with both ischaemic heart disease and neonatal 
disorders ranking among some of the leading causes of 
burden and often resulting in higher-than-expected 
DALYs (fi
 gure 7). Stroke and lower respiratory infections 
resulted in fewer DALYs than expected for most countries 
in south Asia, yet other causes exacted more DALYs than 
expected on the basis of SDI (eg, tuberculosis in India 
and drowning in Bangladesh). Further, the 2015 Nepal 
earthquake resulted in forces of nature being its leading 
cause of DALYs that year. Many countries in central Asia 
experienced observed DALYs that surpassed expected 
levels due to both Group 1 causes (eg, lower respiratory 
Figure 4: Co-evolution of HALE (A), functional health lost (life expectancy minus HALE; B), and life expectancy spent with disability (life expectancy minus HALE, divided by HALE; C) with 
SDI globally and for GBD regions, 1990 to 2015
Coloured lines show global and region values for each metric. Each point in a line represents 1 year starting at 1990 and ending at 2015. In all regions, SDI has increased year on year so progress in SDI is 
associated with later years for a given region. The black lines indicate trajectories for each geography expected on the basis of SDI alone. GBD=Global Burden of Disease. SDI=Socio-demographic Index. 
HALE=healthy life expectancy. DALYs=disability-adjusted life-years.
Global
High-income Asia Pacific
High-income North America
Western Europe
Australasia
Andean Latin America
Tropical Latin America
Central Latin America
Southern Latin America
Caribbean
Central Europe
Eastern Europe
Central Asia
North Africa and Middle East
South Asia
Southeast Asia
East Asia
Oceania
Western sub-Saharan Africa
Eastern sub-Saharan Africa
Central sub-Saharan Africa
Southern sub-Saharan Africa
A
Males
40
50
60
70
HALE
Females
B
6
8
10
Functional health lost (years)
C
0·4
0·6
0·8
0·10
0·12
0·14
0·16
Life expectancy spent with disability (years)
SDI
0·4
0·6
0·8
SDI
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
���
�����
�
�
� � � � � � � � �� � � � � � � � � � � � ��� ��
� ��
�
�
�
�
�
�
�
�
��� � � � � ��������
� �
�
�
�
�
� � � � � � � � � � � � � � � � � � � �
��
�
�
�
�
��������� �
�
�
� � � � � � � �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
���
�����
�
�
� � � � � � � � �� � � � � � � � � � � � ��� ��
� �
�
�
�
�
�
�
�
�
�
��� � �
� � �
�������
� �
�
�
�
�
� � � � � � � � � � � � � � � � � � � �
��
�
�
�
�
�����
���� � � � � � � � � � � �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
���
�
����
�
�
� � � � � � � � �� � � � � � � � � � � � � �� ��
� �
�
�
�
�
�
�
�
�
�
�� � � �
� � �
��
�����
� �
�
�
�
�
�
� � � � � � � � � � � � � � � � � � �
��
�
�
�
�
��������� � � � � � � � � � � �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
���
�
����
�
�
� � � � � � � � �� � � � � � � � � � � � � �� ��
� ��
�
�
�
�
�
�
�
�
��� � �
� � ��������
� �
�
�
�
�
�
� � � � � � � � � � � � � � � � � � �
��
�
�
�
�
���������
�
�
�
� � � � � � � �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
���
�
���
�
�
�
� � � � � � � � �� � � � � � � � � � � � � �� ��
� ��
�
�
�
�
�
�
�
�
��� � � � � ��������
� �
�
�
�
�
�
� � � � � � � � � � � � � � � � � � �
�
�
�
�
�
�
��������� � � � � � � � � � � �
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
�
���
�
���
�
�
�
� � � � � � � � �� � � � � � � � � � � � � �� ��
� ��
�
�
�
�
�
�
�
�
��� � � � � ��������
� �
�
�
�
�
�
� � � � � � � � � � � � � � � � � � �
�
�
�
�
�
�
��������� � � � � � � � � � � �
 Articles
1636 
www.thelancet.com   Vol 388   October 8, 2016
Figure 5: Expected relationship between age-standardised YLL and YLD rates and SDI (A) and all-age YLL and YLD rates (per 100 000) and SDI (B) for 21 GBD 
Level 2 causes
These stacked curves represent the average relationship between SDI and each cause observed across all geographies over the time period 1990 to 2015. In each 
fi
 gure, the y axis goes from lowest SDI to highest SDI. The left side shows rates for YLLs and the right side shows rates for YLDs; higher rates are further from the 
midline. The diff
 erence between (A) and (B) is the eff
 ect of shifts in population age structure expected with SDI. GBD=Global Burden of Disease. 
SDI=Socio-demographic Index. YLDs=years lived with disability. YLLs=years of life lost.
Forces of nature, war, and legal 
intervention
Self-harm and interpersonal 
violence
Unintentional injuries
Transport injuries
Other non-communicable diseases
Musculoskeletal disorders
Diabetes, urogenital, blood, 
and endocrine diseases
Mental and substance use
disorders
Neurological disorders
Digestive diseases
Cirrhosis and other chronic 
liver diseases
Chronic respiratory diseases
Cardiovascular diseases
Neoplasms
Other communicable, maternal,
neonatal, and nutritional diseases
Nutritional deficiencies
Neonatal disorders
Maternal disorders
Neglected tropical diseases 
and malaria
Diarrhoea, lower respiratory, and 
other common infectious diseases
HIV/AIDS and tuberculosis
75 000
100 000
50 000
25 000
0
10 000
20 000
0·25
0·25
0·50
0·75
1·00
0·50
0·75
1·00
A
B
SDI
SDI
Age-standardised rate per 100 000 people
150 000
100 000
50 000
10 000 20 000
0
Crude rate per 100 000 people
YLL
YLD
YLL
YLD
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1637
infections, preterm birth complications, and neonatal 
encephalopathy) and NCDs such as hypertensive heart 
disease. War was the leading cause of DALYs in fi
 ve 
countries in north Africa and the Middle East in 2015, 
including Afghanistan, Iraq, Libya, Syria, and Yemen. 
Although neonatal sepsis frequently led to higher-than-
expected DALYs in sub-Saharan Africa, burden from 
preterm birth complications fell below expected levels, 
on the basis of SDI, in most countries. Notably, NCDs 
such as diabetes ranked among the leading ten causes of 
DALYs for a subset of countries in sub-Saharan Africa 
(eg, South Africa), whereas nutritional defi
 ciencies also 
remained among leading causes of burden in others (eg, 
Ghana and Zimbabwe); in both instances, observed 
DALYs generally exceeded expected levels.
Discussion
GBD 2015 results show that the world has become 
healthier in the past 25 years. Yet, this progress has not 
been universal. From 1990 to 2015, global HALE at birth 
increased from 56·7 years to 62·8 years, with 191 of 
199 countries or territories recording improved HALE. 
Since 1990, global HALE at age 65 years also improved by 
1·8 years, with an increase in 179 countries or territories. 
The global number of years of functional health lost grew 
during this time, from 8·2 years to 9·1 years. With YLL 
rates falling at a much faster pace than YLD rates, non-
fatal health loss accounted for an increasing proportion of 
global DALYs, rising from 21·2% in 1990, to 32·1% in 
2015. Worldwide progress was largely driven by rapid 
reductions in DALYs from communicable, maternal, 
neonatal, and nutritional diseases, although declines in 
age-standardised DALY rates from NCDs and injuries also 
contributed to overarching gains. Despite reductions in 
age-standardised DALY rates, 137 causes had statistically 
signifi
 cant increases in total DALYs since 2005, a trend 
with extensive implications for health systems. Mental and 
substance use disorders, musculoskeletal disorders, and 
a range of other conditions including idiopathic 
developmental intellectual disability, vision and hearing 
impairment, and neurological disorders all saw rising 
disease burden since 2005, and few saw any evidence of 
declining age-specifi
 c YLD rates.
Considerable research and policy attention has 
considered the existence of compression of morbidity, or 
whether people live healthier lives as their lifespans 
extend.30 Beyond its profound consequences for fi
 nancing 
health 
systems, 
compression 
of 
morbidity 
has 
considerable implications for societal structures and 
expectations about longevity of careers or timing of 
Figure 6: Ratio of observed versus expected age-standardised DALY rates (per 100 000) on the basis of SDI alone for both sexes combined, 2015
Ratios are colour-coded in terms of the magnitude of diff
 erences between observed and expected all-ages DALY rates. Blues indicate much lower observed DALYs than expected levels based on SDI, 
whereas reds refl
 ect that observed DALYs far exceed expected levels given SDI. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. 
TLS=Timor-Leste. FSM=Federated States of Micronesia. SDI=Socio-demographic Index. DALY=disability-adjusted life-years.
Persian Gulf
Caribbean
LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa
Eastern 
Mediterranean
Malta
Singapore
Balkan Peninsula
Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
≤0·63
0·63–0·79
0·79–0·90
0·90–1·0
1·0–1·09
1·09–1·24
1·24–1·56
1·56–2·49
>2·49
Ratio
 Articles
1638 
www.thelancet.com   Vol 388   October 8, 2016
retirement. Compression can be interpreted in both 
absolute and relative terms. Absolute compression implies 
that as people live longer lives, they lose fewer years due to 
functional health loss, whereas relative compression 
implies that as people live longer lives, the ratio of years of 
functional health lost to life expectancy declines. Although 
some evidence shows that compression occurs among 
people with specifi
 c diseases such as diabetes and 
dementia,31,32 national studies show more mixed results.33–35 
This might not be surprising, as most national studies 
rely on self-reported health status and chronic conditions, 
which are then further complicated by variations in how 
individuals use the response scales and profound framing 
eff
 ects.36–39 By contrast, the GBD study provides a more 
comprehensive and comparable assessment of changes in 
functional health status by synthesising many types of 
data, by cause, and applying standardised disability 
weights to refl
 ect the public’s average views of severity of 
diff
 erent conditions. GBD 2015 results unequivocally 
show that as life expectancy increases, people spend more 
time with reduced functional health status, and thus 
absolute expansion of morbidity has occurred. This trend 
is driven by marked declines in age-specifi
 c mortality at 
the same time minimal improvement, if any, has occurred 
for age-specifi
 c YLDs per capita. The proportion of 
lifespans spent in ill health has remained comparatively 
constant since 1990, and did not vary as a function of SDI; 
thus, we found nominal evidence of relative compression 
at the global level.
Drawing from our empirical characterisation of 
epidemiological transitions on the basis of SDI, we found 
that life expectancy and HALE increased linearly with 
SDI, whereas years of functional health lost climbed with 
rising SDI. Historically, increases in SDI are associated 
with a rapid decrease in burden from communicable, 
neonatal, maternal, and nutritional diseases, the leading 
killers of children, adolescent girls, and women. Eff
 orts 
to increase income, provide more years of education, and 
reduce adolescent and total fertility rates thus might 
catalyse additional gains for life expectancy, HALE, and 
reduced disease burden, emphasising the critical role of 
policy interventions beyond more traditional health 
service delivery.
At diff
 erent locations in this continuous process of 
change, we see evidence of a so-called double burden of 
disease: from a SDI of approximately 0·35 to 0·60, we 
expect NCDs and Group 1 causes to each account for at 
least 20% of disease burden. The average relationships 
with SDI imply that within a country with wide inequalities 
in SDI, we should also expect wide variation in disease 
burden patterns. Subnational disparities might be 
consistent with variations in subnational SDI, either 
recording higher or lower burden than that of the national 
level. Use of average patterns can help to benchmark a 
country against others, but such assessments can also help 
to provide insights as to whether public action or other 
factors are helping make inequalities narrower than 
expected based on SDI alone. Given the complexity of 
health patterns identifi
 ed for many causes and diff
 erential 
patterns by age and sex, providing some understanding of 
expected patterns on the basis of SDI alone can help to 
anchor the exploration of results and could provide some 
measure of the performance of health systems or the 
magnitude of avertable burden within each country or 
territory.
The Lancet Commission on Investing in Health40 
galvanised considerable interest in the notion of a “grand 
convergence”, such that levels of under-5 mortality, 
maternal mortality, and some infectious diseases could 
converge across all countries within a generation. 
Convergence can be achieved through progress on in-
creasing SDI (ie, increasing per-capita income and 
average years of schooling, and reducing fertility) 
and reducing or inverting high ratios between observed 
and expected (based on SDI alone) health expectancies and 
health gaps. The Commission has argued that, within a 
generation, preventable deaths in children and mothers 
could largely be avoided through increased investment 
of development assistance for health and expanded 
national expenditure on health. The vision inspired 
some of the absolute threshold SDG targets, including 
reducing 
under-5 
mortality 
to 
25 
deaths 
per 
1000 livebirths, neonatal mortality to 12 deaths per 
1000 livebirths, and maternal mortality ratio to 70 deaths 
per 100 000 livebirths. The relationships between these 
health outcomes, broader health measures, and SDI 
off
 er a framework by which the likelihood of such a 
grand convergence can be assessed. Based on GBD 2015 
results, the historical relationship between SDI and 
health suggests that convergence in the sense of reduced 
absolute diff
 erences in rates is likely to occur with faster 
improvements in SDI. However, if convergence means 
smaller relative diff
 erences, then improvements in SDI 
alone might not be suffi
  cient. Our fi
 ndings show that 
continued SDI improvement does not appear to be 
historically associated with absolute convergence in life 
expectancy or HALE. The Lancet Commission also 
emphasised the importance of hastening progress 
through strategic investments by donors and govern-
ments in eff
 ective health technologies, an approach that 
has the potential to catalyse faster progress than what 
would be expected on the basis of SDI alone. 
Convergence in this scenario could then be interpreted 
as reduction in the ratio of observed to expected burden 
for low-income and lower-middle-income countries 
(LMICs), and could be used as an indirect, but summary, 
metric to monitor health system performance and 
overall progress toward the SDGs. Since history provides 
a perspective for identifying which countries have been 
able to reduce their ratio of observed to expected health 
outcomes, the comprehensive and longitudinal approach 
of the GBD is optimally suited for monitoring health 
system-driven convergence at a macro-level. The same 
tools can also therefore be used to generate insights on 
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1639
progress, or lack thereof, on specifi
 c diseases and 
outcomes of interest. In some cases, there might be 
historical or geographical explanations for high burden 
for some conditions. In other cases, eff
 ective preventive 
and treatment measures have just not yet been 
implemented or are not functioning eff
 ectively.
Shifting from the MDGs to the SDGs dramatically 
broadened the global health agenda.2,3 The SDGs include 
17 goals, 169 targets, and 230 indicators; of these 
measures, 11 goals, 28 targets, and 46 indicators are 
health related.41 At present, 33 of the 46 health-related 
indicators are measured by the GBD study. Amid earlier 
(Figure 7 continues on next page)
Global
High income
High-income North America  
Canada
Greenland
USA
Australasia
Australia
New Zealand
High-income Asia Pacific
Brunei
Japan
Singapore
South Korea
Western Europe  
Andorra
Austria
Belgium
Cyprus
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Israel
Italy
IHD
(0·92)
IHD
(0·91)
IHD
(1·79)
Back & neck
(1·31)
Self-harm
(4·70)
IHD
(1·84)
Back & neck
(1·12)
Back & neck
(1·12)
Back & neck
(1·15)
Back & neck
(0·84)
Diabetes
(4·62)
IHD
(0·52)
IHD
(0·92)
Back & neck
(0·90)
Back & neck
(1·27)
Back & neck
(1·41)
IHD
(1·05)
Back & neck
(1·39)
Back & neck
(1·40)
Back & neck
(1·45)
IHD
(1·30)
Back & neck
(1·15)
IHD
(1·27)
IHD
(0·89)
Back & neck
(1·38)
Back & neck
(1·25)
Back & neck
(1·20)
Back & neck
(1·31)
Stroke
(0·93)
Back & neck
(1·11)
Back & neck
(1·08)
IHD
(1·31)
Lung C
(2·65)
Back & neck
(1·05)
IHD
(1·01)
IHD
(1·02)
IHD
(0·96)
Stroke
(0·74)
IHD
(2·13)
Back & neck
(0·82)
LRI
(1·88)
Stroke
(0·97)
IHD
(0·75)
IHD
(0·78)
Back & neck
(1·22)
IHD
(0·85)
IHD
(1·03)
IHD
(1·08)
Back & neck
(1·38)
IHD
(0·43)
Back & neck
(1·48)
Back & neck
(1·28)
IHD
(0·96)
IHD
(1·12)
IHD
(0·54)
IHD
(0·63)
LRI
(0·65)
Sense
(0·94)
Diabetes
(2·48)
Lung C
(1·20)
IHD
(0·74)
Diabetes
(2·57)
Depression
(1·30)
Depression
(1·33)
Depression
(1·14)
IHD
(0·52)
Back & neck
(0·82)
Sense
(1·05)
Back & neck
(0·60)
Self-harm
(1·45)
Sense
(0·94)
Sense
(0·91)
Sense
(0·93)
Lung C
(1·22)
Diabetes
(1·66)
Lung C
(1·22)
Alzheimer's
(0·96)
Sense
(0·92)
Sense
(0·98)
Stroke
(0·67)
Sense
(0·93)
Sense
(0·92)
Diabetes
(1·47)
Sense
(1·09)
Back & neck
(0·96)
Lung C
(0·98)
Lung C
(1·30)
Alzheimer's
(0·92)
Back & neck
(1·10)
Lung C
(1·31)
Other MSK
(1·87)
Other MSK
(1·93)
Diabetes
(1·40)
Sense
(1·04)
Stroke
(1·59)
Stroke
(0·69)
Sense
(1·01)
Diabetes
(1·76)
Lung C
(0·93)
Alzheimer's
(0·66)
Lung C
(0·87)
Sense
(1·06)
Sense
(0·96)
COPD
(2·17)
Stroke
(0·64)
Lung C
(1·01)
Lung C
(0·95)
Sense
(0·95)
Lung C
(0·77)
Depression
(1·07)
Sense
(0·94)
Stroke
(0·49)
NN Preterm
(0·72)
Stroke
(0·59)
Depression
(1·31)
Sense
(0·91)
NN Preterm
(1·60)
Depression
(1·34)
Sense
(0·84)
Sense
(0·84)
Sense
(0·85)
Alzheimer's
(0·68)
Road injuries
(2·44)
Alzheimer's
(0·67)
Stroke
(0·61)
Sense
(1·02)
Stroke
(0·49)
Depression
(1·12)
Alzheimer's
(0·71)
Alzheimer's
(0·83)
Depression
(1·07)
Stroke
(0·78)
Sense
(0·85)
Depression
(1·03)
Stroke
(0·62)
Lung C
(1·00)
Depression
(0·89)
Lung C
(0·88)
Depression
(1·10)
Alzheimer's
(0·81)
Diarrhoea
(0·76)
Diabetes
(1·32)
COPD
(2·35)
Diabetes
(1·75)
Stroke
(0·81)
COPD
(2·49)
Diabetes
(1·36)
Diabetes
(1·36)
Lung C
(0·79)
Self-harm
(1·25)
Skin
(0·94)
LRI
(0·89)
Depression
(0·95)
IHD
(0·46)
Alzheimer's
(0·73)
Lung C
(0·66)
Depression
(1·07)
Stroke
(0·55)
Road injuries
(1·54)
Alzheimer's
(0·86)
Depression
(1·23)
Alzheimer's
(0·63)
Depression
(1·08)
Alzheimer's
(0·75)
Alzheimer's
(0·77)
Skin
(0·90)
Skin
(0·91)
Lung C
(0·82)
Sense
(1·00)
Alzheimer's
(0·77)
Alzheimer's
(0·97)
Depression
(0·98)
Congenital
(0·80)
Drugs
(4·01)
Lung C
(0·78)
Lung C
(0·78)
Stroke
(0·53)
LRI
(0·83)
Depression
(0·90)
Lung C
(0·66)
Skin
(0·94)
Lung C
(0·85)
Depression
(1·05)
Stroke
(0·44)
Stroke
(0·47)
COPD
(1·41)
Stroke
(0·49)
Sense
(0·79)
Falls
(1·62)
Stroke
(0·33)
Alzheimer's
(0·61)
Depression
(1·21)
Migraine
(1·15)
Migraine
(1·14)
Migraine
(1·14)
Diabetes
(1·10)
NN Enceph
(1·17)
Depression
(1·11)
Drugs
(3·82)
Other MSK
(1·56)
COPD
(1·81)
Alzheimer's
(0·98)
Stroke
(0·56)
Stroke
(0·57)
COPD
(1·38)
Lung C
(0·70)
Congenital
(1·56)
Self-harm
(1·20)
Lung C
(0·75)
Liver C
(2·42)
Diabetes
(0·91)
Falls
(1·07)
Diabetes
(1·09)
Depression
(1·01)
Migraine
(1·14)
Diabetes
(1·40)
Lung C
(0·69)
Self-harm
(0·96)
Diabetes
(1·16)
COPD
(0·97)
Skin
(0·77)
Stroke
(0·51)
Stroke
(0·37)
Depression
(1·06)
Road injuries
(0·80)
COPD
(1·24)
Sense
(0·89)
Skin
(1·02)
Other MSK
(2·14)
Sense
(0·89)
Skin
(0·93)
Skin
(0·93)
Skin
(0·93)
Diabetes
(0·93)
Sense
(1·05)
Stomach C
(1·15)
CKD
(1·13)
Depression
(0·83)
COPD
(0·99)
Skin
(0·87)
Migraine
(1·29)
Self-harm
(1·02)
Skin
(0·90)
Depression
(1·10)
Self-harm
(1·00)
Falls
(1·17)
COPD
(1·26)
Road injuries
(1·05)
Stroke
(0·41)
Anxiety
(1·58)
Lung C
(0·68)
Migraine
(1·39)
HIV
(0·66)
Skin
(0·92)
Other MSK
(1·79)
Stroke
(0·55)
Skin
(1·04)
Other MSK
(1·81)
Anxiety
(1·72)
Drugs
(2·93)
Other MSK
(1·52)
Depression
(0·86)
Iron
(1·06)
Colorect C
(0·77)
Colorect C
(0·82)
Skin
(0·91)
Migraine
(1·17)
Migraine
(1·15)
Falls
(1·16)
Diabetes
(1·02)
Lung C
(0·67)
Skin
(0·94)
Diabetes
(0·92)
Diabetes
(0·70)
Colorect C
(0·79)
Diabetes
(0·58)
Anxiety
(1·23)
COPD
(1·28)
Alzheimer's
(0·73)
Skin
(0·85)
1
2
3
4
5
6
7
8
9
10
 Articles
1640 
www.thelancet.com   Vol 388   October 8, 2016
discussions and negotiations over SDG 3 indicators, 
HALE was proposed as an indicator of overarching 
health status and progress;2 this proposal was not 
ultimately adopted in the fi
 nal set of indicators. HALE 
provides a strong summary measure of overall health 
status because it accounts for functional health loss in 
addition to age-specifi
 c mortality. Other summary 
development 
measures, 
such 
as 
the 
Human 
Development Index, have considered replacing life 
expectancy with HALE as an input to the overall 
assessment.42 The GBD study measures health outcomes 
that are both amenable to intervention and could be risk 
(Figure 7 continues on next page)
Back & neck
(1·42)
IHD
(0·67)
Back & neck
(1·50)
Back & neck
(1·59)
Back & neck
(1·34)
Back & neck
(0·97)
IHD
(1·07)
Back & neck
(1·48)
IHD
(0·96)
IHD
(0·92)
IHD
(0·75)
IHD
(1·49)
IHD
(1·07)
IHD
(0·66)
IHD
(0·75)
Back & neck
(0·88)
IHD
(0·49)
IHD
(2·45)
IHD
(3·25)
IHD
(4·09)
IHD
(1·89)
IHD
(2·50)
IHD
(2·21)
IHD
(1·45)
IHD
(3·28)
IHD
(3·35)
IHD
(1·46)
IHD
(0·90)
IHD
(0·90)
Back & neck
(1·31)
IHD
(0·82)
IHD
(1·17)
Stroke
(0·49)
IHD
(0·45)
Back & neck
(1·25)
IHD
(0·95)
Back & neck
(1·17)
Back & neck
(1·17)
Back & neck
(1·11)
Back & neck
(1·23)
Back & neck
(1·15)
Back & neck
(0·88)
Back & neck
(0·87)
IHD
(0·49)
Stroke
(0·57)
Stroke
(1·71)
Stroke
(2·12)
Stroke
(2·00)
Back & neck
(1·16)
Stroke
(1·73)
Stroke
(1·15)
Stroke
(1·05)
Stroke
(2·49)
Stroke
(1·52)
Stroke
(1·19)
Stroke
(0·99)
Sense
(0·92)
Sense
(0·89)
Lung C
(1·28)
Lung C
(0·90)
IHD
(0·32)
Sense
(0·99)
Stroke
(0·57)
Sense
(0·90)
Lung C
(1·00)
Lung C
(0·95)
Lung C
(1·05)
Lung C
(1·42)
Lung C
(1·05)
Stroke
(0·54)
LRI
(1·45)
Stroke
(0·59)
Back & neck
(0·89)
Back & neck
(1·20)
Back & neck
(1·21)
Back & neck
(1·19)
Stroke
(0·92)
Back & neck
(1·24)
Back & neck
(1·23)
Back & neck
(1·20)
Back & neck
(1·20)
Back & neck
(1·26)
Back & neck
(1·29)
Back & neck
(1·37)
Depression
(1·11)
Diabetes
(0·97)
Sense
(0·90)
Alzheimer's
(0·80)
Sense
(0·83)
Alzheimer's
(0·84)
Alzheimer's
(0·78)
Alzheimer's
(0·76)
Stroke
(0·63)
Stroke
(0·61)
Stroke
(0·47)
Stroke
(0·93)
Stroke
(0·65)
LRI
(1·18)
Stroke
(0·52)
Depression
(1·10)
Lung C
(1·19)
Sense
(1·16)
Self-harm
(1·83)
Self-harm
(1·95)
Sense
(1·08)
Sense
(1·22)
Self-harm
(2·03)
Sense
(0·96)
Self-harm
(2·00)
Sense
(1·17)
Lung C
(1·27)
Sense
(0·94)
Lung C
(0·95)
Depression
(1·02)
Alzheimer's
(0·88)
Sense
(0·81)
Diabetes
(0·75)
Depression
(1·09)
Sense
(0·78)
Depression
(1·08)
COPD
(1·60)
Sense
(0·79)
COPD
(1·31)
COPD
(2·12)
Alzheimer's
(0·87)
Depression
(1·07)
Depression
(1·07)
Sense
(0·86)
Sense
(0·80)
Self-harm
(1·42)
Sense
(1·25)
Sense
(1·18)
HTN HD
(7·31)
CMP
(6·87)
Sense
(1·17)
Depression
(1·00)
Sense
(1·30)
Drugs
(8·36)
Sense
(1·10)
Depression
(0·98)
Stroke
(0·59)
Stroke
(0·32)
COPD
(1·60)
Depression
(1·03)
Depression
(1·09)
Lung C
(0·81)
Diabetes
(1·30)
Lung C
(0·81)
Sense
(0·79)
COPD
(1·56)
Sense
(0·73)
Migraine
(1·75)
COPD
(1·66)
Sense
(0·84)
Diabetes
(1·02)
Diabetes
(1·00)
COPD
(1·05)
Lung C
(1·05)
CMP
(7·41)
Road injuries
(2·00)
Depression
(1·25)
Self-harm
(1·20)
Depression
(1·16)
Cirr Alc
(4·21)
CMP
(9·71)
Depression
(1·29)
Diabetes
(1·09)
Lung C
(0·93)
Alzheimer's
(0·71)
Lung C
(0·65)
Diabetes
(1·26)
Stroke
(0·68)
Alzheimer's
(0·73)
Stroke
(0·34)
Depression
(1·05)
Falls
(1·38)
Alzheimer's
(0·73)
Alzheimer's
(0·72)
Depression
(0·97)
Sense
(0·79)
Sense
(0·79)
Diabetes
(0·99)
Sense
(0·84)
Skin
(0·97)
Depression
(1·03)
Depression
(1·10)
Road injuries
(1·74)
Lung C
(1·28)
Lung C
(0·89)
Lung C
(0·95)
Lung C
(0·90)
Self-harm
(1·06)
Road injuries
(2·09)
Self-harm
(1·36)
Depression
(1·06)
Other Cardio
(1·93)
Migraine
(1·28)
Alzheimer's
(0·76)
Stroke
(0·55)
COPD
(1·69)
Lung C
(0·74)
Diabetes
(0·70)
COPD
(1·22)
Skin
(0·88)
Depression
(0·96)
Depression
(0·95)
Alzheimer's
(0·79)
Alzheimer's
(0·75)
Depression
(1·07)
Road injuries
(0·81)
Congenital
(1·09)
Road injuries
(0·81)
Diabetes
(0·68)
LRI
(1·06)
Drugs
(6·23)
Falls
(1·90)
Alcohol
(8·56)
Diabetes
(1·26)
Road injuries
(1·26)
LRI
(0·75)
Alcohol
(10·72)
Lung C
(0·84)
Colorect C
(1·03)
Skin
(0·81)
Diabetes
(1·23)
Skin
(1·00)
Depression
(0·99)
Anxiety
(1·87)
LRI
(0·61)
Migraine
(1·15)
Lung C
(0·63)
Stroke
(0·46)
Skin
(0·90)
Skin
(0·89)
LRI
(0·74)
Depression
(0·97)
Asthma
(2·28)
Congenital
(1·07)
Road injuries
(0·81)
Anxiety
(1·57)
Self-harm
(1·20)
Road injuries
(1·20)
Depression
(1·17)
Drugs
(6·47)
Diabetes
(0·96)
Depression
(0·97)
Diabetes
(0·89)
Skin
(0·94)
Drugs
(5·90)
HIV
(1·64)
Self-harm
(0·86)
Iron
(1·25)
Skin
(0·86)
Migraine
(1·13)
Skin
(0·89)
Diabetes
(1·25)
Colorect C
(0·94)
COPD
(0·84)
Skin
(0·90)
Migraine
(1·08)
LRI
(0·72)
LRI
(0·71)
Skin
(0·88)
Asthma
(2·13)
LRI
(0·77)
Skin
(0·97)
Skin
(0·97)
Self-harm
(0·78)
Road injuries
(0·76)
Diabetes
(0·93)
Alcohol
(8·90)
Depression
(1·15)
Alzheimer's
(0·59)
Alcohol
(6·81)
Alcohol
(7·02)
Road injuries
(0·51)
Depression
(1·14)
Road injuries
(1·12)
Road injuries
(0·93)
Congenital
(0·77)
1
2
3
4
5
6
7
8
9
10
Luxembourg 
Malta 
Netherlands 
Norway 
Portugal 
Spain 
Sweden 
Switzerland 
UK
England
Northern Ireland 
Scotland 
Wales
Southern Latin America
Argentina 
Chile 
Uruguay
Central Europe, eastern
Europe, and central Asia
Eastern Europe 
Belarus 
Estonia
Latvia 
Lithuania 
Moldova 
Russia 
Ukraine
Central Europe
Albania
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1641
standardised, thus off
 ering a useful set of metrics to 
monitor progress toward specifi
 c SDG targets, such as 
the aim of target 3.8 to achieving eff
 ective universal 
health coverage.
DALYs and other health-gap metrics are one of many 
potential inputs when setting health policy and investment 
priorities, but major research organisations and funders 
such as the US National Institutes of Health and others 
note the use of DALYs to inform budgeting decisions.43–46 
Beyond health metrics, many other inputs are required for 
decision making, ranging from the eff
 ectiveness of 
diff
 erent adoptable policies and programmes, to key 
(Figure 7 continues on next page)
IHD
(0·62)
IHD
(1·74)
IHD
(1·00)
IHD
(2·15)
IHD
(1·82)
Stroke
(1·53)
IHD
(1·18)
IHD
(1·67)
IHD
(1·39)
IHD
(1·03)
IHD
(2·05)
Back & neck
(1·35)
IHD
(1·95)
IHD
(1·52)
IHD
(2·31)
IHD
(1·70)
IHD
(2·77)
IHD
(1·62)
IHD
(1·82)
LRI
(1·27)
IHD
(2·96)
IHD
(1·71)
IHD
(0·63)
Violence
(4·78)
Violence
(6·04)
Back & neck
(0·89)
Violence
(8·82)
LRI
(1·04)
Stroke
(0·72)
Stroke
(1·59)
Back & neck
(1·37)
Back & neck
(1·38)
Back & neck
(1·38)
IHD
(0·98)
Stroke
(1·64)
Back & neck
(1·21)
Stroke
(1·53)
Stroke
(1·27)
Back & neck
(1·34)
IHD
(0·76)
Stroke
(1·44)
Stroke
(0·87)
LRI
(3·36)
Stroke
(1·55)
Stroke
(2·18)
Stroke
(1·54)
Stroke
(2·67)
IHD
(1·19)
LRI
(6·42)
LRI
(2·53)
Violence
(4·14)
IHD
(0·60)
IHD
(0·50)
IHD
(0·43)
IHD
(0·57)
Violence
(4·70)
Back & neck
(1·16)
Back & neck
(1·28)
Stroke
(0·85)
Stroke
(1·09)
Stroke
(1·04)
Back & neck
(1·26)
Back & neck
(1·27)
Stroke
(1·02)
Back & neck
(1·33)
Back & neck
(1·31)
Stroke
(1·05)
Stroke
(0·63)
LRI
(2·00)
Diabetes
(1·71)
Stroke
(1·25)
Back & neck
(0·93)
Back & neck
(1·04)
LRI
(1·19)
Self-harm
(3·02)
NN Preterm
(0·66)
Stroke
(2·21)
Stroke
(1·12)
Back & neck
(0·87)
Diabetes
(1·55)
Back & neck
(0·94)
Sense
(1·16)
CKD
(2·01)
Diabetes
(1·44)
Diabetes
(1·08)
Sense
(1·04)
Lung C
(1·21)
Sense
(1·09)
Lung C
(1·61)
Diabetes
(1·22)
Lung C
(1·43)
Lung C
(1·45)
Sense
(1·03)
Lung C
(1·38)
Sense
(1·06)
Sense
(0·99)
Back & neck
(1·01)
Back & neck
(1·00)
Back & neck
(0·98)
Diabetes
(1·26)
Self-harm
(2·14)
NN Preterm
(0·98)
LRI
(2·19)
Stroke
(0·90)
Congenital
(1·76)
Back & neck
(1·00)
Diabetes
(1·21)
Back & neck
(0·86)
Sense
(1·14)
Depression
(1·01)
Back & neck
(0·94)
Diarrhoea
(0·90)
Sense
(0·98)
Lung C
(1·12)
Sense
(0·97)
Lung C
(1·11)
Sense
(1·05)
Sense
(0·99)
Sense
(1·04)
Sense
(1·27)
Lung C
(1·04)
Diabetes
(1·23)
Lung C
(1·02)
Lung C
(0·86)
NN Preterm
(1·00)
Sense
(1·03)
NN Enceph
(7·12)
Sense
(1·05)
Road injuries
(1·46)
NN Enceph
(1·61)
Liver C
(10·57)
Back & neck
(1·06)
Back & neck
(0·94)
NN Enceph
(2·60)
Road injuries
(0·83)
CKD
(1·88)
Depression
(1·02)
Road injuries
(0·63)
Diabetes
(0·88)
Back & neck
(0·96)
Lung C
(1·16)
Diabetes
(1·15)
Diabetes
(0·78)
Diabetes
(1·48)
Diabetes
(1·50)
Lung C
(1·11)
Diabetes
(1·17)
Diabetes
(1·25)
Depression
(1·04)
Sense
(1·00)
Depression
(1·08)
Depression
(1·09)
NN Enceph
(2·17)
Lung C
(1·29)
Diabetes
(1·53)
Road injuries
(1·05)
NN Preterm
(2·88)
Back & neck
(1·04)
NN Enceph
(3·29)
Diarrhoea
(1·02)
NN Preterm
(2·59)
HTN HD
(5·41)
Sense
(1·06)
Sense
(1·12)
Skin
(1·06)
CKD
(1·25)
Road injuries
(0·77)
IHD
(0·47)
CMP
(5·19)
HTN HD
(5·12)
Depression
(1·04)
Depression
(1·13)
Colorect C
(1·31)
Depression
(1·01)
Depression
(1·04)
Depression
(1·07)
HTN HD
(3·57)
Depression
(1·02)
Diabetes
(1·20)
Diabetes
(0·97)
Congenital
(0·86)
Depression
(1·01)
NN Preterm
(2·17)
Depression
(1·01)
Iron
(2·40)
Congenital
(0·92)
Back & neck
(0·98)
Congenital
(0·70)
NN Enceph
(5·53)
Depression
(0·94)
Stroke
(0·55)
Congenital
(0·96)
Road injuries
(0·61)
Congenital
(0·92)
Sense
(0·96)
Congenital
(0·67)
Depression
(0·98)
Other Cardio
(2·40)
Colorect C
(1·13)
Colorect C
(1·15)
Depression
(1·07)
CMP
(3·63)
Skin
(0·88)
Self-harm
(1·06)
LRI
(0·73)
Colorect C
(1·13)
Colorect C
(1·24)
Alzheimer's
(0·62)
Road injuries
(0·70)
Congenital
(1·21)
Sense
(1·08)
Lung C
(0·95)
Congenital
(1·21)
Road injuries
(0·69)
Road injuries
(1·07)
NN Enceph
(0·82)
Diabetes
(1·56)
Diabetes
(0·89)
Depression
(1·08)
Road injuries
(0·72)
Congenital
(0·87)
Skin
(0·91)
Iron
(1·59)
Iron
(1·05)
Skin
(0·86)
Depression
(1·06)
Alzheimer's
(0·69)
Alzheimer's
(0·62)
COPD
(1·46)
Skin
(0·86)
Road injuries
(0·72)
Road injuries
(1·37)
Diabetes
(0·64)
Self-harm
(0·96)
Skin
(0·88)
Self-harm
(0·84)
Sense
(0·98)
COPD
(0·93)
Depression
(1·02)
COPD
(1·07)
LRI
(1·76)
Iron
(1·30)
Congenital
(1·11)
Iron
(1·04)
Depression
(1·00)
Road injuries
(0·60)
LRI
(0·75)
Depression
(0·94)
Diabetes
(0·70)
Diabetes
(0·56)
LRI
(0·60)
CKD
(1·37)
Colorect C
(0·91)
Colorect C
(1·06)
COPD
(0·77)
Skin
(0·87)
Self-harm
(0·96)
Migraine
(0·98)
CMP
(3·14)
Colorect C
(1·03)
Road injuries
(0·81)
Road injuries
(0·71)
LRI
(0·83)
Colorect C
(0·85)
Depression
(0·97)
Road injuries
(0·64)
Congenital
(1·07)
HTN HD
(3·42)
Sense
(1·10)
Depression
(0·91)
NN Preterm
(0·91)
Haemog
(3·79)
Sense
(1·06)
Sense
(0·93)
CKD
(1·34)
LRI
(0·68)
Stroke
(0·35)
Iron
(1·01)
Depression
(0·90)
Sense
(0·94)
1
2
3
4
5
6
7
8
9
10
Bosnia and Herzegovina
Bulgaria 
Croatia 
Czech Republic
Hungary 
Macedonia 
Montenegro 
Poland 
Romania 
Serbia 
Slovakia 
Slovenia
Central Asia 
Armenia 
Azerbaijan 
Georgia 
Kazakhstan 
Kyrgyzstan 
Mongolia 
Tajikistan 
Turkmenistan
Uzbekistan
Latin America and Caribbean
Central Latin America
Colombia 
Costa Rica 
El Salvador 
Guatemala
 Articles
1642 
www.thelancet.com   Vol 388   October 8, 2016
social, cultural, and ethical considerations. Nonetheless, 
DALYs and other summary health measures might have 
an even more prominent role in the future in setting 
research and development priorities within the health 
sector, particularly in the absence of robust information 
on the eff
 ectiveness or likely success of various research 
projects and programmes.47 As global health research 
funders increasingly use DALYs to shape priority-setting 
processes, health challenges faced by populations with 
less health-care market power, namely poor people, will 
inevitably receive more attention. Shifting to the use of 
disease burden for programme design and evaluation 
(Figure 7 continues on next page)
Violence
(5·08)
Diabetes
(2·22)
CKD
(1·76)
Back & neck
(0·91)
Violence
(9·65)
LRI
(1·31)
LRI
(1·04)
IHD
(0·45)
LRI
(1·58)
IHD
(0·93)
Diabetes
(3·67)
IHD
(1·20)
Diabetes
(2·95)
HIV
(1·07)
IHD
(1·82)
IHD
(0·78)
Diabetes
(2·80)
IHD
(0·83)
Diabetes
(3·04)
IHD
(1·34)
HIV
(1·53)
Diabetes
(2·28)
Diabetes
(3·97)
Diabetes
(2·38)
Diabetes
(3·41)
IHD
(0·75)
Diabetes
(6·79)
IHD
(2·41)
IHD
(0·96)
IHD
(0·59)
Back & neck
(0·96)
IHD
(0·48)
IHD
(0·86)
Back & neck
(0·93)
IHD
(0·51)
LRI
(1·18)
Back & neck
(0·92)
Stroke
(0·82)
IHD
(1·07)
Diabetes
(2·82)
IHD
(0·61)
Diabetes
(1·73)
Back & neck
(0·89)
Stroke
(0·57)
IHD
(0·67)
NN Preterm
(1·19)
IHD
(0·91)
HIV
(2·34)
LRI
(0·72)
Stroke
(0·85)
IHD
(1·19)
Stroke
(0·86)
IHD
(0·99)
Stroke
(1·09)
IHD
(1·81)
Diabetes
(3·58)
Stroke
(0·83)
CKD
(2·59)
IHD
(0·44)
Diabetes
(1·40)
Iron
(3·05)
IHD
(0·39)
Back & neck
(1·00)
Back & neck
(0·91)
Sense
(1·14)
Diabetes
(1·58)
Stroke
(1·19)
Stroke
(1·15)
Stroke
(0·73)
Violence
(3·59)
Diabetes
(2·83)
Back & neck
(0·82)
Stroke
(0·72)
Stroke
(0·69)
Stroke
(1·16)
Diabetes
(2·27)
Diarrhoea
(0·71)
IHD
(0·43)
Back & neck
(0·88)
IHD
(0·55)
Stroke
(1·00)
Diabetes
(1·58)
Stroke
(1·30)
Stroke
(1·12)
Congenital
(1·03)
Back & neck
(0·79)
Diabetes
(0·77)
Violence
(4·60)
Road injuries
(1·15)
Sense
(1·07)
Stroke
(0·62)
Road injuries
(0·95)
Depression
(1·11)
HIV
(1·09)
Back & neck
(0·82)
Back & neck
(0·82)
Back & neck
(0·81)
IHD
(0·70)
Depression
(1·25)
Sense
(1·11)
Back & neck
(0·83)
Road injuries
(0·92)
LRI
(2·14)
Stroke
(1·51)
IHD
(1·14)
Violence
(4·13)
Sense
(1·20)
Back & neck
(0·83)
Back & neck
(0·82)
NN Preterm
(1·83)
Back & neck
(0·81)
Back & neck
(0·89)
Back & neck
(0·98)
Sense
(1·17)
Sense
(0·95)
Sense
(1·19)
Back & neck
(0·90)
Depression
(1·09)
Iron
(1·51)
Diabetes
(1·20)
IHD
(0·32)
LRI
(0·80)
Depression
(1·20)
HIV
(2·74)
Sense
(1·07)
LRI
(0·95)
Sense
(1·19)
Lung C
(1·12)
CKD
(2·21)
Back & neck
(0·82)
Back & neck
(0·80)
Self-harm
(2·36)
Stroke
(1·07)
Back & neck
(0·83)
Violence
(22·36)
Sense
(1·05)
Violence
(4·84)
HIV
(0·96)
Violence
(13·68)
Violence
(28·20)
Sense
(0·95)
Congenital
(1·09)
Congenital
(0·71)
Congenital
(1·02)
Diabetes
(1·35)
Road injuries
(0·67)
NN Enceph
(1·16)
Sense
(1·02)
Skin
(1·03)
Back & neck
(0·89)
Sense
(1·21)
Violence
(12·84)
LRI
(1·22)
Back & neck
(0·84)
Stroke
(0·97)
Depression
(1·14)
LRI
(1·38)
HIV
(0·75)
CKD
(2·26)
NN Preterm
(0·97)
Congenital
(1·26)
NN Preterm
(1·48)
Depression
(1·23)
Depression
(1·11)
NN Preterm
(1·94)
Self-harm
(1·97)
Sense
(1·17)
Sense
(1·19)
Skin
(1·04)
Violence
(3·13)
LRI
(0·38)
Road injuries
(0·83)
Sense
(1·12)
Iron
(1·34)
Road injuries
(0·60)
CKD
(1·58)
Iron
(1·28)
Sense
(1·06)
Skin
(1·12)
Sense
(1·19)
Depression
(1·15)
Road injuries
(0·72)
Skin
(1·04)
Diabetes
(0·82)
Sense
(1·07)
Congenital
(0·89)
Depression
(1·11)
LRI
(1·01)
Road injuries
(1·00)
Sense
(1·00)
CKD
(1·97)
LRI
(1·16)
LRI
(1·34)
Back & neck
(0·82)
Depression
(1·18)
CKD
(2·14)
Diabetes
(0·72)
Road injuries
(0·76)
Depression
(0·87)
Depression
(0·99)
Congenital
(0·93)
Skin
(1·01)
NN Preterm
(0·55)
Depression
(1·08)
Road injuries
(0·56)
Congenital
(1·06)
LRI
(1·49)
Depression
(1·18)
Skin
(1·20)
Stroke
(0·68)
HIV
(2·89)
LRI
(0·82)
NN Preterm
(1·91)
Sense
(0·98)
Sense
(1·06)
Back & neck
(0·84)
NN Preterm
(0·46)
Depression
(1·10)
Stroke
(0·61)
Violence
(3·79)
Sense
(1·05)
Road injuries
(0·89)
CKD
(2·22)
Prostate C
(4·76)
Depression
(0·88)
Depression
(0·91)
Skin
(0·94)
Stroke
(0·46)
Stroke
(0·54)
Diabetes
(0·74)
Sense
(0·97)
Congenital
(0·78)
Congenital
(0·65)
Road injuries
(0·85)
CKD
(2·03)
LRI
(1·67)
CKD
(1·39)
NN Preterm
(0·62)
Iron
(1·32)
Skin
(1·08)
Depression
(1·12)
Depression
(1·07)
Skin
(1·18)
Road injuries
(0·80)
NN Enceph
(0·76)
CKD
(1·39)
Skin
(1·09)
Skin
(1·14)
HIV
(0·97)
LRI
(1·19)
Road injuries
(1·36)
Depression
(1·24)
NN Preterm
(0·40)
Skin
(0·93)
Road injuries
(0·39)
LRI
(1·04)
CKD
(1·64)
Congenital
(0·67)
CKD
(1·31)
Iron
(1·32)
Migraine
(1·07)
Depression
(1·11)
NN Preterm
(3·06)
HTN HD
(9·97)
Prostate C
(3·69)
Depression
(1·04)
Lung C
(0·99)
Alzheimer's
(0·85)
Skin
(1·16)
LRI
(0·79)
Road injuries
(0·75)
Violence
(2·80)
Diabetes
(1·65)
Skin
(1·11)
LRI
(1·07)
CKD
(1·46)
Depression
(1·10)
Congenital
(1·09)
HIV
(1·81)
Skin
(1·16)
1
2
3
4
5
6
7
8
9
10
Honduras 
Mexico 
Nicaragua 
Panama 
Venezuela
Andean Latin America
Bolivia 
Ecuador 
Peru
Caribbean 
Antigua 
The Bahamas 
Barbados 
Belize 
Bermuda 
Cuba 
Dominica
Dominican Republic 
Grenada 
Guyana
Haiti 
Jamaica 
Puerto Rico 
St Lucia
Saint Vincent and the Grenadines 
Suriname 
Trinidad and  Tobago
Virgin Islands
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1643
would benefi
 t poor people, but also potentially increase 
overall effi
  ciency of health research.48 For instance, 
individuals who have historically underfunded conditions, 
such as mental health disorders, substance use, and 
musculoskeletal conditions, would benefi
 t from the 
greater use of DALYs in decision-making processes.
Global progress has been especially rapid in reducing 
disease burden due to a number of communicable 
diseases, including diarrhoeal diseases, lower respiratory 
infections, tuberculosis, syphilis, typhoid, paratyphoid, 
and vaccine-preventable infections such as hepatitis B, 
measles, tetanus, and Haemophilus infl
 uenzae type b. To 
(Figure 7 continues on next page)
IHD
(0·67)
IHD
(0·67)
IHD
(0·66)
Stroke
(1·17)
Stroke
(1·14)
Stroke
(1·14)
Stroke
(1·52)
Diabetes
(2·76)
Stroke
(1·23)
IHD
(1·04)
Stroke
(1·70)
LRI
(1·34)
IHD
(1·23)
IHD
(0·49)
Diabetes
(3·86)
Stroke
(1·14)
IHD
(1·11)
IHD
(0·72)
IHD
(0·82)
IHD
(0·44)
LRI
(0·60)
Stroke
(1·07)
LRI
(1·07)
Diabetes
(3·50)
IHD
(1·54)
Diabetes
(7·08)
IHD
(3·95)
Stroke
(2·16)
Violence
(4·65)
Violence
(4·75)
Road injuries
(0·93)
IHD
(0·59)
IHD
(0·53)
IHD
(0·53)
IHD
(0·62)
Back & neck
(0·99)
IHD
(0·75)
LRI
(0·63)
IHD
(0·93)
NN Preterm
(1·23)
LRI
(2·28)
Back & neck
(0·82)
IHD
(0·93)
LRI
(0·86)
LRI
(1·43)
Diabetes
(1·46)
LRI
(2·14)
Stroke
(0·63)
NN Preterm
(0·59)
IHD
(0·40)
IHD
(2·05)
IHD
(1·11)
Diabetes
(2·35)
IHD
(1·95)
Diabetes
(4·34)
Diabetes
(4·10)
Stroke
(0·68)
Stroke
(0·68)
Stroke
(0·76)
Back & neck
(0·86)
Back & neck
(0·89)
Back & neck
(0·88)
COPD
(1·68)
IHD
(0·63)
Diabetes
(1·20)
Stroke
(1·00)
Diabetes
(1·51)
IHD
(1·12)
Stroke
(0·94)
Sense
(0·98)
CKD
(3·13)
TB
(2·15)
Stroke
(1·25)
Back & neck
(0·81)
Back & neck
(0·79)
Road injuries
(1·29)
Congenital
(0·78)
Road injuries
(0·78)
Stroke
(1·82)
Skin
(1·64)
Stroke
(1·38)
LRI
(2·35)
Stroke
(1·91)
IHD
(1·46)
Road injuries
(0·98)
Road injuries
(0·98)
Back & neck
(0·97)
Road injuries
(0·82)
COPD
(1·29)
COPD
(1·28)
Back & neck
(1·05)
Stroke
(0·77)
LRI
(0·89)
NN Preterm
(0·66)
TB
(6·35)
Stroke
(1·08)
Road injuries
(1·18)
Congenital
(0·72)
Stroke
(0·76)
Diabetes
(1·07)
Diabetes
(1·30)
Self-harm
(2·11)
HTN HD
(7·91)
LRI
(1·61)
IHD
(0·68)
Back & neck
(0·85)
Diabetes
(3·91)
Back & neck
(0·90)
LRI
(0·73)
Stroke
(1·27)
Back & neck
(0·94)
LRI
(0·68)
Back & neck
(0·87)
Back & neck
(0·86)
Diabetes
(1·11)
COPD
(1·21)
Road injuries
(0·87)
Road injuries
(0·86)
Road injuries
(0·94)
Sense
(1·08)
Back & neck
(0·81)
Road injuries
(0·69)
Road injuries
(0·76)
Congenital
(1·08)
Back & neck
(0·75)
Iron
(1·35)
Back & neck
(0·82)
IHD
(0·45)
Back & neck
(0·95)
Sense
(1·14)
Stroke
(0·63)
Diabetes
(0·96)
Stroke
(0·66)
Sense
(0·92)
COPD
(3·33)
Stroke
(0·99)
Skin
(1·41)
CKD
(3·13)
Self-harm
(1·45)
NN Preterm
(0·53)
Depression
(1·23)
Depression
(1·23)
Depression
(1·24)
Sense
(0·94)
Sense
(0·91)
Sense
(0·91)
Liver C
(4·38)
Liver C
(3·50)
Road injuries
(0·74)
Back & neck
(0·94)
Back & neck
(0·76)
Road injuries
(0·94)
Diabetes
(1·49)
Skin
(1·06)
Sense
(1·15)
Sense
(1·13)
Congenital
(0·81)
Stroke
(0·56)
CKD
(2·20)
Back & neck
(0·73)
Measles
(3·94)
Diabetes
(0·60)
Asthma
(3·18)
CKD
(2·20)
CKD
(1·91)
Asthma
(3·05)
Lung C
(1·54)
TB
(2·01)
Diabetes
(0·93)
Diabetes
(0·93)
Congenital
(0·83)
Diabetes
(0·67)
Lung C
(1·36)
Lung C
(1·37)
Sense
(0·77)
Lung C
(0·88)
Sense
(1·01)
Congenital
(0·74)
NN Preterm
(0·76)
Diarrhoea
(0·78)
Skin
(1·15)
Depression
(0·75)
Skin
(1·10)
Back & neck
(0·79)
NN Preterm
(0·61)
Asthma
(2·09)
Sense
(1·18)
Sense
(1·04)
Diarrhoea
(0·31)
Lung C
(1·88)
Road injuries
(0·96)
Sense
(1·03)
Back & neck
(0·91)
Back & neck
(0·84)
Skin
(1·38)
Violence
(2·70)
Sense
(0·99)
Sense
(0·99)
NN Preterm
(0·63)
Lung C
(1·25)
Liver C
(3·16)
Liver C
(3·13)
Lung C
(2·11)
Road injuries
(1·47)
TB
(3·43)
Iron
(0·94)
Sense
(0·99)
NN Enceph
(0·76)
Sense
(1·00)
Stroke
(0·34)
Depression
(0·84)
COPD
(1·12)
Sense
(1·05)
Skin
(1·03)
Diabetes
(1·26)
Liver C
(3·94)
NN Enceph
(0·44)
Skin
(1·06)
NN Preterm
(0·42)
LRI
(0·83)
Self-harm
(1·42)
NN Preterm
(1·19)
Sense
(1·27)
Asthma
(2·61)
Anxiety
(2·14)
Anxiety
(2·15)
Sense
(0·97)
Skin
(0·98)
Depression
(0·73)
Depression
(0·74)
Stomach C
(2·43)
Other MSK
(1·57)
NN Preterm
(0·64)
HIV
(0·37)
Diarrhoea
(2·93)
Back & neck
(0·90)
Depression
(0·84)
Diabetes
(0·41)
Other MSK
(1·72)
NN Enceph
(1·08)
TB
(3·97)
Depression
(0·81)
Skin
(1·07)
CKD
(1·34)
Back & neck
(0·87)
Congenital
(0·79)
Iron
(1·06)
Iron
(0·91)
Road injuries
(0·49)
Congenital
(1·04)
LRI
(2·13)
NN Enceph
(0·74)
LRI
(0·67)
LRI
(0·67)
Skin
(1·13)
Depression
(0·74)
Diabetes
(0·47)
Diabetes
(0·45)
LRI
(0·37)
Skin
(0·93)
Skin
(1·07)
Sense
(0·95)
LRI
(0·68)
Diabetes
(1·13)
Other MSK
(1·84)
Self-harm
(0·69)
Asthma
(1·58)
Congenital
(0·84)
Skin
(1·11)
COPD
(0·78)
Depression
(0·84)
HIV
(0·71)
Skin
(1·04)
Depression
(0·77)
CKD
(2·38)
Congenital
(0·43)
COPD
(1·26)
Skin
(1·40)
CKD
(2·92)
Diarrhoea
(0·46)
1
2
3
4
5
6
7
8
9
10
Tropical Latin America
Brazil
Paraguay
Southeast Asia, east Asia, and Oceania
East Asia
China
North Korea
Taiwan (province of China)
Southeast Asia 
Cambodia 
Indonesia 
Laos
Malaysia 
Maldives 
Mauritius 
Myanmar 
Philippines 
Sri Lanka 
Seychelles 
Thailand 
Timor-Leste 
Vietnam
Oceania
American Samoa 
Federated States of Micronesia 
Fiji
Guam
Kiribati
 Articles
1644 
www.thelancet.com   Vol 388   October 8, 2016
these successes, the last decade has seen profound 
declines in the burden from malaria and HIV
/AIDS. NCD 
trends have been much more complicated. For the leading 
cause of disability, low back and neck pain, a lack of 
knowledge about risks limits the opportunity for 
prevention. Occupational ergonomic factors and high 
body-mass index (BMI) are estimated to be responsible for 
30·9% (29·2–32·5) and 5·5% (3·4–7·6) of YLDs due to 
low back pain, respectively.49 The highest occupational risk 
is found in service industries and manual labour, 
especially agriculture.50,51 The relatively small proportion of 
low back pain that is caused by high BMI is amenable to 
(Figure 7 continues on next page)
Diabetes
(3·56)
Diabetes
(4·03)
LRI
(1·02)
IHD
(0·94)
IHD
(2·00)
Diabetes
(2·23)
IHD
(1·88)
IHD
(1·14)
IHD
(1·14)
War
(1033·96)
IHD
(0·65)
Diabetes
(3·31)
IHD
(1·32)
IHD
(1·24)
War
(1932·51)
Congenital
(1·09)
IHD
(1·94)
IHD
(1·01)
War
(1966·75)
Diabetes
(1·70)
IHD
(1·31)
Road injuries
(1·60)
Road injuries
(1·48)
Neck & back
(0·99)
NN Preterm
(1·21)
War
(8475·03)
Diabetes
(1·32)
Neck & back
(1·13)
IHD
(1·61)
Neck & back
(0·86)
IHD
(1·85)
Diabetes
(2·09)
Stroke
(1·67)
IHD
(0·90)
Stroke
(1·81)
War
(796·25)
War
(796·25)
LRI
(0·70)
Diabetes
(1·10)
Neck & back
(0·95)
Congenital
(1·26)
Road injuries
(1·69)
IHD
(1·83)
IHD
(0·69)
Neck & back
(0·88)
War
(5581·30)
IHD
(0·92)
IHD
(0·61)
NN Preterm
(0·69)
Other Cardio
(9·17)
Neck & back
(0·94)
IHD
(0·84)
Congenital
(1·54)
IHD
(1·32)
Neck & back
(1·02)
IHD
(0·53)
Stroke
(1·46)
IHD
(1·39)
Stroke
(1·71)
Stroke
(0·87)
Diabetes
(3·69)
Stroke
(0·75)
Diabetes
(2·60)
Congenital
(1·18)
Congenital
(1·18)
IHD
(4·31)
NN Preterm
(0·75)
IHD
(0·83)
Stroke
(1·04)
Neck & back
(1·03)
Congenital
(1·22)
Neck & back
(1·00)
Depression
(1·18)
Diabetes
(1·72)
Neck & back
(1·04)
Neck & back
(1·14)
Congenital
(0·86)
Neck & back
(0·95)
Diabetes
(2·92)
Road injuries
(1·23)
IHD
(1·59)
Stroke
(0·88)
IHD
(0·46)
Diabetes
(0·97)
CKD
(2·85)
Skin
(1·34)
COPD
(3·50)
Skin
(1·41)
LRI
(0·46)
LRI
(0·72)
LRI
(0·88)
NN Preterm
(0·78)
NN Preterm
(0·78)
Congenital
(1·56)
Neck & back
(1·04)
Depression
(1·11)
LRI
(0·77)
Stroke
(0·76)
NN Preterm
(0·70)
Diabetes
(1·61)
Congenital
(1·62)
Neck & back
(0·83)
Congenital
(1·09)
NN Preterm
(0·57)
Neck & back
(1·06)
Diabetes
(2·26)
Depression
(1·15)
Congenital
(1·29)
LRI
(0·52)
Neck & back
(1·05)
Stroke
(0·59)
Congenital
(0·97)
LRI
(0·78)
Stroke
(1·62)
Diabetes
(3·03)
Neck & back
(0·90)
CKD
(2·65)
Skin
(1·44)
NN Preterm
(0·56)
Road injuries
(0·97)
Road injuries
(0·97)
Stroke
(2·15)
Stroke
(0·69)
Skin
(1·04)
Diabetes
(1·18)
Diabetes
(1·20)
Diabetes
(1·78)
NN Preterm
(0·70)
Road injuries
(1·32)
Depression
(1·02)
Road injuries
(0·83)
Stroke
(0·49)
Depression
(1·29)
IHD
(0·79)
IHD
(0·67)
Depression
(1·11)
Road injuries
(1·58)
Congenital
(0·77)
Depression
(1·00)
Sense
(0·85)
Skin
(1·39)
Depression
(0·82)
Asthma
(3·13)
CKD
(1·78)
COPD
(1·66)
Neck & back
(0·92)
COPD
(1·53)
Neck & back
(1·07)
Neck & back
(1·07)
NN Preterm
(0·77)
Road injuries
(0·69)
Road injuries
(0·57)
Neck & back
(1·08)
Congenital
(1·02)
Stroke
(1·14)
Road injuries
(0·67)
Diabetes
(2·18)
Sense
(0·90)
Stroke
(0·74)
Road injuries
(0·62)
Road injuries
(0·49)
Depression
(1·07)
Migraine
(1·12)
Skin
(0·95)
Diarrhoea
(0·52)
Depression
(0·94)
Sense
(0·82)
Stroke
(0·40)
Neck & back
(0·88)
Road injuries
(1·04)
Road injuries
(0·98)
LRI
(0·54)
NN Preterm
(0·34)
NN Preterm
(0·53)
Skin
(1·42)
Stroke
(0·84)
Stroke
(0·84)
Road injuries
(2·38)
Congenital
(0·93)
Other MSK
(1·92)
Cirr HepC
(7·30)
Depression
(1·05)
NN Sepsis
(2·44)
Depression
(1·01)
Migraine
(1·06)
Stroke
(0·44)
Diabetes
(0·98)
Congenital
(0·78)
Stroke
(0·70)
Congenital
(0·71)
Skin
(0·94)
Migraine
(1·27)
Stroke
(1·05)
LRI
(0·33)
Road injuries
(0·60)
Depression
(0·92)
NN Preterm
(0·48)
Sense
(1·28)
Diarrhoea
(0·43)
Sense
(0·92)
Skin
(1·32)
Sense
(0·83)
Road injuries
(0·63)
LRI
(0·52)
LRI
(0·52)
Other Unint
(9·71)
Depression
(0·95)
Sense
(1·02)
Iron
(1·53)
Sense
(0·94)
Road injuries
(0·68)
Skin
(0·91)
Skin
(0·88)
Congenital
(1·00)
NN Preterm
(0·61)
Sense
(0·79)
LRI
(0·26)
Sense
(1·01)
Congenital
(1·13)
Diabetes
(1·15)
Neck & back
(1·07)
Sense
(0·78)
Congenital
(0·83)
NN Preterm
(0·82)
Iron
(1·23)
Self-harm
(0·64)
Iron
(1·06)
Congenital
(0·45)
Road injuries
(0·65)
COPD
(1·03)
CKD
(1·70)
Diabetes
(1·26)
Diabetes
(1·26)
Diarrhoea
(0·24)
Sense
(0·82)
Congenital
(0·90)
NN Preterm
(0·48)
Other Cardio
(3·76)
Neck & back
(1·08)
Iron
(0·97)
Sense
(1·09)
Skin
(0·93)
Depression
(1·00)
Depression
(0·88)
Skin
(0·81)
Migraine
(1·10)
Sense
(0·96)
Sense
(1·01)
Iron
(0·81)
Road injuries
(0·37)
NN Preterm
(0·60)
Lung C
(1·18)
Road injuries
(0·51)
Other MSK
(1·60)
NN Preterm
(0·38)
Iron
(0·84)
Neck & back
(0·95)
Asthma
(1·67)
Neck & back
(0·91)
Depression
(0·93)
Depression
(0·93)
Violence
(4·00)
Skin
(0·83)
Migraine
(1·07)
Sense
(0·93)
Drugs
(4·09)
LRI
(0·40)
Sense
(0·92)
Iron
(1·18)
Iron
(1·35)
Other Trans
(10·71)
LRI
(0·27)
CKD
(1·22)
Skin
(0·86)
Anxiety
(1·05)
NN Preterm
(1·01)
Diabetes
(1·26)
Skin
(0·78)
Lung C
(1·21)
Road injuries
(0·51)
1
2
3
4
5
6
7
8
9
10
Marshall Islands
Northern Mariana Islands 
Papua New Guinea 
Samoa 
Solomon Islands 
Tonga 
Vanuatu
North Africa and Middle East
North Africa and Middle East
Afghanistan 
Algeria 
Bahrain 
Egypt
Iran 
Iraq 
Jordan 
Kuwait 
Lebanon 
Libya 
Morocco 
Palestine 
Oman 
Qatar
Saudi Arabia
Sudan 
Syria 
Tunisia 
Turkey
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1645
intervention, but the continued escalation of obesity rates 
indicates that these measures might have little 
eff
 ectiveness. With increasing SDI, the proportion of the 
workforce in agriculture would be expected to become 
smaller, which would have some eff
 ect on the burden of 
low back pain. Yet, based on our analyses, nearly 65% of 
the burden would remain. The management of most low 
back and neck pain is largely focused on pain relief and 
prevention of worsening outcomes through physical 
therapy and exercise; given the very large burden and the 
associated economic consequences of lost work time, low 
back and neck pain should be a priority for research to 
(Figure 7 continues on next page)
IHD
(2·63)
War
(1090·72)
IHD
(1·18)
IHD
(1·18)
Stroke
(1·15)
NN Preterm
(1·24)
IHD
(1·15)
Disaster
(1942·61)
NN Enceph
(2·86)
HIV
(2·70)
HIV
(14·25)
HIV
(14·16)
HIV
(19·51)
HIV
(8·67)
HIV
(16·28)
HIV
(21·40)
HIV
(9·51)
Malaria
(8·72)
Malaria
(11·33)
Malaria
(4·96)
HIV
(3·90)
Stroke
(0·85)
Diarrhoea
(1·22)
Malaria
(32·28)
LRI
(0·36)
Malaria
(81·63)
Malaria
(6·85)
LRI
(0·85)
Road injuries
(3·09)
NN Preterm
(1·05)
NN Enceph
(2·15)
NN Enceph
(2·15)
IHD
(0·91)
IHD
(0·74)
NN Preterm
(1·25)
LRI
(0·58)
IHD
(1·73)
Malaria
(5·04)
LRI
(1·74)
TB
(15·79)
Diarrhoea
(3·49)
LRI
(1·38)
Diabetes
(2·67)
LRI
(2·58)
Diarrhoea
(2·40)
Diarrhoea
(0·96)
LRI
(0·70)
LRI
(0·52)
Malaria
(74·07)
LRI
(0·63)
LRI
(0·95)
HIV
(2·73)
NN Sepsis
(2·23)
LRI
(0·98)
LRI
(0·69)
Diarrhoea
(0·88)
Back & neck
(0·99)
IHD
(2·03)
NN Preterm
(1·07)
NN Preterm
(1·07)
NN Enceph
(1·51)
NN Enceph
(1·88)
NN Enceph
(2·08)
IHD
(0·89)
NN Preterm
(0·85)
LRI
(0·65)
TB
(10·72)
LRI
(1·74)
LRI
(1·86)
Diarrhoea
(3·47)
Violence
(7·21)
Diarrhoea
(6·52)
LRI
(1·06)
LRI
(0·73)
Diarrhoea
(0·46)
Diarrhoea
(0·45)
LRI
(1·17)
Back & neck
(1·01)
Malaria
(3·72)
LRI
(0·92)
Diarrhoea
(0·30)
NN Sepsis
(5·51)
Diarrhoea
(0·37)
HIV
(2·52)
Diabetes
(3·48)
Congenital
(1·34)
LRI
(0·74)
LRI
(0·74)
LRI
(0·51)
Back & neck
(1·05)
COPD
(2·29)
NN Enceph
(1·36)
LRI
(0·61)
Diarrhoea
(0·68)
Diarrhoea
(3·65)
Diabetes
(2·21)
TB
(10·10)
TB
(8·56)
LRI
(2·39)
Road injuries
(2·06)
NN Enceph
(1·54)
HIV
(1·80)
NN Sepsis
(2·64)
NN Sepsis
(1·77)
Diarrhoea
(1·08)
IHD
(0·48)
HIV
(1·87)
NN Sepsis
(4·37)
HIV
(0·96)
HIV
(1·20)
NN Sepsis
(2·22)
Malaria
(2·60)
Stroke
(2·11)
Road injuries
(1·54)
COPD
(2·04)
COPD
(2·04)
Back & neck
(1·06)
Iron
(1·49)
LRI
(0·81)
TB
(1·33)
Diarrhoea
(0·88)
NN Sepsis
(2·39)
Diabetes
(2·35)
IHD
(0·92)
NN Preterm
(1·09)
NN Preterm
(0·76)
TB
(17·11)
TB
(14·05)
NN Preterm
(0·60)
NN Sepsis
(3·59)
NN Preterm
(0·53)
Meningitis
(1·00)
NN Sepsis
(4·62)
HIV
(0·53)
NN Sepsis
(2·61)
Diarrhoea
(0·68)
NN Preterm
(0·38)
NN Preterm
(0·50)
NN Preterm
(0·62)
Meningitis
(1·80)
Depression
(1·18)
LRI
(0·38)
Diarrhoea
(1·07)
Diarrhoea
(1·07)
Drowning
(2·59)
LRI
(0·51)
Diarrhoea
(1·31)
COPD
(1·49)
Stroke
(0·86)
NN Enceph
(0·83)
Road injuries
(1·42)
Road injuries
(1·10)
Road injuries
(1·75)
Road injuries
(1·00)
Road injuries
(1·70)
Diabetes
(2·54)
TB
(4·29)
NN Enceph
(0·98)
NN Enceph
(0·78)
NN Enceph
(0·71)
NN Enceph
(0·98)
Congenital
(0·84)
PEM
(1·67)
NN Preterm
(0·68)
NN Enceph
(0·53)
Stroke
(1·03)
NN Enceph
(0·85)
NN Sepsis
(2·87)
Other MSK
(1·90)
Stroke
(1·16)
Stroke
(0·82)
Stroke
(0·82)
COPD
(1·18)
Diabetes
(0·99)
Stroke
(0·78)
Back & neck
(1·13)
Iron
(1·02)
NN Preterm
(0·48)
Violence
(4·87)
Diarrhoea
(3·93)
Other NN
(5·08)
Other NN
(3·68)
IHD
(0·76)
IHD
(1·17)
NN Sepsis
(2·32)
NN Preterm
(0·52)
Meningitis
(1·20)
PEM
(0·87)
NN Preterm
(0·53)
NN Preterm
(0·51)
NN Preterm
(0·64)
NN Enceph
(1·00)
Congenital
(0·67)
NN Enceph
(0·84)
HIV
(1·09)
NN Preterm
(0·71)
Migraine
(1·14)
Diarrhoea
(0·30)
TB
(1·98)
TB
(1·98)
Other MSK
(2·60)
COPD
(1·20)
TB
(2·41)
Diarrhoea
(0·43)
TB
(1·32)
Congenital
(0·92)
IHD
(0·75)
Stroke
(1·10)
Violence
(4·64)
IHD
(0·67)
Back & neck
(1·04)
Stroke
(1·42)
PEM
(3·20)
Meningitis
(1·45)
PEM
(1·43)
Congenital
(0·88)
Congenital
(1·04)
NN Enceph
(0·93)
Meningitis
(1·47)
Congenital
(0·93)
Meningitis
(0·67)
Congenital
(0·82)
Haemog
(3·00)
PEM
(1·74)
Skin
(0·93)
Back & neck
(1·11)
Iron
(1·39)
Iron
(1·39)
Diabetes
(0·99)
Diarrhoea
(0·87)
Iron
(1·60)
Stroke
(0·49)
Diabetes
(1·31)
PEM
(1·24)
Stroke
(0·94)
Self-harm
(1·95)
IHD
(1·21)
NN Enceph
(1·09)
Stroke
(0·92)
Other NN
(3·78)
Stroke
(0·93)
PEM
(1·52)
Congenital
(0·80)
NN Preterm
(0·36)
Meningitis
(1·91)
Depression
(1·05)
NN Enceph
(0·74)
Stroke
(0·96)
PEM
(0·78)
IHD
(0·76)
Meningitis
(0·96)
STD
(3·39)
Drugs
(1·93)
Diabetes
(1·28)
Back & neck
(0·91)
Back & neck
(0·91)
Sense
(0·95)
Sense
(0·98)
Back & neck
(0·89)
Road injuries
(0·64)
Other Unint
(4·33)
Meningitis
(1·10)
Back & neck
(1·03)
Back & neck
(0·98)
Stroke
(1·34)
Diabetes
(1·24)
Diarrhoea
(7·09)
NN Preterm
(0·74)
Road injuries
(0·69)
Congenital
(0·86)
Stroke
(0·88)
TB
(0·73)
PEM
(2·64)
Iron
(1·10)
Congenital
(0·90)
Meningitis
(1·15)
Iron
(0·72)
PEM
(2·99)
PEM
(0·88)
NN Enceph
(0·85)
1
2
3
4
5
6
7
8
9
10
United Arab Emirates
Yemen
South Asia
South Asia 
Bangladesh 
Bhutan 
India
Nepal
Pakistan
Sub-Saharan Africa
Southern sub-Saharan Africa
Botswana 
Lesotho 
Namibia
South Africa
Swaziland
Zimbabwe
Western sub-Saharan Africa
Benin 
Burkina Faso 
Cameroon 
Cape Verde 
Chad
Côte d’Ivoire 
The Gambia 
Ghana 
Guinea
Guinea-Bissau
 Articles
1646 
www.thelancet.com   Vol 388   October 8, 2016
Malaria
(2·88)
Malaria
(5·95)
LRI
(0·60)
Malaria
(1·30)
Malaria
(104·66)
LRI
(0·67)
Diarrhoea
(0·52)
Malaria
(14·10)
Malaria
(17·88)
HIV
(2·56)
LRI
(0·44)
LRI
(0·50)
LRI
(1·11)
Diarrhoea
(0·82)
LRI
(0·43)
HIV
(3·70)
LRI
(0·75)
HIV
(5·07)
HIV
(7·73)
LRI
(0·79)
Diarrhoea
(0·68)
Diarrhoea
(0·93)
HIV
(2·57)
HIV
(2·88)
HIV
(6·46)
Malaria
(3·30)
LRI
(0·95)
Malaria
(6·71)
HIV
(3·37)
Malaria
(2·57)
Malaria
(1125·32)
HIV
(2·84)
LRI
(0·46)
Diarrhoea
(0·40)
NN Sepsis
(3·54)
Diarrhoea
(0·54)
Diarrhoea
(2·09)
NN Sepsis
(2·33)
LRI
(0·42)
LRI
(0·90)
HIV
(2·21)
LRI
(0·58)
Diarrhoea
(0·43)
Diarrhoea
(0·43)
Diarrhoea
(1·08)
LRI
(0·67)
Diarrhoea
(0·36)
Diarrhoea
(1·08)
Diarrhoea
(0·78)
Malaria
(5·01)
Malaria
(4·06)
HIV
(1·15)
LRI
(0·64)
LRI
(0·72)
LRI
(0·78)
LRI
(0·60)
LRI
(0·96)
LRI
(0·55)
Malaria
(25·93)
HIV
(4·23)
Malaria
(109·15)
LRI
(0·46)
HIV
(3·81)
Malaria
(968·41)
Diarrhoea
(0·43)
PEM
(1·48)
Diarrhoea
(0·53)
LRI
(0·39)
HIV
(2·16)
Congenital
(0·83)
NN Sepsis
(2·04)
Haemog
(7·62)
LRI
(0·68)
Diarrhoea
(0·54)
Malaria
(1·33)
Congenital
(0·94)
HIV
(1·03)
PEM
(1·52)
TB
(1·16)
LRI
(0·75)
NN Preterm
(0·52)
LRI
(0·60)
LRI
(0·31)
Congenital
(1·23)
PEM
(0·83)
HIV
(1·90)
Congenital
(1·38)
Malaria
(9·47)
Malaria
(39·51)
Diarrhoea
(0·35)
Diarrhoea
(0·66)
LRI
(0·95)
LRI
(0·97)
Diarrhoea
(0·28)
LRI
(1·87)
LRI
(1·60)
HIV
(1·23)
NN Preterm
(0·87)
NN Preterm
(0·50)
Meningitis
(1·09)
LRI
(1·00)
Stroke
(0·97)
NN Enceph
(0·59)
Diarrhoea
(0·61)
Diarrhoea
(0·54)
Malaria
(2·27)
NN Preterm
(0·54)
NN Preterm
(0·43)
Congenital
(1·26)
Congenital
(0·98)
Congenital
(0·97)
NN Enceph
(0·96)
PEM
(2·24)
Diarrhoea
(0·53)
Diarrhoea
(0·29)
Diarrhoea
(0·42)
TB
(1·18)
Malaria
(2·01)
Malaria
(11·61)
Diarrhoea
(0·50)
Diarrhoea
(1·19)
HIV
(1·53)
HIV
(1·35)
Diarrhoea
(0·68)
Congenital
(1·04)
HIV
(1·28)
NN Sepsis
(6·10)
Congenital
(1·23)
NN Sepsis
(1·98)
NN Sepsis
(2·48)
NN Enceph
(0·81)
PEM
(0·54)
NN Sepsis
(5·39)
Diarrhoea
(0·43)
NN Preterm
(0·39)
Ebola
(97400·61)
NN Sepsis
(3·19)
Congenital
(1·03)
Congenital
(1·01)
NN Enceph
(0·64)
Stroke
(0·83)
Iron
(1·32)
NN Enceph
(0·69)
NN Preterm
(0·46)
Stroke
(1·21)
NN Enceph
(0·72)
NN Enceph
(0·72)
NN Preterm
(0·50)
NN Preterm
(0·64)
PEM
(1·38)
Diarrhoea
(0·52)
NN Enceph
(0·87)
Congenital
(1·05)
PEM
(1·04)
Congenital
(1·09)
TB
(1·82)
NN Sepsis
(3·14)
PEM
(0·86)
Congenital
(1·39)
NN Sepsis
(5·65)
NN Enceph
(0·68)
LRI
(0·29)
Iron
(1·25)
NN Preterm
(0·52)
NN Enceph
(1·25)
NN Enceph
(0·61)
TB
(1·21)
NN Sepsis
(2·97)
NN Enceph
(0·88)
NN Enceph
(0·71)
PEM
(0·93)
NN Sepsis
(1·53)
Iron
(1·32)
TB
(1·24)
HIV
(0·83)
Congenital
(0·86)
Congenital
(0·88)
NN Preterm
(0·49)
Congenital
(0·98)
NN Enceph
(0·75)
Iron
(1·47)
Meningitis
(1·18)
NN Enceph
(0·69)
Congenital
(1·12)
NN Enceph
(0·75)
NN Preterm
(0·46)
NN Sepsis
(2·85)
NN Preterm
(0·73)
Stroke
(1·20)
Other NTD
(3·84)
NN Preterm
(0·73)
Stroke
(1·03)
NN Preterm
(0·48)
NN Enceph
(0·91)
Congenital
(0·89)
NN Sepsis
(1·02)
Haemog
(6·32)
NN Preterm
(0·27)
Congenital
(0·77)
NN Enceph
(1·00)
NN Preterm
(0·55)
NN Preterm
(0·42)
NN Enceph
(0·62)
Iron
(0·86)
NN Preterm
(0·51)
NN Preterm
(0·43)
NN Preterm
(0·36)
Iron
(1·30)
Iron
(1·15)
Congenital
(1·00)
NN Sepsis
(1·33)
PEM
(1·65)
Malaria
(0·32)
NN Preterm
(0·54)
Iron
(1·28)
NN Preterm
(0·46)
Meningitis
(1·93)
Congenital
(0·89)
PEM
(2·45)
Stroke
(1·55)
Diarrhoea
(0·84)
NN Enceph
(0·63)
Diabetes
(1·74)
Diabetes
(1·51)
TB
(1·07)
Meningitis
(0·95)
Back & neck
(1·07)
NN Enceph
(0·54)
NN Preterm
(0·48)
IHD
(0·63)
Meningitis
(0·95)
NN Preterm
(0·66)
Congenital
(0·80)
NN Sepsis
(1·49)
HIV
(0·90)
TB
(0·84)
IHD
(0·70)
NN Enceph
(0·56)
NN Sepsis
(1·42)
Malaria
(2·40)
Malaria
(4·00)
PEM
(1·09)
NN Preterm
(0·37)
NN Sepsis
(2·01)
Congenital
(0·81)
TB
(1·10)
NN Preterm
(0·34)
Meningitis
(1·45)
NN Preterm
(0·33)
NN Sepsis
(1·62)
NN Preterm
(0·38)
PEM
(1·67)
NN Enceph
(0·83)
NN Preterm
(0·48)
Road injuries
(1·05)
Iron
(1·90)
Ebola
(58898·20)
HIV
(1·07)
STD
(2·22)
Congenital
(0·60)
Congenital
(0·90)
Back & neck
(1·04)
Iron
(1·04)
Meningitis
(1·60)
Haemog
(3·11)
PEM
(1·04)
TB
(1·00)
Stroke
(0·61)
TB
(1·54)
Meningitis
(0·91)
Meningitis
(0·76)
Other NTD
(3·37)
NN Sepsis
(1·79)
Meningitis
(0·96)
TB
(0·92)
Road injuries
(0·98)
Meningitis
(0·59)
Congenital
(0·85)
NN Sepsis
(2·06)
NN Sepsis
(1·87)
NN Sepsis
(1·91)
NN Enceph
(0·64)
Meningitis
(1·62)
Road injuries
(2·01)
IHD
(0·85)
Congenital
(0·81)
NN Enceph
(1·22)
Road injuries
(0·93)
Meningitis
(0·78)
Congenital
(0·82)
Meningitis
(0·89)
TB
(0·55)
Meningitis
(2·19)
CKD
(2·03)
Malaria
(1·89)
HIV
(1·15)
Stroke
(0·83)
Meningitis
(0·90)
Meningitis
(0·64)
STD
(1·68)
PEM
(2·98)
Stroke
(0·97)
STD
(1·74)
Meningitis
(1·07)
IHD
(0·86)
NN Sepsis
(1·32)
Stroke
(0·86)
Meningitis
(1·07)
War
(187·71)
Iron
(1·21)
PEM
(1·75)
Haemog
(3·24)
IHD
(1·03)
Other NTD
(3·60)
Road injuries
(1·43)
NN Sepsis
(2·17)
NN Preterm
(0·42)
NN Sepsis
(1·30)
Other NN
(2·72)
IHD
(0·61)
1
2
3
4
5
6
7
8
9
10
Liberia 
Mali 
Mauritania 
Niger 
Nigeria
São Tomé and Príncipe
Senegal 
Sierra Leone 
Togo
Eastern sub-Saharan Africa
Burundi 
Comoros 
Djibouti 
Eritrea 
Ethiopia 
Kenya 
Madagascar 
Malawi 
Mozambique 
Rwanda 
Somalia
South Sudan 
Tanzania 
Uganda 
Zambia
Central sub-Saharan Africa
Angola
Central African Republic
Congo (Brazzaville) 
DR Congo
Equatorial Guinea
Gabon
0–0·63
0·63–0·79
0·79–0·90
0·90–1·00
1·00–1·09
1·09–1·24
1·24–1·56
1·56–2·49
>2·49
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1647
identify more eff
 ective preventive and therapy measures.52 
Similarly, despite broad decreases in age-standardised 
rates of injury burden, the pace of progress for these 
causes has been comparatively slow and ultimately has led 
to minimal changes in the proportion of overall burden 
due to injuries during the past 25 years. Prevention of 
injuries requires strong public safety policies,53 but 
minimising mortality and long-term disability from 
injuries hinges upon having comprehensive trauma care 
systems54,55 that provide timely, evidence-based care,56–58 
including emergency surgical services.59,60
In 2015, sense organ disorders were the second-leading 
cause of YLDs and resulted in more than 68 million 
DALYs. Reducing DALYs from vision impairment is 
achievable through vertically integrated programmes, 
including the delivery of eyeglasses for refractive error, 
curative surgery for cataracts, and onchocerciasis and 
trachoma prevention. Given the availability of cost-
eff
 ective interventions, greater policy attention is needed 
for vision loss burden. Although interventions for hearing 
loss are less clear, the use of timely antibiotics for otitis 
media and meningitis and the provision of hearing aids 
for conductive hearing loss are likely to reduce its burden.
Reductions in age-standardised DALY rates due to some 
NCDs such as cardiovascular diseases, most cancers, 
chronic respiratory diseases, and many digestive 
diseases—some of which can be attributed to reductions 
in risk factors such as tobacco and improvements in cause-
specifi
 c treatment and event survival—mask the eff
 ects of 
population ageing. This means more people had disease 
burden from these causes and total DALYs have remained 
largely unchanged (eg, chronic obstructive pulmonary 
disease) or signifi
 cantly increased (eg, cardiovascular 
diseases, cancers, neurological disorders, diabetes, chronic 
kidney disease, and musculoskeletal disorders such as 
osteoarthritis and low back and neck pain) over time. As 
demographic transitions are widely expected to continue, 
the burden from NCDs is likely to continue expanding. 
Widespread eff
 orts must continue to enact societal and 
environmental policies to reduce risk factor exposure, 
while national and local health systems must adapt to meet 
the prevention, screening, and treatment needs of their 
populations. As we now recognise many of the risk factors 
related to NCDs, low-SDI and middle-SDI countries could 
adopt policies to circumvent the mistakes made by other 
countries as they progressed along the SDI spectrum. 
Mental and substance use disorders are a particularly 
challenging group of conditions with non-trivial levels of 
disease burden in all geographies. Some countries provide 
excellent mental health resources, whereas others, 
particularly LMICs, do not have screening or treatment 
programmes. Addressing the growing burden and 
disparity in mental health disorders will be an especially 
pressing challenge during the SDG era.
A number of emerging and growing health threats also 
deserve special attention in policy planning, including 
infectious diseases such as outbreaks of dengue fever, 
Ebola virus disease, Zika virus, and pandemic infl
 uenza, 
and antimicrobial-resistant pathogens, which represent 
acute threats to life and highlight health-system defi
 ciencies 
where they occur; substance abuse disorders, particularly of 
opioids and cocaine, in eastern Europe, Australia, and 
North America; and intentional fi
 rearm injuries, especially 
in Latin America, the USA, and South Africa. In the case of 
dengue fever and potentially other yet to be identifi
 ed 
infectious diseases, urbanisation and global environmental 
change have contributed to an increased incidence and 
future climate change scenarios depict a rising trend in the 
coming years.61 Other emerging infectious diseases, 
including Zika and chikungunya viruses, have yet to be 
comprehensively analysed by the GBD.
A major change in the GBD 2015 assessment has been 
the closer integration of the assessments of mortality and 
disease sequelae prevalence in modelling. For cancers, 
HIV
/AIDS, and injuries, previous iterations of the GBD 
modelled mortality, incidence, and prevalence in a 
coherent manner. For some other diseases, the modelling 
of disease prevalence and cause-specifi
 c mortality rates 
largely used diff
 erent data sources and modelling 
techniques. Independent estimation of prevalence and 
mortality led in some cases to patterns across locations of 
excess mortality rates that were not consistent with 
expected relationships related to health-system access. 
For GBD 2015, we built the modelling of cause-specifi
 c 
mortality, excess mortality, incidence, and prevalence 
into nearly every cause. The eff
 ect of this approach has 
led to increases in the number of DALYs from injuries 
due to YLDs and changes in prevalence for other 
conditions, particularly those with minimal data for 
prevalence or incidence. More attention will be paid in 
future iterations of the GBD study to identifying 
unpublished data from cohort studies or linkage studies 
Figure 7: Leading ten causes of DALYs with the ratio of observed DALYs to DALYs expected on the basis of SDI in 2015, by location
The ratio of observed DALYs to DALYs expected based on SDI is provided in brackets for each cause and cells are colour coded by ratio ranges (calculated to place a roughly equal number of cells into each bin). 
Shades of blue represent much lower observed DALYs than expected levels based on SDI, whereas red shows observed DALYs that exceed expected levels. IHD=ischaemic heart disease. Back & neck=low back 
and neck pain. Diabetes=diabetes mellitus. Stroke=Cerebrovascular disease. Lung C=lung, bronchus, and trachea cancers. Sense=sense organ diseases. Depression=depressive disorders. Alzheimer’s=Alzheimer’s 
disease and other dementias. Oth MSK=other musculoskeletal disorders. COPD=chronic obstructive pulmonary disease. NN Preterm=neonatal preterm birth complications. Diarrhoea=diarrhoeal diseases. 
Skin=skin and subcutaneous diseases. NN Enceph=neonatal encephalopathy due to birth asphyxia and trauma. Drugs=drug use disorders. Congenital=congenital anomalies. Liver C=liver cancer. 
Stomach C=stomach cancer. CKD=chronic kidney disease. Anxiety=anxiety disorders. Iron=iron-defi
 ciency anaemia. HIV=HIV/AIDS. Colorect C=colon and rectum cancer. LRI=lower respiratory infections. 
Cirr HepC=cirrhosis due to hepatitis C. CMP=cardiomyopathy and myocarditis. Cirr alc=cirrhosis due to alcohol use. Other Cardio=other cardiovascular and circulatory diseases. Alcohol=alcohol use disorders. 
Violence=interpersonal violence. HTN HD=hypertensive heart disease. Haemog=haemoglobinopathies and haemolytic anaemias. TB=tuberculosis. Prostate C=prostate cancer. War=collective violence and legal 
intervention. Other Unint= other unintentional injuries. Oth trans=other transport injuries. Other NN=Other neonatal disorders. NN Sepsis=neonatal sepsis and other neonatal infections. PEM=protein-energy 
malnutrition. STD=sexually transmitted diseases excluding HIV. Ebola=Ebola virus disease. Other NTD=other neglected tropical diseases. GBD=Global Burden of Disease. SDI=Socio-demographic Index. 
DALYs=disability-adjusted life-years.
 Articles
1648 
www.thelancet.com   Vol 388   October 8, 2016
on levels of excess mortality by age and sex, especially in 
LMICs, to further strengthen modelling eff
 orts.
A major development for the GBD 2015 has been 
adaptation of the GATHER guidelines endorsed by WHO, 
the Institute for Health Metrics and Evaluation (IHME), 
and other organisations.22,23 GATHER compliance, 
including the sharing of statistical code for each of the 
many analytical steps in the GBD, provides a new level of 
transparency for the overall enterprise. We expect that 
many researchers will want to investigate, propose 
improvements, and provide alternative assessments for 
many components of the GBD. We welcome the debate 
that will follow on the best way to analyse diff
 erent 
components of the GBD. We believe enhanced 
transparency will lead to healthy debate and exchange 
and to improved methods, data, and results for many 
aspects of the GBD. Transparency will not necessarily 
lead to consensus but it will broaden everyone’s 
understanding of the available evidence on descriptive 
epidemiology. Adoption by the GBD of the GATHER 
guidelines will hopefully stimulate other organisations to 
adopt the guidelines in all aspects of their work as well.
Although the volume of input data to the GBD has 
continued to increase substantially, major data gaps 
remain.12,20,62,63 Geographical and temporal coverage of all-
cause and cause-specifi
 c mortality datasets are variable, as 
is the quality of the data contained in such systems. 
Development of methods to report overall evidence grades 
for each outcome–location–year combination would be 
valuable to help to guide strategies for improving data 
quality and closing data gaps. Investing to develop and 
improve cause of death and vital registration systems is 
crucial to improve the quality of insights from the GBD; 
incorporation of existing data from existing and new 
collaborators that are not currently in the GBD is another 
important aspect of this eff
 ort. Several countries have 
experienced signifi
 cant recent turmoil, especially armed 
confl
 ict in Syria, Yemen, and other countries in north 
Africa and the Middle East. Burden from many conditions 
is believed to have increased during and following those 
events, but due to disruption of data-collection systems, the 
full eff
 ect of such events has been diffi
  cult to quantify. For 
non-fatal health outcomes, some of the most notable data 
gaps pertain to aspects of individual diseases and injuries 
that are not typically included as part of standard 
epidemiological reports such as distribution of symptoms 
for those with chronic conditions at various stages of 
illness, duration of disability following acute events, or 
long-term disability after major acute injuries. Therefore, 
our recommendations regarding data gaps pertaining to 
non-fatal health loss are twofold. First, reports and scientifi
 c 
journals should strive to include reporting on functional 
health status including severity, distribution, and duration 
of symptoms with all epidemiological studies. Second, 
countries should work to centralise and compile existing 
non-fatal health data and invest to collect population-level 
epidemiological data on important causes of YLDs.
The iterative and now annual cycle of the GBD revisions 
provide opportunities to improve the estimation or scope 
of the GBD. Due to the high interest in Zika virus, we 
believe that we should try to quantify the burden related 
to Zika virus disease in the GBD 2016 analysis. Given the 
focus in the SDGs on various forms of sexual violence, we 
believe careful investigation of the evidence base for 
estimation is warranted. As noted in the GBD papers on 
mortality and non-fatal outcomes,12,20 there are also a 
number of opportunities to improve data processing and 
estimation methods that will be explored for the next 
cycle of estimation. We also expect to include more 
subnational analyses, particularly for large countries.
Our analysis has several limitations. First and foremost, 
the calculation of DALYs and HALE refl
 ects the limitations 
of all the underlying analyses of the GBD, including all-
cause mortality, cause-specifi
 c mortality, prevalence, 
incidence, disability-weight derivation, and simulation of 
comorbidity. Second, as discussed above, data limitations 
are apparent in a number of facets of our analysis. Third, 
inherent to the GBD approach is the eff
 ort to quantify 
specifi
 c sequelae of each disease and injury. This means 
that the full disease burden of certain conditions such as 
heart failure, anaemia, vision and hearing loss, infertility, 
epilepsy, and intellectual disability are not as readily 
apparent in high-level review of the GBD results. However, 
the YLDs for these impairments are reported elsewhere.20 
Fourth, our analysis of the relationship between SDI, 
DALYs, and HALE refl
 ects the average historical 
relationship between SDI and each measure, so despite 
often strong correlation with SDI it cannot be interpreted 
as being causal in nature. In some cases, association of SDI 
with health indicators could be considered a confounder 
when the same elements (education, income, and fertility) 
are used to develop both the index and as a covariate in 
cause-specifi
 c models. SDI utility might be improved in the 
future through consideration of additional societal 
elements such as inequality in each component. Other 
measures that capture the status of women in society, such 
as the female labour-force participation, could be considered 
in future revisions. Fifth, we have assumed independence 
of uncertainty between YLLs and YLDs as well as between 
YLDs and life expectancy. Empirical evidence to guide 
alternative assumptions, however, is currently very limited. 
Sixth, recent events in Syria and Libya and the resulting 
mass migration have led to considerable health loss, 
including drownings of many migrants. New migrants 
have diff
 erent health problems than the populations of the 
countries to which they have moved. Both the drownings 
and the change in health status in countries receiving 
migrants are not adequately captured in this assessment 
due to the time-lags in data collection and data capture 
intrinsic in all health data systems. Seventh, estimates of 
expected burden from SDI alone are based on the average 
levels of burden at each level of SDI. For endemic diseases, 
comparisons of observed rates to expected rates will lead to 
high observed over expected ratios in endemic countries 
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1649
and low ratios in non-endemic countries. Interpretation of 
the ratios for conditions that are endemic in only some 
countries needs to take this into account.
WHO has estimated DALYs by cause for the single years 
of 2000 and 2012.13,17 They used published GBD 2010 results 
used to generate WHO 2012 DALYs for 132 causes with 
some modifi
 cations. First, WHO life tables were used 
instead of GBD life tables.14 WHO life tables are diff
 erent 
from the UN Population Division life tables and use a set of 
methods developed by Murray and colleagues in the late 
1990s;11,64 this approach does not benefi
 t from the many 
improvements in data processing and estimation methods 
that have emerged in the last 15 years.12,65,66 Second, WHO 
altered the empirical disability weights, which were derived 
from 
an 
international 
sample 
of 
more 
than 
60 000 respondents from the GBD analysis26 for 32 out 
-
comes using the opinions of 45 respondents.13,67 Third, 
WHO calculated YLLs after changing from the GBD 2010 
normative standard life expectancy of 86·0 years to 
91·9 years.68 Fourth, rather than using GBD results, WHO 
elected to use alternative estimates for 12 causes of death, 
including tuberculosis, HIV
/AIDS and other sexually 
transmitted infections, malaria, whooping cough, measles, 
schistosomiasis, maternal disorders, cancers, alcohol and 
drug use disorders, epilepsy, confl
 ict and natural disasters, 
and road traffi
  c accidents.13 Finally, WHO substituted 
prevalence estimates produced internally for vision loss, 
hearing loss, intellectual disability, infertility, anaemia, back 
pain, alcohol use disorders, headache, and skin diseases. 
The fi
 nal hybrid estimates of DALYs do not provide 
uncertainty measures and have not been peer-reviewed. 
WHO has also produced HALE estimates for three 
time periods, 2000, 2012, and 2015, using GBD 2010 
results as described above for 2000 and 2012, and GBD 
2013 results for 2015, also without uncertainty measures.14 
Diff
 erences between their estimates and those for HALE 
from GBD 2015 refl
 ect changes in age-specifi
 c YLDs per 
capita from GBD 2013 to GBD 2015 and diff
 erences in 
WHO life expectancy (appendix p 85). The EC and the 
OECD also report healthy life expectancy estimates based 
on self-reported health status from 2004 through 2014, 
but without specifi
 c consideration of prevalence or 
incidence of disease.52,53 Comparison of 2014 estimates 
from the EC and GBD mostly show lower estimates from 
EC (appendix pp 86–87). EC estimates also report much 
wider ranges in HALE across countries in Europe than 
those estimated through GBD. Further, in a number of 
countries, EC estimates point to lower HALE among 
women than for men. These diff
 erences, both in terms of 
absolute estimates and those by sex, are probably due to 
the inclusion of non-health factors in self-reported 
assessments of disability.
In conclusion, HALE has increased steadily throughout 
the world over the MDG era, with a concomitant decrease 
in age-standardised DALY rates from most conditions. 
Declines occurred in overall health loss due to many 
communicable, maternal, neonatal, and nutritional 
diseases. Much of the evolution of health is consistent with 
the expected changes in disease burden with development 
that have been quantifi
 ed in this study. Substantial 
variation in burden compared with levels expected on the 
basis of SDI suggests wide heterogeneity in the ability of 
governments and health systems to adequately meet the 
health needs of their populations. Progress in reducing 
these gaps will be crucial to achieving the ambitious SDG 
agenda. Demographic changes leading to increased 
population size and older average age have off
 set otherwise 
important gains in age-specifi
 c DALY rates leading to 
rising burden on health systems for many ailments of 
ageing. Emerging health threats and causes with lagging 
progress should be viewed as essential foci for investment 
in health infrastructure and health data systems to improve 
the global community’s insights into the aggregate quality 
of care and the overall health of populations.
GBD 2015 DALYs and HALE Collaborators
Nicholas J Kassebaum, Megha Arora, Ryan M Barber, Zulfi
 qar A Bhutta, 
Jonathan Brown, Austin Carter, Daniel C Casey, Fiona J Charlson, 
Matthew M Coates, Megan Coggeshall, Leslie Cornaby, Lalit Dandona, 
Daniel J Dicker, Holly E Erskine, Alize J Ferrari, Christina Fitzmaurice, 
Kyle Foreman, Mohammad H Forouzanfar, Nancy Fullman, 
Peter W Gething, Ellen M Goldberg, Nicholas Graetz, 
Juanita A Haagsma, Simon I Hay, Catherine O Johnson, Laura Kemmer, 
Ibrahim A Khalil, Yohannes Kinfu, Michael J Kutz, Hmwe H Kyu, 
Janni Leung, Xiaofeng Liang, Stephen S Lim, Rafael Lozano, 
George A Mensah, Joe Mikesell, Ali H Mokdad, Meghan D Mooney, 
Mohsen Naghavi, Grant Nguyen, Elaine Nsoesie, David M Pigott, 
Christine Pinho, Zane Rankin, Nikolas Reinig, Joshua A Salomon, 
Logan Sandar, Alison Smith, Reed J D Sorensen, Jeff
 rey Stanaway, 
Caitlyn Steiner, Stephanie Teeple, Chris Troeger, Thomas Truelsen, 
Amelia VanderZanden, Joseph A Wagner, Valentine Wanga, 
Harvey A Whiteford, Maigeng Zhou, Leo Zoeckler, 
Amanuel Alemu Abajobir*, Kalkidan Hassen Abate*, 
Cristiana Abbafati*, Kaja M Abbas*, Foad Abd-Allah*, Biju Abraham*, 
Ibrahim Abubakar*, Laith J Abu-Raddad*, Niveen M E Abu-Rmeileh*, 
Tom Achoki*, Ilana N Ackerman*, Akindele Olupelumi Adebiyi*, 
Isaac Akinkunmi Adedeji*, José C Adsuar*, Kossivi Agbelenko Afanvi*, 
Ashkan Afshin*, Emilie Elisabet Agardh*, Arnav Agarwal*, 
Sanjay Kumar Agarwal*, Muktar Beshir Ahmed*, 
Aliasghar Ahmad Kiadaliri*, Hamid Ahmadieh*, Nadia Akseer*, 
Ziyad Al-Aly*, Khurshid Alam*, Noore K M Alam*, 
Saleh Fahed Aldhahri*, Miguel Angel Alegretti*, Alicia V Aleman*, 
Zewdie Aderaw Alemu*, Lily T Alexander*, Raghib Ali*, Ala’a Alkerwi*, 
François Alla*, Peter Allebeck*, Christine Allen*, Ubai Alsharif*, 
Khalid A Altirkawi*, Elena Alvarez Martin*, Nelson Alvis-Guzman*, 
Azmeraw T Amare*, Alemayehu Amberbir*, Adeladza Kofi
  Amegah*, 
Heresh Amini*, Walid Ammar*, Stephen Marc Amrock*, 
Gregory M Anderson*, Benjamin O Anderson*, 
Carl Abelardo T Antonio*, Palwasha Anwari*, Johan Ärnlöv*, 
Valentina S Arsic Arsenijevic*, Al Artaman*, Hamid Asayesh*, 
Rana Jawad Asghar*, Euripide Frinel G Arthur Avokpaho*, 
Ashish Awasthi*, Beatriz Paulina Ayala Quintanilla*, Peter Azzopardi*, 
Umar Bacha*, Alaa Badawi*, Kalpana Balakrishnan*, 
Amitava Banerjee*, Aleksandra Barac*, Suzanne L Barker-Collo*, 
Till Bärnighausen*, Lars Barregard*, Lope H Barrero*, Sanjay Basu*, 
Tigist Assefa Bayou*, Justin Beardsley*, Neeraj Bedi*, Ettore Beghi*, 
Brent Bell*, Michelle L Bell*, Corina Benjet*, Derrick A Bennett*, 
Isabela M Bensenor*, Adugnaw Berhane*, Eduardo Bernabé*, 
Balem Demtsu Betsu*, Addisu Shunu Beyene*, Neeraj Bhala*, 
Anil Bhansali*, Samir Bhatt*, Sibhatu Biadgilign*, Kelly Bienhoff
 *, 
Boris Bikbov*, Aref A Bin Abdulhak*, Stan Biryukov*,Donal Bisanzio*, 
Espen Bjertness*, Jed D Blore*, Rohan Borschmann*, 
Soufi
 ane Boufous*, Rupert R A Bourne*, Michael Brainin*, 
Alexandra Brazinova*, Nicholas J K Breitborde*, Traolach S Brugha*, 
 Articles
1650 
www.thelancet.com   Vol 388   October 8, 2016
Rachelle Buchbinder*, Geoff
 rey Colin Buckle*, Zahid A Butt*, 
Bianca Calabria*, Ismael Ricardo Campos-Nonato*, 
Julio Cesar Campuzano*, Hélène Carabin*, Jonathan R Carapetis*, 
Rosario Cárdenas*, Juan Jesus Carrero*, Carlos A Castañeda-Orjuela*, 
Jacqueline Castillo Rivas*, Ferrán Catalá-López*, Fiorella Cavalleri*, 
Jung-Chen Chang*, Peggy Pei-Chia Chiang*, Mirriam Chibalabala*, 
Chioma Ezinne Chibueze*, Vesper Hichilombwe Chisumpa*, 
Jee-Young Jasmine Choi*, Lincoln Choudhury*, Hanne Christensen*, 
Liliana G Ciobanu*, Valentina Colistro*, Mercedes Colomar*, 
Samantha M Colquhoun*, Monica Cortinovis*, John A Crump*, 
Albertino Damasceno*, Rakhi Dandona*, Paul I Dargan*, 
José das Neves*, Gail Davey*, Adrian C Davis*, Diego De Leo*, 
Louisa Degenhardt*, Liana C Del Gobbo*, Sarah Derrett*, 
Don C Des Jarlais*, Gabrielle A deVeber*, Samath D Dharmaratne*, 
Preet K Dhillon*, Eric L Ding*, Kerrie E Doyle*, Tim R Driscoll*, 
Leilei Duan*, Manisha Dubey*, Bruce Bartholow Duncan*, 
Hedyeh Ebrahimi*, Richard G Ellenbogen*, Iqbal Elyazar*, 
Aman Yesuf Endries*, Sergey Petrovich Ermakov*, Babak Eshrati*, 
Alireza Esteghamati*, Kara Estep*, Saman Fahimi*, Talha A Farid*, 
Carla Sofi
 a e Sa Farinha*, André Faro*, Maryam S Farvid*, 
Farshad Farzadfar*, Valery L Feigin*, 
Seyed-Mohammad Fereshtehnejad*, Jeff
 erson G Fernandes*, 
Joao C Fernandes*, Florian Fischer*, Joseph R A Fitchett*, 
Nataliya Foigt*, F Gerry R Fowkes*, Richard C Franklin*, 
Joseph Friedman*, Joseph Frostad*, Thomas Fürst*, Neal D Futran*, 
Belinda Gabbe*, Fortuné Gbètoho Gankpé*, Alberto L Garcia-Basteiro*, 
Tsegaye Tewelde Gebrehiwot*, Amanuel Tesfay Gebremedhin*, 
Johanna M Geleijnse*, Katherine B Gibney*, Richard F Gillum*, 
Ibrahim Abdelmageem Mohamed Ginawi*, Ababi Zergaw Giref*, 
Maurice Giroud*, Melkamu Dedefo Gishu*, 
Giorgia Giussani*,William W Godwin*, Hector Gomez-Dantes*, 
Philimon Gona*, Amador Goodridge*, Sameer Vali Gopalani*, 
Carolyn C Gotay*, Atsushi Goto*, Hebe N Gouda*, Harish Gugnani*, 
Yuming Guo*, Rahul Gupta*, Rajeev Gupta*, Vipin Gupta*, 
Reyna A Gutiérrez*, Nima Hafezi-Nejad*, Demewoz Haile*, 
Alemayehu Desalegne Hailu*, Gessessew Bugssa Hailu*, 
Yara A Halasa*, Randah Ribhi Hamadeh*, Samer Hamidi*, 
Mouhanad Hammami*, Alexis J Handal*, Graeme J Hankey*, 
Hilda L Harb*, Sivadasanpillai Harikrishnan*, Josep Maria Haro*, 
Mohammad Sadegh Hassanvand*, Tahir Ahmed Hassen*, 
Rasmus Havmoeller*, Roderick J Hay*, Mohammad T Hedayati*, 
Ileana Beatriz Heredia-Pi*, Pouria Heydarpour*, Hans W Hoek*, 
Daniel J Hoff
 man*, Masako Horino*, Nobuyuki Horita*, 
H Dean Hosgood*, Damian G Hoy*, Mohamed Hsairi*, 
Hsiang Huang*, John J Huang*, Kim Moesgaard Iburg*, 
Bulat T Idrisov*, Kaire Innos*, Manami Inoue*, Kathryn H Jacobsen*, 
Alejandra Jauregui*, Achala Upendra Jayatilleke*, 
Panniyammakal Jeemon*, Vivekanand Jha*, Guohong Jiang*, 
Ying Jiang*, Tariku Jibat*, Aida Jimenez-Corona*, Ye Jin*, Jost B Jonas*, 
Zubair Kabir*, Dan K Kajungu*, Yogeshwar Kalkonde*, Ritul Kamal*, 
Haidong Kan*, Amit Kandel*, André Karch*, Corine Kakizi Karema*, 
Chante Karimkhani*, Amir Kasaeian*, Marzieh Katibeh*, Anil Kaul*, 
Norito Kawakami*, Dhruv S Kazi*, Peter Njenga Keiyoro*, 
Andrew Haddon Kemp*, Andre Pascal Kengne*, Andre Keren*, 
Chandrasekharan Nair Kesavachandran*, Yousef Saleh Khader*, 
Abdur Rahman Khan*, Ejaz Ahmad Khan*, Young-Ho Khang*, 
Tawfi
 k Ahmed Muthafer Khoja*, Jagdish Khubchandani*, 
Christian Kieling*, Cho-il Kim*, Daniel Kim*, Yun Jin Kim*, 
Niranjan Kissoon*, Miia Kivipelto*, Luke D Knibbs*, 
Ann Kristin Knudsen*, Yoshihiro Kokubo*, Dhaval Kolte*, 
Jacek A Kopec*, Parvaiz A Koul*, Ai Koyanagi*, 
Barthelemy Kuate Defo*, Ricardo S Kuchenbecker*, 
Burcu Kucuk Bicer*, Ernst J Kuipers*, G Anil Kumar*, Gene F Kwan*, 
Ratilal Lalloo*, Tea Lallukka*, Anders Larsson*, Asma Abdul Latif*, 
Pablo M Lavados*, Alicia Elena Beatriz Lawrynowicz*, Janet L Leasher*, 
James Leigh*, Ricky Leung*, Yichong Li*, Yongmei Li*, 
Steven E Lipshultz*, Patrick Y Liu*, Yang Liu*, Belinda K Lloyd*, 
Giancarlo Logroscino*, Katharine J Looker*, Paulo A Lotufo*, 
Robyn M Lucas*, Raimundas Lunevicius*, Ronan A Lyons*, 
Hassan Magdy Abd El Razek*, Mahdi Mahdavi*, Marek Majdan*, 
Azeem Majeed*, Reza Malekzadeh*, Deborah Carvalho Malta*, 
Wagner Marcenes*, Jose Martinez-Raga*, Felix Masiye*, 
Amanda J Mason-Jones*, Richard Matzopoulos*, Bongani M Mayosi*, 
John J McGrath*, Martin McKee*, Peter A Meaney*, Alem Mehari*, 
Yohannes Adama Melaku*, Peter Memiah*, Ziad A Memish*, 
Walter Mendoza*, Atte Meretoja*, Tuomo J Meretoja*, 
Yonatan Moges Mesfi
 n*, Francis Apolinary Mhimbira*, 
Anoushka Millear*, Ted R Miller*, Edward J Mills*, Mojde Mirarefi
 n*, 
Erkin M Mirrakhimov*, Philip B Mitchell*, Charles N Mock*, 
Karzan Abdulmuhsin Mohammad*, Alireza Mohammadi*, 
Shafi
 u Mohammed*, Lorenzo Monasta*, 
Julio Cesar Montañez Hernandez*, Marcella Montico*, 
Maziar Moradi-Lakeh*, Rintaro Mori*, Ulrich O Mueller*, 
John Everett Mumford*, Michele E Murdoch*, 
Gudlavalleti Venkata Satyanarayana Murthy*, Jean B Nachega*, 
Aliya Naheed*, Luigi Naldi*, Vinay Nangia*, John N Newton*, 
Marie Ng*, Frida Namnyak Ngalesoni*, Quyen Le Nguyen*, 
Muhammad Imran Nisar*, Patrick Martial Nkamedjie Pete*, 
Joan M Nolla*, Ole F Norheim*, Rosana E Norman*, Bo Norrving*, 
Carla Makhlouf Obermeyer*, Felix Akpojene Ogbo*, In-Hwan Oh*, 
Olanrewaju Oladimeji*, Pedro R Olivares*, 
Bolajoko Olubukunola Olusanya*, Jacob Olusegun Olusanya*, 
Eyal Oren*, Alberto Ortiz*, Erika Ota*, Abayomi Samuel Oyekale*, 
Mahesh PA*, Eun-Kee Park*, Mahboubeh Parsaeian*, Scott B Patten*, 
George C Patton*, João Mário Pedro*, David M Pereira*, 
Norberto Perico*, Konrad Pesudovs*, Max Petzold*, 
Michael Robert Phillips*, Frédéric B Piel*, Julian David Pillay*, 
Farhad Pishgar*, Dietrich Plass*, Suzanne Polinder*, Svetlana Popova*, 
Richie G Poulton*, Farshad Pourmalek*, Noela M Prasad*, 
Mostafa Qorbani*, Rynaz H S Rabiee*, Amir Radfar*, Anwar Rafay*, 
Kazem Rahimi*, Vafa Rahimi-Movaghar*, Mahfuzar Rahman*, 
Mohammad Hifz Ur Rahman*, Sajjad Ur Rahman*, Dheeraj Rai*, 
Rajesh Kumar Rai*, Sasa Rajsic*, Murugesan Raju*, Usha Ram*, 
Kavitha Ranganathan*, Amany H Refaat*, Marissa B Reitsma*, 
Giuseppe Remuzzi*, Serge Resnikoff
 *, Alex Reynolds*, 
Antonio L Ribeiro*, Stefano Ricci*, Hirbo Shore Roba*, 
David Rojas-Rueda*, Luca Ronfani*, Gholamreza Roshandel*, 
Gregory A Roth*, Ambuj Roy*, Ben Benasco Sackey*, Rajesh Sagar*, 
Juan R Sanabria*, Maria Dolores Sanchez-Niño*, Itamar S Santos*, 
João Vasco Santos*, Rodrigo Sarmiento-Suarez*, Benn Sartorius*, 
Maheswar Satpathy*, Miloje Savic*, Monika Sawhney*, 
Maria Inês Schmidt*, Ione J C Schneider*, Aletta E Schutte*, 
David C Schwebel*, Soraya Seedat*, Sadaf G Sepanlou*, 
Edson E Servan-Mori*, Saeid Shahraz*, Masood Ali Shaikh*, 
Rajesh Sharma*, Jun She*, Sara Sheikhbahaei*, Jiabin Shen*, 
Kevin N Sheth*, Kenji Shibuya*, Mika Shigematsu*, Min-Jeong Shin*, 
Rahman Shiri*, Inga Dora Sigfusdottir*, Diego Augusto Santos Silva*, 
Jonathan I Silverberg*, Edgar P Simard*, Abhishek Singh*, 
Jasvinder A Singh*, Prashant Kumar Singh*, Vegard Skirbekk*, 
Jens Christoff
 er Skogen*, Michael Soljak*, Kjetil Søreide*, 
Reed J D Sorensen*, Chandrashekhar T Sreeramareddy*, 
Vasiliki Stathopoulou*, Nicholas Steel*, Dan J Stein*, Murray B Stein*, 
Timothy J Steiner*, Lars Jacob Stovner*, Saverio Stranges*, 
Konstantinos Stroumpoulis*, Bruno F Sunguya*, Patrick J Sur*, 
Soumya Swaminathan*, Bryan L Sykes*, Cassandra E I Szoeke*, 
Rafael Tabarés-Seisdedos*, Nikhil Tandon*, David Tanne*, 
Mohammad Tavakkoli*, Bineyam Taye*, Hugh R Taylor*, 
Braden J Te Ao*, Teketo Kassaw Tegegne*, Dejen Yemane Tekle*, 
Abdullah Sulieman Terkawi*, Gizachew Assefa Tessema*, J S Thakur*, 
Alan J Thomson*, Andrew L Thorne-Lyman*, Amanda G Thrift*, 
George D Thurston*, Ruoyan Tobe-Gai*, Marcello Tonelli*, 
Roman Topor-Madry*, Fotis Topouzis*, Bach Xuan Tran*, 
Thomas Truelsen*, Zacharie Tsala Dimbuene*, Miltiadis Tsilimbaris*, 
Abera Kenay Tura*, Emin Murat Tuzcu*, Stefanos Tyrovolas*, 
Kingsley N Ukwaja*, Eduardo A Undurraga*, Chigozie Jesse Uneke*, 
Olalekan A Uthman*, Coen H van Gool*, Jim van Os*, 
Tommi Vasankari*, Ana Maria Nogales Vasconcelos*, 
Narayanaswamy Venketasubramanian*, Francesco S Violante*, 
Vasiliy Victorovich Vlassov*, Stein Emil Vollset*, Gregory R Wagner*, 
Mitchell T Wallin*, Linhong Wang*, Scott Weichenthal*, 
Elisabete Weiderpass*, Robert G Weintraub*, Andrea Werdecker*, 
Ronny Westerman*, Tissa Wijeratne*, James D Wilkinson*, 
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1651
Hywel C Williams*, Charles Shey Wiysonge*, 
Solomon Meseret Woldeyohannes*, Charles D A Wolfe*, Sungho Won*, 
Gelin Xu*, Ajit Kumar Yadav*, Bereket Yakob*, Lijing L Yan*, 
Yuichiro Yano*, Mehdi Yaseri*, Pengpeng Ye*, Paul Yip*, 
Naohiro Yonemoto*, Seok-Jun Yoon*, Mustafa Z Younis*, 
Chuanhua Yu*, Zoubida Zaidi*, Maysaa El Sayed Zaki*, Hajo Zeeb*, 
Sanjay Zodpey*, David Zonies*, Liesl Joanna Zuhlke*, Theo Vos†, 
Alan D Lopez†, Christopher J L Murray†.
*Authors listed alphabetically. †Joint senior authors.
Affi
  liations
 
Institute for Health Metrics and Evaluation (N J Kassebaum MD, 
M Arora BSA, R M Barber BS, J Brown MAIS, A Carter BS, 
D C Casey BA, F J Charlson PhD, M M Coates MPH, M Coggeshall BA, 
L Cornaby BS, Prof L Dandona MD, D J Dicker BS, H E Erskine PhD, 
A J Ferrari PhD, C Fitzmaurice MD, K Foreman PhD, 
M H Forouzanfar MD, N Fullman MPH, E M Goldberg BS, 
N Graetz MPH, J A Haagsma PhD, Prof S I Hay DSc, C O Johnson PhD, 
L Kemmer PhD, I A Khalil MD, Y Kinfu PhD, M J Kutz BS, 
H H Kyu PhD, J Leung PhD, Prof S S Lim PhD, Prof R Lozano PhD, 
J Mikesell BS, Prof A H Mokdad PhD, M D Mooney BS, 
Prof M Naghavi MD PhD, G Nguyen MPH, E Nsoesie PhD, 
D M Pigott DPhil, C Pinho BA, Z Rankin BS, N Reinig BS, L Sandar BS, 
A Smith BA, R J D Sorensen MPH, J Stanaway PhD, C Steiner MPH, 
S Teeple BA, B A Thomas MD, C Troeger MPH, A VanderZanden MSc, 
J A Wagner BS, V Wanga MS, Prof H A Whiteford PhD, 
Prof M Zhou PhD, L Zoeckler BA, T Achoki MD, A Afshin MD, 
L T Alexander BA, C Allen BA, G M Anderson MSEE, B Bell MLIS, 
K Bienhoff
  MA, S Biryukov BS, J D Blore PhD, K Estep MPA, 
J Friedman BA, J Frostad MPH, W W Godwin BS, P Y Liu BA, 
F Masiye PhD, A Millear BA, M Mirarefi
 n MPH, M Moradi-Lakeh MD, 
J E Mumford BA, M Ng PhD, M B Reitsma BS, A Reynolds BA, 
G A Roth MD, P J Sur BA, Prof S E Vollset DrPH, Prof T Vos PhD, 
Prof A D Lopez PhD, Prof C J L Murray DPhil), Harborview/UW 
Medicine (R G Ellenbogen MD), Harborview Injury Prevention and 
Research Center (C N Mock PhD), University of Washington, Seattle, 
WA, USA (Prof B O Anderson MD, N D Futran MD); Centre of 
Excellence in Women and Child Health (Prof Z A Bhutta PhD), Aga 
Khan University, Karachi, Pakistan (M I Nisar MSc); Centre for Global 
Child Health (Prof Z A Bhutta PhD, N Akseer MSc), The Hospital for 
Sick Children, Toronto, ON, Canada (G A deVeber MD); School of Public 
Health (F J Charlson PhD, H E Erskine PhD, J Leung PhD, 
Prof H A Whiteford PhD, A A Abajobir MPH, A J Ferrari PhD, 
L D Knibbs PhD), School of Dentistry (Prof R Lalloo PhD), University of 
Queensland, Brisbane, QLD, Australia 
(N K M Alam MPH, H N Gouda PhD, Y Guo PhD, 
Prof J J McGrath MD); Queensland Centre for Mental Health Research, 
Brisbane, QLD, Australia (F J Charlson PhD, H E Erskine PhD, 
J Leung PhD, Prof H A Whiteford PhD, A J Ferrari PhD); Centre for 
Control of Chronic Conditions (P Jeemon PhD), Public Health 
Foundation of India, New Delhi, India (Prof L Dandona MD, 
R Dandona PhD, G A Kumar PhD); Department of Zoology 
(P W Gething PhD), Oxford Big Data Institute, Li Ka Shing Centre for 
Health Information and Discovery, University of Oxford, Oxford, UK 
(Prof S I Hay DSc), and Nuffi
  eld Department of Medicine 
(D Bisanzio PhD), University of Oxford, Oxford, UK (R Ali FRCP, 
D A Bennett PhD, Prof V Jha DM, K Rahimi DM); Department of Public 
Health, Erasmus MC, University Medical Center, Rotterdam, 
Netherlands (J A Haagsma PhD); Centre for Research & Action in Public 
Health, Faculty of Health, University of Canberra, Canberra, ACT, 
Australia (Y Kinfu PhD); National Center for Chronic and 
Noncommunicable Disease Control and Prevention (L Duan MD, 
Y Jin MS, Y Li MPH, Prof L Wang MD, P Ye MPH, Prof M Zhou PhD), 
Chinese Center for Disease Control and Prevention, Beijing, China 
(Prof X Liang MD); Center for Translation Research and Implementation 
Science, National Heart, Lung, and Blood Institute, National Institutes of 
Health, Bethesda, MD, USA (G A Mensah MD); Department of Global 
Health and Population (Prof J A Salomon PhD), Department of 
Nutrition (A L Thorne-Lyman ScD), Harvard T H Chan School of Public 
Health (Prof T Bärnighausen MD, I R Campos-Nonato PhD, 
E L Ding ScD, M S Farvid PhD, G R Wagner MD), Harvard University, 
Boston, MA, USA (J R A Fitchett MD); Jimma University, Jimma, 
Ethiopia (K H Abate MS, M B Ahmed MPH, T T Gebrehiwot MPH, 
A T Gebremedhin MPH); La Sapienza, University of Rome, Rome, Italy 
(C Abbafati PhD); Virginia Tech, Blacksburg, VA, USA 
(Prof K M Abbas PhD); Department of Neurology, Cairo University, 
Cairo, Egypt (Prof F Abd-Allah MD); NMSM Government College 
Kalpetta, Kerala, India (Prof B Abraham MPhil); Institute for Global 
Health (Prof I Abubakar PhD), Farr Institute of Health Informatics 
Research (A Banerjee DPhil), University College London, London, UK; 
Infectious Disease Epidemiology Group, Weill Cornell Medical College 
in Qatar, Doha, Qatar (L J Abu-Raddad PhD); Institute of Community 
and Public Health, Birzeit University, Ramallah, Palestine 
(N M Abu-Rmeileh PhD); Department of Epidemiology and Preventive 
Medicine, School of Public Health and Preventive Medicine 
(I N Ackerman PhD, Prof R Buchbinder PhD, Prof B Gabbe PhD), 
Department of Medicine, School of Clinical Sciences at Monash Health, 
(Prof A G Thrift PhD), Eastern Health Clinical School (B K Lloyd PhD), 
Monash University, Melbourne, VIC, Australia; College of Medicine, 
University of Ibadan, Ibadan, Nigeria (A O Adebiyi MD); University 
College Hospital, Ibadan, Nigeria (A O Adebiyi MD); Olabisi Onabanjo 
University, Ago-Iwoye, Nigeria (I A Adedeji MS); University of 
Extremadura, Cáceres, Spain (Prof J C Adsuar PhD); Direction du 
District Sanitaire de Haho, Notse, Togo (K A Afanvi MD); Faculte des 
Sciences de Santé, Universite de Lomé, Lomé, Togo (K A Afanvi MD); 
Institution of Public Health Sciences, Stockholm, Sweden 
(E E Agardh PhD); Dalla Lana School of Public Health (N Akseer MSc), 
Department of Nutritional Sciences, Faculty of Medicine 
(A Badawi PhD), Centre for Addiction and Mental Health 
(S Popova PhD), University of Toronto, Toronto, ON, Canada 
(A Agarwal BHSc); McMaster University, Hamilton, ON, Canada 
(A Agarwal BHSc); All India Institute of Medical Sciences, New Delhi, 
India (Prof S K Agarwal MD, A Roy DM, R Sagar MD, M Satpathy PhD, 
Prof N Tandon PhD); Department of Clinical Sciences Lund, 
Orthopedics, Clinical Epidemiology Unit (A Ahmad Kiadaliri PhD), 
Skane University Hospital, Department of Clinical Sciences Lund 
(Prof B Norrving PhD), Lund University, Lund, Sweden; Health Services 
Management Research Center, Institute for Futures Studies in Health, 
Kerman University of Medical Sciences, Kerman, Iran 
(A Ahmad Kiadaliri PhD); Ophthalmic Research Center 
(H Ahmadieh MD, M Yaseri PhD), Ophthalmic Epidemiology Research 
Center (M Katibeh MD), Shahid Beheshti University of Medical 
Sciences, Tehran, Iran; Department of Ophthalmology, Labbafi
 nejad 
Medical Center, Tehran, Iran (H Ahmadieh MD); Washington University 
in Saint Louis, St Louis, MO, USA (Z Al-Aly MD); Murdoch Childrens 
Research Institute (K Alam PhD, P Azzopardi MEpi, 
R Borschmann PhD, S M Colquhoun PhD, Prof G C Patton MD, 
R G Weintraub MBBS), Department of Paediatrics (P Azzopardi MEpi), 
Department of Medicine (A Meretoja PhD), Institute of Health and 
Ageing (Prof C E I Szoeke PhD), Melbourne School of Population and 
Global Health (Prof A D Lopez PhD), University of Melbourne, 
Melbourne, VIC, Australia (K Alam PhD, R Borschmann PhD, 
Prof H R Taylor AC, Prof T Wijeratne MD); Sydney School of Public 
Health (Prof T R Driscoll PhD), University of Sydney, Sydney, NSW, 
Australia (K Alam PhD, J Leigh PhD, Prof A H Kemp PhD); Queensland 
Health, Herston, QLD, Australia (N K M Alam MPH); King Saud 
University, Riyadh, Saudi Arabia (S F Aldhahri MD, K A Altirkawi MD); 
Department of Anesthesiology (A S Terkawi MD), King Fahad Medical 
City, Riyadh, Saudi Arabia (S F Aldhahri MD); Department of Preventive 
and Social Medicine, Faculty of Medicine (M A Alegretti MD), School of 
Medicine (A V Aleman MD), Faculty of Medicine (F Cavalleri BS), 
University of the Republic, Montevideo, Uruguay (V Colistro MSc); 
Debre Markos University, Debre Markos, Ethiopia (Z A Alemu MPH, 
T K Tegegne MPH); Luxembourg Institute of Health (LIH), Strassen, 
Luxembourg (A Alkerwi PhD); School of Public Health, University of 
Lorraine, Nancy, France (Prof F Alla PhD); Department of Public Health 
Sciences (P Allebeck PhD, R H S Rabiee MPH), Department of Clinical 
Science, Intervention and Technology (Prof J J Carrero PhD), 
Department of Neurobiology, Care Sciences and Society (NVS) 
(S M Fereshtehnejad PhD), Aging Research Center 
(Prof M Kivipelto PhD), Department of Medical Epidemiology and 
Biostatistics (E Weiderpass PhD), Karolinska Institutet, Stockholm, 
Sweden (R Havmoeller PhD, Shireen Sindi PhD); Charité 
 Articles
1652 
www.thelancet.com   Vol 388   October 8, 2016
Universitätsmedizin, Berlin, Germany (U Alsharif MPH); Spanish 
Observatory on Drugs, Government Delegation for the National Plan on 
Drugs, Ministry of Health, Social Policy and Equality, Madrid, Spain 
(E Alvarez Martin PhD); Universidad de Cartagena, Cartagena de Indias, 
Colombia (Prof N Alvis-Guzman PhD); School of Medicine 
(A T Amare MPH, Y A Melaku MPH), University of Adelaide, Adelaide, 
SA, Australia (L G Ciobanu MS, G A Tessema MPH); College of 
Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia 
(A T Amare MPH); Dignitas International, Zomba, Malawi 
(A Amberbir PhD); University of Cape Coast, Cape Coast, Ghana 
(A K Amegah PhD); National Hospital, Abuja, Nigeria 
(Prof E A Ameh MBBS); Environmental Health Research Center, 
Kurdistan University of Medical Sciences, Sanandaj, Iran 
(H Amini MSPH); Department of Epidemiology and Public Health 
(H Amini MSPH, T Fürst PhD), Swiss Tropical and Public Health 
Institute, Basel, Switzerland (C K Karema MSc); University of Basel, 
Basel, Switzerland (H Amini MSPH, T Fürst PhD); Ministry of Public 
Health, Beirut, Lebanon (W Ammar PhD, H L Harb MPH); Oregon 
Health and Science University, Portland, OR, USA (S M Amrock PhD, 
D Zonies MD); Department of Health Policy and Administration, 
College of Public Health, University of the Philippines Manila, Manila, 
Philippines (C A T Antonio MD); Self-employed, Kabul, Afghanistan 
(P Anwari MD); Department of Medical Sciences, Uppsala University, 
Uppsala, Sweden (Prof J Ärnlöv PhD, Prof A Larsson PhD); Dalarna 
University, Falun, Sweden (Prof J Ärnlöv PhD); School of 
Medicine, Institute of Microbiology and Immunology 
(Prof V S Arsic Arsenijevic PhD), Faculty of Medicine (A Barac PhD), 
University of Belgrade, Belgrade, Serbia; University Children Hospital, 
Belgrade, Serbia (Prof V S Arsic Arsenijevic PhD); University of 
Manitoba, Winnipeg, MB, Canada (A Artaman PhD); Department of 
Medical Emergency, School of Paramedic, Qom University of Medical 
Sciences, Qom, Iran (H Asayesh PhD); South Asian Public Health 
Forum, Islamabad, Pakistan (R J Asghar MD); Institut de Recherche 
Clinique du Bénin, Cotonou, Benin (E F G A Avokpaho MPH); 
Laboratoire d’Etudes et de Recherche-Action en Santé (LERAS Afrique), 
Parakou, Benin (E F G A Avokpaho MPH, F G Gankpé MD); Sanjay 
Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 
(A Awasthi MSc); The Judith Lumley Centre for Mother, Infant and 
Family Health Research, La Trobe University, Melbourne, VIC, Australia 
(B P Ayala Quintanilla PhD); Peruvian National Institute of Health, 
Lima, Peru (B P Ayala Quintanilla PhD); Wardliparingga Aboriginal 
Research Unit, South Australian Health and Medical Research Institute, 
Adelaide, SA, Australia (P Azzopardi MEpi); School of Health Sciences, 
University of Management and Technology, Lahore, Pakistan 
(U Bacha PhD); Public Health Agency of Canada, Toronto, ON, Canada 
(A Badawi PhD); Department of Environmental Health Engineering, Sri 
Ramachandra University, Chennai, India (K Balakrishnan PhD); School 
of Psychology, University of Auckland, Auckland, New Zealand 
(S L Barker-Collo PhD); Africa Health Research Institute, Mtubatuba, 
South Africa (Prof T Bärnighausen MD); Institute of Public Health, 
Heidelberg University, Heidelberg, Germany (Prof T Bärnighausen MD, 
S Mohammed PhD); Department of Occupational and Environmental 
Health (Prof L Barregard MD), Health Metrics Unit 
(Prof M Petzold PhD), University of Gothenburg, Gothenburg, Sweden; 
Department of Industrial Engineering, School of Engineering, Pontifi
 cia 
Universidad Javeriana, Bogotá, Colombia (L H Barrero ScD); Stanford 
University, Stanford, CA, USA (S Basu PhD, L C Del Gobbo PhD); 
School of Public Health (Y A Melaku MPH), Mekelle University, 
Mekelle, Ethiopia (T A Bayou BS, B D Betsu MPH, G B Hailu MSc, 
D Y Tekle MS); Oxford University, Ho Chi Minh City, Vietnam 
(J Beardsley MBChB); College of Public Health and Tropical Medicine, 
Jazan, Saudi Arabia (N Bedi MD); IRCCS—Istituto di Ricerche 
Farmacologiche Mario Negri, Milan, Italy (E Beghi MD); School of 
Medicine (K N Sheth MD), Yale University, New Haven, CT, USA 
(Prof M L Bell PhD, J J Huang MD); National Institute of Psychiatry 
Ramon de la Fuente, Mexico City, Mexico (C Benjet PhD, 
R A Gutiérrez PhD); Internal Medicine Department 
(Prof I S Santos PhD), University of São Paulo, São Paulo, Brazil 
(I M Bensenor PhD, Prof P A Lotufo DrPH); Debre Berhane University, 
Debre Berhan, Ethiopia (A Berhane PhD); Division of Health and Social 
Care Research (Prof C D Wolfe MD), King’s College London, London, 
UK (E Bernabé PhD, Prof R J Hay DM); College of Health and Medical 
Sciences (H S Roba MPH), Haramaya University, Harar, Ethiopia 
(A S Beyene MPH, T A Hassen MS, Y M Mesfi
 n MPH); Queen 
Elizabeth Hospital Birmingham, Birmingham, UK (N Bhala DPhil); 
University of Otago Medical School, Wellington, New Zealand 
(N Bhala DPhil); Postgraduate Institute of Medical Education and 
Research, Chandigarh, India (A Bhansali DM); Department of Infectious 
Disease Epidemiology (T Fürst PhD), Department of Epidemiology and 
Biostatistics (F B Piel PhD), Division of Brain Sciences 
(Prof T J Steiner PhD), Imperial College London, London, UK 
(S Bhatt DPhil, Prof A Majeed MD, M Soljak PhD); Independent Public 
Health Consultants, Addis Ababa, Ethiopia (S Biadgilign MPH); 
Department of Nephrology Issues of Transplanted Kidney, Academician 
V I Shumakov Federal Research Center of Transplantology and Artifi
 cial 
Organs, Moscow, Russia (B Bikbov MD); University of Iowa Hospitals 
and Clinics, Iowa City, IA, USA (A A Bin Abdulhak MD); Department of 
Community Medicine, University of Oslo, Oslo, Norway 
(Prof E Bjertness PhD); Vision & Eye Research Unit, Anglia Ruskin 
University, Cambridge, UK (Prof R R A Bourne FRCOphth); Danube-
University Krems, Krems, Austria (Prof M Brainin PhD); Faculty of 
Health Sciences and Social Work, Department of Public Health, Trnava 
University, Trnava, Slovakia (A Brazinova PhD, M Majdan PhD); 
International Neurotrauma Research Organization, Vienna, Austria 
(A Brazinova PhD); College of Medicine (J Shen PhD), Ohio State 
University, Columbus, OH, USA (Prof N J K Breitborde PhD); German 
Cancer Research Center, Heidelberg, Germany (Prof H Brenner MD); 
University of Leicester, Leicester, UK (Prof T S Brugha MD); Monash 
Department of Clinical Epidemiology, Cabrini Institute, Melbourne, 
VIC, Australia (Prof R Buchbinder PhD); University of California, San 
Francisco, San Francisco, CA, USA (G C Buckle MD); Al Shifa Trust Eye 
Hospital, Rawalpindi, Pakistan (Z A Butt PhD); National Centre for 
Epidemiology and Population Health, The Australian National 
University, Canberra, ACT, Australia (B Calabria PhD, 
Prof R M Lucas PhD); Transport and Road Safety (TARS) Research 
(S Boufous PhD), National Drug and Alcohol Research Centre 
(Prof L Degenhardt PhD), Brien Holden Vision Institute 
(Prof S Resnikoff
  MD), University of New South Wales, Kensington, 
NSW, Australia (B Calabria PhD, Prof P B Mitchell MD); National 
Institute of Public Health, Cuernavaca, Mexico 
(I R Campos-Nonato PhD, J C Campuzano PhD, H Gomez-Dantes MSc, 
I B Heredia-Pi PhD, A Jauregui MSc, J C Montañez Hernandez MSc, 
Prof E E Servan-Mori MSc); Department of Biostatistics and 
Epidemiology, University of Oklahoma Health Sciences Center, 
Oklahoma City, OK, USA (H Carabin PhD); Telethon Kids Institute, the 
University of Western Australia, Princess Margaret Hospital for 
Children, Subiaco, WA, Australia (Prof J R Carapetis PhD); Metropolitan 
Autonomous University, Mexico City, Mexico (R Cárdenas ScD); 
Colombian National Health Observatory, Instituto Nacional de Salud, 
Bogotá, Colombia (C A Castañeda-Orjuela MSc); Epidemiology and 
Public Health Evaluation Group, Public Health Department, 
Universidad Nacional de Colombia, Bogotá, Colombia 
(C A Castañeda-Orjuela MSc); Caja Costarricense de Seguro Social, San 
Jose, Costa Rica (Prof J Castillo Rivas MPH); Universidad de Costa Rica, 
San Pedro, Montes de Oca, Costa Rica (Prof J Castillo Rivas MPH); 
Department of Medicine, University of Valencia/INCLIVA Health 
Research Institute and CIBERSAM, Valencia, Spain 
(F Catalá-López PhD); Clinical Epidemiology Program, Ottawa Hospital 
Research Institute, Ottawa, ON, Canada (F Catalá-López PhD); School of 
Nursing, College of Medicine, National Taiwan University, Taipei, 
Taiwan (Prof J Chang PhD); Clinical Governance Unit, Gold Coast 
Health, Southport, QLD, Australia (P P Chiang PhD); Crowd Watch 
Africa, Lusaka, Zambia (M Chibalabala BS); National Center for Child 
Health and Development, Setagaya, Japan (C E Chibueze PhD, 
R Mori PhD); University of Zambia, Lusaka, Zambia 
(V H Chisumpa MPhil, F Masiye PhD); University of Witwatersrand, 
Johannesburg, South Africa (V H Chisumpa MPhil); Seoul National 
University Medical Library, Seoul, South Korea (J J Choi PhD); World 
Bank, New Delhi, India (L Choudhury MPH); Bispebjerg University 
Hospital, Copenhagen, Denmark (Prof H Christensen DMSCi); 
Ministerio de Salud Pública, Montevideo, Uruguay (V Colistro MSc); 
UNICEM, Montevideo, Uruguay (M Colomar MSc); Centre for 
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1653
International Health, Dunedin School of Medicine 
(Prof J A Crump MD), Injury Prevention Research Unit, Department of 
Preventive and Social Medicine, Dunedin School of Medicine 
(Prof S Derrett PhD), University of Otago, Dunedin, New Zealand 
(Prof R G Poulton PhD); IRCCS—Istituto di Ricerche Farmacologiche 
Mario Negri, Bergamo, Italy (G Giussani Biol D, M Cortinovis Biotech D, 
N Perico MD, Prof G Remuzzi MD); Faculty of Medicine, Eduardo 
Mondlane University, Maputo, Mozambique (Prof A Damasceno PhD); 
Guy’s and St Thomas’ NHS Foundation Trust, London, UK 
(Prof P I Dargan FRCP); i3S—Instituto de Investigação e Inovação em 
Saúde and INEB—Instituto de Engenharia Biomédica 
(J das Neves PhD), EPIUnit—Institute of Public Health (J M Pedro MS), 
University of Porto, Porto, Portugal (J V Santos BHlthSc); Wellcome 
Trust Brighton & Sussex Centre for Global Health Research, Brighton, 
UK (Prof G Davey MD); Public Health England, London, UK 
(Prof A C Davis PhD, Prof J N Newton FRCP, Prof N Steel PhD); Griffi
  th 
University, Brisbane, QLD, Australia (Prof D De Leo DSc); Mount Sinai 
Beth Israel, New York, NY, USA (Prof D C Des Jarlais PhD); Icahn 
School of Medicine at Mount Sinai, New York, NY, USA 
(Prof D C Des Jarlais PhD); Department of Community Medicine, 
Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka 
(S D Dharmaratne MD); Centre for Control of Chronic Conditions 
(P Jeemon PhD), Public Health Foundation of India, Gurgaon, India 
(P K Dhillon PhD, Prof S Zodpey PhD); RMIT University, Bundoora, 
VIC, Australia (Prof K E Doyle PhD); International Institute for 
Population Sciences, Mumbai, India (M Dubey MPhil, 
M H U Rahman MPhil, Prof U Ram PhD, A Singh PhD, 
A K Yadav MPhil); Federal University of Rio Grande do Sul, Porto 
Alegre, Brazil (B B Duncan PhD, C Kieling MD, Prof M I Schmidt MD); 
University of North Carolina, Chapel Hill, NC, USA (B B Duncan PhD); 
Non-Communicable Diseases Research Center, Endocrinology and 
Metabolism Population Sciences Institute (H Ebrahimi MD, 
Prof A Esteghamati MD, F Farzadfar MD, N Hafezi-Nejad MD, 
A Kasaeian PhD, M Parsaeian PhD, F Pishgar MD, S Sheikhbahaei MD), 
Liver and Pancreaticobiliary Diseases Research Center, Digestive Disease 
Research Institute, Shariati Hospital (H Ebrahimi MD), Digestive 
Diseases Research Institute (S Fahimi PhD, Prof R Malekzadeh MD, 
G Roshandel PhD, S G Sepanlou PhD), Center for Air Pollution 
Research, Institute for Environmental Research (M S Hassanvand PhD), 
Multiple Sclerosis Research Center, Neuroscience Institute 
(P Heydarpour MD), Hematology-Oncology and Stem Cell 
Transplantation Research Center (A Kasaeian PhD), Department of 
Epidemiology and Biostatistics, School of Public Health 
(M Parsaeian PhD), Uro-Oncology Research Center (F Pishgar MD), 
Sina Trauma and Surgery Research Center 
(Prof V Rahimi-Movaghar MD), Tehran University of Medical Sciences, 
Tehran, Iran (M Yaseri PhD); Eijkman-Oxford Clinical Research Unit, 
Jakarta, Indonesia (I Elyazar PhD); Arba Minch University, Arba Minch, 
Ethiopia (A Y Endries MPH); The Institute of Social and Economic 
Studies of Population, Russian Academy of Sciences, Moscow, Russia 
(Prof S P Ermakov DSc); Federal Research Institute for Health 
Organization and Informatics, Ministry of Health of the Russian 
Federation, Moscow, Russia (Prof S P Ermakov DSc); Ministry of Health 
and Medical Education, Tehran, Iran (B Eshrati PhD); Arak University of 
Medical Sciences, Arak, Iran (B Eshrati PhD); University of Louisville, 
Louisville, KY, USA (T A Farid MD, A R Khan MD); DGS Directorate 
General of Health, Lisbon, Portugal (C S E S Farinha MSc); Universidade 
Aberta, Lisbon, Portugal (C S E S Farinha MSc); Federal University of 
Sergipe, Aracaju, Brazil (Prof A Faro PhD); Harvard/MGH Center on 
Genomics, Vulnerable Populations, and Health Disparities, Mongan 
Institute for Health Policy, Massachusetts General Hospital, Boston, 
MA, USA (M S Farvid PhD); National Institute for Stroke and Applied 
Neurosciences (V L Feigin PhD), Auckland University of Technology, 
Auckland, New Zealand (B J Te Ao MPH); Institute of Education and 
Sciences, German Hospital Oswaldo Cruz, São Paulo, Brazil 
(Prof J G Fernandes PhD); Centre for Experimental Medicine & 
Rheumatology, William Harvey Research Institute, Barts and The 
London School of Medicine & Dentistry, Queen Mary University of 
London, London, UK (J C Fernandes PhD); Bielefeld University, 
Bielefeld, Germany (F Fischer MPH); Institute of Gerontology, Academy 
of Medical Science, Kiev, Ukraine (N Foigt PhD); University of 
Edinburgh, Edinburgh, UK (Prof F G R Fowkes PhD); James Cook 
University, Townsville, QLD, Australia (R C Franklin PhD); CHU 
Hassan II, Fès, Morocco (F G Gankpé MD); Manhiça Health Research 
Center, Manhiça, Mozambique (A L Garcia-Basteiro MSc Epidemiology); 
Barcelona Institute for Global Health, Barcelona, Spain 
(A L Garcia-Basteiro MSc Epidemiology); Ludwig Maximilians 
University, Munich, Germany (A T Gebremedhin MPH); Division of 
Human Nutrition (J M Geleijnse PhD), Wageningen University, 
Wageningen, Netherlands (T Jibat MS); The Peter Doherty Institute for 
Infection and Immunity, University of Melbourne & The Royal 
Melbourne Hospital, Melbourne, VIC, Australia (K B Gibney FRACP); 
The Royal Melbourne Hospital, Melbourne, VIC, Australia 
(K B Gibney FRACP); College of Medicine, Howard University, 
Washington, DC, USA (R F Gillum MD, A Mehari MD); College of 
Medicine, University of Hail, Hail, Saudi Arabia (I A Ginawi MD); 
School of Public Health (A D Hailu MPH), Addis Ababa University, 
Addis Ababa, Ethiopia (A Z Giref PhD, D Haile MPH, T Jibat MS); 
University Hospital of Dijon, Dijon, France (Prof M Giroud MD); 
College of Health and Medical Sciences (H S Roba MPH), Haramaya 
University, Dire Dawa, Ethiopia (M D Gishu MS A K Tura MPH); Kersa 
Health and Demographic Surveillance System, Harar, Ethiopia 
(M D Gishu MS); University of Massachusetts Boston, Boston, MA, USA 
(Prof P Gona PhD); Instituto de Investigaciones Cientifi
 cas y Servicios 
de Alta Tecnologia—INDICASAT-AIP, Ciudad del Saber, Panamá 
(A Goodridge PhD); Department of Health and Social Aff
 airs, 
Government of the Federated States of Micronesia, Palikir, Federated 
States of Micronesia (S V Gopalani MPH); University of British 
Columbia, Vancouver, BC, Canada (C C Gotay PhD, Prof N Kissoon MD, 
J A Kopec PhD, F Pourmalek PhD); Division of Epidemiology, Center for 
Public Health Sciences (A Goto PhD), National Cancer Center, Tokyo, 
Japan (M Inoue MD); Departments of Microbiology and Epidemiology & 
Biostatistics, Saint James School of Medicine, The Quarter, Anguilla 
(Prof H Gugnani PhD); West Virginia Bureau for Public Health, 
Charleston, WV, USA (R Gupta MD); Eternal Heart Care Centre and 
Research Institute, Jaipur, India (R Gupta PhD); Department of 
Anthropology, University of Delhi, Delhi, India (V Gupta PhD); 
Department of Global Public Health and Primary Care 
(A K Knudsen PhD, Prof S E Vollset DrPH), University of Bergen, 
Bergen, Norway (A D Hailu MPH, Prof O F Norheim PhD); Kilte 
Awlaelo Health and Demographic Surveillance System, Mekelle, 
Ethiopia (G B Hailu MSc); Brandeis University, Waltham, MA, USA 
(Y A Halasa MS, E A Undurraga PhD); Arabian Gulf University, 
Manama, Bahrain (Prof R R Hamadeh DPhil); Hamdan Bin Mohammed 
Smart University, Dubai, United Arab Emirates (S Hamidi PhD); Wayne 
County Department of Health and Human Services, Detroit, MI, USA 
(M Hammami MD); University of New Mexico, Albuquerque, NM, USA 
(A J Handal PhD); School of Medicine and Pharmacology, University of 
Western Australia, Perth, WA, Australia (Prof G J Hankey MD); Harry 
Perkins Institute of Medical Research, Nedlands, WA, Australia 
(Prof G J Hankey MD); Western Australian Neuroscience Research 
Institute, Nedlands, WA, Australia (Prof G J Hankey MD); Sree Chitra 
Tirunal Institute for Medical Sciences and Technology, Trivandrum, 
India (S Harikrishnan DM); Parc Sanitari Sant Joan de Déu—
CIBERSAM, Sant Boi de Llobregat (Barcelona), Spain (J M Haro MD); 
Universitat de Barcelona, Barcelona, Spain (J M Haro MD); International 
Foundation for Dermatology, London, UK (Prof R J Hay DM); 
Department of Medical Mycology and Parasitology, School of Medicine, 
Mazandaran University of Medical Sciences, Sari, Iran 
(Prof M T Hedayati PhD); Department of Psychiatry, University Medical 
Center Groningen (Prof H W Hoek MD), University of Groningen, 
Groningen, Netherlands (A K Tura MPH); Department of Epidemiology, 
Mailman School of Public Health (Prof H W Hoek MD), Columbia 
University, New York, NY, USA (Prof V Skirbekk PhD); Rutgers 
University, New Brunswick, NJ, USA (D J Hoff
 man PhD); Nevada 
Division of Public and Behavioral Health, Department of Health and 
Human Services, Carson City, NV, USA (M Horino MPH); Department 
of Pulmonology, Yokohama City University Graduate School of 
Medicine, Yokohama, Japan (N Horita MD); Albert Einstein College of 
Medicine, Bronx, NY, USA (Prof H D Hosgood PhD); Public Health 
Division, The Pacifi
 c Community, Noumea, New Caledonia 
(D G Hoy PhD); Department of Epidemiology, Salah Azaiz Institute, 
 Articles
1654 
www.thelancet.com   Vol 388   October 8, 2016
Tunis, Tunisia (Prof M Hsairi MD); Cambridge Health Alliance, 
Cambridge, MA, USA (H Huang MD); Aarhus University, Aarhus, 
Denmark (K M Iburg PhD); Boston Medical Center (B T Idrisov MD), 
School of Medicine (G F Kwan MD), Boston University, Boston, MA, 
USA; National Institute for Health Development, Tallinn, Estonia 
(K Innos PhD); Graduate School of Medicine (M Inoue MD), School of 
Public Health (Prof N Kawakami MD), University of Tokyo, Tokyo, Japan 
(K Shibuya MD); Department of Global and Community Health, 
George Mason University, Fairfax, VA, USA (K H Jacobsen PhD); 
Postgraduate Institute of Medicine, Colombo, Sri Lanka 
(A U Jayatilleke PhD); Institute of Violence and Injury Prevention, 
Colombo, Sri Lanka (A U Jayatilleke PhD); Centre for Chronic Disease 
Control, New Delhi, India (P Jeemon PhD); George Institute for Global 
Health India, New Delhi, India (Prof V Jha DM); Tianjin Centers for 
Disease Control and Prevention, Tianjin, China (G Jiang MD); 
Department of Health Development, Institute of Industrial Ecological 
Sciences, University of Occupational and Environmental Health, 
Kitakyushu, Japan (Y Jiang PhD); Department of Ocular Epidemiology 
and Visual Health, Institute of Ophthalmology Conde de Valencia, 
Mexico City, Mexico (A Jimenez-Corona PhD); General Directorate of 
Epidemiology, Ministry of Health, Mexico City, Mexico 
(A Jimenez-Corona PhD); Department of Ophthalmology, Medical 
Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, 
Germany (Prof J B Jonas MD); University College Cork, Cork, Ireland 
(Z Kabir PhD); Sante Stat & Analytical Research Institute, Kampala, 
Uganda (D K Kajungu MS); Mildmay Uganda, Kampala, Uganda 
(D K Kajungu MS); Society for Education, Action and Research in 
Community Health, Gadchiroli, India (Y Kalkonde MD); CSIR—Indian 
Institute of Toxicology Research, Lucknow, India (R Kamal MSc, 
C N Kesavachandran PhD); Department of Pulmonary Medicine, 
Zhongshan Hospital (J She MD), Fudan University, Shanghai, China 
(H Kan MD); University at Buff
 alo, Buff
 alo, NY, USA (A Kandel MBBS); 
Epidemiological and Statistical Methods Research Group, Helmholtz 
Centre for Infection Research, Braunschweig, Germany (A Karch MD); 
Hannover-Braunschweig Site, German Center for Infection Research, 
Braunschweig, Germany (A Karch MD); Quality and Equity Health Care, 
Kigali, Rwanda (C K Karema MSc); Case Western University Hospitals, 
Cleveland, OH, USA (C Karimkhani MD); Oklahoma State University, 
Tulsa, OK, USA (A Kaul MD); University of California San Francisco, 
San Francisco, CA, USA (D S Kazi MD); Institute of Tropical and 
Infectious Diseases, Nairobi, Kenya (P N Keiyoro PhD); School of 
Continuing and Distance Education, Nairobi, Kenya (P N Keiyoro PhD); 
Farr Institute (Prof R A Lyons MD), Swansea University, Swansea, UK 
(Prof A H Kemp PhD); South African Medical Research Council, Cape 
Town, South Africa (A P Kengne PhD, R Matzopoulos PhD, 
Prof C S Wiysonge PhD); School of Public Health and Family Medicine 
(R Matzopoulos PhD), Department of Psychiatry (Prof D J Stein PhD), 
University of Cape Town, Cape Town, South Africa (A P Kengne PhD, 
Prof B M Mayosi DPhil); Assuta Hospitals, Assuta Hashalom, Tel Aviv, 
Israel (Prof A Keren MD); Jordan University of Science and Technology, 
Irbid, Jordan (Prof Y S Khader ScD); Health Services Academy, 
Islamabad, Pakistan (E A Khan MPH); College of Medicine 
(Prof Y H Khang MD), Graduate School of Public Health 
(Prof S Won PhD), Seoul National University, Seoul, South Korea; 
Executive Board of the Health Ministers’ Council for Cooperation 
Council States, Riyadh, Saudi Arabia (Prof T A M Khoja FRCP); Ball 
State University, Muncie, IN, USA (J Khubchandani PhD); Hospital de 
Clínicas de Porto Alegre, Porto Alegre, Brazil (C Kieling MD); Korea 
Health Industry Development Institute, Cheongju-si, South Korea 
(C Kim PhD); Department of Health Sciences, Northeastern University, 
Boston, MA, USA (Prof D Kim DrPH); Southern University College, 
Skudai, Malaysia (Y J Kim PhD); Centre for Disease Burden 
(A K Knudsen PhD, Prof S E Vollset DrPH), Department of Health 
Promotion (J C Skogen PhD), Norwegian Institute of Public Health, 
Oslo, Norway (M Savic PhD, Prof V Skirbekk PhD); Department of 
Preventive Cardiology, National Cerebral and Cardiovascular Center, 
Suita, Japan (Y Kokubo PhD); Division of Cardiology, Brown University, 
Providence, RI, USA (D Kolte MD); Sher-i-Kashmir Institue of Medical 
Sciences, Srinagar, India (Prof P A Koul MD); Research and 
Development Unit, Parc Sanitari Sant Joan de Deu (CIBERSAM), 
Barcelona, Spain (A Koyanagi MD); Department of Demography and 
Public Health Research Institute (Prof B Kuate Defo PhD), Department 
of Social and Preventive Medicine, School of Public Health 
(Prof B Kuate Defo PhD), University of Montreal, Montreal, QC, Canada; 
Graduation Studies in Epidemiology Universidade Federal do Rio 
Grande do Sul, Porto Alegre, Brazil (Prof R S Kuchenbecker PhD); 
Institute of Public Health, Hacettepe University, Ankara, Turkey 
(B Kucuk Bicer PhD); Erasmus MC, University Medical Center 
Rotterdam, Rotterdam, Netherlands (Prof E J Kuipers PhD); Work 
Organizations, Work Disability Prevention, The Finnish Institute of 
Occupational Health, Helsinki, Finland (T Lallukka PhD, R Shiri PhD); 
Department of Public Health, Faculty of Medicine (T Lallukka PhD), 
University of Helsinki, Helsinki, Finland (T J Meretoja PhD); 
Department of Zoology, Lahore College for Women University, Lahore, 
Pakistan (A A Latif PhD); Servicio de Neurologia, Clinica Alemana, 
Universidad del Desarrollo, Santiago, Chile (P M Lavados MD); Instituto 
Nacional de Epidemiología “Dr Juan H Jara,” Mar del Plata, Argentina 
(A E B Lawrynowicz MPH); College of Optometry, Nova Southeastern 
University, Fort Lauderdale, FL, USA (J L Leasher OD); State University 
of New York, Albany, Rensselaer, NY, USA (R Leung PhD); San Francisco 
VA Medical Center, San Francisco, CA, USA (Y Li PhD); School of 
Medicine, Wayne State University, Detroit, MI, USA 
(Prof S E Lipshultz MD, Prof J D Wilkinson MD); Children’s Hospital of 
Michigan, Detroit, MI, USA (Prof S E Lipshultz MD); Rollins School of 
Public Health (E P Simard PhD), Emory University, Atlanta, GA, USA 
(Prof Y Liu PhD, Prof M R Phillips MD); Turning Point, Eastern Health, 
Melbourne, VIC, Australia (B K Lloyd PhD); University of Bari, Bari, 
Italy (Prof G Logroscino PhD); University of Bristol, Bristol, UK 
(K J Looker PhD, D Rai PhD); Aintree University Hospital National 
Health Service Foundation Trust, Liverpool, UK 
(Prof R Lunevicius PhD); School of Medicine, University of Liverpool, 
Liverpool, UK (Prof R Lunevicius PhD); Mansoura Faculty of Medicine, 
Mansoura, Egypt (H Magdy Abd El Razek MBBCH); Social Security 
Organization Research Institute, Tehran, Iran (M Mahdavi PhD); 
Institute of Health Policy and Management, Erasmus University 
Rotterdam, Rotterdam, Netherlands (M Mahdavi PhD); Universidade 
Federal de Minas Gerais, Belo Horizonte, Brazil (Prof D C Malta PhD); 
Division of Population and Patient Health, King’s College London 
Dental Institute, London, UK (Prof W Marcenes PhD); University 
Hospital Doctor Peset, University of Valencia, Valencia, Spain 
(J Martinez-Raga PhD); CEU Cardenal Herrera University, Moncada 
(Valencia), Spain (J Martinez-Raga PhD); Department of Health 
Sciences, University of York, York, UK (A J Mason-Jones PhD); London 
School of Hygiene & Tropical Medicine, London, UK 
(Prof M McKee DSc, Prof G V S Murthy MD); Perelman School of 
Medicine, University of Pennsylvania, Philadelphia, PA, USA 
(P A Meaney MD); Children’s Hospital of Philadelphia, Philadelphia, 
PA, USA (P A Meaney MD); University of West Florida, Pensacola, FL, 
USA (P Memiah PhD); Saudi Ministry of Health, Riyadh, Saudi Arabia 
(Prof Z A Memish MD); College of Medicine, Alfaisal University, 
Riyadh, Saudi Arabia (Prof Z A Memish MD); United Nations 
Population Fund, Lima, Peru (W Mendoza MD); Department of 
Neurology, Helsinki University Hospital, Helsinki, Finland 
(A Meretoja PhD); Helsinki University Hospital, Comprehensive Cancer 
Center, Breast Surgery Unit, Helsinki, Finland (T J Meretoja PhD); 
Ifakara Health Institute, Bagamoyo, Tanzania (F A Mhimbira MS); 
Pacifi
 c Institute for Research & Evaluation, Calverton, MD, USA 
(T R Miller PhD); Centre for Population Health, Curtin University, 
Perth, WA, Australia (T R Miller PhD); University of Ottawa, Ottawa, 
ON, Canada (E J Mills PhD); Kyrgyz State Medical Academy, Bishkek, 
Kyrgyzstan (Prof E M Mirrakhimov PhD); National Center of Cardiology 
and Internal Disease, Bishkek, Kyrgyzstan (Prof E M Mirrakhimov PhD); 
University of Salahaddin, Erbil, Iraq (K A Mohammad PhD); 
Neuroscience Research Center, Baqiyatallah University of Medical 
Sciences, Tehran, Iran (A Mohammadi PhD); Health Systems and Policy 
Research Unit, Ahmadu Bello University, Zaria, Nigeria 
(S Mohammed PhD); Institute for Maternal and Child Health, IRCCS 
Burlo Garofolo, Trieste, Italy (L Monasta DSc, M Montico MSc, 
L Ronfani PhD); Department of Community Medicine, Gastrointestinal 
and Liver Disease Research Center, Preventive Medicine and Public 
Health Research Center, Iran University of Medical Sciences, Tehran, 
Iran (M Moradi-Lakeh MD); Competence Center Mortality-Follow-Up of 
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1655
the German National Cohort (A Werdecker PhD), Federal Institute for 
Population Research, Wiesbaden, Germany (Prof U O Mueller PhD, 
R Westerman PhD); West Herts Hospitals NHS Trust, Watford, UK 
(M E Murdoch FRCP); Indian Institute of Public Health 
(Prof G V S Murthy MD), Public Health Foundation of India, Gurgaon, 
India (P K Dhillon PhD, Prof S Zodpey PhD); Graduate School of Public 
Health, University of Pittsburgh, Pittsburgh, PA, USA 
(Prof J B Nachega PhD); Stellenbosch University, Cape Town, South 
Africa (Prof J B Nachega PhD, Prof S Seedat PhD, 
Prof C S Wiysonge PhD); Bloomberg School of Public Health 
(Prof J B Nachega PhD), Johns Hopkins University, Baltimore, MD, USA 
(B X Tran PhD); International Centre for Diarrhoeal Disease Research, 
Bangladesh (icddr,b), Dhaka, Bangladesh (A Naheed PhD); Azienda 
Ospedaliera Papa Giovanni XXIII, Bergamo, Italy (Prof L Naldi MD, 
Prof G Remuzzi MD); Suraj Eye Institute, Nagpur, India (V Nangia MD); 
Ministry of Health and Social Welfare, Dar es Salaam, Tanzania 
(F N Ngalesoni MSc); Institute for Global Health Innovations, Duy Tan 
University, Da Nang, Vietnam (Q L Nguyen MD); Institute For Research, 
Socio-Economic Development and Communication, Yaoundé, Cameroon 
(P M Nkamedjie Pete MS); Hospital Universitari de Bellvitge, 
L’Hospitalet, Spain (J M Nolla PhD); Institute of Health and Biomedical 
Innovation, Queensland University of Technology, Brisbane, QLD, 
Australia (R E Norman PhD); Center for Research on Population and 
Health, Faculty of Health Sciences, American University of Beirut, 
Beirut, Lebanon (Prof C M Obermeyer DSc); Centre for Health 
Research, Western Sydney University, Sydney, NSW, Australia 
(F A Ogbo MPH); Department of Preventive Medicine, School of 
Medicine, Kyung Hee University, Seoul, South Korea (Prof I Oh PhD); 
Human Sciences Research Council, Durban, South Africa 
(O Oladimeji MD); University of KwaZulu-Natal, Durban, South Africa 
(O Oladimeji MD, Prof B Sartorius PhD); Universidad Autonoma de 
Chile, Talca, Chile (Prof P R Olivares PhD); Center for Healthy Start 
Initiative, Lagos, Nigeria (B O Olusanya PhD, J O Olusanya MBA); 
University of Arizona, Tucson, AZ, USA (Prof E Oren PhD); IIS-
Fundacion Jimenez Diaz-UAM, Madrid, Spain (Prof A Ortiz PhD); St 
Luke’s International University, Tokyo, Japan (E Ota PhD); Hypertension 
in Africa Research Team (HART) (Prof A E Schutte PhD), North-West 
University, Mafi
 keng, South Africa (Prof A S Oyekale PhD); JSS Medical 
College, JSS University, Mysore, India (Prof M PA DNB); Department of 
Medical Humanities and Social Medicine, College of Medicine, Kosin 
University, Busan, South Korea (E Park PhD); Department of 
Community Health Sciences (Prof S B Patten PhD), University of 
Calgary, Calgary, AB, Canada (Prof M Tonelli MD); Health Research 
Centre of Angola, Caxito, Angola (J M Pedro MS); REQUIMTE/LAQV, 
Laboratório de Farmacognosia, Departamento de Química, Faculdade de 
Farmácia, Universidade do Porto, Porto, Portugal 
(Prof D M Pereira PhD); Flinders University, Adelaide, SA, Australia 
(Prof K Pesudovs PhD); University of the Witwatersrand, Johannesburg, 
South Africa (Prof M Petzold PhD); Shanghai Jiao Tong University 
School of Medicine, Shanghai, China (Prof M R Phillips MD); Durban 
University of Technology, Durban, South Africa (J D Pillay PhD); 
Exposure Assessment and Environmental Health Indicators, German 
Environment Agency, Berlin, Germany (D Plass DrPH); Department of 
Public Health, Erasmus University Medical Center, Rotterdam, 
Netherlands (S Polinder PhD); The Fred Hollows Foundation, Sydney, 
NSW, Australia (N M Prasad DO); Centre for Eye Research Australia, 
Melbourne, VIC, Australia (N M Prasad DO); Department of 
Community Medicine, School of Medicine, Alborz University of Medical 
Sciences, Karaj, Iran (M Qorbani PhD); A T Still University, Kirksville, 
MO, USA (A Radfar MD); Contech School of Public Health, Lahore, 
Pakistan (A Rafay MS); Research and Evaluation Division, BRAC, Dhaka, 
Bangladesh (M Rahman PhD); Hamad Medical Corporation, Doha, 
Qatar (S U Rahman FCPS); Society for Health and Demographic 
Surveillance, Suri, India (R K Rai MPH); ERAWEB Program, UMIT, Hall 
in Tirol, Austria (S Rajsic MD); University of Missouri, Columbia, MO, 
USA (M Raju PhD); University of Michigan Health Systems, Ann Arbor, 
MI, USA (K Ranganathan MD); Walden University, Minneapolis, MN, 
USA (Prof A H Refaat PhD); Suez Canal University, Ismailia, Egypt 
(Prof A H Refaat PhD); Department of Biomedical and Clinical Sciences 
L Sacco, University of Milan, Milan, Italy (Prof G Remuzzi MD); 
Hospital das Clinicas da Universidade Federal de Minas Gerais, Belo 
Horizonte, Brazil (Prof A L Ribeiro MD); UO Neurologia USL Umbria 1, 
Città di Castello, Italy (S Ricci FRCPEd); (ISGlobal) Instituto de Salud 
Global de Barcelona, Barcelona, Spain (D Rojas-Rueda PhD); Golestan 
Research Center of Gastroenterology and Hepatology, Golestan 
University of Medical Sciences, Gorgan, Iran (G Roshandel PhD); 
World Health Organization, Accra, Ghana (B B Sackey MS); Marshall 
University J Edwards School of Medicine, Huntington, WV, USA 
(J R Sanabria MD); Case Western Reserve University, Cleveland, OH, 
USA (J R Sanabria MD); IIS-Fundacion Jimenez Diaz, Madrid, Spain 
(M D Sanchez-Niño PhD); Universidad Ciencias Aplicadas y 
Ambientales, Bogotá, Colombia (R Sarmiento-Suarez MPH); Marshall 
University, Huntington, WV, USA (M Sawhney PhD); Federal University 
of Santa Catarina, Florianópolis, Brazil (I J C Schneider PhD, 
D A S Silva PhD); South African Medical Research Council, 
Potchefstroom, South Africa (Prof A E Schutte PhD); University of 
Alabama at Birmingham, Birmingham, AL, USA (D C Schwebel PhD, 
J A Singh MD); Tufts Medical Center, Boston, MA, USA 
(S Shahraz PhD); Independent Consultant, Karachi, Pakistan 
(M A Shaikh MD); Indian Institute of Technology Ropar, Rupnagar, 
India (R Sharma MA); Research Institute at Nationwide Children’s 
Hospital, Columbus, OH, USA (J Shen PhD); National Institute of 
Infectious Diseases, Tokyo, Japan (M Shigematsu PhD); Sandia National 
Laboratories, Albuquerque, NM, USA (M Shigematsu PhD); 
Department of Public Health Science, Graduate School 
(Prof M Shin PhD), Department of Preventive Medicine, College of 
Medicine (S Yoon PhD), Korea University, Seoul, South Korea; Reykjavik 
University, Reykjavik, Iceland (I D Sigfusdottir PhD); Feinberg School of 
Medicine (J I Silverberg MD), Department of Preventive Medicine 
(Y Yano MD), Northwestern University, Chicago, IL, USA; Institute for 
Human Development, New Delhi, India (P K Singh PhD); Alcohol and 
Drug Research Western Norway (J C Skogen PhD), Stavanger University 
Hospital, Stavanger, Norway (K Søreide PhD); Department of 
Community Medicine, International Medical University, Kuala Lumpur, 
Malaysia (C T Sreeramareddy MD); Attikon University Hospital, Athens, 
Greece (V Stathopoulou PhD); University of East Anglia, Norwich, UK 
(Prof N Steel PhD); South African Medical Research Council Unit on 
Anxiety & Stress Disorders, Cape Town, South Africa 
(Prof D J Stein PhD); University of California, San Diego, La Jolla, CA, 
USA (M B Stein MD); Department of Neuroscience, Norwegian 
University of Science and Technology, Trondheim, Norway 
(Prof T J Steiner PhD, Prof L J Stovner PhD); Norwegian Advisory Unit 
on Headache, St Olavs Hospital, Trondheim, Norway 
(Prof L J Stovner PhD); Luxembourg Institute of Health, Strassen, 
Luxembourg (S Stranges PhD); Alexandra General Hospital of Athens, 
Athens, Greece (K Stroumpoulis PhD); Centre Hospitalier Public du 
Cotentin, Cherbourg, France (K Stroumpoulis PhD); Muhimbili 
University of Health and Allied Sciences, Dar es Salaam, Tanzania 
(B F Sunguya PhD); Indian Council of Medical Research, New Delhi, 
India (S Swaminathan MD); Departments of Criminology, Law & 
Society, Sociology, and Public Health, University of California, Irvine, 
Irvine, CA, USA (Prof B L Sykes PhD); Department of Medicine, 
University of Valencia, INCLIVA Health Research Institute and 
CIBERSAM, Valencia, Spain (Prof R Tabarés-Seisdedos PhD); Chaim 
Sheba Medical Center, Tel Hashomer, Israel (Prof D Tanne MD); Tel Aviv 
University, Tel Aviv, Israel (Prof D Tanne MD); New York Medical 
College, Valhalla, NY, USA (M Tavakkoli MD); Department of Biology, 
Colgate University, Hamilton, NY, USA (B Taye PhD); Department of 
Anesthesiology, University of Virginia, Charlottesville, VA, USA 
(A S Terkawi MD); Outcomes Research Consortium (A S Terkawi MD), 
Cleveland Clinic, Cleveland, OH, USA (Prof E M Tuzcu MD); University 
Of Gondar, Gondar, Ethiopia (G A Tessema MPH); School of Public 
Health, Post Graduate Institute of Medical Education and Research, 
Chandigarh, India (Prof J Thakur MD); Adaptive Knowledge 
Management, Victoria, BC, Canada (A J Thomson PhD); WorldFish, 
Penang, Malaysia (A L Thorne-Lyman ScD); Nelson Institute of 
Environmental Medicine, School of Medicine, New York University, 
Tuxedo, NY, USA (Prof G D Thurston ScD); National Center for Child 
Health and Development, Tokyo, Japan (R Tobe-Gai PhD); Institute of 
Public Health, Faculty of Health Sciences, Jagiellonian University 
Medical College, Kraków, Poland (R Topor-Madry PhD); Faculty of 
Health Sciences, Wroclaw Medical University, Wroclaw, Poland (R Topor-
 Articles
1656 
www.thelancet.com   Vol 388   October 8, 2016
Madry PhD); Aristotle University of Thessaloniki, Thessaloniki, Greece 
(Prof F Topouzis PhD); Hanoi Medical University, Hanoi, Vietnam 
(B X Tran PhD); Department of Neurology, Rigshospitalet, University of 
Copenhagen, Copenhagen, Denmark (T Truelsen DMSc); Department of 
Population Sciences and Development, Faculty of Economics and 
Management, University of Kinshasa, Kinshasa, Democratic Republic of 
the Congo (Z Tsala Dimbuene PhD); African Population and Health 
Research Center, Nairobi, Kenya (Z Tsala Dimbuene PhD); Department 
of Medicine, University of Crete, Heraklion, Greece 
(Prof M Tsilimbaris PhD); Parc Sanitari Sant Joan de Déu, Fundació Sant 
Joan de Déu, Universitat de Barcelona, CIBERSAM, Barcelona, Spain 
(S Tyrovolas PhD); Department of Internal Medicine, Federal Teaching 
Hospital, Abakaliki, Nigeria (K N Ukwaja MD); Ebonyi State University, 
Abakaliki, Nigeria (C J Uneke PhD); Warwick Medical School, University 
of Warwick, Coventry, UK (O A Uthman PhD); National Institute for 
Public Health and the Environment, Bilthoven, Netherlands 
(C H van Gool PhD); Maastricht University Medical Centre, Maastricht, 
Netherlands (Prof J van Os PhD); UKK Institute for Health Promotion 
Research, Tampere, Finland (Prof T Vasankari PhD); University of 
Brasilia, Brasília, Brazil (Prof A M N Vasconcelos PhD); Raffl
  es 
Neuroscience Centre, Raffl
  es Hospital, Singapore, Singapore 
(N Venketasubramanian FRCP); University of Bologna, Bologna, Italy 
(Prof F S Violante MD); National Research University Higher School of 
Economics, Moscow, Russia (Prof V V Vlassov MD); National Institute 
for Occupational Safety and Health, Washington, DC, USA 
(G R Wagner MD); VA Medical Center, Washington, DC, USA 
(M T Wallin MD); Neurology Department, Georgetown University, 
Washington, DC, USA (M T Wallin MD); McGill University, Montreal, 
QC, Canada (S Weichenthal PhD); Department of Research, Cancer 
Registry of Norway, Institute of Population-Based Cancer Research, Oslo, 
Norway (E Weiderpass PhD); Department of Community Medicine, 
Faculty of Health Sciences, University of Tromsø, The Arctic University 
of Norway, Tromsø, Norway (E Weiderpass PhD); Genetic Epidemiology 
Group, Folkhälsan Research Center, Helsinki, Finland 
(E Weiderpass PhD); Royal Children’s Hospital, Melbourne, VIC, 
Australia (R G Weintraub MBBS); German National Cohort Consortium, 
Heidelberg, Germany (R Westerman PhD); Western Health, Footscray, 
VIC, Australia (Prof T Wijeratne MD); Children’s Hospital of Michigan, 
Detroit, MI, USA (Prof J D Wilkinson MD); Centre of Evidence-based 
Dermatology, University of Nottingham, Nottingham, UK 
(Prof H C Williams DSc); Department of Epidemiology and Biostatistics, 
Institute of Public Health, University of Gondar, Gondar, Ethiopia 
(S M Woldeyohannes MPH); National Institute for Health Research 
Comprehensive Biomedical Research Centre, Guy’s & St Thomas’ NHS 
Foundation Trust and King’s College London, London, UK 
(Prof C D Wolfe MD); Department of Neurology, Jinling Hospital, 
Nanjing University School of Medicine, Nanjing, China 
(Prof G Xu PhD); Discipline of Public Health Medicine, School of 
Nursing and Public Health, University of KwaZulu Natal, Durban, South 
Africa (B Yakob PhD); Global Health Research Center, Duke Kunshan 
University, Kunshan, China (Prof L L Yan PhD); Social Work and Social 
Administration Department and The Hong Kong Jockey Club Centre for 
Suicide Research and Prevention, University of Hong Kong, Hong Kong, 
China (Prof P Yip PhD); Department of Biostatistics, School of Public 
Health, Kyoto University, Kyoto, Japan (N Yonemoto MPH); Jackson 
State University, Jackson, MS, USA (Prof M Z Younis DrPH); 
Department of Epidemiology and Biostatistics, School of Public Health 
(Prof C Yu PhD), Global Health Institute (Prof C Yu PhD), Wuhan 
University, Wuhan, China; University Hospital, Setif, Algeria 
(Prof Z Zaidi PhD); Faculty of Medicine, Mansoura University, 
Mansoura, Egypt (Prof M E Zaki PhD); Leibniz Institute for Prevention 
Research and Epidemiology, Bremen, Germany (Prof H Zeeb PhD); 
Red Cross War Memorial Children’s Hospital, Cape Town, South Africa 
(L J Zuhlke PhD)
Contributors
CJLM, NK, and NF prepared the fi
 rst draft. CJLM and ADL conceived 
of the study and provided overall guidance. All other authors provided 
data, developed models, reviewed results, initiated modelling 
infrastructure, and/or reviewed and contributed to the report.
Declaration of interests
Benjamin O Anderson is supported by the Susan G Komen Leadership 
Grant Research Project, award number SAC160001. Itamar S Santos 
reports grants from FAPESP (Brazilian Public Agency), outside the 
submitted work. Carl Abelardo T Antonio reports grants, personal fees, 
and non-fi
 nancial support from Johnson & Johnson (Philippines), 
outside the submitted work. Rafael Tabarés-Seisdedos and Ferrán 
Catalá-López are supported in part by grant PROMETEOII/2015/021 
from Generalitat Valenciana, and Rafael Tabarés-Seisdedos is supported 
by the national grant PI14/00894 from ISCIII-FEDER. Pablo M Lavados 
reports grants, personal fees, and non-fi
 nancial support from Bayer, 
non-fi
 nancial support from Boehringer Ingelheim, grants and personal 
fees from AstraZeneca, grants from CONICYT, and grants from The 
George Institute for Global Health, outside the submitted work. 
Jasvinder A Singh serves as the principal investigator for an 
investigator-initiated study funded by Horizon pharmaceuticals through 
a grant to DINORA, a 501c3 entity, and is on the steering committee of 
OMERACT, an international organization that develops measures for 
clinical trials and receives arms-length funding from 36 pharmaceutical 
companies. Ai Koyanagi’s work is supported by the Miguel Servet 
contract fi
 nanced by the CP13/00150 and PI15/00862 projects, 
integrated into the National R+D+I and funded by the ISCIII General 
Branch Evaluation and Promotion of Health Research and the European 
Regional Development Fund (ERDF-FEDER). Aletta E Schutte is funded 
by the Medical Research Council of South Africa, and the South African 
Research Chair Initiative by the National Research Foundation. 
Ana Maria Nogales Vasconcelos and her team in Brazil has received 
funding from Ministry of Health (process number: 
25000192049/2014-14). Mahesh PA acknowledges the Indian Council of 
Medical Research for fi
 nancial support (ICMR Grant number 
5/8/4-4 (Env)/2003-NCD-I). Katharine J Looker has received funding 
from the World Health Organization for the HSV-2 seroprevalence 
review which informs this work; during the study, KJL also received 
separate funding from the World Health Organization, USAID/PATH, 
Sexual Health 24, and the National Institute for Health Research 
(NIHR) Health Protection Research Unit (HPRU) in Evaluation of 
Interventions at the University of Bristol. Donal Bisanzio is supported 
by Bill & Melinda Gates Foundation (#OPP1068048). Thomas Fürst 
received fi
 nancial support from the Swiss National Science Foundation 
(SNSF; project no P300P3-154634. Jost B Jonas reports personal fees 
from Consultant for Mundipharma (Cambridge, UK); from Patent 
holder with Biocompatibles UK (Franham, Surrey, UK; Treatment of eye 
diseases using encapsulated cells encoding and secreting 
neuroprotective factor and/or anti-angiogenic factor; Patent number: 
20120263794), patent application with University of Heidelberg 
(Heidelberg, Germany; Agents for use in the therapeutic or prophylactic 
treatment of myopia or hyperopia; Europäische Patentanmeldung 
15 000 771.4), outside the submitted work. Rodrigo Sarmiento-Suarez 
receives institutional support from Universidad de Ciencias Aplicadas y 
Ambientales, UDCA, Bogotá, Colombia. Stefanos Tyrovolas’s work is 
supported by the Foundation for Education and European Culture 
(IPEP), the Sara Borrell postdoctoral programme (reference no 
CD15/00019 from the Instituto de Salud Carlos III (ISCIII—Spain) 
and the Fondos Europeo de Desarrollo Regional (FEDER). 
Beatriz Paulina Ayala Quintanilla acknowledges institutional support of 
PRONABEC (National Program of Scholarship and Educational Loan), 
provided by the Peruvian Government, while studying for her doctoral 
course at the Judith Lumley Centre of La Trobe University funded by 
PRONABEC. Manami Inoue is the benefi
 ciary of a fi
 nancial 
contribution from the AXA Research fund as chair holder of the AXA 
Department of Health and Human Security, Graduate School of 
Medicine, The University of Tokyo from Nov 1, 2012; the AXA Research 
Fund has no role in this work. Laith J Abu-Raddad acknowledges the 
support of Qatar National Research Fund (NPRP 9-040-3-008) who 
provided the main funding for generating the data provided to the 
GBD-IHME eff
 ort. Yogeshwar Kalkonde is a Wellcome Trust/ DBT 
India Alliance Intermediate Fellow in Public Health. Sarah Derrett 
reports grants and fees from the Euroqol Foundation, outside the 
submitted work. Dan J Stein reports personal fees from Lundbeck, 
Novartis, AMBRF, Biocodex, Sevier, SUN, and CIPLA, and grants from 
 Articles
www.thelancet.com   Vol 388   October 8, 2016 
1657
NRGF and MRC, outside the submitted work. Tea Lallukka reports 
funding from The Academy of Finland, grant 287488, as an Academy 
Research Fellow. Charles D A Wolfe’s research was funded/supported 
by the National Institute for Health Research (NIHR) Biomedical 
Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust 
and King’s College London. The views expressed are those of the 
authors and not necessarily those of the NHS, the NIHR, the UK 
Department of Health, Public Health England, or the World Health 
Organization. All other authors declare no competing interests.
Acknowledgments
We would like to thank the countless individuals who have contributed to 
the Global Burden of Disease Study 2015 in various capacities. The data 
reported here have been supplied by the US Renal Data System 
(USRDS). Data for this research was provided by MEASURE Evaluation, 
funded by the United States Agency for International Development 
(USAID). Collection of these data was made possible by the US Agency 
for International Development (USAID) under the terms of cooperative 
agreement GPO-A-00-08-000_D3-00. Views expressed do not necessarily 
refl
 ect those of USAID, the US Government, or MEASURE Evaluation. 
Parts of this material are based on data and information provided by the 
Canadian institute for Health Information. However, the analyses, 
conclusions, opinions and statements expressed herein are those of the 
author and not those of the Canadian Institute for Health information. 
The Palestinian Central Bureau of Statistics granted the researchers 
access to relevant data in accordance with license no SLN2014-3-170, after 
subjecting data to processing aiming to preserve the confi
 dentiality of 
individual data in accordance with the General Statistics Law, 2000. The 
researchers are solely responsible for the conclusions and inferences 
drawn upon available data. This paper uses data from SHARE Waves 1, 2, 
3 (SHARELIFE), 4 and 5 (DOIs: 10.6103/SHARE.w1.500, 10.6103/
SHARE.w2.500, 10.6103/SHARE.w3.500, 10.6103/SHARE.w4.500, 
10.6103/SHARE.w5.500), see Börsch-Supan and colleagues, 2013, for 
methodological details. The SHARE data collection has been primarily 
funded by the European Commission through FP5 
(QLK6-CT-2001-00360), FP6 (SHARE-I3: RII-CT-2006-062193, 
COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-2006-028812) 
and FP7 (SHARE-PREP: number 211909, SHARE-LEAP: number 227822, 
SHARE M4: number 261982). Additional funding from the German 
Ministry of Education and Research, the US National Institute on Aging 
(U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_
AG025169, Y1-AG-4553-01, IAG_BSR06-11, and OGHA_04-064) and from 
various national funding sources is gratefully acknowledged. This study 
has been realised using the data collected by the Swiss Household Panel 
(SHP), which is based at the Swiss Centre of Expertise in the Social 
Sciences FORS. The project is fi
 nanced by the Swiss National Science 
Foundation. The following individuals would like to acknowledge various 
forms of institutional support: Simon I Hay is funded by a Senior 
Research Fellowship from the Wellcome Trust (#095066), and grants 
from the Bill & Melinda Gates Foundation (OPP1119467, OPP1093011, 
OPP1106023 and OPP1132415). Amanda G Thrift is supported by a 
fellowship from the National Health and Medical Research Council 
(GNT1042600). Panniyammakal Jeemon is supported by the Wellcome 
Trust-DBT India Alliance, Clinical and Public Health, Intermediate 
Fellowship (2015–2020). Boris Bikbov, Norberto Percio, and 
Giuseppe Remuzzi acknowledge that work related to this paper has been 
done on the behalf of the GBD Genitourinary Disease Expert Group 
supported by the International Society of Nephrology (ISN). 
Amador Goodridge acknowledges funding from Sistema Nacional de 
Investigadores de Panamá-SNI. José das Neves was supported in his 
contribution to this work by a Fellowship from Fundação para a Ciência e 
a Tecnologia, Portugal (SFRH/BPD/92934/2013). Lijing L Yan is 
supported by the National Natural Sciences Foundation of China grants 
(71233001 and 71490732). Olanrewaju Oladimeji is an African Research 
Fellow at Human Sciences Research Council (HSRC) and Doctoral 
Candidate at the University of KwaZulu-Natal (UKZN), South Africa, and 
would like to acknowledge the institutional support by leveraging on the 
existing organisational research infrastructure at HSRC and UKZN. 
Nicholas Steel received funding from Public Health England as a Visiting 
Scholar in the Institute for Health Metrics and Evaluation in 2016. 
No individuals acknowledged received additional compensation for their 
eff
 orts.
References
1 
UN. Sustainable development goals. Oct 29, 2015. http://www.
un.org/sustainabledevelopment/sustainable-development-goals/ 
(accessed Oct 29, 2015).
2 
Murray CJL. Choosing indicators for the health-related SDG targets. 
Lancet 2015; 386: 1314–17
.
3 
Murray CJL. Shifting to Sustainable Development Goals—
Implications for global health. N Engl J Med 2015; 373: 1390–93.
4 
Nilsson M, Griggs D, Visbeck M. Policy: Map the interactions 
between Sustainable Development Goals. Nature News 2016; 534: 320.
5 
UN. United Nations Sustainable Development. http://www.un.org/
sustainabledevelopment/health/ (accessed June 26, 2016).
6 
Murray CJL, Salomon JA, Mathers CD, Lopez AD. Summary Measures 
in Population Health: Concepts, Ethics, Measurement, and 
Applications. Geneva: World Health Organization, 2002.
7 
Sullivan DF. A single index of mortality and morbidity. 
HSMHA Health Rep 1971; 86: 347–54.
8 
Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD. Healthy 
life expectancy in 191 countries, 1999. Lancet 2001; 357: 1685–91.
9 
Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years 
(DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: 
a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2197–223.
10 
Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and 
national disability-adjusted life years (DALYs) for 306 diseases and 
injuries and healthy life expectancy (HALE) for 188 countries, 
1990–2013: quantifying the epidemiological transition. Lancet 2015; 
386: 2145–91.
11 
Murray CJ. Quantifying the burden of disease: the technical basis 
for disability-adjusted life years. Bull World Health Organ 1994; 
72: 429–45.
12 
GBD 2015 Mortality and Causes of Death Collaborators. Global, 
regional, and national life expectancy, all-cause mortality, and cause-
specifi
 c mortality for 249 causes of death, 1980–2015: a systematic 
analysis for the Global Burden of Disease Study 2015. Lancet 2016; 
388: 1459–544.
13 
WHO. WHO methods and data sources for global burden of disease 
estimates 2000–2011. Geneva: World Health Organization, 2013.
14 
WHO. WHO methods and data sources for life tables 1990–2015. 
Geneva: World Health Organization, 2016.
15 
EHLEIS. Bibliography on Health Expectancy in Europe, April 2015. 
http://www.eurohex.eu/pdf/Reports_2015/2015_TR4%204_
Bibliography.pdf (accessed June 7, 2016).
16 
WHO. WHO methods and data sources for country-level causes of 
death 2000–2012. Geneva: World Health Organization, 2014.
17 
WHO. Estimates for 2000–2012. http://www.who.int/healthinfo/
global_burden_disease/estimates/en/ (accessed June 11, 2016).
18 
European Commission. Healthy Life Years (HLY). http://ec.europa.
eu/health/indicators/healthy_life_years/hly_en.htm#fragment2 
(accessed June 7, 2016).
19 
OECD. Health at a Glance: Europe 2012. Paris: Organisation for 
Economic Co-operation and Development, 2012. http://www.oecd-
ilibrary.org/content/book/9789264183896-en (accessed June 7, 2016).
20 GBD 2015 Risk Factors Collaborators. Global, regional, and national 
incidence, prevalence, and years lived with disability for 310 diseases 
and injuries during 1990–2015: a systematic analysis for the Global 
Burden of Disease Study 2015. Lancet 2016; 388: 1545–604.
21 
Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: design, 
defi
 nitions, and metrics. Lancet 2012; 380: 2063–66.
22 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and 
Transparent Health Estimates Reporting: the GATHER statement. 
Lancet 2016; published online June 28. http://dx.doi.org/10.1016/
S0140-6736(16)30388-9.
23 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and 
Transparent Health Estimates Reporting: the GATHER statement. 
PLoS Med 2016; 13: e1002056.
24 
Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden 
of dengue: an analysis from the Global Burden of Disease Study 
2013. Lancet Infect Dis 2016; 16: 712–23.
25 Salomon JA, Vos T, Hogan DR, et al. Common values in assessing 
health outcomes from disease and injury: disability weights 
measurement study for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2129–43.
For funding for SHARE see 
http://www.share-project.org
 Articles
1658 
www.thelancet.com   Vol 388   October 8, 2016
26 Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the 
Global Burden of Disease 2013 study. Lancet Glob Health 2015; 
3: e712–23.
27 
Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy 
for 187 countries, 1990–2010: a systematic analysis for the Global 
Burden Disease Study 2010. Lancet 2012; 380: 2144–62.
28 Calculating the Indices. Human Development Reports. http://hdr.
undp.org/en/content/calculating-indices (accessed April 27, 2016).
29 WHO Ebola Response Team. West African Ebola epidemic after one 
year— slowing but not yet under control. N Engl J Med 2015; 
372: 584–87
.
30 Fries JF. The compression of morbidity. Milbank Q 2005; 83: 801–23.
31 
Langa KM, Larson EB, Karlawish JH, et al. Trends in the prevalence 
and mortality of cognitive impairment in the United States: is there 
evidence of a compression of cognitive morbidity? 
Alzheimers Dement 2008; 4: 134–44.
32 Bardenheier BH, Lin J, Zhuo X, et al. Compression of disability 
between two birth cohorts of US adults with diabetes, 1992–2012: 
a prospective longitudinal analysis. Lancet Diabetes Endocrinol 2016; 
4: 686–94.
33 Beltran-Sanchez H, Preston S, Canudas-Romo V. An integrated 
approach to cause-of-death analysis: cause-deleted life tables and 
decompositions of life expectancy. Demogr Res 2008; 19: 1323–50.
34 
Jagger C, Matthews R, Matthews F, et al. The burden of diseases on 
disability-free life expectancy in later life. 
J Gerontol A Biol Sci Med Sci 2007; 62: 408–14.
35 van Gool CH, Picavet HSJ, Deeg DJ, et al. Trends in activity 
limitations: the Dutch older population between 1990 and 2007
. 
Int J Epidemiol 2011; 40: 1056–67
.
36 King G, Murray CJL, Salomon JA, Tandon A. Enhancing the validity 
and cross-cultural comparability of measurement in survey 
research. Am Polit Sci Rev 2004; 98: 191–207
.
37 
Salomon JA, Tandon A, Murray CJL. Comparability of self rated 
health: cross sectional multi-country survey using anchoring 
vignettes. BMJ 2004; 328: 258.
38 Tandon A, Murray CJL, Salomon JA, King G. Statistical Models for 
Enhancing Cross-Population Comparability. Geneva: World Health 
Organization, 2002.
39 Bowling A. Commentary: Trends in activity limitation. 
Int J Epidemiol 2011; 40: 1068–70.
40 
Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: 
a world converging within a generation. Lancet 2013; 382: 1898–955.
41 
GBD 2015 SDG Collaborators. Measuring the health-related 
Sustainable Development Goals in 188 countries: a baseline analysis 
from the Global Burden of Disease Study 2015. Lancet 2016; 
388: 1815–52.
42 
Engineer MH, Roy N, Fink S. ‘Healthy’ Human Development 
Indices. Soc Indic Res 2009; 99: 61–80.
43 
National Institutes of Health (NIH). NIH unveils FY2016–2020 
Strategic Plan. Dec 15, 2015. http://www.nih.gov/news-events/
news-releases/nih-unveils-fy2016–2020-strategic-plan (accessed 
March 26, 2016).
44 
Gillum LA, Gouveia C, Dorsey ER, et al. NIH disease funding levels 
and burden of disease. PLoS One 2011; 6: e16837
.
45 
Emdin CA, Odutayo A, Hsiao AJ, et al. Association between 
randomised trial evidence and global burden of disease: cross 
sectional study (Epidemiological Study of Randomized Trials—
ESORT). BMJ 2015; 350: h117
.
46 
Catalá-López Ferrán, García-Altés Anna, Álvarez-Martín E, 
Gènova-Maleras R, Morant-Ginestar C. Does the development of 
new medicinal products in the European Union address global and 
regional health concerns? Popul Health Metr 2010; 8: 34.
47 
WHO. Investing in health research and development. http://www.
who.int/tdr/publications/tdr-research-publications/investing-in-
health/en/ (accessed June 11, 2016).
48 
Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase 
value and reduce waste when research priorities are set. Lancet 
2014; 383: 156–65.
49 
GBD 2015 Risk Factors Collaborators. Global, regional, and national 
comparative risk assessment of 79 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, 1990–2015: 
a systematic analysis for the Global Burden of Disease Study 2015. 
Lancet 2016; 388: 1661–736.
50 Leigh JP, Sheetz RM. Prevalence of back pain among fulltime United 
States workers. Br J Ind Med 1989; 46: 651–57
.
51 
Leino-Arjas P, Hänninen K, Puska P. Socioeconomic variation in 
back and joint pain in Finland. Eur J Epidemiol 1998; 14: 79–87
.
52 Waddell G, Burton AK. Occupational health guidelines for the 
management of low back pain at work: evidence review. 
Occup Med (Lond) 2001; 51: 124–35.
53 Haddon W. Advances in the epidemiology of injuries as a basis for 
public policy. Public Health Rep 1980; 95: 411–21.
54 
Moore L, Evans D, Hameed SM, et al. Mortality in Canadian trauma 
systems: a multicenter cohort Study. Ann Surg 2016; published online 
Jan 7
. DOI:10.1097/SLA.0000000000001614.
55 Uthkarsh PS, Gururaj G, Reddy SS, Rajanna MS. Assessment and 
availability of trauma care services in a district hospital of 
south India: a fi
 eld observational study. Bull Emerg Trauma 2016; 
4: 93–100.
56 Ghajar J. Traumatic brain injury. Lancet 2000; 356: 923–29.
57 
Cheatham ML, Malbrain ML, Kirkpatrick A, et al. Results from the 
International Conference of Experts on Intra-abdominal 
Hypertension and Abdominal Compartment Syndrome. II. 
Recommendations. Intensive Care Med 2007; 33: 951–62.
58 Stuke LE, Pons PT, Guy JS, Chapleau WP, Butler FK, McSwain NE. 
Prehospital spine immobilization for penetrating trauma—review 
and recommendations from the Prehospital Trauma Life Support 
Executive Committee. J Trauma 2011; 71: 763–69.
59 Rickard JL, Ntakiyiruta G, Chu KM. Associations with perioperative 
mortality rate at a major referral hospital in Rwanda. World J Surg 
2015; 40: 784–90.
60 Odhiambo FO, Beynon CM, Ogwang S, et al. Trauma-related 
mortality among adults in rural western Kenya: characterising deaths 
using data from a Health and Demographic Surveillance System. 
PLoS One 2013; 8: e79840.
61 
Naish S, Dale P, Mackenzie JS, McBride J, Mengersen K, Tong S. 
Climate change and dengue: a critical and systematic review of 
quantitative modelling approaches. BMC Infect Dis 2014; 14: 167
.
62 GBD 2015 Child Mortality Collaborators. Global, regional, national, 
and selected subnational levels of stillbirths, neonatal, infant, and 
under-5 mortality, 1980–2015: a systematic analysis for the Global 
Burden of Disease Study 2015. Lancet 2016; 388: 1727–76.
63 GBD 2015 Maternal Mortality Collaborators. Maternal mortality 1990 
to 2015: a systematic analysis of the Global Burden of Disease 2015 
Study. Lancet 2016; 388: 1777–814.
64 
Murray CJL, Ferguson BD, Lopez AD, Guillot M, Salomon JA, 
Ahmad O. Modifi
 ed logit life table system: principles, empirical 
validation, and application. Popul Stud 2003; 57: 165–82.
65 Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specifi
 c and 
sex-specifi
 c mortality in 187 countries, 1970–2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet 2012; 
380: 2071–94.
66 GBD 2013 Mortality and Causes of Death Collaborators. Global, 
regional, and national age-sex specifi
 c all-cause and cause-specifi
 c 
mortality for 240 causes of death, 1990–2013: a systematic analysis for 
the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–71.
67 
Stouthard ME, Essink-Bot M, Bonsel G, Barendregt J, Kramers P. 
Disability weights for diseases in the Netherlands. Rotterdam: 
Department of Public Health, Erasmus University, 1997
.
68 UN, Department of Economic and Social Aff
 airs, Population 
Division. World Population Prospects: The 2012 Revision, 
Key Findings and Advance Tables. Working Paper number 
ESA/P/WP.227
. New York: United Nations, 2013.
